IL322109A - Tricyclic compounds for the treatment of cancer - Google Patents

Tricyclic compounds for the treatment of cancer

Info

Publication number
IL322109A
IL322109A IL322109A IL32210925A IL322109A IL 322109 A IL322109 A IL 322109A IL 322109 A IL322109 A IL 322109A IL 32210925 A IL32210925 A IL 32210925A IL 322109 A IL322109 A IL 322109A
Authority
IL
Israel
Prior art keywords
dimethyl
pyridyl
thia
methoxyethyl
tetrazahexacyclo
Prior art date
Application number
IL322109A
Other languages
Hebrew (he)
Inventor
Jianguo Chen
Lei Guo
Haixia Liu
Hong Shen
Junwei Xi
Weixing Zhang
Dan Zhao
Wei Zhu
Original Assignee
Hoffmann La Roche
Jianguo Chen
Lei Guo
Haixia Liu
Hong Shen
Junwei Xi
Weixing Zhang
Dan Zhao
Wei Zhu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Jianguo Chen, Lei Guo, Haixia Liu, Hong Shen, Junwei Xi, Weixing Zhang, Dan Zhao, Wei Zhu filed Critical Hoffmann La Roche
Publication of IL322109A publication Critical patent/IL322109A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Description

Case 38270 Tricyclic compounds for the treatment of cancer The present invention relates to organic compounds useful for therapy and/or prophylaxis in a mammal, and in particular to inhibition of KRAS mutant useful for treating cancers. FIELD OF THE INVENTION RAS is one of the most well-known proto-oncogenes. Approximately 30% of human cancers contain mutations in three most notable members, KRAS, HRAS, and NRAS, making them the most prevalent oncogenic drivers. KRAS mutations are generally associated with poor prognosis especially in colorectal cancer, pancreatic cancer, lung cancers. As the most frequently mutated RAS isoform, KRAS has been intensively studied in the past years. Among the most commonly occurring KRAS alleles (including G12D, G12V, G12C, G13D, G12R, G12A, G12S, Q61H, etc), G12C, G12D, G12V represent more than half of all KRAS-driven cancers across colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), lung adenocarcinoma (LUAD). Of note, KRAS wild-type amplifications are also found in around 7% of all KRAS- altered cancers (ovarian, esophagogastric, uterine), ranking among the top alterations.All RAS proteins belong to a protein family of small GTPases that hydrolyze GTP to GDP. KRAS is structurally divided into an effector binding lobe followed by the allosteric lobe and a carboxy-terminal region that is responsible for membrane anchoring. The effector lobe comprises the P-loop, switch I, and switch II regions. The switch I/II loops play a critical role in KRAS downstream signaling through mediating protein protein interactions with effector proteins that include RAF in the mitogen-activated protein kinase (MAPK) pathway or PI3K in the phosphatidylinositol 3 - kinase (PI3K)/protein kinase B (AKT) pathway.KRAS protein switches between an inactive to an active form via binding to GTP and GDP, respectively. Under physiological conditions, the transition between these two states is regulated by guanine nucleotide exchange factors (GEFs), such as Son Of Sevenless Homolog 1 (SOS1), or GTPase-activating proteins (GAPs) that involve catalyzing the exchange of GDP for GTP, potentiating intrinsic GTPase activity or accelerating RAS-mediated GTP hydrolysis. In response to extracellular stimuli, the inactive RAS-GDP is converted to active RAS-GTP which directly binds to RAF RAS binding domains (RAFrbd), recruiting RAF kinase family from cytoplasm to membranes, where they dimerize and become active. The activated RAF subsequently carries out a chain of phosphorylation reactions to its downstream Mitogen-activated protein kinase (MEK) and extracellular signal-regulated kinase (ERK), and propagates the growth signal. Of the RAF family of protein kinases (three known isoforms ARAF, BRAF, CRAF/RAF1), BRAF is most frequently mutated and remains the most potent activator of MEK. Despite that individual RAS and RAF family members revealed distinct binding preferences, all RAFs possess the conserved RBD for forward transmission of MARK singnaling, frequently used for characterize KRAS inhibition (e.g. KRAS-BRAF™0 herein). For KRAS, mutations at positions 12, 13, 61, and 146 lead to a shift toward the active KRAS form through impairing nucleotide hydrolysis or activating nucleotide exchange, leading to hyper-activation of the MAPK pathway that results in tumorigenesis.Despite its well-recognized importance in cancer malignancy, continuous efforts in the past failed to develop approved therapies for KRAS mutant cancer until recently, the first selective drug AMG510 has fast approval as second line treatment in KRAS G12C driven non-small cell lung cancer (NSCLC). Nevertheless, the clinical acquired resistance to KRAS G12C inhibitors emerge rigorously with disease progresses after around 6 month of treatment. All of the mutations converge to reactivate RAS-MAPK signaling, with secondary RAS mutants at oncogenic hotspots (e.g. G12/G13/Q61) and within the switch II pocket (e.g. H95, R68, and Y96) have been observed; moreover, over 85% of all KRAS-mutated or wild-type amplified driven cancers still lack novel agents. Altogether, both the myriad of escape mechanism and various oncogenic alleles, highlight the urgent medical need for additional RAS therapies. As such, we invented oral compounds that target and inhibit RAS alleles for the treatment of RAS mutant driven cancers. SUMMARY OF THE INVENTION The present invention relates to novel compounds of formula (Ib), wherein R1 is 2-oxabicyclo[2.1.1]hexanyl,3-oxabicyclo [3.1.0]hexanyl,6-bicyclo[3.1.0]hexanyl substituted twice by halogen,6-tricyclo[3. 1.1.03,6]heptanyl,C3-7cycloalkyl substituted once, twice or three times by the substituentsindependently selected from C!-6alkyl, C!-6alkylpyridinyl, C1.6alkylpyrimidinyl,C!-6alkyltetrazolyl, C3-7cycloalkyl, haloC!.6alkyl, halogen, halophenyl, hydroxy, phenyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl and thiazolyl, or tetrahydropyranyl;R2 is l,3,4,6,7,8,9,9a-octahydropyrido[l,2-a]pyrazinyl,3,4,6,7,9,9a-hexahydro- 1 H-pyrazino [2,1 -c] [ 1,4]oxazinyl,morpholinyl, orpiperazinyl unsubstituted or substituted by substituents independently selected from C!-6alkoxyC1-6alkyl, C!-6alkyl, C3-7cycloalkyl, haloC!.6alkyl, hydro xyC1.6alkyl, morpholinylC1-6alkyl, oxetanyl, oxopyrrolidinylC1-6alkyl andtetrahydro furanyloxyC 1 -6alkyl;R3 is H or halogen;M is C!-6alkylene or 0;L is C!-6alkylene, hydroxyC1-6alkylene or halo C -alkylene;or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof.The invention also relates to their manufacture medicaments based on a compound in accordance with the invention and their production as well as the use of compounds of formula (I), (la), (1b) or (Ic) thereof as inhibitor of KRAS.The compounds of formula (1), (la), (lb) or (Ic) showed good KRAS inhibition for G12C, G12DandG12V.In another embodiment, the compounds of current invention have significantly improved single dose pharmacokinetics (PK) properties comparing with the reference compounds suggesting that compounds of this invention are more suitable for treating cancers with RAS mutation as an orally therapeutic active ingredient in clinic (Example 128).In another embodiment, the compounds of this invention showed superior human hepatocyte stability which is advantageous to improve in vivo performance of the compound, such as dose reduction, exposure enhancement, and half-life prolongation (Example 129).
In another embodiment, the compounds of this invention exhibited less inhibitory effect on hERG potassium channel compared to reference compound, suggesting that compounds of this invention could have less concern regarding cardiovascular toxicity associated with hERG channel blockade (Example 138).In another embodiment, the compounds of this invention showed better selectivity compared to reference compounds on WT KRAS/HRAS/NRAS potentially indicating an improved tolerability and safety profile (Example 132).In another embodiment, the compounds of this invention consistently exhibited more potent anti-proliferative activity across 119 cell panels, significantly differentiated from reference compound treated group, that potentially could result in more robust anti-tumor responses in clinic (Example 131).In another embodiment, the compounds of this invention exhibited longer and sustained pathway inhibition over treatment period, and demonstrated significantly enhanced anti-tumor activities compared with reference compound that potentially could result in more durable anti- tumor responses in clinic (Example 130).In another embodiment, the compounds of this invention showed much higher binding affinity to CYPA and an obviously much lower dissociation rate that revealed a stronger stability of formed CYPA-compound binary complex. This result is consistent with the less potency shift of Example 24 observed in washout assay in Example 140, which further suggesting more persistent cell growth inhibition that would be advantageous for achieving durable efficacy in clinic (Example 139 and 140).In addition, the compounds of current invention showed excellent tumor growth inhibition (TGI) in brain metastasis intracranial model, improved toxicity and solubility profiles. Furthermore, the compounds of current invention avoided generating unfavorable or even toxic metabolite in vivo compared to reference compounds.
BRIEF DESCRIPTION OF THE FIGURES Figure 1.Absolute configuration structure of compound F6 in the form of its (2S,3S)-2,3-bis[(4- methylbenzoyl)oxy]butanedioic acid salt acetonitrile solvate. Figure 2. Bio luminescence signal changes and body weight change after administering vehicle or test articles to female BALB/c nude mice bearing NCI-H1373-luc intracranial tumors. Data points represent mean ±SEM. Figure 3. Tumor bioluminescence picture of each group from Figure 2.
Figure 4.DUSP6 express levels in brain samples of NCI-H1373-luc intracranial tumor model from Figure 2. All data were analyzed using Prism GraphPad software. *** indicates p < 0.001. Error bars represented Standard Error of Mean (SEM). Figure 5.DUSP6 express levels in tumor samples of SHP77 xenograft model. The differences of DUSP6 inhibition for EX24 group were determined to be statistically significant versus A1group at both 48h and 72h post dosing, via two-tailed t test. * indicates p < 0.05. Error bars represented Standard Error of Mean (SEM). All data were analyzed using Prism GraphPad software. Figure 6.Tumor volume changes and body weight change after administering vehicle or test articles to female CB-17 SCID mice bearing SHP-77 SCLC tumors. Data points represent mean ±SEM. Tumor volumes at day 14 for EX24 group were determined to be statistically significant versus A122 group via two-tailed t test. * indicates P < 0.05. p.o.: oral administration; QD: once a day. Figure 7.Scatter plot of the IC50 values of RAS addicted cell panels (n=l 19) from Table 3. Median IC50 of EX24 group (0.95nM) was determined to be statistically significant versus median IC50 of A122 group (1.90nM) via two-tailed t test. **** indicates P < 0.00 DETAILED DESCRIPTION OF THE INVENTION DEFINITIONS The term "C1-6alkyl" denotes a saturated, linear or branched chain alkyl group containing to 6, particularly 1 to 4 carbon atoms, for example methyl, ethyl, /?-propyl, isopropyl, /?-butyl, isobutyl, tert-butyl and the like. Particular "C!-alkyl" groups are methyl, ethyl and /?-propyl.The term ‘־C! ^alkylene" denotes a linear saturated divalent hydrocarbon group of 1 to carbon atoms or a divalent branched saturated hydrocarbon group of 3 to 6 carbon atoms.Examples of C!_<؛alkylene groups include methylene, ethylene, propylene, 2-methylpropylene, butylene, 2-ethylbutylene, pentylene, hexylene.The term "halogen " and "halo" are used interchangeably herein and denote fluoro, chloro, bromo, or iodo.The term "haloC!-6alkyl " denotes a C!.6alkyl group wherein at least one of the hydrogen atoms of the C!_6alkyl group has been replaced by same or different halogen atoms, particularly fluoro atoms. Examples of haloalkyl include mono fluoro-, difluoro- or trifluoro-methyl, -ethyl or -propyl, for example 3,3,3-trifluoropropyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, fluoro methyl, or trifluoromethyl.
The term "haloC!-6alkylene " denotes a C!.6alkylene group wherein at least one of the hydrogen atoms of the C!.6alkylene group has been replaced by same or different halogen atoms.The term "halophenyl" denotes a phenyl group wherein at least one of the hydrogen atoms of the phenyl group has been replaced by same or different halogen atoms.The term "C3-7cycloalkyl " denotes a monovalent saturated monocyclic or bicyclic hydrocarbon group of 3 to 7 ring carbon atoms. Bicyclic means consisting of two saturated carbocycles having one or more carbon atoms in common. Examples for monocyclic cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. Examples for bicyclic cycloalkyl are bicyclo[1.1.0]butyl, bicyclo[2.2.1]heptanyl, bicyclo[l.l.l]pentanyl, or bicyclo[2.2.2]octanyl.The term "cis" and "trans" denote the relative stereochemistry of the molecule or moiety. For example: intermediate Ri as the trans-isomer, refers to a mixture of and . The way of showing relative stereochemistry also applies to the final compounds.
The skilled of the art would understand that the following structures of compounds of formula (la) and (la’) are equal especially for the chiral centers: (la’) (la)The term "pharmaceutically acceptable salts" denotes salts which are not biologically or otheiwise undesirable. Pharmaceutically acceptable salts include both acid and base addition salts. -ר- The term "pharmaceutically acceptable acid addition salt" denotes those pharmaceutically acceptable salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, carbonic acid, phosphoric acid, and organic acids selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, gluconic acid, lactic acid, pyruvic acid, oxalic acid, malic acid, maleic acid, maloneic acid, succinic acid, fumaric acid, tartaric acid, citric acid, aspartic acid, ascorbic acid, glutamic acid, anthranilic acid, benzoic acid, cinnamic acid, mandelic acid, embonic acid, phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and salicyclic acid.The term "pharmaceutically acceptable base addition salt" denotes those pharmaceutically acceptable salts formed with an organic or inorganic base. Examples of acceptable inorganic bases include sodium, potassium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum salts. Salts derived from pharmaceutically acceptable organic nontoxic bases includes salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperizine, piperidine, A-ethylpiperidine, and polyamine resins.The term "A pharmaceutically active metabolite " denotes a pharmacologically active product produced through metabolism in the body of a specified compound or salt thereof. After entry into the body, most drugs are substrates for chemical reactions that may change their physical properties and biologic effects. These metabolic conversions, which usually affect the polarity of the compounds of the invention, alter the way in which drugs are distributed in and excreted from the body. However, in some cases, metabolism of a drug is required for therapeutic effect.The term "therapeutically effective amount " denotes an amount of a compound or molecule of the present invention that, when administered to a subject, (i) treats or prevents the particular disease, condition or disorder, (ii) attenuates, ameliorates or eliminates one or more symptoms of the particular disease, condition, or disorder, or (hi) prevents or delays the onset of one or more symptoms of the particular disease, condition or disorder described herein. The therapeutically effective amount will vary depending on the compound, the disease state being treated, the severity of the disease treated, the age and relative health of the subject, the route and form of administration, the judgement of the attending medical or veterinary practitioner, and other factors.The term "pharmaceutical composition " denotes a mixture or solution comprising a therapeutically effective amount of an active pharmaceutical ingredient together with pharmaceutically acceptable excipients to be administered to a mammal, e.g., a human in need thereof.The terms "pharmaceutically acceptable excipient ", "pharmaceutically acceptable carrier " and "therapeutically inert excipient " can be used interchangeably and denote any pharmaceutically acceptable ingredient in a pharmaceutical composition having no therapeutic activity and being non-toxic to the subject administered, such as disintegrators, binders, fdlers, solvents, buffers, tonicity agents, stabilizers, antioxidants, surfactants, carriers, diluents or lubricants used in formulating pharmaceutical products.
INHIBITOR OF KRAS The present invention relates to (i’) a compound of formula (lb), whereinR1 is 2-oxabicyclo[2.1.1]hexanyl,3-oxabicyclo[3.1.0]hexanyl,6-bicyclo[3.1.0]hexanyl substituted twice by halogen,6-tricyclo[3. 1.1.03,6]heptanyl,C3-7cycloalkyl substituted once, twice or three times by the substituentsindependently selected from C!_6alkyl, C!.6alkylpyridinyl, C!-6alkylpyrimidinyl, C1-6alkyltetrazolyl, C3-7cycloalkyl, haloC!.6alkyl, halogen, halophenyl, hydroxy, phenyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl and thiazolyl, or tetrahydropyranyl;R2 is l,3,4,6,7,8,9,9a-octahydropyrido[l,2-a]pyrazinyl,3,4,6,7,9,9a-hexahydro- 1 H-pyrazino [2,1 -c] [ 1,4]oxazinyl, morpholinyl, orpiperazinyl unsubstituted or substituted by substituents independently selected fromC1-6alkoxyC!-6alkyl, C!.6alkyl, C3-7cycloalkyl, haloC!-6alkyl, hydroxyC!.6alkyl, morpholinylC1-6alkyl, oxetanyl, oxopyrrolidinylC!.6alkyl and tetrahydro furanylo xyC! _6alkyl;R3 is H or halogen;M is C1-6alkylene or O;L is C!-d alkylene, hydroxyC1. 6alkylene orhaloC1-alkylene;or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof.Another embodiment of present invention is (ii’) a compound of formula (Ic), whereinR1 is 2-oxabicyclo[2.1.1]hexanyl,3-oxabicyclo[3.1.0]hexanyl,6-bicyclo[3.1.0]hexanyl substituted twice by halogen,6-tricyclo [3.1.1.03,6]heptanyl,C3-7cycloalkyl substituted once, twice or three times by the substituentsindependently selected from C!.6alkyl, C!.6alkylpyridinyl, C!.6alkylpyrimidinyl, C!-6alkyltetrazolyl, C3-7cycloalkyl, haloC!.6alkyl, halogen, halophenyl, hydroxy, phenyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl and thiazolyl, or tetrahydropyranyl;R2 is 1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazinyl,3,4,6,7,9,9a-hexahydro- 1 H-pyrazino [2,1 -c] [ 1,4]oxazinyl, morpholinyl, orpiperazinyl unsubstituted or substituted by substituents independently selected from C1-6alkoxyC1.6alkyl, C!.6alkyl, C3-7cycloalkyl, haloC!.6alkyl, hydro xyC!.6alkyl, morpholinylC1-6alkyl, oxetanyl, oxopyrrolidinylC1-6alkyl andtetrahydro furanyloxyC 1 -6alkyl;R3 is H or halogen;M is C1-6alkylene or O;L is C1-6alkylene, hydroxyC 1-alkylene or haloC1. 6alkylene;or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof.A further embodiment of present invention is (iii’) a compound of formula (1b) or (Ic) according to (i‘) or (ii’), or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof, wherein R1 is C3-7cycloalkyl substituted once or twice by the substituents independently selected from C!-6alkyl and pyridinyl.A further embodiment of present invention is (iv’) a compound of formula (1b) or (Ic), according to any one of (i‘) to (iii’), or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof, wherein R1 is cyclopropyl once substituted by pyridinyl or twice substituted by methyl.A further embodiment of present invention is (v’) a compound of formula (1b) or (Ic), or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof, according to any one of (f) to (iv’), wherein R1 is 2,3-dimethyl-cyclopropyl or 2-(3-pyridinyl)cyclopropyl.A further embodiment of present invention is (vi’) a compound of formula (1b) or (Ic), or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof ״ according to any one of (i‘) to (v’), wherein R2 is morpholinyl or C1-6alkylpiperazinyl.A further embodiment of present invention is (vii‘) a compound of formula (1b) or (Ic), or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof, according to any one of (i‘) to (vi’), wherein R2 is morpholinyl or 4-methylpiperazin-l-yl.A further embodiment of present invention is (viii’) a compound of formula (1b) or (Ic), or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof, according to any one of (i‘) to (vii‘), wherein M is C!-6alkylene.
A further embodiment of present invention is (ix‘) a compound of formula (1b) or (Ic), or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof, according to any one of (i’) to (viii’), wherein M is CH2.A further embodiment of present invention is (x‘) a compound of formula (1b) or (Ic), or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof, according to any one of (i’) to (ix‘), wherein L is ethylene or difluoro ethylene.A further embodiment of present invention is (xi‘) a compound of formula (1b) or (Ic), or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof, according to any one of Fsal - ؛ LC_CF ؟ H2 H2 ؛(f) to (x’), wherein L is or , wherein bond "a" connects to M.A further embodiment of present invention is (xii’) a compound of formula (1b) or (Ic), according to any one of (i‘) to (xi‘), whereinR1 is C3-7cyc 10alkyl substituted once or twice by the substituents independently selected from C!-6alkyl and pyridinyl;R2 is morpholinyl or C!-6alkylpiperazinyl;R3 is H;M is C!-6alkylene;L is C!-6alkylene or haloC!.6alkylene;or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof.A further embodiment of present invention is (xiii’) a compound of formula (1b) or (Ic), according to any one of (i‘) to (xii’), whereinR1 is 2,3-dimethyl-cyclopropyl or 2-(3-pyridinyl)cyclopropyl;R2 is morpholinyl or 4-methylpiperazin-1 -yl;R3 is H;M is CH2; FLC_C ! -salF ؟ H2 H2 ؛L is or , wherein bond ،،a" connects to M;or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof.
The present invention relates to (i) a compound of formula (I), wherein R1 is 2-oxabicyclo[2.1.1]hexanyl,3-oxabicyclo [3.1.0]hexanyl,6-bicyclo[3.1.0]hexanyl substituted twice by halogen,6-tricyclo [3.1.1.03,6]heptanyl,C3-7cycloalkyl substituted once, twice or three times by the substituents independently selected from C!_6alkyl, C1-6alkyltetrazolyl, C3.?cyclo alkyl, haloC!-6alkyl, halogen, halophenyl, hydroxy, phenyl, pyridazinyl, pyridinyl and pyrimidinyl, ortetrahydropyranyl;R2 is l,3,4,6,7,8,9,9a-octahydropyrido[l,2-a]pyrazinyl, 3,4,6,7,9,9a-hexahydro-lH- pyrazino [2,1-c][ 1,4] oxazinyl, morpholinyl, (haloC!.6alkyl)piperazinyl or C!_ 6alkylpiperazinyl;M is C!-6alkylene or O;L is C!-6alkylene or haloC!.6alkylene;or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof.Another embodiment of present invention is (h) a compound of formula (la), wherein R1 is 2-oxabicyclo[2.1.1]hexanyl,3-oxabicyclo [3.1.0]hexanyl,6-bicyclo[3.1.0]hexanyl substituted twice by halogen,6-tricyclo[3. 1.1.03,6]heptanyl,C3-7cycloalkyl substituted once, twice or three times by the substituents independently selected from C!.6alkyl, C!.6alkyltetrazolyl, C3.?cycloalkyl, haloC!.6alkyl, halogen, halophenyl, hydroxy, phenyl, pyridazinyl, pyridinyl and pyrimidinyl, ortetrahydropyranyl;R2 is l,3,4,6,7,8,9,9a-octahydropyrido[l,2-a]pyrazinyl, 3,4,6,7,9,9a-hexahydro-lH- pyrazino [2,1-c][ 1,4] oxazinyl, morpholinyl, (haloC!.6alkyl)piperazinyl or C!_ 6alkylpiperazinyl;M is C!-6alkylene or O;L is C!-6alkylene or haloC!.6alkylene;or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof.A further embodiment of present invention is (iii) a compound of formula (1) or (la) according to (i) or (ii), or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof, wherein R1 is C3.?cycloalkyl substituted once or twice by the substituents independently selected from C!.6alkyl and pyridinyl.A further embodiment of present invention is (iv) a compound of formula (I) or (la), according to any one of (i) to (iii), or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof, wherein R1 is cyclopropyl once substituted by pyridinyl or twice substituted by methyl.
A further embodiment of present invention is (v) a compound of formula (1) or (la) according to any one of (i) to (iv), wherein R1 is 2,3-dimethyl-cyclopropyl or 2-(3- pyridinyl)cyclopropyl.A further embodiment of present invention is (vi) a compound of formula (I) or (la), or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof, according to any one of (i) to (v), wherein R2 is morpholinyl or C!-6alkylpiperazinyl.A further embodiment of present invention is (vii) a compound of formula (1) or (la), or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof, according to any one of (i) to (vi), wherein R2 is morpholinyl or 4-methylpiperazin-l-yl.A further embodiment of present invention is (viii) a compound of formula (1) or (la), or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof, according to any one of (i) to (vii), wherein M is C1_6alkylene.A further embodiment of present invention is (ix) a compound of formula (I) or (la), or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof, according to any one of (i) to (viii), wherein M is CH2.A further embodiment of present invention is (x) a compound of formula (1) or (la), or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof, according to any one of (i) to (ix), wherein L is ethylene or difluoroethylene.A further embodiment of present invention is (xi) a compound of formula (1) or (la), or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof, according to any one of Fs,al - ؛ LC_C H2 H2 * F ؛(i) to (x), wherein L is or , wherein bond "a" connects to M.A further embodiment of present invention is (xii) a compound of formula (I) or (la), according to any one of (i) to (xi), whereinR1 is C3-7cycloalkyl substituted once or twice by the substituents independently selected from C!-6alkyl and pyridinyl;R is morpholinyl or C!-6alkylpiperazinyl;M is C!-6alkylene;L is C!-6alkylene or haloC!-6alkylene;or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof A further embodiment of present invention is (xiii) a compound of formula (I) or (la), according to any one of (i) to (xii), whereinR1 is 2,3-dimethyl-cyclopropyl or 2-(3-pyridinyl)cyclopropyl;R2 is morpholinyl or 4-methylpiperazin-l-yl;M is CH2; FLC_C ! -S,a L is or , wherein bond "a" connects to M;or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof.In a more particular embodiment, the present invention is a compound of formula (F), whereinR1, R2 are as defined previously,or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof.In a more particular embodiment, the present invention is a compound of formula (F), whereinR1 is 2,3-dimethyl-cyclopropyl or 2-(3-pyridinyl)cyclopropyl; andR־ is morpholinyl or 4-methylpiperazin-l-yl;or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof.
In a more particular embodiment, the present invention is a compound of formula (Fa), whereinR1, R2 are as defined previously, or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof.
In a more particular embodiment, the present invention is a compound of formula (Fa), whereinR1 is 2,3-dimethyl-cyclopropyl or 2-(3-pyridinyl)cyclopropyl; andR2 is morpholinyl or 4-methylpiperazin-1 -yl;or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof.
Another embodiment of present invention is (xiv‘) a compound of formula (I), (la), (lb) or (Ic) selected from the following:(lS,2S)-A4(7S,13S)-(203^-20-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17- dimethyl-8, 14-dioxo- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] -2-methyl-cyclopropanecarboxamide ;- 3 (- 1 - methoxyethyl]-5-(4-methylp1peraz1n-1-yl .؟(- 11 -] 2 -] 20 ^(- 20 ،؟(-) 13 ،؟, 7 -]) V ،؟(-. 2 ؟, L )pyridyl] -17,17-dimethyl-8, 14-dioxo- 15-oxa-4-thia-9,2 1,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] -2-methyl-cyclopropanecarboxamide ; (15,25)-7V-[(75,135)-(207l4)-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin- 1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] -2-methyl-cyclopropanecarboxamide ;(15,25)-7V-[(75,135)-(207l4)-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin- 1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15,24-dioxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26- hexaen-7-yl]-2-methyl-cyclopropanecarboxamide;(15,25)-2-(difluoromethyl)-7V-[(75,135)-(207l7)-20-[2-[(15)-l-methoxyethyl]-5- morpholino-3-pyridyl]-17,1 7-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] cyclopropanecarboxamide ;(15,57?, 6r)-7V-[(75,135)-(2037)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17- dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 -tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-3-oxabicyclo[3. 1.0]hexane-6-carboxamide;(15,25)-A^-[(75,135)-(2037)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17- dimethyl-8, 14-dioxo- 15,24-dioxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] -2-methyl-cyclopropanecarboxamide ;(15,25)-2-(difluoromethyl)-7V-[(75,135)-(2037)-20-[2-[(15)-l-methoxyethyl]-5- morpholino-3-pyridyl]-17,1 7-dimethyl-8, 14-dioxo- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3. 1.12’5. l9J3.0l9’27.0212]hentriaconta- 1(28),2,5(31), 19,25(29),26-hexaen-7- yl] cyclopropanecarboxamide;(15,57?, 6r)-7V-[(75, 135)-(20M)-20-[2-[(15)-1 -methoxyethyl]-5-morpholino-3-pyridyl]-17,17- dimethyl-8,14-dioxo- 15,24-dioxa-4-thia-9,2 1,30,31 -tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-3-oxabicyclo[3.1.0]hexane-6-carboxamide;(15,25)-2-(difluoromethyl)-7V-[(75,135)-(207k0-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,2,2- trifluoroethyl)piperazin- 1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15,24-dioxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26- hexaen-7-yl] eye lopropanecarboxamide ; (15,5A,6r)-W-[(75,135)-(20A0-20-[2-[(lS)-l-methoxyethyl]-5-[4-^^^trifluoroethyl)piperazin- 1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15,24-dioxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9 13.019’27.02L26]hentriaconta-l(28),2,5(31),19,25(29),26- hexaen-7-yl]-3-oxabicyclo[3. 1.0]hexane-6-carboxamide;(15,5A,6r)-W-[(75,135)-(20A0-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,^^trifluoroethyl)piperazin- 1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-3-oxabicyclo[3.1.0]hexane-6-carboxamide;(15,25)-2-(difluoromethyl)-7V-[(7S,135)-(20A0-20-[2-[(15)-l-methoxyethyl]-5-(4- methylpiperazin- 1 -yl)-3-pyridyl] -17,17-dimethyl-8 ,14-dioxo- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] cyclopropanecarboxamide ;(15,57?, 6^-^-[(75,13،S)-(20A/)-20-[2-[(lS)-1-metho xyethyl]-5-(4-methylpiperazin- 1-yl)-3- pyridyl]- 17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-3-oxabicyclo[3. 1.0]hexane-6-carboxamide;(lA,2lS)-2-cyclopropyl-7V-[(7S,13>S)-(2037)-20-[2-[(l lS)-l-methoxyethyl]-5-(4- methylpiperazin- 1 -yl)-3-pyridyl] -17,17-dimethyl-8 ,14-dioxo- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] cyclopropanecarboxamide ;(15,25)-A^-[(75,135)-(2037)-20-[2-[(llS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]- 17,17-dimethyl-8, 14-dioxo- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’l3.0l9’27.02l’26]hentriaconta- 1(28),2,5(31 ),19,25(29),26-hexaen-7- yl] -2-methyl-cyclopropanecarboxamide ;(15,21S)-^-[(7S,131S)-23,23-difluoro-(20M)-20-[2-[(lS)-l-methoxyethyl]-5-(4- methylpiperazin- 1 -yl)-3 -pyridyl] -17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] -2-methyl-cyclopropanecarboxamide ;2,2-difluoro-7V-[(75,13S)-(20Af)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)- 3-pyridyl]- 17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] -1 -methyl-cyclopropanecarboxamide ; (15,2S)-2-(difluoromethyl)-7V-[(7S,13S)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,2,2- trifluoroethyl)piperazin- 1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,21 ,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] cyclopropanecarboxamide ;(15,25)-A^-[(7S,,13.S)-(20A/)-20-[2-[(llS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]- 17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] -2-phenyl-cyclopropanecarboxamide ;(lr,27?,35)-A^-[(75, 135)-(20A/)-20-[2-[(l>S)-1-metho xyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]- 17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(15,25)-^-[(75,135)-(2037)-20-[5-[(9«5)-3,4,6,7,9,9a-hexahydro-177-pyrazino[2,l- c][l,4]oxazin-8-yl]-2-[(15)-l-methoxyethyl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4- thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31), 19,25(29),26-hexaen-7-yl]-2-methyl-cyclopropanecarboxamide;(17?,27?)-2-(2-fluorophenyl)-7V-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4- methylpiperazin- 1 -yl)-3-pyridyl] -17,17-dimethyl-8 ,14-dioxo- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9,13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] cyclopropanecarboxamide ;(15,25)-2-(2-fluorophenyl)-7V-[(75,135)-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-(4- methylpiperazin- 1 -yl)-3-pyridyl] -17,17-dimethyl-8, 14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3. 1.12’5. l9J3.0l9’27.0212]hentriaconta- 1(28),2,5(31), 19,25(29),26-hexaen-7- yl] cyclopropanecarboxamide ;(1 S,2S)-N-VC?S, 135)-(20M)-20-[2-[( 15)-1 -methoxyethyl]-5-(4-methylpiperazin- 1 -yl)-3- pyridyl] -17,17-dimethyl-8, 14-dioxo- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-(2-pyridyl)cyclopropanecarboxamide;(lS,2S)-JV-[(75,13S)-23,23-difluoro-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin- 1 -yl)-3 -pyridyl] -17,17-dimethyl-8 ,14-dioxo- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7-yl]-2- (difluoromethyl)cyclopropanecarboxamide; (15,25)-A ^-[(75,135)-(20A/)-20-[2-[(15)-1-metho xyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]- 17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-methyl-cyclopropanecarboxamide ;(15,25)-2-(difluoromethyl)-7V-[(75,135)-(20A0-20-[2-[(15)-l-methoxyethyl]-5-(4- methylpiperazin- 1 -yl)-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] cyclopropanecarboxamide ;(15,55,6/j-.V-[(75,135)-(20A/)-20-[2-[(15)-1 -metho xyethyl]-5-(4-methylpiperazin- 1 -yl)-3- pyridyl]- 17,17-dimethyl-8,14-dioxo- 15,24-dioxa-4-thia-9,2 1,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-3-oxabicyclo[3.1.0]hexane-6-carboxamide;(15,25)-2-cyclopropyl-7V-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-morpho lino-3- pyridyl]- 17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7- y 1] eye lopropanecarboxamide ;(15,25)-JV-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17,23,23-tetramethyl-8,14-dioxo- 15,24-dioxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-methyl-cyclopropanecarboxamide;(15,55,6r)-7V-[(75,135)-(20M)-20-[5-[(9N-V(1S, 135)-(20M)-20-[2-[(15)-1 -methoxyethyl]-5-(4-methylpiperazin- 1 -yl)-3- pyridyl]- 17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 -tetrazahexacyc lo[23. 3.1.12’5.19’13.019,27.021,26]hentriaconta- 1(28),2,5(31), 19,25(29),26-hexaen-7- yl]-3-oxabicyclo[3.1.0]hexane-6-carboxamide; (15,25)-Af-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17- dimethyl-8, 14-dioxo- 15,24-dioxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7-yl]-2- phenyl-cyclopropanecarboxamide ;(15,25)-iV-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin- 1 -yl]-3-pyridyl] -17,17-dimethyl-8, 14-dioxo- 15,24-dioxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27- hexaen-7-yl]-2-phenyl-cyclopropanecarboxamide;(lr,25,37?)-jV-[(75,135)-(20.A7)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]- 17,17-dimethyl-8,14-dioxo- 15,24-dioxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(15,25)-A^-[(75,135)-(20Af)-20-[2-[(15)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17- dimethyl-8, 14-dioxo- 15-oxa-4-thia-9,2 1,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7-yl]-2- phenyl-cyclopropanecarboxamide ;(15,25)-A^-[(75,135)-(20Af)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]- 17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9,13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] -2-pyrimidin- 5-yl-cyclopropanecarboxamide ;(15,57?)-3,3-difluoro-7V-[(75,135)-(200-20-[2-[(15)-l-methoxyethyl]-5-(4- methylpiperazin- 1 -yl)-3-pyridyl] -17,17-dimethyl-8, 14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3. 1.12’5. l9J3.0l9’27.0212]hentriaconta- 1(28),2,5(31), 19,25(29),26-hexaen-7- yl] bicyclo [3.1.0]hexane-6-carboxamide;(15,25)-^ -[(75,135)-(20M)-20-[5-[(9a7?)-1,3,4,6,7,8,9,9a-octahydropyrido[ 1,2-a]pyrazin- 2-yl]-2-[( 15)-1-methoxyethyl]-3-pyridyl]- 17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-methyl-cyclopropanecarboxamide;(15,25)-7V-[(75,135)-(20A0-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl] -17,17-dimethyl-8, 14-dioxo- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-pyrimidin-4-yl-cyclopropanecarboxamide; (15,2lS)-jV-[(75,135)-(20Af)-20-[2-[(llS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]- 17,17-dimethyl-8,14-dioxo- 15,24-dioxa-4-thia-9,2 1,30,31־ tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7-yl]-2- phenyl-cyclopropanecarboxamide;(17?,55,65)-A^-[(75,135)-(2037)-20-[2-[( 15)-1 -methoxyethyl]-5-(4-methylpiperazin- 1 -yl)-3 - pyridyl]- 17,17-dimethyl-8,14-dioxo- 15,24-dioxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-3-oxabicyclo[3.1.0]hexane-6-carboxamide;(15,25)-A^-[(75,135,22S)-(20M)-20-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17,22-trimethyl-8,14-dioxo- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-methyl-cyclopropanecarboxamide;2,2-difluoro-7V-[(75,13 lS)-(2037)-20-[2-[(llS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)- 3-pyridyl]- 17,17-dimethyl-8,14-dioxo- 15,24-dioxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7-yl]-l- methyl- eye lopropanecarboxamide ;[(75,13،S)-(2037)-20-[2-[( 15)-1-methoxyethyl] -5-(4-methylpiperazin- 1-yl)-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15,24-dioxa-4-thia-9,2 1,30,31 -tetrazahexacyclo[23.3.1.1 2’5.l9,13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7-yl]- 1,2-dimethyl-cyclopropanecarboxamide;(15,25)-A^-[(75,135)-(20Af)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]- 17,17-dimethyl-8, 14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo [23.3.1.12’5. l9>l3.0l9>27.0212]hentriaconta- 1(28),2,5(31), 19,25(29),26-hexaen-7- yl]-2-(3-pyridyl)cyclopropanecarboxamide;(1 S,2S)-N-V(1S, 13S)-(20M)-20-[2-[( 1S)-1 -methoxyethyl]-5-(4-methylpiperazin- 1 -yl)-3- pyridyl]- 17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-(4-pyridyl)cyc lopropanecarboxamide;(17?,27?)-7V-[(75,13،S)-(20M)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl] -17,17-dimethyl-8, 14-dioxo- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-(4-pyridyl)cyc lopropanecarboxamide; 2-(4-fluorophenyl)-A^-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylp iperazin- l-yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9, 21,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7- yl]cyclopropanecarboxamide;(15,57?, 6^-^-[(75,13S)-23,23-difluoro-(20A0-20-[2-[(15)- 1-methoxyethyl]-5-(4- methyip iperazin- 1 -yl)-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-3-oxabicyclo[3.1.0]hexane-6-carboxamide;(lr,27?,3،S)-A^-[(75,13،S)-(20A/)-20-[2-[(l،S)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17,23,23-tetramethyl-8,14-dioxo- 15,24-dioxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(15,25)-iV-[(75,135)-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]- 17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-pyridazin-3-yl-cyclopropanecarboxamide;(17?,2،S)-2-cyclopropyl-7V-[(75,13S)-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-(4- methyip iperazin- l-yl)-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9,13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7- yl] cyclopropanecarboxamide ;3,3-difluoro-7V-[(75,13S)-(2047)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)- 3-pyridyl]- 17,17-dimethyl-8, 14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3. 1.12’5. l9J3.0l9’27.0212]hentriaconta- 1(28),2,5(31), 19,25(29),26-hexaen-7- yl] cyclopentanecarboxamide ;7V-[(75,13S)-(20A/)-20-[2-[( 1S)-1 -methoxyethyl]-5-(4-methylpiperazin- 1 -yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 -tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] -2-oxabicyclo [2.1.1 ]hexane-1 -carboxamide;(15,2S)-^-[(75,13S)-23,23-difluoro-(207lO-20-[2-[(lS)-l-methoxyethyl]-5-[4-(2,2,2- trifluoroethyl)p iperazin- 1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] -2-methyl-cyclopropanecarboxamide ; (Ir, 25,35)-7V-[(75,135)-(20A/)-20-[2-[(15)-1-metho xyethyl]-5-morpho lino-3-pyridyl]-17,17-dimethyl-8,14-dioxo- 15,24-dioxa-4-thia-9,2 1,30,31 -tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7-yl]- 2,3- dimethyl-cyclopropanecarboxamide ;(Ir, 25,37?)-7V-[(75,135)-(2037)-20-[2-[(15)-1-metho xyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]- 17,17,23,23-tetramethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;tran5-A^-[(75,135)-(2037)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]- 17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7-yl]-4- (1 -methyltetrazo l-5-yl)cyclo hexanecarboxamide;tran5-4-hydroxy-7V-[(75,135)-(203/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l- yl)-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-4-methyl-cyclo hexanecarboxamide;A^-[(75,135)-(2037)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 -tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- y !]tricyclo[ 3.1.1.03,6]heptane-6-carboxamide;(lr,25,37?)-7V-[(75,135)-(2037)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17-dimethyl-8, 14-dioxo- 15-oxa-4-thia-9,2 1,30,31 -tetrazahexacyclo[23.3.1.1 2’5.l9’l3.0l9’27.02l’26]hentriaconta-l(28),2,5(31), 19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(15,25)-^-[(75,135)-23,23-difluoro-(20M)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3- pyridyl]- 17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-methyl-cyclopropanecarboxamide;(lr,25,3/?)-JV-[(75,135)-23,23-difluoro-(20A0-20-[2-[(15)-l-methoxyethyl]-5-morpholino- 3-py1־idyl]- 17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide; ^-[(75,13،S)-(20A/)-20-[2-[( 15)-1-methoxyethyl]-5-(4-methylpiperazin- 1-yl)-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 -tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]tetrahydropyran-4-carboxamide;(lS,2S)-A4(7S,13S)-23,23-difluoro-(20A0-20-[2-[(lS)-l-methoxyethyl]-5-(4- methylpiperazin- 1 -yl)-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-phenyl-cyclopropanecarboxamide ;(15,25)-^-[(75,135)-23,23-difluoro-(20A0-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3- pyridyl]- 17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-phenyl-cyclopropanecarboxamide;(15,25)-A^-[(75,135)-(20A/)-20-[2-[(l lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]- 17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-pyrimidin-2-yl-cyclopropanecarboxamide ;(17?,27?)-jV-[(7S,135)-20-[2-[(llS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 -tetrazahexacyclo[23.3.1.1 2,5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-pyrimidin-2-yl-cyclopropanecarboxamide ;(lr,25,3^)-lV-[(75,13S)-23,23-difluoro-(20A0-20-[2-[(lS)-l-methoxyethyl]-5-(4- methylpiperazin- 1 -yl)-3-pyridyl] -17,17-dimethyl-8, 14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3. 1.12’5. l9J3.0l9’27.0212]hentriaconta- 1(29),2,5(31), 19,25,27-hexaen-7-yl]- 2,3-dimethyl-cyclopropanecarboxamide;(1 r^S3R)-N-V(JS, 13S)-(20O-20-[2-[( 1S)-1 -methoxyethyl]-5-[4-(2,2,2- trifluoroethyl)piperazin- 1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15,24-dioxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26- hexaen-7-yl] -2,3 -dimethyl-cyclopropanecarboxamide ;(lr,27?,3S)-lV-[(75,13S)-(20A0-20-[2-[(lS)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin- 1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,21 ,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide; (lr,2S,37?)-7V-[(7S,13S)-23,23-difluoro-(203O-20-[2-[(lS)-l-methoxyethyl]-5-[4-(2,2,2- trifluoroethyl)piperazin- 1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(lS,2S)-Af-[(7S,13S)-(2047)-20-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17- dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-pyrimidin-5-yl-cyclopropanecarboxamide;(lS,2S)-Af-[(7S,13S)-(2047)-20-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17- dimethyl-8,14-dioxo-15-oxa-4-thia-9, 21,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-(3-pyridyl)cyclopropanecarboxamide;(15,25)-^-[(75,135)-(20A0-20-[2-[(lS)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin- 1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-(3-pyridyl)cyclopropanecarboxamide;(IS,2S)-jV-[(7S,13S)-23,23-difluoro-(20_A7)-20-[2-[(lS)-l-methoxyethyl]-5-morpho lino-3- pyridyl]- 17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 -tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-(3-pyridyl)cyclopropanecarboxamide;(lS,2S)-A4(7S,13S)-23,23-difluoro-(2037)-20-[2-[(lS)-l-methoxyethyl]-5-(4- methylpiperazin- 1 -yl)-3-pyridyl] -17,17-dimethyl-8, 14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3. 1.12’5. l9J3.0l9’27.0212]hentriaconta- 1(28),2,5(31), 19,25(29),26-hexaen-7- yl]-2-(3-pyridyl)cyclopropanecarboxamide;(1 S,2S)-^-[(7S, 13S)-(2037)-20-[2-[( 1S)-1 -methoxyethyl]-5-(4-methylpiperazin- 1 -yl)-3- pyridyl]- 17,17-dimethyl-8,14-dioxo- 15,24-dioxa-4-thia-9,2 1,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-pyrimidin-5-yl-cyclopropanecarboxamide;(1S,2S)-A^-[(7S, 13S)-(20A0-20-[2-[( 1S)-1-methoxyethyl]-5-morpholino-3-pyridyl] -17,17- dimethyl-8, 14-dioxo- 15-oxa-4-thia-9,2 1,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-pyrimidin-5-yl-cyclopropanecarboxamide; (15,25)-A4(75,135)-23,23-difluoro-(2037)-20-[2-[(15)-l-methoxyethyl]-5-(4- methylpiperazin- 1 -yl)-3-pyridyl] -17,17-dimethyl-8 ,14-dioxo- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-pyrimidin-5-yl-cyclopropanecarboxamide;(15,25)-jV-[(75,135)-(20.A7)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]- 17,17-dimethyl-8,14-dioxo- 15,24-dioxa-4-thia-9,2 1,30,31-2,5 9,13 19,27 21,26tetrazahexacyclo[23.3.1.1 .1 .0 .0 ]hentnaconta-l(28),2,5(31),19,25(29),26-hexaen-7-yl]-2-(3-pyridyl)cyclopropanecarboxamide;(15,25)-A^-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17- dimethyl-8, 14-dioxo- 15,24-dioxa-4-thia-9,2 1,30,31-5 9 13 19 27 21 26tetrazahexacyclo [23.3.1.1 .1 ’ .0 ’ .0 ]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7-yl]-2-(3-pyridyl)cyclopropanecarboxamide;(15,25)-A^-[(75,135)-(20A0-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,2,2- trifluoroethyl)piperazin- 1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15,24-dioxa-4-thia-2,5 9,13 19,27 21.269,21,30,31-tetrazahexacyclo[23.3.1.1 .1 .0 .0 ]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7-yl]-2-(3-pyridyl)cyclopropanecarboxamide;(15,25)-A^-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl] -17,17-dimethyl-8, 14-dioxo- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-pyrazin-2-yl-cyclopropanecarboxamide;(1 r.3R3S)-N-^nS. 135)-(20A/)-20-[2-[( 1S)-1 -metho xyethyl]-5-(4-methylpiperazin- 1 -yl)-3- pyridyl]- 17,17-dimethyl-8, 14-dioxo- 15,25-dioxa-4-thia-9,2 1,31,32-tetrazahexacyclo [24.3.1.12’5.19’13.0l9’28.021 ’27]dotriaconta- 1 (29),2,5(32), 19,26(30),27-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(Ir, 25,37?)-75-[(75,135)-(207^)-20-[5-[(9^7?)-1,3,4,6,7,8,9,9a-octahydropyrido[l, 2- a]pyrazin-2-yl]-2-[(15)- 1 -methoxyethyl] -3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26- hexaen-7-yl] -2,3 -dimethyl-cyclopropanecarboxamide ;(15,25)-A^-[(75,135)-(20Af)9)]-5]-20־ti5)-l,3,4,6,7,8,9,9ti-octahydropyrido[l,2-a]pyrazin- 2-yl]-2-[(15)-l-methoxyethyl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9, 21,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-(3-pyridyl)cyclopropanecarboxamide; un סyl]-2,3-dimethyl-cyclopropanecarboxamide;(lr,27?,3S)-7V-[(7SJ3S,23S)-23-hydroxy-(20M)-20-[2-[(l^-l-methoxyetV^^ morpholino-3-pyridyl]-17,1 7-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2 ’ 5.l9’1 3 .01 9 ’ 27.02 1 ’ 2 6 ]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide; yl]-2,3-dimethyl-cyclopropanecarboxamide; (lr,27?,3S)-Af-[(7S,13S)-(20A/)-20-[5-[4-(3-hydroxypropyl)piperazin-l-yl]-2-[(l.S')-l- methoxyethyl] -3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(17?,27?)-A^-[(75,135)-(204S)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl] -17,17-dimethyl-8, 14-dioxo- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-thiazol-4-yl-cyclopropanecarboxamide;(lr,25,37?)-7V-[(75,135)-(20X)-20-[2-[(15)-l-methoxyethyl]-5-[4-(2-methoxyethyl)piperazin- 1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9,13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(17?,27?)-A^-[(7S,13lS)-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]- 17,17-dimethyl-8, 14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3. 1.12’5. l9J3.0l9’27.0212]hentriaconta- 1(28),2,5(31), 19,25(29),26-hexaen-7- yl]-2-(2-methyl-3-pyridyl)cyclopropanecarboxamide;(1 r,2R,3S)-N-VC?S, 13S)-(20M)-20-[2-[( 1S)-1 -methoxyethyl]-5-(4-tetrahydropyran-4- ylpiperazin- 1 -yl)-3 -pyridyl] -17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(lr,27?,3 1S)-7V-[(7S,13.S)-(20d^)-20-[2-[(lS)-l-methoxyethyl]-5-[4-(oxetan-3-yl)piperazin-l- yl]-3-pyridyl]-! 7,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,21 ,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide; lr,2S,37Q-W-[(7S,13S)-(20A0-20-[2-[(lS)-l-methoxyethyl]-5-[4-[[(2S)-morphol ^^^ )- 9,21,30,31 - yl ]methyl]piperazin- 1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia - 7 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen ; yl]-2,3-dimethyl-cyclopropanecarboxamide- 3 (- 13 ، S)-(20A/)-20-[2-[( 15)-1-methoxyethyl]-5-(4-methylpiperazin- 1-yl ،؟, 7 ?(-^-]) 27 ?, 17 )- 9,21,30,31 - pyridyl]- 17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia- 7 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaenyl]-2-(5-methyl-3-pyridyl)cyclopropanecarboxamide ;( lr,27?,3 lS)-7V-[(75,13.S)-(20d7)-20-[2-[(l lS)-l-methoxyethyl]-5-[4-[2-(2-oxopyrrolidin-l -- 9,21,30,31 - yl )ethyl]piperazin- 1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia - 7 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen yl]-2,3-dimethyl-cyclopropanecarboxamide ;- 3 - ( lr,27?,35)-Af-[(7S,135)-(20d7)-20-[2-[(lS)-l-methoxyethyl]-5-[4-(2-tetrahydrofuran- 9,21,30,31 - yl oxyethyl)piperazin- 1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia - 7 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen ; yl]-2,3-dimethyl-cyclopropanecarboxamide,? 35 ([-^-) 75,13 ، S)-(20A/)-20-[2-[( 15)-1-metho xyethyl]-5-[4-(3-methoxy-3-methyl - /־, 1 )- 9,21,30,31 - bu tyl)piperazin- 1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia - 7 - tetrazahexacyclo[23.3.1.1 2’5.l9,13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen yl]-2,3-dimethyl-cyclopropanecarboxamide ;( lr,2S,37<)-W-[(7S,13S)-29-fluoro-(20^-20-[2-[(lS)-l-methoxyethyl ^^-]- 9,21,30,31 - me thylpiperazin- 1 -yl)-3-pyridyl] -17,17-dimethyl-8, 14-dioxo- 15-oxa-4-thia - 7 - tetrazahexacyclo[23.3. 1.12’5. l9J3.0l9’27.0212]hentriaconta- 1(28),2,5(31), 19,25(29),26-hexaen yl]-2,3-dimethyl-cyclopropanecarboxamide ;( 15,2S)-^-[(75,13،S)-(20A0-20-[2-[( 1S)-1 -methoxyethyl]-5-morpholino-3-pyridyl -]- 9,21,30,31-17,17,22,22 - tetramethyl-8, 14-dioxo- 15-oxa-4-thia21,26 19,27 9,13 2,5- 2 [- tetrazahexacyclo[23.3.1.1 .1 .0 .0 ]hentnaconta-l(29),2,5(31),19,25,27-hexaen-7-ylmethyl- eye lopropanecar boxamide ;( lr,2/?,3،S)-JV-[(75,13،S)-(20A0-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl -]- 9,21,31,32-17,17 - dimethyl-8,14-dioxo- 15-oxa-4-thia21,27 19,28 9,13 2,5- 7 - tetrazahexacyclo[24.3.1.1 .1 .0 .0 ]dotnaconta-l(29),2,5(32),19,26(30),27-hexaenyl]-2,3-dimethyl-cyclopropanecarboxamide; and (Ir,2A,3،S)-A-[(7،S', 13،S)-(20A/)-20-[2-[(l>S)-1-metho xyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]- 17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,32,33-2,5 9,13 19,29 21,28tetrazahexacyclo[25.3.1.1 .1 .0 .0 ]tntnaconta-l(30),2,5(33),19,27(31),28-hexaen-7-yl]-2,3-dimethyl-cyclopropanecarboxamide;or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof.A further embodiment of present invention is (xv’) a compound selected from: (Example 24); (Example 56); (Example 73); (Example 89);or a pharmaceutically acceptable salt, enantiomers and diastereomers thereof.Another embodiment of present invention is related to (xvi) a process for the preparation ofa compound according to any one of (i) to (xiii) and (xv’) comprising the following step:a) coupling reaction between compound of formula (II), (II), and acid (III), OH (III), in thepresence of a coupling reagent and a base to form the compound of formula (lb);wherein R1, R2, M and L are defined as in any one of (i) to (xiii); the coupling reagent is T3P, HATU, PyBOP or EDCI/HOBt; the base is TEA, DIEP A or DMAP.
Another embodiment of present invention is related to (xvi‘) a process for the preparation of a compound according to any one of (i‘) to (xv’) comprising the following step:a) coupling reaction between compound of formula (lib), the presence of a coupling reagent and a base to form the compound of formula (lb);wherein R1, R2, M and L are defined as in any one of (i‘) to (xiii’); the coupling reagent is T3P, HATU, PyBOP or EDCI/HOBt; the base is TEA, DIEP A or DMAP.Another embodiment of present invention is (xvii‘) a compound or pharmaceutically acceptable salt according to any one of (i‘) to (xv’) or (i) to (xiii) for use as therapeutically active substance.Another embodiment of present invention is (xviii‘) a pharmaceutical composition comprising a compound in accordance with any one of (i‘) to (xv’) or (i) to (xiii) and a pharmaceutically acceptable excipient.Another embodiment of present invention is (xix‘) the use of a compound according to any one of (F) to (xv’) or (i) to (xiii) for treating a KRAS G12C protein-related disease.Another embodiment of present invention is (xx‘) the use of a compound according to any one of (i’) to (xv’) or (i) to (xiii) for treating a KRAS G12C, G12D and G12V protein-related disease.Another embodiment of present invention is (xxi‘) the use of a compound according to any one of (i’) to (xv’) or (i) to (xiii) for inhibiting RAS interaction with downstream effectors, wherein the downstream effectors are RAF and PI3K.Another embodiment of present invention is (xxii‘) the use of a compound according to any one of (i’) to (xv’) or (i) to (xiii) for inhibiting the propagating oncogenic MAPK and PI3K signaling.
Another embodiment of present invention is (xxiii‘) the use of a compound according to any one of (F) to (xv’) or (i) to (xiii) for the treatment or prophylaxis of cancers in a subject in need thereof, wherein the cancer comprises a first RAS mutation that is G12C and a second RAS mutation at aposition selected from the group consisting of V8A, V9Y, S17E, A59T, T58I, D69P, M72I, S65W, R68S, D92R, H95N, Y96D, Q99W and F156L.Another embodiment of present invention is (xxiv’) the use of a compound according to any one of (F) to (xv’) or (i) to (xiii) for the preparation of a medicament for the treatment or prophylaxis of cancers in a subject in need thereof, wherein the cancer comprises a first RAS mutation that is G12C and a second RAS mutation at a position selected from the group consisting 0fV8A, V9Y, SUE, A59T, T58I, D69P, M72I, S65W, R68S, D92R, H95N, Y96D, Q99W andF156L.Another embodiment of present invention is (xxv’) the use of a compound according to any one of (F) to (xv’) or (i) to (xiii) for the treatment or prophylaxis of KRAS mutation driven cancers, wherein the cancer is selected from pancreatic cancer, colorectal cancer, lung cancer, esophageal cancer, gallbladder cancer, melanoma ovarian cancer and endometrial cancer.Another embodiment of present invention is (xxvF) the use of a compound according to any one of (F) to (xv’) or (i) to (xiii) for the treatment or prophylaxis of KRAS mutation driven cancers, wherein the cancer is selected from pancreatic adenocarcinoma, colorectal cancer and non-small cell lung cancer.Another embodiment of present invention is (xxvii‘) the use of a compound according to any one of (F) to (xv’) or (i) to (xiii) for the treatment or prophylaxis of primary central nervous system (CNS) tumors harboring RAS mutations or RAS driven cancers with brain metastases; wherein the CNS tumor is primary melanocytic tumors of the CNS harboring NRAS mutation; wherein the cancer is selected from pancreatic adenocarcinoma, colorectal cancer, non-small cell lung cancer.Another embodiment of present invention is (xxviii‘) the use of a compound according to any one of (F) to (xv’) or (i) to (xiii) for the treatment or prophylaxis of primary central nervous system (CNS) tumors harboring RAS mutations or RAS driven cancers with brain metastases; wherein the CNS tumor is primary melanocytic tumors of the CNS harboring NRAS mutation; wherein the cancer is non-small cell lung cancer.Another embodiment of present invention is (xxix‘) a compound or pharmaceutically acceptable salt according to any one of (F) to (xv’) or (i) to (xiii) for the treatment or prophylaxis of KRAS mutation driven cancers, wherein the cancer is selected from pancreatic adenocarcinoma, colorectal cancer and non-small cell lung cancer.Another embodiment of present invention is (xxx‘) the use of a compound according to any one of (i’) to (xv‘) or (i) to (xiii) for the preparation of a medicament for the treatment or prophylaxis of KRAS mutation driven cancers, wherein the cancer is selected from pancreatic adenocarcinoma, colorectal cancer and non-small cell lung cancer.Another embodiment of present invention is (xxxi‘) a method for the treatment or prophylaxis of KRAS mutation driven cancers, wherein the cancer is selected from pancreatic adenocarcinoma, colorectal cancer and non-small cell lung cancer, which method comprises administering a therapeutically effective amount of a compound as defined in any one of (i’) to (xv‘) or (i) to (xiii).Another embodiment of present invention is (xxxii‘) a compound or pharmaceutically acceptable salt according to any one of (i‘) to (xv’) or (i) to (xiii), when manufactured according to a process of (xvi) or (xvi‘).
PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATION Another embodiment provides pharmaceutical compositions or medicaments containing the compounds of the invention and a therapeutically inert carrier, diluent or excipient, as well as methods of using the compounds of the invention to prepare such compositions and medicaments. In one example, compounds of formula (I) may be formulated by mixing at ambient temperature at the appropriate pH, and at the desired degree of purity, with physiologically acceptable carriers, i.e., carriers that are non-toxic to recipients at the dosages and concentrations employed into a galenical administration form. The pH of the formulation depends mainly on the particular use and the concentration of compound, but preferably ranges anywhere from about to about 8. In one example, a compound of formula (1) is formulated in an acetate buffer, at pH 5. In another embodiment, the compounds of formula (1) are sterile. The compound may be stored, for example, as a solid or amorphous composition, as a lyophilized formulation or as an aqueous solution.Compositions are formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The "effective amount " of the compound to be administered will be governed by such considerations, and is the minimum amount necessary to inhibit mutant RAS (e.g. KRAS G12C) interaction with RAF, blocking the oncogenic MAPK signaling. For example, such amount may be below the amount that is toxic to normal cells, or the mammal as a whole.In one example, the pharmaceutically effective amount of the compound of the invention administered parenterally per dose will be in the range of about 0.1 to 1000 mg/kg, alternatively about 0.1 to 1000 mg/kg of patient body weight per day, with the typical initial range of compound used being 0.3 to 15 mg/kg/day. In another embodiment, oral unit dosage forms, such as tablets and capsules, preferably contain from about 1 to about 1000 mg of the compound of the invention.The compounds of the invention may be administered by any suitable means, including oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intradermal, intrathecal and epidural and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.The compounds of the present invention may be administered in any convenient administrative form, e.g., tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc. Such compositions may contain components conventional in pharmaceutical preparations, e.g., diluents, carriers, pH modifiers, sweeteners, bulking agents, and further active agents.A typical formulation is prepared by mixing a compound of the present invention and a carrier or excipient. Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, e.g., Ansel, Howard C., et al., Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004; Gennaro, Alfonso R., et al. Remington: The Science and Practice of Pharmacy . Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe, Raymond C. Handbook of Pharmaceutical Excipients . Chicago, Pharmaceutical Press, 2005. The formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e., medicament).
An example of a suitable oral dosage form is a tablet containing about 1 to 1000 mg of the compound of the invention compounded with about 1 to 1000 mg anhydrous lactose, about 1 to 1000 mg sodium croscarmellose, about 1 to 1000 mg polyvinylpyrrolidone (PVP) K30, and about 1 to 1000 mg magnesium stearate. The powdered ingredients are first mixed together and then mixed with a solution of the PVP. The resulting composition can be dried, granulated, mixed with the magnesium stearate and compressed to tablet form using conventional equipment. An example of an aerosol formulation can be prepared by dissolving the compound, for example to 400mg, of the invention in a suitable buffer solution, e.g. a phosphate buffer, adding a tonicifier, e.g. a salt such sodium chloride, if desired. The solution may be filtered, e.g., using a 0.2 micron filter, to remove impurities and contaminants.An embodiment, therefore, includes a pharmaceutical composition comprising a compound of formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof. In a further embodiment includes a pharmaceutical composition comprising a compound of formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or excipient.Another embodiment includes a pharmaceutical composition comprising a compound of formula (I) for use in the treatment of mutant KRAS-driven cancers. Another embodiment includes a pharmaceutical composition comprising a compound of Formula (I) for use in the treatment of mutant KRAS-driven cancers.The following composition A and B illustrate typical compositions of the present invention, but serve merely as representative thereof.
Composition A A compound of the present invention can be used in a manner known per se as the active ingredient for the production of tablets of the following composition: 425 mg Per tabletActive ingredient 200 mgMicrocrystalline cellulose 155 mgCorn starch 25 mgTalc 25 mgHydroxypropylmethy ice llulo se 20 mg Composition B A compound of the present invention can be used in a manner known per se as the active ingredient for the production of capsules of the following composition: 220.0 mg Per capsuleActive ingredientCorn starch100.0 mg20.0 mgLactose 95.0 mgTalc 4.5 mgMagnesium stearate 0.5 mg INDICATIONS AND METHODS OF TREATMENT The compounds of the invention induce a new binding pocket in KRAS by driving formation of a high affinity tri-complex between KRAS protein and the widely expressed cyclophilin A (CYPA), which inhibit KRAS interaction with downstream effectors, such as RAF and PI3K. Accordingly, the compounds of the invention are useful for inhibiting the propagating oncogenic MAPK and PI3K signaling, reducing cell proliferation, in particular cancer cells. Compounds of the invention are useful for termination of RAS signaling in cells that express RAS mutant, e.g. KRAS mutation driven pancreatic cancer, colorectal cancer, lung cancer, esophageal cancer, gallbladder cancer, melanoma ovarian cancer, endometrial cancer, etc. Alternatively, compounds of the invention are useful for termination of RAS signaling in malignant solid tumor where the oncogenic role of KRAS mutation is reinforced by dysregulation or mutation of effector pathways as MAPK, PI3K-AKT-mTOR (Mammalian target of rapamycin) driven signaling, for targeted therapy in pancreatic adenocarcinoma, colorectal cancer, non-small cell lung cancer, etc.Another embodiment includes a method of treating or preventing cancer in a mammal in need of such treatment, wherein the method comprises administering to said mammal a therapeutically effective amount of a compound of formula (I), a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.
SYNTHESIS The compounds of the present invention can be prepared by any conventional means.Suitable processes for synthesizing these compounds as well as their starting materials are provided in the schemes below and in the examples. All substituents, in particular, R1, R2, M and L are as defined above unless otherwise indicated. Furthermore, and unless explicitly otherwise stated, all reactions, reaction conditions, abbreviations and symbols have the meanings well known to a person of ordinary skill in organic chemistry.General synthetic routes for preparing the compound of formula (1) or (la) are shown below.
Scheme 1 Intermediate B to V. Compound of formula (1b)can be obtained by a coupling reaction between acid (III)and compound of formula (11b)with coupling reagent(s), such as T3P, HATU, PyBOP and EDCI/HOBt, in the presence of a base, such as TEA, DIEP A and DMAP.Compounds of this invention can be obtained as mixtures of diastereomers or enantiomers, which can be separated by methods well known in the art, e.g. (chiral) HPLC or SEC. In another embodiment, compound of formula (la)and (Ic)can be obtained according to above scheme by using corresponding chiral starting materials.This invention also relates to a process for the preparation of a compound of formula (I), (la), (lb) and (Ic) comprising following step:a) coupling reaction between compound of formula (IIb), (11b), and acid (III), (III),in the presence of a coupling reagent and a base to form the compound of formula (lb); wherein in step a) the coupling reagent can be, for example, T3P, HATU, PyBOP or EDCI/HOBt; the base can be, for example, TEA, DIEP A or DMAP.A compound of formula (I), (la), (lb) and (Ic) when manufactured according to the above process is also an object of the invention.
EXAMPLES The invention will be more folly understood by reference to the following examples. They should not, however, be construed as limiting the scope of the invention. ABBREVIATIONS The invention will be more folly understood by reference to the following examples. They should not, however, be construed as limiting the scope of the invention.Abbreviations used herein are as follows:ACN acetonitrileaq. AqueousAd 2nBuP-Pd-G 3 [(Di( 1 -adamantyl)-butylphosphine)-2-(2'-amino- 1,1'- biphenyl)] palladium(!!) methanesulfonate(Boc)2O (A)-binap CDC13: Di-tert-butyldicarbonate(7?)-(+)-2,2'-Bis(diphenylphosphino)- 1,1 '-binaphthyl deuterated chloroformCui copper(I) iodideDIEPA: N, A-diethylpropylamineDMAP: 4-Dimethylaminopyridine EDCI:EtOAc or EA:N-Ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride ethyl acetateFRET fluorescence resonance energy transferHATU: (1 - [Bis(dimethylamino)methylene] -1 TA 1,2,3-biazolo [4,5 -b]pyridinium 3-oxid hexafluorophosphate)hr(s): hour(s)HPLC: high performance liquid chromatographyHOBt: A-hydroxybcnzotriazolcLDA: Lithium diisopropylamideMS: (ESI): mass spectroscopy (electron spray ionization)min(s) minute(s)MTBE Methyl te/Abutyl etherNMI 1 -Methylimidazo leNMM A-Methylmorpho lineNBS A-Bromo succinimideNIS A-iodosuccinimideNMR: nuclear magnetic resonanceobsd. ObservedPd(dppf)C12 [1,1 ׳-Bis(diphenylphosphino)ferrocene] dichloropalladium(II)Pd(dtbpf)Cl 2 [1,1 ׳-Bis(di-tert-butylphosphino)ferrocene] dichloropalladium(II)prep-HPLC preparative high performance liquid chromatographyPyBOP: benzotriazol- 1 -yloxytripyrrolidinophosphoniumhexafluoropho sphateRT or rt: room temperaturesat. saturatedSelectfluor 1 -Chloromethyl-4-fluoro-1 ,4-diazoniabicyclo[2.2.2]octanebis(tetrafluoroborate)SFC: supercritical fluid chromatographyTCFH: [chloro(dimethylamino)methylene]-dimethyl-ammonium;hexafluorophosphateTEA: triethylamineTFA: trifluoroacetic acidT3P: propylphosphonic anhydride GENERAL EXPERIMENTAL CONDITIONS Intermediates and final compounds were purified by flash chromatography using one of the following instruments: i) Biotage SP1 system and the Quad 12/25 Cartridge module, ii) ISCO combi-flash chromatography instrument. Silica gel brand and pore size: i) KP-SIL 60 A, particle size: 40-60 pm; ii) CAS registry NO: Silica Gel: 63231-67-4, particle size: 47-60 micron silica gel; iii) ZCX from Qingdao Haiyang Chemical Co., Ltd, pore: 200-300 or 300-400.Intermediates and final compounds were purified by preparative HPLC on reversed phase column using XBridge™ Prep-C18 (5 pm, OBDTM 30 x 100 mm) column, SunFire™ Prep-C(5 pm, OBD™ 30 x !00 mm) column, Phenomenex Synergi-C18 (10 pm, 25 x !50 mm) or Phenomenex Gemini-C18 (10 pm, 25 x 150 mm). Waters AutoP purification System (Sample Manager 2767, Pump 2525, Detector: Micromass ZQ and UV 2487, solvent system: acetonitrile and 0.1% ammonium hydroxide in water; acetonitrile and 0.1% FA in water or acetonitrile and 0.1% TFA in water). Or Gilson-281 purification System (Pump 322, Detector: UV 156, solvent system: acetonitrile and 0.05% ammonium hydroxide in water; acetonitrile and 0.225% FA in water; acetonitrile and 0.05% HC1 in water; acetonitrile and 0.075% TFA in water; or acetonitrile and water).For SFC chiral separation, intermediates were separated by chiral column (Daicel chiralpak IC, 5 pm, 30 x250 mm), AS (10 pm, 30 x250 mm) or AD (10 pm, 30 x250 mm) using Mettler Toledo Multigram III system SFC, Waters 80Q preparative SFC or Thar 80 preparative SFC, solvent system: CO2 and IP A (0.5% TEA in IP A) or CO2 and MeOH (0.1% NHJH,O in MeOH), back pressure lOObar, detection UV@ 254 or 220 nm.LC/MS spectra of compounds were obtained using a LC/MS (Waters™ Alliance 2795- Micromass ZQ, Shimadzu Alliance 2020-Micromass ZQ or Agilent Alliance 6110-Micromass ZQ), LC/MS conditions were as follows (running time 3 or 1.5 mins):Acidic condition 1: A: 0.1% TFA in HO; B: 0.1% TFA in acetonitrile;Acidic condition II: A: 0.0375% TFA in HO; B: 0.01875% TFA in acetonitrile;Basic condition 1: A: 0.1% NH3 H20 in HO; B: acetonitrile;Basic condition II: A: 0.025% NH3 H20 in H,O; B: acetonitrile;Neutral condition: A: H2O; B: acetonitrile.Mass spectra (MS): generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion (MH)+.NMR Spectra were obtained using Bruker Avance 400 MHz or 500MHz.
The microwave assisted reactions were carried out in a Biotage Initiator Sixty microwave synthesizer. All reactions involving air-sensitive reagents were performed under an argon or nitrogen atmosphere. Reagents were used as received from commercial suppliers without further purification unless otherwise noted.
PREPARATIVE EXAMPLES The following examples are intended to illustrate the meaning of the present invention but should by no means represent a limitation within the meaning of the present invention: Preparation of Intermediate Intermediate B Methyl (3S)-l-[(2S)-3-(4-bromothiazol-2-yl)-2-(tert- butoxycarbonylamino)propanoyl]hexahydropyridazine-3-carboxylate The intermediate B was prepared according to the following scheme: N. ,Br B8 Intermediate B Step 1: Preparation of (4-bromothiazol-2-yl)methanol (compound B2) To a solution of 4-bromothiazole-2-carboxaldehyde (compound Bl،6.0 g, 31.25 mmol) in methanol (70 mL) was added sodium borohydride (1.7 g, 46.87 mmol) at 0 The mixturewas stirred at 25 for 1 hour. The reaction was quenched with water (300 mL) at 0 and the reaction mixture was extracted by ethyl acetate (200 mL, three times). The combined organic phase was washed with brine (150 mL, twice), dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under vacuum to afford (4-bromothiazol-2-yl)methanol (compound B2,6g) as colorless oil. Step 2: Preparation of 4-bromo-2-(bromomethyl)thiazole (compound B3) To a solution of (4-bromothiazol-2-yl)methanol (compound B2,6.0 g, 30.92 mmol) in DCM (80 mL) was added CBr4 (15.4 g, 46.38 mmol) and triphenylphosphine (12.1 g, 46.mmol) at 0 CC. After being stirred at 25 for 1 hour, the mixture was filtered and the filtrate was concentrated under vacuum. The residue was purified by silica gel column, eluted with ethyl acetate in petroleum ether (0—10%) to afford 4-bromo-2-(bromomethyl)thiazole (compound B3, 6.0 g) as yellow oil. MS calc ’d 255.9 (MH+), measured 255.9 (MH+). Step 3: Preparation of4-bromo-2-II(2S,5R)-5-isopropyl-3,6-dimethoxy-2,5- dihydropyrazin-2-yl] methyl] thiazole (compound B5) To a mixture of (27?)-2-isopropyl-3,6-dimethoxy-2,5-dihydropyrazine (compound B4, 4.3 g, 23.45 mmol) in THF (60 mL) was added n-butyllithium (10 mL, 25.22 mmol, 2.5 M) at -slowly. After addition, the mixture was stirred for 0.5 hour at -78 ،C. 4-bromo-2- (bromomethyl)thiazole (compound B3, 5.4 g, 21.02 mmol) was added into above mixture at - which was stirred for another 1 hour. The reaction was quenched with saturated solution of NH4C1 (100 mL) and the reaction mixture was extracted with EtOAc (100 mL, twice). The combined organic layer was washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under vacuum. The residue was purified by reversed- phase chromatography to afford 4-bromo-2-[[(2 lS',57?)-5-isopropyl-3,6-dimethoxy-2,5- dihydropyrazin-2-yl]methyl]thiazole (compound B5, 3.6 g) as yellow oil. MS calc ’d 360 (MH+), measured 359.9 (MH+). Step 4: Preparation of methyl (25)-2-amino-3-(4-bromothiazol-2-yl)propanoate (compound B6) To a solution of 4-bromo-2-[[(2 lS',57?)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazm-2- yl]methyl]thiazole (compound B5,3.6 g, 10 mmol) in ACN (20 mL) was added hydrochloric acid (66.6 mL, 0.3 M). The mixture was stirred at 25 for 2 hours. The mixture was basified by saturated solution of NaHCO3 until pH=8. The mixture was extracted with EtOAc (80 mL, six times). The combined organic layer was dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under vacuum to afford methyl (2S)-2-amino-3-(4-bromothiazol-2- yl)propanoate (compound B6,3.1 g) as yellow oil. MS calc ’d 264.9 (MH+), measured 264.(MH+). Step 5: Preparation of methyl (2S)-3-(4-bromothiazol-2-yl)-2-(tert- butoxycarbonylamino)propanoate (compound B7) To a solution of methyl (2S)-2-amino-3-(4-bromothiazol-2-yl)propanoate (compound B6, 3.1 g, 11.69 mmol) in DCM (40 mL) were added TEA (2.9 g, 29.23 mmol) and (Boc)2O (3.8 g, 17.54 mmol). After being stirred at 30 for 12 hours, the mixture was concentrated under vacuum. The residue was purified by silica gel column, eluted with ethyl acetate in petroleum ether (0~30%) to afford methyl (2S)-3-(4-bromothiazol-2-yl)-2-(/ert- butoxycarbonylamino )propanoate (compound B7,3.2 g) as yellow oil. MS calc ’d 387(MNa+), measured 386.9 (MNa+). Step 6: Preparation of (2lS)-3-(4-bromothiazol-2-yl)-2-(te/7-butoxycarbonylamino)- propanoic acid (compound B8) To a solution of methyl (2S)-3-(4-bromothiazol-2-yl)-2-(tert- butoxycarbonylamino )propanoate (compound B7,3.2 g, 8.76 mmol) in THF (30 mL), methanol (2 mL) and water (10 mL) was added lithium hydroxide (0.4 mL, 43.81 mmol). After being stirred at 25 for 1 hour, the reaction mixture was acidified by 1 M solution of HCI until pH=5. The mixture was extracted with EtOAc (40 mL, twice). The combined organic layer was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under vacuum to afford (2S)-3-(4-bromothiazol-2-yl)-2-(te7y- butoxycarbonylamino )propanoic acid (compound B8,3.1 g) as yellow oil. MS calc ’d 373(MNa+), measured 372.9 (MNa+). Step 7: Preparation of methyl (35)-l-[(2lS)-3-(4-bromothiazol-2-yl)-2-(tert- butoxycarbonylamino)propanoyl]hexahydropyridazine-3-carboxylate (Intermediate B) To a solution of (25)-3-(4-bromothiazol-2-yl)-2-(terLbutoxycarbonylamino)propanoic acid (compound B8,3.1 g, 8.83 mmol) in DCM (50 mL) was added methyl (3S)- hexahydropyridazine-3-carboxylate;hydrochloride (compound B9,2.4 g, 13.24 mmol), EDCI (3.4 g, 17.65 mmol), 1-Hydroxybenzotriazole (238.5 mg, 1.77 mmol) and NMM (9.92 mL, 88.mmol) at 0 TS. After being stirred at 25 TS for 1 hour, the reaction mixture was diluted with water (60 mL) and extracted with EtOAc (60 mL, three times). The combined organic layer was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under vacuum. The residue was purified by silica gel column and eluted with ethyl acetate in petroleum ether (10-30%) to afford methyl (3S)-l-[(2S)-3-(4-bromothiazol-2-yl)-2- (terLbutoxycarbonylamino)propanoyl]hexahydropyridazine-3-carboxylate (intermediate B, 2.g). MS calc ’d 477(MH+), measured 476.9 (MH+).
Intermediate Cl Benzyl 4-[5-ethynyl-6-[(l.S)-l-methoxyethyl]-3-pyridyl]piperazine-l-carboxylate Cbz The compound Clwas prepared according to the following scheme: TMS A3 A5 Pd(PPh3)2CI2, Cui, TEA,DMF, 100 °C KF, MeOH Step 1: Preparation of benzyl 4-[5-bromo-6-[(lS)-l-methoxyethyl]-3- pyridyl] piperazine-1-carboxylate (compound A5) To a solution of 3-bromo-5-iodo-2-[(lS)-l-methoxyethyl]pyridine (compound A3,660 mg, 1.9 mmol, CAS 2641451-76-3, PBWZ170, PharmaBlock (Nanjing) R&D Co. Ltd) and l-Cbz- piperazine (compound A4,425.1 mg, 1.9 mmol) in toluene (10 mL) were added cesiumcarbonate (1.6 g, 4.83 mmol), (/?)-BINAP (60.1 mg, 0.1 mmol) and palladium (II) acetate (43.mg, 0.19 mmol). After being stirred at 100 ،C for 12 hrs under N2 protection, the mixture was filtered and then the filtrate was concentrated under vacuum. The residue was purified by silica gel chromatography (EA/PE: 0-50%) to afford benzyl 4-[5-bromo-6-[(15)-l-methoxyethyl]-3- pyridyl]piperazine-l-carboxylate (compound A5,740 mg) as a yellow solid. MS cak ’d 434.(MH+), measured 434.1 (MH+). Step 2: Preparation of benzyl 4-[6-[(LS)-l-methoxyethyl]-5-(2-trimethylsilylethynyl)-3- pyridyl]piperazine-l-carboxylate (compound Cl-a) To a solution of benzyl 4-[5-bromo-6-[(l>S)-l-methoxyethyl]-3-pyridyl]piperazine-l- carboxylate (compound A5,33.0 g, 75.98 mmol) in DMF (I L) was added trimethylsilylacetylene (85.9 mL, 607.83 mmol), Pd(PPh3)2C12 (5.3 g, 7.6 mmol), Cui (1.5 g, 7.mmol) and TEA (52.9 mL, 379.9 mmol) under a nitrogen atmosphere. The reaction mixture was degassed with nitrogen for three times and then it was stirred at 100 ° for 12 hrs. After the reaction was completed, the reaction mixture was cooled to room temperature, filtered and the filtrate was added with H2O (3 L). The reaction mixture was extracted with EtOAc (IL, three times). The combined organic layer was washed with brine (3 L), dried over Na2SO4, fdtered and concentrated under vacuum to give a residue, which was purified by column chromatography to afford benzyl 4-[6-[(l،S)-l-methoxyethyl]-5-(2-trimethylsilylethynyl)-3-pyridyl]piperazine-l- carboxylate (compound Cl-a,21.0 g) as a yellow solid. MS cak ’d 452.2 (MH+), measured 452.(MH+). Step 3: Preparation of benzyl 4-[5-ethynyl-6-[(LS)-l-methoxyethyl]-3- pyridyl]piperazine-l-carboxylate (intermediate Cl) To a solution of benzyl 4-[6-[(l،S)-l-methoxyethyl]-5-(2-trimethylsilylethynyl)-3- pyridyl]piperazine-l-carboxylate (compound Cl-a,31g, 68.6 mmol) in Methanol (500 mL) was added potassium fluoride (8.1 g, 139.8 mmol) at 0 The mixture was stirred at 20 for 1 h. After the reaction was completed, the reaction mixture was concentrated under vacuum to give a residue, which was purified by column chromatography to afford benzyl 4-[5-ethynyl-6-[( 15)-1 - methoxyethyl]-3-pyridyl]piperazine-l-carboxylate (intermediate Cl,25 g) as a brown solid. MS cak ’d 380.2 (MH+), measured 380.2 (MH+).
Intermediate C2 4-[5-ethynyl-6-[(lS)-l-methoxyethyl]-3-pyridyl] morpholine The title compound was prepared in analogy to the preparation of Intermediate Clby using morpholine instead of 1-Cbz-piperazine (compound A4).
Intermediate C3 l-[5-ethynyl-6-[(15)-l-methoxyethyl]-3-pyridyl]-4-(2,2,2-trifluoroethyl)piperazine The title compound was prepared in analogy to the preparation of Intermediate Clby using l-(2,2,2-trifluoroethyl)piperazine instead of 1-Cbz-piperazine (compound A4).
Intermediate C4 (9tir1S)-8-[5-ethynyl-6-[(lS)-l-methoxyethyl]-3-pyridyl]-3,4,6,7,9,9«-hexahydro-lJT- pyrazino[2,l-c][l,4]oxazine The title compound was prepared in analogy to the preparation of Intermediate Cl by using (9aS)-1,3,4,6,7,8,9,9<2-octahydropyrazino[2,l-c][l,4]oxazine instead of 1-Cbz-piperazine (compound A4).
Intermediate C5 (9tirl?)-2-[5-ethynyl-6-[(15)-l-methoxyethyl]-3-pyridyl]-l,3,4,6,7,8,9,9«-octahydropyrido[l,2- a] pyrazine O The title compound was prepared in analogy to the preparation of Intermediate Clby using (9aR)-2,3,4,6,7,8,9,9<3-octahydro-177-pyrido[l,2-a]pyrazine instead of 1-Cbz-piperazine (compound A4).
Intermediate DI 6-bromo-8-iodo-l,2,3,4-tetrahydroquinoline ...65 The compound was prepared according to the following scheme:|_| |NBS I [J DMF BrAAJ Dl-a DiTo a solution of 6-bromo- 1,2,3,4-tetrahydroquinoline (compound Dl-a,40.0 g, 188.mmol) in DMF (1.3 L) was added NIS (42.4 g, 188.6 mmol) portion-wise at 0 TF. After being stirred for 2 h at 25 TF, the reaction mixture was poured into water (4 L) and extracted with EtOAc (2 L, three times). The combined organic layer was washed with brine (2 L, three times), dried with anhydrous Na2S04, filtered and concentrated under vacuum to give a residue. Theresidue was purified by reversed phase chromatography to give 6-bromo-8-iodo-l,2,3,4- tetrahydroquinoline (Intermediate D1,37 g) as a brown gum. MS cak ’d 337.9 (MH ), measured 338.0 (MH+).
Intermediate D2 7-bromo-5-iodo-3,4-dihydro-2Z/-l,4-benzoxazine The compound was prepared according to the following scheme: Brp-toluenesulfonyl chlorideTEA.DCMsilver sulfatel2, EtOH Br NH2 D2-C D2-a D2-b D2-d D2-e D2 Step 1: Preparation of (2-amino-5-bromo-phenyl) 4-methylbenzenesulfonate (compound D2-b) To a solution of 2-amino-5-bromophenol (compound D2-a,75.0 g, 398.89 mmol) and TEA (66.7 mL, 478.67 mmol) in DCM (1.5 L) was added p-toluenesulfonyl chloride (83.6 g, 438.mmol). After being stirred at 25 for 1 h, the reaction was quenched with sat. NaHCO3 aq. (400 mL) and EtOAc (500 mL, three times). The organic layer was washed with brine (200 mL), dried over Na2SO4, filtered and concentrated under vacuum to afford crude (2-amino-5-bromo- phenyl) 4-methylbenzenesulfonate (compound D2-b,146.5 g) as a dark brown solid, which was used in the next step without purification. MS calc ’d 342 (MH+), measured 342 (MH+). Step 2: Preparation of (2-amino-5-bromo-3-iodo-phenyl) 4-methylbenzenesulfonate (compound D2-c) To a solution of (2-amino-5-bromo-phenyl) 4-methylbenzenesulfonate (compound D2-b, 146.5 g, 428.1 mmol) in ethanol (1.5 L) was added silver sulfate (133.5 g, 428.1 mmol) and iodine (108.7 g, 428.1 mmol). After being stirred at 25 for 12 hrs, the reaction was quenched by sat. NaHCO3 aq. (400 mL) and EtOAc (500 mL, three times). The organic layer was washed with brine (200 mL), dried over Na2S04, filtered and concentrated under vacuum to afford (2- amino-5-bromo-3-iodo-phenyl) 4-methylbenzenesulfonate (compound D2-c,210.0 g) as a dark brown solid, which was used directly in the next step without purification. MS cak ’d 467.(MH+), measured 467.8 (MH+). Step 3: Preparation of 2-amino-5-bromo-3-iodo-phenol (compound D2-d) To a solution of (2-amino-5-bromo-3-iodo-phenyl) 4-methylbenzenesulfonate (compound D2-c,210.0 g, 448.62 mmol) in ethanol (1.5 L) and THF (500 mL) was added sodium hydroxide (62.8 g, 1570.18 mmol). The mixture was heated to reflux for l h. After being cooled to room temperature, the reaction mixture was concentrated under vacuum to give a residue. The residue was neutralized until pH = 7 by using 6 N HCI and extracted with EtOAc (IL, twice). The organic layer was dried with Na2SO4, filtered and concentrated under vacuum to give a residue. The crude product was purified by column chromatography to afford 2-amino-5-bromo-3-iodo- phenol (compound D2-d,120.0 g) as a dark brown solid. MS cak ’d 313.9 (MH+), measured 313.9 (MH+). Step 4: Preparation of 7-bromo-5-iodo-4Z7-l,4-benzoxazin-3-one (compound D2-e) To a solution of 2-amino-5-bromo-3-iodo-phenol (compound D2-d,50.0 g, 159.28 mmol) and potassium carbonate (33.0 g, 238.91 mmol) in DMF (2 L) was added chloro acetyl chloride (19.0 mL, 238.91 mmol). After being stirred at 25 for 12 hrs, the reaction mixture was concentrated under vacuum to give a residue. The residue was poured into H2O (I L), and extracted with EtOAc (1 L, three times). The organic layer was washed with brine (1.5 L, twice), dried over Na2SO4, filtered and concentrated under vacuum to give a residue. The crude product was triturated with MTBE (100 mL) at 25 TF for 30 min. The suspension was filtered, the collected solid was collected to afford 7-bromo-5-iodo-4//-l,4-benzoxazin-3-one (compound D2-e,175.0 g) as a dark brown solid. MS cak ’d 353.9 (MH+), measured 353.9 (MH+). Step 5: Preparation of 7-bromo-5-iodo-3,4-dihydro-277-l,4-benzoxazine (Intermediate D2) To a stirred solution of 7-bromo-5-iodo-477-l,4-benzoxazin-3-one (compound D2-e,20.0 g, 56.51 mmol) in THF (500 mL) under N2 atmosphere was added borane tetrahydro furan complex solution (113.0 mL, 113.01 mmol) at 0؟F. After being stirred at 80 for 1 h, the mixture was cooled to room temperature, and then follow by addition of MeOH (100 mL). The mixture was poured into H2O (100 mL), extracted with EtOAc (200 mL, three times). The organic layer was washed with brine (100 mL, twice), dried over Na2SO4, filtered and concentrated under vacuum to give a residue. The crude product was purified by column chromatography to afford 7-bromo- 5-iodo-3,4-dihydro-2H-l,4-benzoxazine (intermediate D2,17.6 g) as a pink solid. MS cak ’d 340.0 (MH+), measured 340.0(MH+). 1H NMR (400 MHz, DMSO-d) ،5 = 7.31 (d, J= 2.4 Hz, 1H), 6.88 (d, J= 2.4 Hz, 1H), 5.42 (br s, 1H), 4.07 (t, J= 4.4 Hz, 2H), 3.38 - 3.33 (m, 2H).
Intermediate D3 6-bromo-3,3-difluoro-8-iodo-2,4-dihydro-lZ7-quinoline The compound was prepared according to the following scheme: Step 1: Preparation of3,3-difluoro-1H-quinoline-2,4-dione (compound D3-b) To a solution of 177-quinoline-2,4-dione (compound D3-a,8.0 g, 49.64 mmol) and potassium carbonate (13.7 g, 99.28 mmol) in ACN (160 mL) and water (80 mL) was added Selectfluor (40.0 g, 112.91 mmol) at 0 After being stirred at 25 for 1 h, the reaction mixture was concentrated in vacuo and the residue was filtered. The filtrate was added to water (1 L). The resultant mixture was extracted with EtOAc (400 mL, three times). The combined organic layer was washed with brine (400 mL, twice), dried over Na2SO4, filtered and concentrated in vacuo to afford 3,3-difluoro-177-quinoline-2,4-dione (compound D3-b,46.0 g) as a yellow solid. 1H NMR (400 MHz, CHLOROFORM-d) 3 = 9.77 (s, 1H), 8.22 - 7.94 (m, 1H), 7.81 - 7.64 (m, 1H), 7.33 - 7.28 (m, 1H), 7.17 (d, J= 8.0 Hz, 1H). Step 2: Preparation of3,3-difluoro-2,4-dihydro-1H-quinolin-4-ol (compound D3-c) To a solution of 3,3-difluoro-177-quinoline-2,4-dione (compound D3-b,69.0 g, 350.mmol) in THF (700 mL) was added borane-tetrahydrofuran complex (700.0 mL, 700.0 mmol) at CC. After being stirred at 25 %' for 16 hrs, the reaction was quenched with MeOH (500 mL) at 0 ،C dropwise, and then concentrated in vacuo to afford 3,3-difluoro-2,4-dihydro-lH-quinolin-4- (compound D3-C, 64.8 g) as yellow oil. MS calc ’d 185.1 (MH+), measured 168.0, (M-0H+H+). Step 3: Preparation of 3,3-difluoro-2,4-dihydro-lZ7-quinoline (compound D3-d) To a solution of 3,3-difluoro-2,4-dihydro-177-quinolin-4-ol (compound D3-C,64.8 g, 349.mmol) in EtzSiH (206.8 mL, 1.29 mol) was added TFA (405.4 mL, 5.26 mol) at 0 ،C. After being stirred at 25 for 16 hrs, the reaction mixture was concentrated in vacuo and adjusted to pH=8 by adding sat. NaHCOg aq., extracted with EtOAc (1 L, twice). The combined organic layer was washed by brine (1.6 L), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to give a residue, which was purified by silica gel column chromatography to afford 3,3-difluoro-2,4-dihydro-177-quinoline (compound D3-d,45.0 g) as a yellow solid. MS calc ’d 170.1 (MH+), measured 170.0 (MH+). Step 4: Preparation of 6-bromo-3,3-difluoro-2,4-dihydro-l/7-quinoline (compound D3- e) To a solution of 3,3-difluoro-2,4-dihydro-177-quinoline (compound D3-d,50.0 g, 295.mmol) in DMF (800 mL) was added NBS (50.0 g, 280.92 mmol) at 0 After being stirred at for 1 h, the mixture was poured into water (1200 mL) and the resulting mixture was extracted with EtOAc (800 mL, three times). The combined organic layer was washed with brine (IL, three times), dried over Na2S04, filtered and concentrated in vacuo, which was purified by column chromatography to afford 6-bromo-3,3-difluoro-2,4-dihydro-177-quinoline (compound D3-e,57.0 g) as a yellow solid. MS calc ’d 248.0 (MH+), measured 247.9 (MH+). Step 5: Preparation of 6-bromo-3,3-difluoro-8-iodo-2,4-dihydro-LH-quinoline (Intermediate D3) To a solution of 6-bromo-3,3-difluoro-2,4-dihydro-177-quinoline (compound D3-e,49.0 g, 197.52 mmol) in DMF (700 mL) was added NIS (48.9 g, 217.28 mmol) at 0 After being stirred at 0 ؟ for 5 hrs, the reaction mixture was poured into water (1.2 L) and the resultant mixture was extracted with EtOAc (650 mL, three times). The combined organic layer was washed with brine (1000 mL, three times), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography to afford 6-bromo-3,3-difluoro-8-iodo-2,4- dihydro-1H-quinoline (intermediate D3,68.0 g) as a white solid. MS calc ’d 373.9 (MH ), measured 373.9 (MH+).
Intermediate D4 7-bromo-5-iodo-2,2-dimethyl-3,4-dihydro-l,4-benzoxazine The title compound was prepared in analogy to the preparation of Intermediate D2by using ethyl 2-bromo-2-methyl-propanoate instead of chloroacetyl chloride.
Intermediate D5 7-bromo-5-iodo-3-methyl-3,4-dihydro-2/7-l,4-benzoxazine The compound was prepared according to the following scheme: OH D2-d Actone, K2CO3 D5-a NaBH3CN TFA D5 Step 1: Preparation of 7-bromo-5-iodo-3-methyl-2H-1,4-benzoxazine (compound D5-a) To a solution of 2-amino-5-bromo-3-iodo-phenol (compound D2-d,18 g, 57.34 mmol) in acetone (300 mL) was added potassium carbonate (15.8 g, 114.68 mmol) and chloroacetone (10.6 g, 114.68 mmol). After being stirred at 25 CCfor 18 hrs, the reaction mixture was poured into EtOAc (200 mL)/water (400 mL), and layers were separated. The aqueous phase was extracted with EtOAc (200 mL, twice). The combined organic layer was washed with brine (3mL), dried over Na2S04, filtered, and concentrated under vacuum to give a residue. The residue was purified by flash chromatography to give 7-bromo-5-iodo-3-methyl- 2/7-1,4-benzoxazine (compound D5-a,20 g) as light brown solid. MS cak ’d 351.9 (MH), measured 351.9 (MH+). Step 2: Preparation of 7-bromo-5-iodo-3-methyl-3,4-dihydro-2/7-l,4-benzoxazine (Intermediate D5) To a solution of 7-bromo-5-iodo-3-methyl-2/7-l,4-benzoxazine (compound D5-a,20.0 g, mmol) in TFA (1 L, 12.98 mmol) was added sodium cyanoborohydride (17 g, 270 mmol) and then stirred at 25 for 2 hrs. The mixture was slowly added to NaOH aq. (150 mL, 2M) and then extracted with EtOAc (100 mL, twice). The organic layer was washed with water, brine, dried over sodium sulfate, filtered, concentrated under vacuum to give a residue. The residue was purified by silica gel chromatography to afford 7-bromo-5-iodo-3-methyl-3,4-dihydro-27T-l,4- benzoxazine (Intermediate D5,14.6 g) as brown thick oil. MS calc ’d 353.9 (MH+), measured 353.9 (MH+).
Intermediate D6 6-bromo-8-iodo-3,3-dimethyl-2,4-dihydro-lZ7-quinoline The title compound was prepared in analogy to the preparation of Intermediate D1by using 6-bromo-3,3-dimethyl-2,4-dihydro-l//-quinoline instead of 6-bromo-l,2,3,4- tetrahydroquinoline (compound Dl-a).
Intermediate D7 8-bromo-6-iodo-2,3,4,5-tetrahydro-l,5-benzoxazepine I H The compound was prepared according to the following scheme: D2-d D7-b Step 1: Preparation of 4-bromo-2-[2-(l,3-dioxolan-2-yl)ethoxy]-6-iodo-aniline (compound D7-b). To a solution of 2-amino-5-bromo-3-iodo-phenol (compound D2-d,3.5 g, 11.05 mmol) in anhydrous DMF (80 mL) at 25 was added 2-(2-bromoethyl)-1,3-dioxo lane (compound D7-a, 4.0 g, 22.11 mmol) and K2CO3 (4.6 g, 33.16 mmol). After being stirred at 25 for 15 hrs, the reaction mixture was poured into EtOAc (100 mE)/water (100 mL), and layers were separated. The aqueous phase was extracted with EtOAc (100 mL, twice). The combined organic layer was washed with brine (100 mL), dried over Na2S04, filtered, and concentrated under vacuum to give K2CO3, DMF TFA, Et3SiH a residue. The residue was purified by flash chromatography to afford 4-bromo-2-[2-(l,3- dioxolan-2-yl)ethoxy]-6-iodo-aniline (compound D7-b,3.3 g) as a yellow solid. MS calc ’d 414.(MH+), measured 414.0 (MH+). Step 2: Preparation of 8-bromo-6-iodo-2,3,4,5-tetrahydro-l,5-benzoxazepine (intermediate D7). To a solution of 4-bromo-2-[2-(l,3-dioxolan-2-yl)ethoxy]-6-iodo-aniline (compound D7-b, 3.3 g, 7.97 mmol) in DCM (24 mL) al 0 was added TFA (6.0 mL) via a syringe dropwise over 1 min under nitrogen atmosphere. After being stirred at 25 for 60 min, the reaction mixture was added with triethylsilane (4.63 g, 39.78 mmol) and stirred at 25 for another hrs. After the reaction completed, the mixture was concentrated under vacuum to get a residue. The residue was diluted with sat. NaHCO3 aq. (50 mL) and extracted with EtOAc (20 mL, three times). The combined organic layer was washed by brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to give a residue, which was purified by column chromatography to afford 8-bromo-6-iodo-2,3,4,5-tetrahydro-l,5-benzoxazepine (intermediate D7,1.98 g) as brown oil. MS calc ’d 353.9 (MH+), measured 354.0 (MH+).
Intermediate D9 6-bromo-8-iodo-l,2,3,4-tetrahydroquinolin-3-ol The title compound was prepared in analogy to the preparation of Intermediate D3by using l,2,3,4-tetrahydroquinolin-3-ol instead of 3,3-difluoro-2,4-dihydro-l/7-quinoline (compound D3-d).
Intermediate D10 6-bromo-5-fluoro-8-iodo-l,2,3,4-tetrahydroquinoline The compound was prepared according to the following scheme: Step 1: Preparation of methyl (£)-3-(2-fluoro-6-nitro-phenyl)prop-2-enoate (compound DIO-b). To a mixture of 2-bromo-l-fluoro-3-nitro-benzene (compound DIO-a,14.2 g, 64.55 mmol) and methyl acrylate (9 g, 104.31 mmol) in NMP (150 mL) was added N,N- dicyclohexylmethylamine (37.8 g, 193.64 mmol), tetrabutylammonium chloride (1.8 g, 6.mmol) and Pd(dtbpf)C12 (4.21 g, 6.45 mmol) in one portion. The mixture was purged under vacuum and degassed with nitrogen for 3 times before stirred at 80 Tf for 12 hrs. After the reaction completed, the reaction mixture was cooled to rt and poured into water (300 mL). The mixture was extracted with EtOAc (100 mL, three times). The combined organic layer was washed with brine (100 mL), dried over anhydrous Na2S04, filtered and concentrated under vacuum to get a residue. The residue was purified by column chromatography (PE:EtOAc = 1:to 3:1) to afford methyl (E)-3-(2-fluoro-6-nitro-phenyl)prop-2-enoate (compound DIO-b,6-21 g) as a yellow solid. ,H NMR (400 MHz, CHLOROFORM-d) 8 = 7.80 (d, J= 8.0 Hz, 1H), 7.72 (d, J= 16.4 Hz, 1H), 7.50 (dt, J =5.2, 8.4 Hz, 1H), 7.46 - 7.39 (m, 1H), 6.54 (dd, J= 2.0, 16.4 Hz, 1H), 3.85 (s, 3H). Step 2: Preparation of 5-fluoro-3,4-dihydro-lZ7-quinolin-2-one (compound DIO-c). To a mixture of methyl (£)-3-(2-fluoro-6-nitro-phenyl)prop-2-enoate (compound DIO-b, 6.0 g, 26.65 mmol) in methanol (60 mL) was added Pd on activated carbon (2.8 g, 2.66 mmol) under Ar atmosphere. The reaction mixture was degassed and purged with Ar for 3 times before degassed and purged with hydrogen for 3 times. The mixture was stirred at 60 under hydrogen atmosphere (15 Psi) for 16 hrs. After the reaction completed, the mixture was filtered and the filtrate was concentrated under vacuum to afford 5-fluoro-3,4-dihydro-l//-quinolin-2- one (compound D10-C,4.37 g) as an off-white solid. MS calc ’d 166.1 (MH+), measured 166.(MH+). Step 3: Preparation of 5-fluoro-l,2,3,4-tetrahydroquinoline (compound DIO-d). To a solution of 5-fluoro-3,4-dihydro-177-quinolin-2-one (compound D10-C,4.0 g, 24.mmol) in THF (80 mL) was added borane-tetrahydrofuran complex (48 mL, 48.44 mmol, 1 M) slowly at 0 under nitrogen atmosphere. After being stirred at 25 for 12 hrs, the reaction was quenched by addition of MeOH (100 mL) drop wise at 0 and stirred for 30 min. Then the mixture was concentrated under vacuum to remove most solvent, and then water (100 mL) was added and extracted with EtOAc (30 mL, three times). The combined organic layer was washed with brine (30 mL ), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to give a residue, which was purified by column chromatography to afford 5-fluoro- 1,2,3,4-tetrahydroquinoline (compound DIO-d,3.74 g) as yellow oil. MS calc ’d 152.1 (MH+), measured 152.0 (MH+). Step 4: Preparation of 6-bromo-5-fluoro-l,2,3,4-tetrahydroquinoline (compound D10- e). To a solution of 5-fluoro-l,2,3,4-tetrahydroquinoline (compound DIO-d,3.5 g, 23.42 mmol) in DMF (60 mL) was added NBS (4.2 g, 23.42 mmol) slowly at 0 The mixture was stirred at %' for 0.25 hour. After the reaction completed, the mixture was poured into water (30 mL) and extracted with EtOAc (100 mL, three times). The combined organic layer was washed by brine (100 mL, three times), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to give a residue, which was purified by column chromatography to afford 6-bromo-5- fluoro-1,2,3,4-tetrahydroquinoline (compound DIO-e,4.0 g) as yellow oil. MS calc ’d 230.(MH+), measured 230.2 (MH+). Step 5: Preparation of 6-bromo-5-fluoro-8-iodo-l,2,3,4-tetrahydroquinoline (intermediate D10). To a solution of 6-bromo-5-fluoro- 1,2,3,4-tetrahydroquinoline (compound DIO-e,3.5 g, 15.21 mmol) in DMF (50 mL) cooled to -10 was added TFA (3.5 mL, 45.64 mmol) followed by addition of a solution of NIS (3.6 g, 15.97 mmol) in ACN (20 mL)/DMF (20 mL). The reaction solution was stirred for another 30 minutes under nitrogen atmosphere. The reaction was quenched with slow addition of sat. Na2S03 solution (100 mL) upon stirring. Then the reaction mixture was poured into water (300 mL) and the mixture was extracted with EtOAc (100 mL, three times). The combined organic layer was washed with brine (100 mL, five times), dried over Na2S04, filtered and concentrated under vacuum to give a residue which was purified by column chromatography to afford 6-bromo-5-fluoro-8-iodo-l,2,3,4-tetrahydroquinoline (intermediate D10,5.77 g) as a white solid. MS cak ’d 355.9 (MH+), measured 356.0 (MH+).
Intermediate E (7S,13.S)-7-amino-(20A/)-20-[2-[(llS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]- 17,17-dimethyl-15-oxa-4-thia-9,21,30,31- 2,5 9,13 19,27 21,26 tetrazahexacyclo [23.3.1.1 .1 .0 .0 Jhentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione The compound was prepared according to the following scheme: Intermediate D1 E3 E4 Intermediate B E6 Pd(dtbpf)CI2,K3POtoluene, dioxane, water EDCI, HOBt, DIEADCM Intermediate E Step 1: Preparation of benzyl 4-[5-[2-(6-bromo-l,2,3,4-tetrahydroquinolin-8- yl)ethynyl]-6-[(l،؟)-l-methoxyethyl]-3-pyridyl]piperazine-l-carboxylate (compound El). To a solution of benzyl 4-[5-ethynyl-6-[(lS)-l-methoxyethyl]-3-pyridyl]piperazine-l- carboxylate (Intermediate Cl,26.1 g, 68.8 mmol) in DMF (400 mL) were added 6-bromo-8- iodo-l,2,3,4-tetrahydroquinoline (Intermediate DI, 23.3 g, 68.8 mmol), TEA (47.9 mL, 343.mmol), Cui (1.3 g, 6.88 mmol) and Pd(PPh3)2C12 (4.8 g, 6.88 mmol). The reaction mixture was degassed and purged with nitrogen for three times and then it was stirred at 25 for 12 hrs. After the reaction was completed, the reaction mixture was poured into water (1.4 L), and extracted with EtOAc (800 mL, three times). The combined organic layer was washed with brine (800 mL, four times), dried over Na2S04, filtered and concentrated under vacuum to give a residue, which was purified by column chromatography to afford benzyl 4-[5-[2-(6-bromo- l,2,3,4-tetrahydroquinolin-8-yl)ethynyl]-6-[(l>S)-l-methoxyethyl]-3-pyridyl]piperazine-l- carboxylate (compound El,30.0 g) as a yellow solid. MS calc ’d 589.2 (MH+), measured 589.2(MH+). Step 2: Preparation of benzyl 4-[5-(6-bromo-l-azatricyclo[6.3.1.04,l2]dodeca- 2,4,6,8(12)-tetraen-2-yl)-6-[(l1S)-l-methoxyethyl]-3-pyridyl]piperazine-l-carboxylate (compound E2). To a solution of benzyl 4-[5-[2-(6-bromo-l,2,3,4-tetrahydroquinolin-8-yl)ethynyl]-6-[(l،S)- l-methoxyethyl]-3-pyridyl]piperazine-l-carboxylate (compound El,27.0 g, 45.8 mmol) in DMF (270 mL) was added PdC12 (1.6 g, 9.16 mmol) in one portion. The reaction mixture was degassed under vacuum, flashed with nitrogen for three times and then heated to 70 ’Ll for 16 hrs. After being cooled to the room temperature, the mixture was poured into water (800 mL), and extracted with EtOAc (300 mL, three times). The combined organic layer was washed with brine (300 mL, three times), dried over Na2S04, filtered and concentrated under vacuum to give a residue, which was purified by column chromatography to afford benzyl 4-[5-(6-bromo-l- azatricyclo [6.3.1.041 2]dodeca-2,4,6,8( 12)-tetraen-2-yl)-6-[( 1S)-1 -methoxyethyl] -3- pyridyl]piperazine- 1-carboxylate (compound E2,19.2 g) as a yellow solid. MS calc ’d 589.(MH+), measured 589.2 (MH+). Step 3: Preparation of benzyl 4-[5-(6-bromo-3-formyl-l-azatricyclo[6.3.1.04,l2]dodeca- 2,4,6,8(12)-tetraen-2-yl)-6-[(lA)-l-methoxyethyl]-3-pyridyl]piperazine-l-carboxylate (compound E3). Phosphorus oxychloride (30.4 mL, 325.69 mmol) was added into DMF (350 mL) dropwise slowly at 03؟. After being stirred at 0 for 0.5 h, the reaction mixture was added with a solution of benzyl 4-[5-(6-bromo-l-azatricyclo[6.3.1.0 4’12]dodeca-2,4,6,8(12)-tetraen-2-yl)-6- [(1S)-1-methoxyethyl]-3-pyridyl]piperazine-1-carboxylate (compound E2,19.2 g, 32.57 mmol) in DMF (150 mL) dropwise at 0 ،C. The reaction mixture was heated to 45 ،C, and then stirred for another l h. The reaction was quenched with sat. NaHCO ; aq. solution (1.5 L), extracted with EtOAc (500 mL, three times). The organic phase was washed with brine (500 mL, three times), dried over anhydrous Na2S04, filtered and concentrated under vacuum to give a residue. The residue was purified by column chromatography to afford benzyl 4-[5-(6-bromo-3-formyl-1- azatricyclo[6.3.1.0 4’12]dodeca-2,4,6,8(12)-tetraen-2-yl)-6-[(l>S)-l-methoxyethyl]-3- pyridyl]piperazine-l-carboxylate (compound E3,14.6 g) as a yellow solid. MS calc ’d 616.(MH+), measured 617.2 (MH+). Step 4: Preparation of benzyl 4-[5-[6-bromo-3-(l-hydroxy-3-methoxy-2,2-dimethyl-3- 4,12 oxo-propyl)-l-azatricyclo[6.3.1.0 ]dodeca-2,4,6,8(12)-tetraen-2-yl]-6-[(LS)-l- methoxyethyl]-3-pyridyl]piperazine-l-carboxylate (compound E4) To a solution of methyl isobutyrate (13.4 g, 131.17 mmol) in THF (150 mL) was added LDA (65.58 mL, 131.17 mmol) dropwise at -70 under nitrogen atmosphere. After being stirred for 0.5 h, the reaction mixture was added with a solution of benzyl 4-[5-(6-bromo-3- formyl-l-azatricyclo[6.3.1.0 4’12]dodeca-2,4,6,8(12)-tetraen-2-yl)-6-[(15)-l-methoxyethyl]-3- pyridyl]piperazine-l-carboxylate (compound E3,13.5 g, 21.86 mmol) in THF (50 mL) dropwise at -70 ،C. The reaction mixture was then allowed warm up to room temperature and stirred for h. After the reaction was completed, the mixture was quenched with sat. NH4C1 (600 mL) aqueous solution and extracted with EtOAc (200 mL, three times). The organic phase was washed with brine (500 mL), dried with anhydrous Na2SO4, filtered and concentrated under vacuum to give a residue. The residue was purified by column chromatography to afford benzyl 4-[5-[6-bromo-3-(l-hydroxy-3-methoxy-2,2-dimethyl-3-oxo-propyl)-l-4,12azatricyclo [6.3.1.0 ]dodeca-2,4,6,8(12)-tetraen-2-yl]-6-[(lS)-l-methoxyethyl]-3- pyridyl]piperazine- 1-carboxylate (compound E4,14.01 g) as a yellow gum. MS calc ’d 719.(MH+), measured 719.2 (MH+). Step 5: Preparation of benzyl 4-[5-[6-bromo-3-(3-methoxy-2,2-dimethyl-3-oxo-propyl)- l-azatricyclo[6.3.1.04’l2]dodeca-2,4,6,8(12)-tetraen-2-yl]-6-[(lS)-l-methoxyethyl]-3- pyridyl] piperazine-1-carboxylate (compound E5) To a solution of benzyl 4-[5-[6-bromo-3-(l-hydroxy-3-methoxy-2,2-dimethyl-3-oxo- propyl)-l-azatricyclo[6.3.1.0 4’12]dodeca-2,4,6,8(12)-tetraen-2-yl]-6-[(15)-l-methoxyethyl]-3- pyridyl]piperazine-l-carboxylate (compound E4,14.0 g, 19.45 mmol) and EtzSiH (18.1 g, 155.63 mmol) in DCM (280 mL) was added TFA (57.8 mL, 778.15 mmol) at 0 After being stirred at 25 for 12 hrs, the reaction mixture was concentrated under vacuum to give a residue, which was diluted with sat. NaHCO ; aq. until pH=9 and extracted with EtOAc (300 mL, three times). The combined organic layer was dried with anhydrous Na2S04, filtered and concentrated under vacuum to give a residue. The residue was purified by column to afford benzyl 4-[5-[6- bromo-3-(3-methoxy-2,2-dimethyl-3-oxo-propyl)-l-azatricyclo[6.3.1.0 412]dodeca-2,4,6,8(12)- tetraen-2-yl]-6-[(l،S)-l-methoxyethyl]-3-pyridyl]piperazine-l-carboxylate (compound E5,14 g) as a yellow gum. MS calc ’d 703.2 (MH+), measured 703.2 (MH+). Step 6: Preparation of benzyl 4-[(54/)-5-[6-bromo-3-(3-hydroxy-2,2-dimethyl-propyl)- l-azatricyclo[6.3.1.04’12]dodeca-2,4,6,8(12)-tetraen-2-yl]-6-[(l lS)-l-methoxyethyl]-3- pyridyl]piperazine-1-carboxylate (compound E6) To a solution of benzyl 4-[5-[6-bromo-3-(3-methoxy-2,2-dimethyl-3-oxo-propyl)-l- azatricyclo[6.3.1.0 4’12]dodeca-2,4,6,8(12)-tetraen-2-yl]-6-[(l>S)-l-methoxyethyl]-3- pyridyl]piperazine-l-carboxylate (compound E5,14.0 g, 19.9 mmol) in THF (150 mL) was added lithium borohydride (99.48 mL, 198.96 mmol) dropwise under N2 at O^. After being stirred at 20 for 15 hrs, the reaction was quenched by sat. NH4C1 aq. (600 mL) at 0 and the resultant mixture was extracted with EtOAc (100mL, three times). The combined organic layer was washed with brine (200 mL), dried over Na2SO4, filtered and concentrated in vacuo to give a residue. The residue was purified by column chromatography to afford benzyl 4-[(5Af)-5-[6- bromo-3-(3-hydroxy-2,2-dimethyl-propyl)-l-azatricyclo[6.3.1.0 4l2]dodeca-2,4,6,8(12)-tetraen-2- yl]-6-[(llS)-l-methoxyethyl]-3-pyridyl]piperazine-l-carboxylate (compound E6,7 g, faster eluted) as a yellow solid. MS calc ’d 675.3 (MH+), measured 675.2 (MH+). Step 7: Preparation of benzyl 4-[(53/)-5-[3-(3-hydroxy-2,2-dimethyl-propyl)-6-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-l-azatricyclo[6.3.1.04’12]dodeca-2,4(12),5,7-tetraen-2- yl]-6-[(lS)-l-methoxyethyl]-3-pyridyl]piperazine-l-carboxylate (compound E7) To a solution of benzyl 4-[(5A/)-5-[6-bromo-3-(3-hydroxy-2,2-dimethyl-propyl)-l- azatricyclo[6.3 .1.0412]dodeca-2,4,6,8( 12)-tetraen-2-yl]-6-[( 1S)-1 -methoxyethyl] -3- pyridyl]piperazine- 1-carboxylate (compound E6,7.0 g, 10.36 mmol) and bis(pinacolato)diboron (3.95 g, 15.54 mmol) in toluene (140 mL) was added KO Ac (2.56 g, 26.05 mmol) and Pd(dppf)C12 (760.87 mg, 1.04 mmol). The mixture was degassed, purged with nitrogen for three times and stirred at 75 for 16 hrs. After being cooled to the room temperature, the reaction mixture was filtered and concentrated under vacuum to give a residue. The residue was purified by column chromatography to afford benzyl 4-[(5Lf)-5-[3-(3-hydroxy-2,2-dimethyl-propyl)-6- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l-azatricyclo[6.3.1.0 4’12]dodeca-2,4(12),5,7- tetraen-2-yl]-6-[(l،S)-l-methoxyethyl]-3-pyridyl]piperazine-l-carboxylate (compound E7,7.3 g) as a yellow solid.MS calc ’d 723.4 (MH+), measured 723.4 (MH).
Step 8: Preparation of methyl (3S)-l-[(2S)-3-[4-[(2A/)-2-[5-(4- benzyloxycarbonylpiperazin-l-yl)-2-[(lS)-l-methoxyethyl]-3-pyridyl]-3-(3-hydroxy-2,2- dimethyl-propyl)-l-azatricyclo[6.3.1.04’12]dodeca-2,4(12),5,7-tetraen-6-yl]thiazol-2-yl]-2- (teff-butoxycarbonylamino)propanoyl]hexahydropyridazine-3-carboxylate (compound E8) To a solution of benzyl 4-[(5Af)-5-[3-(3-hydroxy-2,2-dimethyl-propyl)-6-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-l-azatricyclo[6.3.1.0 412]dodeca-2,4(12),5,7-tetraen-2-yl]- 6-[(lS)-l-methoxyethyl]-3-pyridyl]piperazine-l-carboxylate (compound E7,6.8 g, 9.41 mmol) and methyl (3S)-l-[(2S)-3-(4-bromothiazol-2-yl)-2-(te/^- butoxycarbonylamino )propanoyl]hexahydropyridazine-3-carboxylate (Intermediate B, 4.9 g, 10.35 mmol) in toluene (90 mL)/l,4-dioxane (30 mL)/water (30 mL) was added KzPO4 (5.0 g, 23.52 mmol) and Pd(dtbpf)C12 (613.2 mg, 0.94 mmol) in one portion. The mixture was degassed, purged with nitrogen for three times and then stirred at 70 for 15 hrs. After being cooled to room temperature, the reaction mixture was filtered and the filtrate was concentrated under vacuum to give a residue. The residue was purified by column chromatography to afford methyl (3S)-1 -[(2S)-3-[4-[(2Af)-2-[5-(4-benzyloxycarbonylpiperazin- 1 -yl)-2-[(15)-1 -methoxyethyl] -3- pyridyl]-3-(3-hydroxy-2,2-dimethyl-propyl)-l-azatricyclo[6.3.1.0 4’l2]dodeca-2,4(12),5,7-tetraen- 6-yl]thiazol-2-yl]-2-(te/ ־t-butoxycarbonylamino)propanoyl]hexahydropyridazine-3-carboxylate (compound E8,8.1 g) as a yellow solid. MS calc ’d 993.7 (MH+), measured 993.7 (MH+). Step 9: Preparation of (3S)-l-[(2S)-3-[4-[(2A/)-2-[5-(4-benzyloxycarbonylpiperazin-l- yl)-2-[(lS)-l-methoxyethyl]-3-pyridyl]-3-(3-hydroxy-2,2-dimethyl-propyl)-l- azatricyclo [6.3.1.04’12] dodeca-2,4(l 2),5,7-tetraen-6-yl] thiazol-2-yl]-2-^tert- butoxycarbonylamino)propanoyl]hexahydropyridazine-3-carboxylic acid (compound E9) To the mixture of methyl (3S)-l-[(2S)-3-[4-[(2Tf)-2-[5-(4-benzyloxycarbonylpiperazin-l- yl)-2-[( IS)-1 -methoxyethyl]-3-pyridyl]-3-(3-hydroxy-2,2-dimethyl-propyl)- 1 - azatricyclo[6.3.1.0 4’l2]dodeca-2,4(12),5,7-tetraen-6-yl]thiazol-2-yl]-2-(tert- butoxycarbonylamino )propanoyl]hexahydropyridazine-3-carboxylate (compound E8,8.1 g, 8.mmol) in DCE (160 mL) was added trimethyltin hydroxide (5.9 g, 32.62 mmol) in one portion. After being stirred at 60 CCfor 16 hrs, the reaction mixture was poured into water (200 mL) and extracted with EtOAc (100 mL, three times). The combined organic layer was washed with brine (200 mL), dried over anhydrous Na2S04, filtered. The filtrate was concentrated under vacuum to afford (3S)-1 -[(2S)-3-[4-[(2Af)-2-[5-(4-benzyloxycarbonylpiperazin- 1 -yl)-2-[(1S)-1 - methoxy ethyl] -3 -pyridyl] -3 -(3 -hydro xy-2,2-dimethyl-propyl)- 1 -azatricyclo [6.3.1.04’ 12] dodeca- 2,4(12),5,7-tetraen-6-yl]thiazol-2-yl]-2-(tert- butoxycarbonylamino )propanoyl]hexahydropyridazine-3-carboxylic acid (compound E9,7.9 g) as a brown solid. MS calc ’d 979.5 (MH+), measured 979.5 (MH+). Step 10: Preparation of benzyl 4-[(5Af)-5-[(75,135)-7-(/^r/-butoxycarbonylamino)- 17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 20-yl]-6-[(l،S)-l-methoxy ethyl]-3-pyridyl]piperazine-l-carboxylate (compound E10) To a solution of (3،S)-l-[(2،S)-3-[4-[(2A/)-2-[5-(4-benzyloxycarbonylpiperazin-l-yl)-2-[(15)- l-methoxyethyl]-3-pyridyl]-3-(3-hydroxy-2,2-dimethyl-propyl)-l-azatricyclo[6.3.1.0 412]dodeca- 2,4(12),5,7-tetraen-6-yl]thiazol-2-yl]-2-(te;y- butoxycarbonylamino )propanoyl]hexahydropyridazine-3-carboxylic acid (compound E9, 6.8 g, 6.94 mmol) in DCM (700 mL) was added DIEA (24.2 mL, 138.89 mmol), EDCI (19.9 g, 104.mmol) and HOBt (2.4 g, 17.36 mmol) at OTS. After being stirred at 30 for 15 hrs, the reaction mixture was poured into water (500 mL), and extracted with EtOAc (300 mL, three times). The combined organic layer was washed with brine (300 mL), dried over Na2SO4, filtered. The filtrate was concentrated under vacuum to give a residue, which was purified by silica column to afford benzyl 4-[(5Af)-5-[(7S, 13>S)-7-(teA-butoxycarbonylamino)- 17,17-dimethyl-8,14-dioxo- 15- oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’l3.0l9’27.02l’26]hentriaconta- 1(28),2,5(31), 19,25(29),26-hexaen-20-yl]-6-[(lS)-l-methoxyethyl]-3-pyridyl]piperazine-l- carboxylate (compound E10,5.6 g) as a yellow solid. MS calc ’d 961.5 (MH+), measured 961.(MH+). Step 11: Preparation of tert-butyl A-[(75,135)-(20Af)-20-[2-[(llS)-l-methoxyethyl]-5-(4- methylpiperazin-l-yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9l3.0l9’27.02l’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]carbamate (compound Ell) To a solution of benzyl 4-[(5L/)-5-[(7S, 13>S)-7-(terLbutoxycarbonylamino)- 17,17-dimethyl- 8,14-dioxo-15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’:'.l9’13.019’27.021’26]hentriaconta- l(28),2,5(31),19,25(29),26-hexaen-20-yl]-6-[(lS)-l-methoxyethyl]-3-pyridyl]piperazine-l- carboxylate (compound E10,5.6 g, 5.83 mmol) and formaldehyde (1.9 g, 23.3 mmol) in methanol (150 mL) was added Pd(OH)2 on activated carbon (3.0 g, 2.91 mmol) under nitrogen atmosphere. The reaction mixture was degassed and purged with H2 for three times and then it was stirred at 35 for 15 hrs under H2 (15psi). After being cooled to room temperature, the reaction mixture was filtered and the filtrate was concentrated under vacuum to give a residue. EtOAc (50 mL) and water (50 mL) were added into the residue and the layers were separated.
The aqueous phase was extracted with EtOAc (50 mL, twice). The combined organic layer was washed with brine (60 mL), dried over Na2SO4, filtered. The filtrate was concentrated under vacuum to give Ze/7-butyl A-[(7S',13S)-(20L/)-20-[2-[(lS)-l-methoxyethyl]-5-(4- methyip iperazin- 1 -yl)-3-pyridyl] -17,17-dimethyl-8 ,14-dioxo- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]carbamate (compound Ell,3.9 g) as a yellow solid which was used in the next step without further purification. MS cak ’d 841.5 (MH+), measured 841.4 (MH+). Step 12: Preparation of (75,135)-7-amino-(20Af)-20-[2-[(llS)-l-methoxyethyl]-5-(4- methylpiperazin-l-yl)-3-pyridyl]-17,17-dimethyl-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate E) To a solution of tert-butyl 7V-[(7S,13S)-(20L/)-20-[2-[(lS)-l-methoxyethyl]-5-(4- methyip iperazin- 1 -yl)-3-pyridyl] -17,17-dimethyl-8 ,14-dioxo- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]carbamate (compound Ell,3.9 g, 4.6 mmol) in DCM (30 mL) was added TEA (15.0 mL) in one portion. After being stirred at 25 TL for l h, the mixture was poured into water (100 mL) and extracted with EtOAc (200 mL). The organic phase was washed with water (50 mL, twice). The combined aqueous phase was basified with sat. NaHCO3 aq. until pH = 9 and extracted with EtOAc (100 mL, three times). The combined organic layer was washed with brine (200 mL), dried over anhydrous Na2S04, filtered and concentrated under vacuum to afford (75,135)-7- amino-(20Af)-20-[2- [(1 ،S)-1-methoxyethyl]-5-(4-methylp iperazin- 1-yl)-3-pyridyl] -17,17- dimethyl-15-oxa-4-thia-9, 21,30,3 l-tetrazahexacyclo[23. 3.1.12,19,13.0 .כl9,27.02l,26]hentriaconta- (28),2,5(31), 19,25(29),26-hexaene-8,14-dione (Intermediate E, 2.95 g) as a yellow solid. MS cak ’d 741.5 (MH+), measured 741.4 (MH+).
Intermediate F (7S,,13S)-7-amino-(20A/)-20-[2-[(lA)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17- dimethyl-15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione The compound was prepared according to the following scheme: Intermediate D1 F10 Intermediate F Step 1: Preparation of 4-[5-[2-(6-bromo-l,2,3,4-tetrahydroquinolin-8-yl)ethynyl]-6- [(lS)-l-methoxyethyl]-3-pyridyl]morpholine (compound F1). To a solution of 4-[5-ethynyl-6-[(lS)-l-metho xyethyl]-3-pyridyl]morpholine (intermediate C2,27.6 g, 112.06 mmol) in DMF (650 mL) were added 6-bromo-8-iodo-l,2,3,4- tetrahydroquinoline (intermediate DI, 37.9 g, 112.14 mmol), TEA (78 mL, 560.73 mmol), Cui (2.14 g, 11.24 mmol) and Pd(PPh3)2C12 (7.9 g, 11.24 mmol). The reaction mixture was degassed and purged with nitrogen for three times and then it was stirred at 25 for 12 hrs. After thereaction completed, the reaction mixture was poured into water (1.4 L), and extracted with EtOAc (800 mL, three times). The combined organic layer was washed with brine (800 mL, four times), dried over Na2S04, filtered and concentrated under vacuum to give a residue, which was purified by column chromatography to afford 4-[5-[2-(6-bromo-l,2,3,4-tetrahydroquinolin-8- yl)ethynyl]-6-[( 15)- l-methoxyethyl]-3-pyridyl]morpholine (compound F1,33.0 g) as a yellow solid. MS cak ’d 456.1 (MH+), measured 456.1 (MH+). Step 2: Preparation of 4-[5-(6-bromo-l-azatricyclo[6.3.1.0412]dodeca-2,4,6,8(12)- tetraen-2-yl)-6-[(lS)-l-methoxyethyl]-3-pyridyl] morpholine (compound F2). To a solution of 4-[5-[2-(6-bromo-l,2,3,4-tetrahydroquinolin-8-yl)ethynyl]-6-[(15)-l- methoxyethyl]-3-pyridyl]morpholine (compound Fl,33.0 g, 72.31 mmol) in DMF (400 mL) was added PdC12 (2.6 g, 14.46 mmol) in one portion. The reaction mixture was degassed under vacuum, flashed with nitrogen for three times and then heated to 60 for 15 hrs. After being cooled to the room temperature, the mixture was poured into water (800 mL), and extracted with EtOAc (500 mL, three times). The combined organic layer was washed with brine (400 mL, three times), dried over Na2S04, filtered and concentrated under vacuum to give a residue, which was purified by column chromatography to afford 4-[5-(6-bromo-l- azatrkyclo[6.3.1.0 4,12]dodeca-2,4,6,8(12)-tetraen-2-yl)-6-[(15)-l-methoxyethyl]-3- pyridyl]morpholine (compound F2,25.0 g) as a yellow solid. MS cak ’d 456.1 (MH+), measured 456.1 (MH+). Step 3: Preparation of 6-bromo-2-[2-[(llS)-l-methoxyethyl]-5-morpholino-3-pyridyl]- l-azatricyclo[6.3.1.04’l2]dodeca-2,4,6,8(12)-tetraene-3-carbaldehyde (compound F3). Phosphorus oxychloride (51.1 mL, 547.83 mmol) was added into DMF (500 mL) dropwise slowly at 0°C. After being stirred at 0 for 0.5 h, the reaction mixture was added with a solution of 4-[5-(6-bromo-l-azatricyclo[6.3.1.0 4’12]dodeca-2,4,6,8(12)-tetraen-2-yl)-6-[(15)-l- methoxyethyl]-3-pyridyl]morpholine (compound F2,25.0 g, 54.78 mmol) in DMF (375 mL) dropwise at 0 ،€. The reaction mixture was heated to 45 CC, and then stirred for another 1.5 h. The reaction was quenched with sat. NaHCO3 aq. solution (1.5 L), extracted with EtOAc (1 L, three times). The organic phase was washed with brine (600 mL, three times), dried over anhydrous Na2S04, filtered and concentrated under vacuum to give a residue. The residue was purified by column chromatography to afford 6-bromo-2-[2-[(15)-l-methoxyethyl]-5- morpholino-3-pyridyl]-l-azatrkyclo[6.3.1.0 4’12]dodeca-2,4,6,8(12)-tetraene-3-carbaldehyde (compound F3, 20.0 g) as a yellow solid. MS cak ’d 484.1 (MH ), measured 484.1 (MH+). Step 4: Preparation of methyl 3-[6-bromo-2-[2-[(lS)-l-methoxyethyl]-5-morpholino-3- pyridyl]-l-azatricyclo[6.3.1.0412]dodeca-2,4,6,8(12)-tetraen-3-yl]-3-hydroxy-2,2-dimethyl- propanoate (compound F4) To a solution of methyl isobutyrate (25.3 g, 247.72 mmol) in THF (700 mL) was added LDA (123.8 mL, 247.73 mmol) dropwise at -70 under nitrogen atmosphere. After being stirred for 0.5 h, the reaction mixture was added with a solution of 6-bromo-2-[2-[(15)-l- methoxyethyl]-5-morpholino-3-pyridyl]-l-azatrkyclo[6.3.1.0 412]dodeca-2,4,6,8(12)-tetraene-3- carbaldehyde (compound F3,20.0 g, 41.29 mmol) in THF (200 mL) dropwise at -70 The reaction mixture was then allowed to warm up to room temperature and stirred for l h. After the reaction completed, the mixture was quenched with sat. NH4C1 (IL) aqueous solution and extracted with EtOAc (800 mL, three times). The organic phase was washed with brine (500 mL), dried with anhydrous Na2S04, filtered and concentrated under vacuum to give a residue. The residue was purified by column chromatography to afford methyl 3-[6-bromo-2-[2-[(15)-l- methoxyethyl]-5-morpholino-3-pyridyl]-l-azatricyclo[6.3.1.0 412]dodeca-2,4,6,8(12)-tetraen-3- yl]-3-hydroxy-2,2-dimethyl-propanoate (compound F4,20 g) as a yellow solid. MS cak ’d 586.(MH+), measured 586.2 (MH+). Step 5: Preparation of methyl 3-[6-bromo-2-[2-[(LS)-l-methoxyethyl]-5-morpholino-3- pyridyl]-l-azatricyclo[6.3.1.04’12]dodeca-2,4,6,8(12)-tetraen-3-yl]-2,2-dimethyl-propanoate (compound F5) To a solution of methyl 3-[6-bromo-2-[2-[(l lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]-l- azatricyclo[6.3.1.0 4’12]dodeca-2,4,6,8(12)-tetraen-3-yl]-3-hydroxy-2,2-dimethyl-propanoate (compound F4,20 g, 34.1 mmol) and EtzSiH (31.7 g, 272.87 mmol) in DCM (550 mL) was added TFA (110.0 mL, 1480.88 mmol) at 0 After being stirred at 25CC for 12 hrs, the reaction mixture was concentrated under vacuum to give a residue, which was diluted with sat. NaHCO3 aq. until pH=9 and extracted with EtOAc (500 mL, three times). The combined organic layer was dried over anhydrous Na2S04, filtered and concentrated under vacuum to give a residue. The residue was purified by column to afford methyl 3-[6-bromo-2-[2-[(15)-l- methoxyethyl]-5-morpholino-3-pyridyl]- 1 -azatricyclo[6.3. 1.04’12]dodeca-2,4,6,8(l 2)-tetraen-3- yl]-2,2-dimethyl-propanoate (compound F5,17 g) as a yellow solid. MS cak ’d 570.2 (MH+), measured 570.2 (MH+). Step 6: Preparation of 3-[6-bromo-(2A/)-2-[2-[(L؟)-l-methoxyethyl]-5-morpholino-3- pyridyl]-l-azatricyclo[6.3.1.04’12]dodeca-2,4,6,8(12)-tetraen-3-yl]-2,2-dimethyl-propan-l-ol (compound F6) To a solution of methyl 3-[6-bromo-2-[2-[(l>S)-l-methoxyethyl]-5-morpholino-3-pyridyl]-l- azatricyclo[6.3. 1.04’12]dodeca-2,4,6,8(12)-tetraen-3-yl]-2,2-dimethyl-propanoate (compound F5, g, 29.8 mmol) in THF (370 mL) was added lithium borohydride (7.8 g, 358.03 mmol) under N2 at 0،C. After being stirred at 25 %' for 15 hrs, the reaction was quenched by sat. NH4CI aq. (500 mL) at 0 and the resultant mixture was extracted with EtOAc (600mL, three times). The combined organic layer was washed with brine (200 mL), dried over Na2S04, filtered and concentrated in vacuo to give a residue. The residue was purified by column chromatography to afford 3-[6-bromo-(2A/)-2-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]-l-azatricyclo [6.3.1.04’12]dodeca-2,4,6,8(12)-tetraen-3-yl]-2,2-dimethyl-propan-l -01 (compound F6, 7.9 g, faster eluted) as a yellow solid. MS calc ’d 542.2 (MH+), measured 542.2 (MH+). X-ray crystallographic analysis of compound F6 Absolute configuration structure of compound F6 was confirmed by X-ray crystallographic analysis of its (2S,3S)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid salt acetonitrile solvate. (Figure 1).
Step 7: Preparation of 3-[(2A/)-2-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]-6- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l-azatricyclo[6.3.1.04’l2[dodeca-2,4(12),5,7- tetraen-3-yl]-2,2-dimethyl-propan-l-ol (compound F7) To a solution of 3-[6-bromo-(27IT)-2-[2-[(l lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]-l- azatricyclo[6.3. 1.04’12]dodeca-2,4,6,8(12)-tetraen-3-yl]-2,2-dimethyl-propan-l -01 (compound F6, 7.3 g, 13.46 mmol) and bis(pinacolato)diboron (5.1 g, 20.2 mmol) in toluene (130 mL) was added KO Ac (3.3 g, 33.63 mmol) and Pd(dppf)C12 (993.0 mg, 1.36 mmol). The mixture was degassed, purged with nitrogen for three times and stirred at 90 CCfor 12 hrs. After being cooled to the room temperature, the reaction mixture was filtered and concentrated under vacuum to give a residue. The residue was purified by column chromatography to afford 3-[(2Af)-2-[2- [(l1S)-l-methoxyethyl]-5-morpholino-3-pyridyl]-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)- l-azatricyclo[6.3.1.0 4’12]dodeca-2,4(12),5,7-tet1 ־aen-3-yl]-2,2-dimethyl-propan-l-ol (compound F7,7.14 g) as a yellow solid.MS calc ’d 590.4 (MH), measured 590.4 (MH ). Step 8: Preparation of methyl (3S)-l-[(2S)-2-(te/7-butoxycarbonylamino)-3-[4-[3-(3- hydro xy-2,2-dimethyl-propyl)-(2A/)-2-[2-[(lS)-l-methoxyethyl]-5-morphohno-3-pyridyl[-l- azatricyclo[6.3.1.04’12]dodeca-2,4(12),5,7-tetraen-6-yl]thiazol-2- yl]propanoyl]hexahydropyridazine-3-carboxylate (compound F8) ts! x0 To a solution of 3-[(2A/)-2-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]-6-(4,4,5,5- tetramethyl- 1,3,2-dioxaborolan-2-yl)-l-azatricyclo [6.3.1.0412]dodeca-2, 4(12), 5,7-tetraen-3-yl]- 2,2-dimethyl-propan-l-ol (compound F7,7.14 g, 12.11 mmol) and methyl (35)-l-[(25)-3-(4- bromothiazol-2-yl)-2-(te/V-butoxycarbonylamino )propano yl]hexahydropyridazine-3-carboxylate (Intermediate B, 4.8 g, 10.1 mmol) in toluene (90 mL)/l,4-dioxane (30 mL)/water (30 mL) was added KPO4 (5.4 g, 25.3 mmol) and Pd(dtbpf)C12 (1.3 g, 2.03 mmol) in one portion. The mixture was degassed, purged with nitrogen for three times and then stirred at 70 for 12 hrs. After being cooled to room temperature, the reaction mixture was filtered and the filtrate was concentrated under vacuum to give a residue. The residue was purified by column chromatography to afford methyl (3>S)-l-[(2lS)-2-(tert-butoxycarbonylamino)-3-[4-[3-(3- hydroxy-2,2-dimethyl-propyl)-(2A/)-2-[2-[( 15)-1 -methoxyethyl]-5-morpholino-3 -pyridyl] -1 - azatricyclo[6.3.1.0 4’12]dodeca-2,4(12),5,7-tetraen-6-yl]thiazol-2- yl]propanoyl]hexahydropyridazine-3-carboxylate (compound F8,7.9 g) as a yellow solid. MS cak ’d 860.4 (MH+), measured 860.4 (MH+). Step 9: Preparation of (35)-l-[(25)-2-(tert-butoxycarbonylamino)-3-[4-[3-(3-hydroxy- 2,2-dimethyl-propyl)-(2A/)-2-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]-l- azatricyclo [6.3.1.04’12] dodeca-2,4(l 2),5,7-tetraen-6-yl] thiazol-2- yl]propanoyl]hexahydropyridazine-3-carboxylic acid (compound F9) To the mixture of methyl (3S)-l-[(2S)-2-(tert-butoxycarbonylamino)-3-[4-[3-(3-hydroxy- 2,2-dimethyl-propyl)-(2A/)-2-[2-[(l>S)-l-metho xyethyl]-5-morpholino-3-pyridyl]-l- azatricyclo[6.3.1.0 4’12]dodeca-2,4(12),5,7-tetraen-6-yl]thiazol-2- yl]propanoyl]hexahydropyridazine-3-carboxylate (compound F8,7.9 g, 9.19 mmol) in DCE (1mL) was added trimethyltin hydroxide (8.3 g, 45.99 mmol) in one portion. After being stirred at for 15 hrs, the reaction mixture was poured into water (80 mL) and extracted with EtOAc (200 mL, three times). The combined organic layer was washed with brine (200 mL), dried over anhydrous Na2SO4, filtered. The filtrate was concentrated under vacuum to afford (35)-l-[(25)-2- (ter/-butoxycarbonylamino)-3-[4-[3-(3-hydroxy-2,2-dimethyl-propyl)-(2Af)-2-[2-[(15)-l- methoxyethyl]-5-mo1 ־pholino-3-pyridyl]-l-azatricyclo[6.3.1.0 4’12]dodeca-2,4(12),5,7-tetraen-6- yl]thiazol-2-yl]propanoyl]hexahydropyridazine-3-carboxylic acid (compound F9, 7.5 g) as a yellow solid. MS cak ’d 846.4 (MH+), measured 846.4 (MH). Step 10: Preparation oftert-butylN-I(7S,13S)-(20M)-20-[2-[(1S)-1-methoxyethyl/-5- morpholino-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl] carbamate (compound F10) To a solution of (3،S)-l-[(2،S)-2-(te/^-butoxycarbonylamino)-3-[4-[3-(3-hydroxy-2,2- dimethyl-propyl)-(2A/)-2-[2-[(l،S)-l-metho xyethyl]-5-morpholino-3-pyridyl]-l- azatricyclo[6.3.1.0 4’12]dodeca-2,4(12),5,7-tetraen-6-yl]thiazol-2- yl]propanoyl]hexahydropyridazine-3-carboxylic acid (compound F9,7.5 g, 8.86 mmol) in DCM (1.5 L) was added DIEA (22.9 g, 177.38 mmol), EDCI (25.6 g, 133.61 mmol) and HOBt (3.0 g, 22.2 mmol) at 0^. After being stirred at 25 for 12 hrs, the reaction mixture was poured into water (200 mL), and extracted with EtOAc (300 mL, three times). The combined organic layer was washed with brine (300 mL), dried over Na2SO4, and then filtered. The filtrate was concentrated under vacuum to give a residue, which was purified by column chromatography to afford te/V-butyl7V-[(75,13 lS)-(20L/)-20-[2-[(l>S)-l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]carbamate (compound F10,5.9 g) as a yellow solid. MS calc ’d 828.4 (MH+), measured 828.(MH+). - 5 [- l-methoxyethyl ،؟(- 7 - amino-(20A/)-20-[2-[(l ،؟(- 13 ،؟, 7 ) Step 11: Preparation of morpholino-3-pyridy 1] -17,17-dimethyl-l 5-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F) To a solution of tezAbutyl 7V-[(75,13S)-(207l7)-20-[2-[(lS)-l-methoxyethyl]-5-morpholino- 3-pyridyl]- 17,17-dimethyl-8, 14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo [23.3.1.12’5. l9>l3.0l9>27.0212]hentriaconta- 1(28),2,5(31), 19,25(29),26-hexaen-7- yl]carbamate (compound F10,1.0 g, 1.21 mmol) in DCM (7 mL) was added TEA (3.5 mL) in one portion. After being stirred at 25for 1 h, the mixture was poured into water (50 mL) and extracted with EtOAc (20 mL). The organic phase was washed with water (50 mL, twice). The combined aqueous phase was basified with sat. NaHCOg aq. until pH = 9 and extracted with EtOAc (100 mL, three times). The combined organic layer was washed with brine (200 mL), dried over anhydrous Na2S04, filtered and concentrated under vacuum to afford (75,13S)-7- amino-(20A/)-20-[2-[(l،S)-l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4- thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F, 760 mg) as a yellow solid. MS calc ’d 741.4 (MH), measured 741.4 (MH+).
Intermediate G (7S,135)-7-amino-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin-l- yl] -3-pyridyl] -17,17-dimethyl-l 5-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12,5.19,13.019,27.021,26]hentriaconta-l(28),2,5(31),19,25(29),26- hexaene-8,14-dione The compound was prepared according to the following scheme: TFADCM Intermediate G Step 1: Preparation oftert-butylN-1(7S,13S)-(20M)-20-[2-I(1S)-1-methoxyethyl]-5- piperazin-l-yl-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl] carbamate (compound G1) - S)-7-(/er/-butoxycarbonylamino)-17,17-dimethyl ؛ 13 ؟, ؛ 7 -]) 5 /(- To a solution of benzyl 4-[(5A8,14-dioxo-15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- l(28),2,5(31),19,25(29),26-hexaen-20-yl]-6-[(l>S)-l-methoxyethyl]-3-pyridyl]piperazine-l- carboxylate (compound E10,400.0 mg, 0.42 mmol) in EtOAc (8 mL) was added Pd/C on activated carbon (200.0 mg) under nitrogen atmosphere. The mixture was degassed and purged with H2 for three times and then stirred at 25 for 48 hrs under H2 (15psi). The reaction mixture was filtered and the filtrate was concentrated under vacuum to give tert-butyl TV- [(75,135)-(20A/)-20-[2-[(l،S)-1-methoxyethyl]-5-piperazin- 1-yl-3-pyridyl]-17,1 7-dimethyl-8, 14- dioxo-15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-7-yl]carbamate (compound Gl,320.0 mg) as an off-white solid, which was used in the next step without further purification. MS calc ’d 827.6 (MH+), measured 827.4 (MH+). - 4 -] 5 [- l-methoxyethyl ،؟(- 20A/)-20-[2-[(l ،؟(-) 13 ،؟, 7 -]) Step 2: Preparation of tert-butyl TV (2,2,2-trifluoroethyl)piperazin-l-yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-7-yl]carbamate (compound G2). To a solution of tert-butyl TV-[(75,13.S)-(20TI7)-20-[2-[(lS)-l-methoxyethyl]-5-piperazin-l- yl-3-pyridyl]-17,1 7-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]carbamate (compound Gl, 290.0 mg, 0.35 mmol) in THF (6 mL) was added TEA (0.15 mL, 1.05 mmol) and CF3CH2OTf (162.8 mg, 0.7 mmol). After being stirred at 60 for 15 hrs, the reaction mixture was concentrated under vacuum to give a residue. The residue was purified by silica gel column to afford tert-butyl TV-[(75,135)-(20TI7)-20-[2-[(15)-l-methoxyethyl]-5-[4- (2,2,2-trifluoroethyl)piperazin- 1 -yl]-3-pyridyl]- 17,17-dimethyl-8, 14-dioxo- 15-oxa-4-thia- 9,21,30,31 -tetrazahexacyclo [23.3.1.12’5.19’13.019’27.021’26]hentriaconta- 1 (28),2,5(31), 19,25(29),26- hexaen-7-yl]carbamate (compound G2,230.0 mg) as a white solid. MS calc ’d 909.4 (MH+), measured 909.4 (MH+). Step 3: Preparation of (75,13S)-7-amino-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-[4- (2,2,2-trifluoroethyl)piperazin-l-yl]-3-pyridyl]-17,17-dimethyl-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate G). To a solution of ter-butylN-[(7S,13S)-(20M)-20-[2-[(1S)-1-methoxyethyl]-5-[4-(2,2,2- trifluoroethyl)piperazin- 1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]carbamate (compound G2,230.0 mg, 0.25 mmol) in DCM (2 mL) was added TFA (2 mL).
After being stirred at 20 for 1 h, sat. NaHCO3 solution (40 mL) was added into the reaction mixture and it was extracted with EtOAc (50 mL, three times). The combined organic layer was washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered. The filtrate was concentrated under vacuum to afford (7S,13S)-7-amino-(20Af)-20-[2-[(15)-l-methoxyethyl]-5- [4-(2,2,2-trifluoroethyl)piperazin- 1 -yl]-3-pyridyl] -17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate G, 200.0 mg) as a yellow solid which was used in the next step without further purification. MS cak ’d 809.4 (MH+), measured 809.4 (MH+).
Intermediate H (71S',13S)-7-amino-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]- 17,17-dimethyl-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione The title compound was prepared in analogy to the preparation of Intermediate E by using 7-bromo-5-iodo-3,4-dihydro-277-l,4-benzoxazine (Intermediate D2)instead of 6-bromo-8-iodo- 1,2,3,4-tetrahydroquino line (Intermediate DI).
Intermediate I (7S,,13S)-7-amino-(20A/)-20-[2-[(lA)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin-l- yl] -3-pyridyl] -17,17-dimethyl-15,24-dioxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione The title compound was prepared in analogy to the preparation of Intermediate E by using- [5-cthyny I-6-[( LS)-1 -methoxyethyl] -3 -pyridyl] -4-(2,2,2-trifluoroethyl)piperazine (Intermediate C3)and 7-bromo-5-iodo-3,4-dihydro-277-l,4-benzoxazine (Intermediate D2) instead of Benzyl 4-[5-ethynyl-6-[(l،S)-l-methoxyethyl]-3-pyridyl]piperazine-l-carboxylate (Intermediate Cl)and 6-bromo-8-iodo-l,2,3,4-tetrahydroquinoline (Intermediate Dl).
Intermediate J (7.S',13S)-7-amino-(20A/)-20-[2-[(l 1S)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17- dimethyl-15,24-dioxa-4-thia-9,21,30,31־ tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26[hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione The title compound was prepared in analogy to the preparation of Intermediate E by using 4-[5-ethynyl-6-[(l،S)-l-methoxyethyl]-3-pyridyl]mo1 ־pholine (Intermediate C2)and 7-bromo-5-iodo-3,4-dihydro-2//-l,4-benzoxazine (Intermediate D2)instead of benzyl 4-[5-ethynyl-6-[(l،؟)- l-methoxyethyl]-3-pyridyl]piperazine-l-carboxylate (Intermediate C1)and6-bromo-8-iodo- 1,2,3,4-tetrahydroquinoline (Intermediate Dl).
Intermediate K (75,135)-7-amino-23,23-difluoro-(20A/)-20-[2-[(l lS)-l-methoxyethyl]-5-(4-methylpiperazin- 1 -yl)-3-py ridyl] -17,17-dimethyl-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione The title compound was prepared in analogy to the preparation of Intermediate E by using 6-bromo-3,3-difluoro-8-iodo-2,4-dihydro-177-quinoline (Intermediate D3)instead of 6-bromo-8- iodo-1,2,3,4-tetrahydroquinoline (Intermediate D1).
Intermediate L (75,131S)-(20A/)-20-[5-[(9«1S)-3,4,6,7,9,9«-hexahydro-lZ7-pyrazino[2,l-c][l,4]oxazin-8-yl]-2- [(l1S)-l-methoxyethyl]-3-pyridyl]-7-amino-17,17-dimethyl-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione The title compound was prepared in analogy to the preparation of Intermediate E by using (9aS)-8-[5-ethynyl-6-[(lS)-l-methoxyethyl]-3-pyridyl]-3,4,6,7,9,9a-hexahydro-lH- pyrazino[2,l-c][l,4]oxazine (Intermediate C4)instead of benzyl 4-[5-ethynyl-6-[(15)-l- methoxy ethyl] -3 -pyridyl] piperazine-1 -carboxylate (Intermediate Cl).
Intermediate L2 (75,13S)-(20M)-20-[5-[(9«/?)-l,3,4,6,7,8,9,9«-octahydropyrido[l,2-a]pyrazin-2-yl]-2-[(lS)-l- methoxyethyl]-3-pyridyl]-7-amino-17,17-dimethyl-15-oxa-4-thia-9,21,30,31- 2,5 9,13 19,27 21,26 tetrazahexacyclo [23.3. LI .1 .0 .0 ]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione 15 The title compound was prepared in analogy to the preparation of Intermediate L byusing (9a7?)-2-[5-ethynyl-6-[(l>S)-l-methoxyethyl]-3-pyridyl]-l,3,4,6,7,8,9,9a-octahydropyrido[l,2-a]pyrazine (Intermediate C5)instead of (9aS)-8-[5-ethynyl-6-[(lS)-l-methoxyethyl]-3-pyridyl] -3,4,6,7,9,9a-hexahydro- 1 H-pyrazino [2,1 -c] [ 1,4]oxazine (Intermediate C4) Intermediate M (71S',13S)-7-amino-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17,23,23- tetramethyl-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26[hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione The title compound was prepared in analogy to the preparation of Intermediate E by using 7-bromo-5-iodo-2,2-dimethyl-3,4-dihydro-l,4-benzoxazine (Intermediate D4)and 4-[5-ethynyl-6-[(15)-l-methoxyethyl]-3-pyridyl]morpholine (Intermediate C2)instead of 6-bromo-8-iodo- 1,2,3,4-tetrahydroquinoline (compound D1)and benzyl 4-[5-ethynyl-6-[(15)-l-methoxyethyl]-3-pyridyl]piperazine-l-carboxylate (Intermediate Cl).
Intermediate N (7S,13S,22S)-7-amino-(20M)-20-[2-I(1S)-1-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17,22-trimethyl-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione The title compound was prepared in analogy to the preparation of Intermediate E by using 7-bromo-5-iodo-3-methyl-3,4-dihydro-277-l,4-benzoxazine (Intermediate D5)and 4-[5-ethynyl- 6-[(15)-l-methoxyethyl]-3-pyridyl]morpholine (Intermediate C2)instead of 6-bromo-8-iodo-1,2,3,4-tetrahydroquinoline (compound D1)and benzyl 4-[5-ethynyl-6-[(15)-l-methoxyethyl]-3- pyridyl]piperazine-l-carboxylate (Intermediate Cl).
Intermediate O (75,13S)-7-amino-23,23-difluoro-(20A0-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,2,2- trifluoroethyl)piperazin-l-yl]-3-pyridyl]-17,17-dimethyl-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9l3.0l9’27.02l’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione The title compound was prepared in analogy to the preparation of Intermediate E by using 6-bromo-3,3-difluoro-8-iodo-2,4-dihydro-177-quinoline (Intermediate D3)and l-[5-ethynyl-6- [(15)-l-methoxyethyl]-3-pyridyl]-4-(2,2,2-trifluoroethyl)piperazine (Intermediate C3)instead of 6-bromo-8-iodo-l,2,3,4-tetrahydroquinoline (Intermediate D1)and benzyl 4-[5-ethynyl-6-[(15)- -methoxyethyl]-3-pyridyl]piperazine- 1 -carboxylate (Intermediate Cl).
Intermediate P (7S,13.S)-7-amino-(20A/)-20-[2-[(llS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]- 17,17,23,23-tetramethyl-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione The title compound was prepared in analogy to the preparation of Intermediate E by using 6-bromo-8-iodo-3,3-dimethyl-2,4-dihydro-l//-quinoline (Intermediate D6)instead of 6-bromo- 8-iodo-l ,2,3,4-tetrahydroquinoline (Intermediate Dl).
Intermediate Q (7S,13S)-7-amino-23,23-difluoro-(20M)-20-[2-I(1S)-1-methoxyethyl]-5-morpholino-3- pyridyl] -17,17-dimethyl-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione The title compound was prepared in analogy to the preparation of Intermediate E by using 6-bromo-3,3-difluoro-8-iodo-2,4-dihydro-l//-quinoline (Intermediate D3)and 4-[5-ethynyl-6- [(lS)-l-methoxyethyl]-3-pyridyl]morpholine (Intermediate C2)instead of 6-bromo-8-iodo- 1,2,3,4-tetrahydroquinoline (compound D1)and benzyl 4-[5-ethynyl-6-[(15)-l-methoxyethyl]-3-pyridyl]piperazine-l-carboxylate (Intermediate Cl).
Intermediate RI 7rans-2-pyrimidin-5-ylcyclopropanecarboxylic acid o The compound was prepared according to the following scheme: Ad2nBuP-Pd-G3Cs2CO3, toluene R1-C Intermediate RIRl־a Step 1: trans-ethyl 2-pyrimidin-5-ylcyclopropanecarboxylate (compound Rl-c) To a solution of 5-bromopyrimidine (compound Rl-a,200.0 mg, 1.26 mmol), potassium (trans-2-(ethoxycarbonyl)cyclopropyl)trifluoroborate (compound Rl-b,276.8 mg, 1.26 mmol) in toluene/water (3 mL/0.3 mL) were added C82CO3 (819.7 mg, 2.52 mmol), Ad2nBuP-Pd-G(45.8 mg, 0.06 mmol). After being stirred at 90 for 16 hrs, the reaction mixture was cooled to room temperature. EtOAc (10 mL) and water (10 mL) were added to the reaction mixture and the layers were separated. The aqueous phase was extracted with EtOAc (10 mL, twice). The combined organic layer was washed with brine (10mL), dried over Na2S04, filtered and concentrated under vacuum to give a residue. The residue was purified by reversed-phase chromatography to afford trans-ethyl 2-pyrimidin-5-ylcyclopropanecarboxylate (compound RI- c,100.0 mg) as yellow oil. MS calc ’d 193.1 (MH+), measured 193.1 (MH+). Step2: tr««s-2-pyrimidin-5-ylcyclopropanecarboxylic acid (Intermediate RI) To a solution of trans-ethyl 2-pyrimidin-5-ylcyclopropanecarboxylate (compound Rl-c, 85.0 mg, 0.44 mmol) in ethanol (1 mL) was added NaOH aq. (IM, 0.5 mL, 0.53 mmol). After being stirred at 30 *G for 16 hrs, the reaction mixture was acidified by 1 M solution of HCI until pH=5. The mixture was concentrated directly and purified by reversed phase chromatography to give trans-2-pyrimidin-5-ylcyclopropanecarboxylic acid (Intermediate RI, 50.0 mg) as a white solid. MS calc ’d 165.1 (MH+), measured 165.1 (MH+).
Intermediate R2 Trans-2-pyridazin-3-ylcyclopropanecarboxylic acid The title compound was prepared in analogy to the preparation of Intermediate RI by using 3-bromopyridazine instead of 5-bromopyrimidine (compound Rl-a).
Intermediate R3 2-pyrimidin-4-ylcyclopropanecarboxylic acid The compound was prepared according to the following scheme: R3-a R3-c R3-d Intermediate R3 Step 1: ethyl (E)-3-pyrimidin-4-ylprop-2-enoate (compound R3-c) To a stirred solution of pyrimidine-4-carboxaldehyde (compound R3-a,400.0 mg, 3.mmol) and triethyl phosphonoacetate (compound R3-b,829.6 mg, 3.7 mmol) in THF (10 mL) was added sodium hydride (177.6 mg, 7.4 mmol, 60 % dispersion in mineral oil) at 0 After the reaction mixture was stirred for 2 hrs at 0 the reaction was quenched with H2O (5 mL) at the same temperature. The mixture was diluted by H2O (10mL) and extracted by EA (20 mL, three times). The combined organic layer was washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated under vacuum to give a residue. The residue was purified by flash chromatography to give ethyl (£)-3-pyrimidin-4-ylprop-2-enoate (compound R3-c,530.0 mg) as a white solid. MS calc ’d 179.1 (MH+), measured 179.1 (MH+). Step 2: ethyl 2-pyrimidin-4-ylcyclopropanecarboxylate (compound R3-d) To a solution of trimethylsulfoxonium iodide (2.2 g, 9.76 mmol) in DMSO (3 mL) was added sodium hydride (156.3 mg, 6.51 mmol, 60 % dispersion in mineral oil) at 0 After being stirred at room temperature for 20 min under N2, the reaction mixture was added with a solution of ethyl (E)-3-pyrimidin-4-ylprop-2-enoate (compound R3-c,580.0 mg, 3.25 mmol) in THF (3 mL). After being stirred at room temperature for 1 h, EtOAc (10 mL) and water (10 mL) were added to the reaction mixture and the layers were separated. The aqueous phase was extracted with EtOAc (10 mL, twice). The combined organic layer was washed with brine (10mL), dried over Na2SO4, filtered and concentrated under vacuum to give a residue. The residue was purified by flash chromatography to give ethyl 2-pyrimidin-4- ylcyclopropanecarboxylate (compound R3-d,220.0 mg) as a white solid. MS calc ’d 193.(MH+), measured 193.1 (MH+). Step 3: 2-pyrimidin-4-ylcyclopropanecarboxylic acid (Intermediate R3) To a solution of ethyl 2-pyrimidin-4-ylcyclopropanecarboxylate (compound R3-d,150.mg, 0.78 mmol) in ethanol (3 mL) was added NaOH aq. (IM, 0.9 mL, 0.9 mmol). After being stirred at 30 °C for 16 h, the reaction mixture was acidified by 1 M solution of HCI until pH=5. The mixture was concentrated directly and purified by reversed phase chromatography to give 2- pyrimidin-4-ylcyclopropanecarboxylic acid (Intermediate R3,55.0 mg) as a white solid. MS calc ’d 165.1 (MH+), measured 165.1 (MH+).
Intermediate R4 Tra«s-2-(4-pyridyl)cyclopropanecarboxylic acid o The title compound was prepared in analogy to the preparation of Intermediate RI by using 4-bromopyridine instead of 5-bromopyrimidine (compound Rl-a).
Intermediate R5 2-pyrimidin-2-ylcyclopropanecarboxylic acid The title compound was prepared in analogy to the preparation of Intermediate R3by using pyrimidine-2-carbaldehyde instead of pyrimidine-4-carboxaldehyde (compound R3-a) Intermediate R6 2 - pyrazin-2-ylcyclopropanecarboxylic acid ،؟(- 2 ،؟, tra«s-(l /N A The title compound was prepared in analogy to the preparation of Intermediate RI by using 2-bromopyrazine instead of 5-bromopyrimidine (compound Rl-a).
Intermediate R7 O 2 (- 4 - methylpynm1d1n-5-yl)cyclopropanecarboxyl1c acid ،؟(- 2 ،؟, tra«s-(l The title compound was prepared in analogy to the preparation of Intermediate RI by using 5-bromo-4-methyl-pyrimidine instead of 5-bromopyrimidine (compound Rl-a).
Intermediate R8 2 - thiazol-4-ylcyclopropanecarboxylic acid ،؟(- 2 ،؟, tra«s-(l The title compound was prepared in analogy to the preparation of Intermediate RI by using 4-bromothiazole instead of 5-bromopyrimidine (compound Rl-a).
Intermediate R9 2 (- 2 - methyl-3-pyridyl)cyclopropanecarboxylic acid ،؟(- 2 ،؟, tra«s-(l The title compound was prepared in analogy to the preparation of Intermediate RI by using 3-bromo-2-methyl-pyridine instead of 5-bromopyrimidine (compound Rl-a).
Intermediate R10 2 (- 5 - methyl-3-pyridyl)cyclopropanecarboxylic acid ،؟(- 2 ،؟, trans- (l The title compound was prepared in analogy to the preparation of Intermediate RI by using 3-bromo-5-methyl-pyridine instead of 5-bromopyrimidine (compound Rl-a).
Intermediate S [- l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl ،؟(- 7 - amino-(20Af)-20-[2-[(l ،؟(- 13 ،؟, 7 ) 17,17-dimethyl-15,25-dioxa-4-thia-9,21,31,32- tetrazahexacyclo[24.3.1.12’5.l9’13.019’28.021’27]dotriaconta-l(29),2,5(32),19,26(30),27-hexaene- 8,14-dione The title compound was prepared in analogy to the preparation of Intermediate E by using8-bromo-6-iodo-2,3,4,5-tetrahydro-l,5-benzoxazepine (intermediate D7) instead of 6-bromo-8- iodo-l,2,3,4-tetrahydroquinoline (Intermediate Dl).
Intermediate T - 3 - l-methoxyethyl]-5-morpholino ،؟(- 7 - amino-23-benzyloxy-(20A/)-20-[2-[(l ،؟(- 13 ،؟, 7 ) pyridyl]-17,17-dimethyl-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione The compound was prepared according to the following scheme: Intermediate D9 Intermediate BPd(dtbpf)CI 2,K3POtoluene, dioxane, water T10 Step 1: Preparation of 6-bromo-8-[2-[2-[(llS)-l-methoxyethyl]-5-morpholino-3- pyridyl]ethynyl]-l,2,3,4-tetrahydroquinolin-3-ol (compound Tl). A suspension of 2-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]ethynyl-trimethyl- silane (1.8 g, 5.65 mmol), 6-bromo-8-iodo-l,2,3,4-tetrahydroquinolin-3-ol (intermediate D9, 2 g, 5.65 mmol), EtN (1.71 g, 2.35 mL, 16.89 mmol), copper (I) iodide (107.3 mg, 0.56 mmol) and CsF (858.2 mg, 5.65 mmol) in THF (21 mL) was stirred at rt for 12 hrs under nitrogen atmosphere. After the reaction completed, the reaction mixture was filtered. The collected solid was washed with EtOAc (40 mL). The combined filtrate was washed with brine (10 mL), dried over Na2SO4 and concentrated under vacuum. The resulting residue was purified by silica gel chromatography to afford 6-bromo-8-[2-[2-[(l>S)-l-methoxyethyl]-5-morpho lino-3- pyridyl]ethynyl]-l,2,3,4-tetrahydroquinolin-3-ol (compound Tl, 1.7 g) as a light yellow solid. MS cak ’d 472.1 (MH+), measured 472.1 (MH+). Step 2: Preparation of 6-bromo-2-[2-[(llS)-l-methoxyethyl]-5-morpholino-3-pyridyl]- l-azatricyclo[6.3.1.04’l2]dodeca-2,4,6,8(12)-tetraen-10-ol (compound T2). To a solution of palladium (II) chloride (60 mg, 340.83 umol) in DMF (25 mL) was stirred at 70 for 15 min under nitrogen atmosphere. A solution of 6-bromo-8-[2-[2-[(lS)-l- methoxyethyl]-5-morpholino-3-pyridyl]ethynyl]- 1,2,3,4-tetrahydroquinolin-3-ol (compound Tl, 1610 mg, 3.41 mmol) in DMF (25 mL) was added to the reaction mixture. After being stirred for another 18 hrs, the reaction mixture was added with water and then extracted with EA (100 mL, three times). The combined organic layer was concentrated and then purified by reversed-phase chromatography to afford 6-bromo-2-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]-l- azatricyclo[6.3.1.0 4’12]dodeca-2,4,6,8(12)-tetraen-10-ol (compound T2,970 mg) as orange foam. MS cak ’d 472.1 (MH+), measured 472.1 (MH+). Step 3: Preparation of 4-[5-(10-benzyloxy-6-bromo-l-azatricyclo[6.3.1.04’12]dodeca- 2,4,6,8(12)-tetraen-2-yl)-6-[(llS)-l-methoxyethyl]-3-pyridyl]morpholine (compound T3).
A suspension of 6-bromo-2-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]-l- azatricyclo[6.3.1.0 4’12]dodeca-2,4,6,8(12)-tetraen-10-ol (compound T2,970 mg, 1.95 mmol) in DMF (24 mL) was added NaH (60%, 156 mg, 3.9 mmol) at rt under nitrogen atmosphere. After being stirred at rt for l h, the reaction mixture was cooled to 0 and added with benzyl bromide (667 mg, 464 uL, 3.9 mmol). The reaction mixture was stirred at rt for 12 hrs. The reaction mixture was cooled to 0،C and then the reaction was quenched with sat. NELCI aq. (mL). EA (40 mL) was added to the reaction mixture and the water phase was extracted with EA (40 mL, three times). The combined organic layer was washed with brine and dried over Na2S04, filtered and concentrated. The residue was purified by silica gel chromatography to afford 4-[5- (10-benzyloxy-6-bromo-l-azatricyclo[6.3.1.0 4’12]dodeca-2,4,6,8(12)-tetraen-2-yl)-6-[(lS)-l- methoxyethyl]-3-pyridyl]morpholine (compound T3,1 g) as orange oil. MS calc ’d 562.1 (MH+), measured 562.1 (MH+). Step 4: Preparation of 10-benzyloxy-6-bromo-2-[2-[(l،؟)-l-methoxyethyl]-5- morpholino-3-pyridyl]-l-azatricyclo[6.3.1.04’12]dodeca-2,4,6,8(12)-tetraene-3-carbaldehyde (compound T4) Phosphorus oxychloride (1 mL, 10.73 mmol) was added into DMF (10 mL) at 0 under nitrogen atmosphere. After being stirred at 0 for 0.5 h, the reaction mixture was added with a solution of 4-[5-(10-benzyloxy-6-bromo-l-azatricyclo[6.3.1.0 4’l2]dodeca-2,4,6,8(12)-tetraen-2- yl)-6-[(l1S)-l-methoxyethyl]-3-pyridyl]morpholine (compound T3,1 g, 1.78 mmol) in DMF (extra dry, 0.2 mL) dropwise under nitrogen atmosphere. After being stirred at room temperature for 2 hours, the reaction mixture was poured into cooled Sat. NaHCO3 aq. (30 mL) at 07؟ and then extracted with EA (30 mL, three times). The combined organic layer was washed with brine (10 mL), dried over Na2S04 and concentrated under vacuum to get a residue. The resulting residue was purified by silica gel chromatography to afford 10-benzyloxy-6-bromo-2-[2-[(lS)-l- methoxyethyl]-5-morpholino-3-pyridyl]- 1 -azatricyclo[6.3. 1.04 2]dodeca-2,4,6,8(l 2)-tetraene-3- carbaldehyde (compound T4,900 mg, 77.16%) as an orange solid. MS calc ’d 590.2 (MH+), measured 590.2 (MH+). Step 5: Preparation of [10-benzyloxy-6-bromo-2-[2-[(lS)-l-methoxyethyl]-5- morpholino-3-pyridyl]-l-azatricyclo[6.3.1.0412]dodeca-2,4,6,8(12)-tetraen-3-yl]methanol (compound T5) A solution of 10-benzyloxy-6-bromo-2-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]- l-azatricyclo[6.3.1.0 4’12]dodeca-2,4,6,8(12)-tetraene-3-carbaldehyde (compound T4, 900 mg, 1.37 mmol) in MeOH (20 mL) was added NaBH4 (103.8 mg, 2.74 mmol) at rt. The reaction mixture was stirred at rt for l h. The solution was removed under vacuum to get a residue. The residue was purified by silica gel chromatography to afford [10-benzyloxy-6-bromo-2-[2-[(15)- l-methoxyethyl]-5-morpholino-3-pyridyl]-l-azatricyclo[6.3.1.0 412]dodeca-2,4,6,8(12)-tetraen-3- yl]methanol (compound T5,740 mg) as light yellow oil. MS calc ’d 592.2 (MH+), measured 592.2 (MH+). Step 6: Preparation of methyl 3-[10-benzyloxy-6-bromo-2-[2-[(llS)-l-methoxyethyl]-5- morpholino-3-pyridyl]-l-azatricyclo[6.3.1.04’12]dodeca-2,4,6,8(12)-tetraen-3-yl]-2,2- dimethyl-propanoate (compound T6) A solution of 1-methoxy-l-(trimethylsiloxy)-2-methyl-l-propene (653.1 mg, 759.41 pL, 3.75 mmol) and [10-benzyloxy-6-bromo-2-[2-[(l>S)-l-methoxyethyl]-5-morpholino-3-pyridyl]-l- azatricyclo[6.3.1.0 412]dodeca-2,4,6,8(12)-tetraen-3-yl]methanol (compound T5,740 mg, 1.mmol) in DCM (10 mL) was stirred at rt for 15 min. The reaction mixture was added with magnesium perchlorate (557.5 mg, 2.5 mmol) and then stirred for another 12 hrs. The reaction was quenched with Sat. NaHCO3 aq. (10 mL) and DCM (30 mL).The organic layer was washed with water (3 mL, three times), brine (3 mL), dried over Na2S04 and concentrated under vacuum to get a residue. The resulting residue was purified by silica gel chromatography to afford methyl 3-[10-benzyloxy-6-bromo-2-[2-[(l>S)-l-methoxyethyl]-5-morpholino-3-pyridyl]-l- azatricyclo[6.3. 1.04’12]dodeca-2,4,6,8(12)-tetraen-3-yl]-2,2-dimethyl-propanoate (compound T6, 560 mg) as light yellow oil. MS calc ’d 676.2 (MH+), measured 676.2 (MH+). Step 7: Preparation of 3-[10-benzyloxy-6-bromo-2-[2-[(LS)-l-methoxyethyl]-5- morpholino-3-pyridyl]-l-azatricyclo[6.3.1.04’12]dodeca-2,4,6,8(12)-tetraen-3-yl]-2,2- dimethyl-propan-l-ol (compound T7) To a solution of methyl 3-[10-benzyloxy-6-bromo-2-[2-[(lS)-l-methoxyethyl]-5- morpholino-3-pyridyl]-l-azatricyclo[6.3.1.0 4’l2]dodeca-2,4,6,8(12)-tetraen-3-yl]-2,2-dimethyl- propanoate (compound T6,560 mg, 0.828 mmol) in THF (5 mL) was added 2 M LiBH4 (827 pL, 1.66 mmol) dropwise under N2 at 0 ،C. After being stirred at rt for 15 hrs, the reaction was quenched by sat. NHCl aq. (10 mL) at 0 and the resultant mixture was extracted with EtOAc (10 mL, three times). The combined organic layer was washed with brine (20 mL), dried over Na2S04, filtered and concentrated in vacuo to give a residue. The residue was purified by column chromatography to afford 3-[10-benzyloxy-6-bromo-2-[2-[(lS)-l-methoxyethyl]-5-morpholino- 3-py1־idyl]-l-azatricyclo[6.3.1.0 4’12]dodeca-2,4,6,8(12)-tetraen-3-yl]-2,2-dimethyl-propan-l-ol (compound T7, 525 mg) as light yellow oil. MS calc ’d 648.2 (MH ), measured 648.2 (MH+).
Step 8: Preparation of3-[10-benzyloxy-2-[2-[(1S)-1-methoxyethyl]-5-morpholino-3- pyridyl]-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l-azatricyclo[6.3.1.0412]dodeca- 2,4(12),5,7-tetraen-3-yl]-2,2-dimethyl-propan-l-ol (compound T8) To a solution of 3-[10-benzyloxy-6-bromo-2-[2-[(l lS)-l-methoxyethyl]-5-morpholino-3- pyridyl]-l-azatricyclo[6.3.1.0 4’12]dodeca-2,4,6,8(12)-tetraen-3-yl]-2,2-dimethyl-propan-l-ol (compound T7,525 mg, 809.4 umol), bis(pinacolato)diboron (246.6 mg, 971.28 umol) and KO Ac (198 mg, 2.02 mmol) in 1,4-dioxane (6 mL) was added Pd(dppf)C12 (66 mg, 80.94 !umol). The mixture was degassed and purged with nitrogen atmosphere for three times and the mixture was stirred at 90 T1 for 2 hrs. After the reaction completed, the mixture was cooled to room temperature, then fdtered, and the filtrate was concentrated in vacuo to give a residue. The residue was purified by silica column chromatography to afford 3-[10-benzyloxy-2-[2-[(15)-l- methoxyethyl]-5-morpholino-3-pyridyl]-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l- azatricyclo[6.3. 1.04’12]dodeca-2,4(12),5,7-tetraen-3-yl]-2,2-dimethyl-propan-l -01 (compound T8, 525 mg, 93.24%) as light yellow oil. MS calc ’d 696.4 (MH+), measured 696.4 (MH+). Step 9: Preparation of methyl (35)-l-[(2lS)-3-[4-[10-benzyloxy-3-(3-hydroxy-2,2- dimethyl-propyl)-2-[2-[(l،؟)-l-methoxyethyl]-5-morpholino-3-pyridyl]-l- azatricyclo [6.3.1.04’12] dodeca-2,4(l 2),5,7-tetraen-6-yl] thiazol-2-yl]-2-(tert- butoxycarbonylamino)propanoyl]hexahydropyridazine-3-carboxylate (compound T9) To a solution of 3-[10-benzyloxy-2-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]-6- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l-azatricyclo[6.3.1.0 4’l2]dodeca-2,4(12),5,7- tetraen-3-yl]-2,2-dimethyl-propan-l-ol (compound T8, 525 mg, 754.65 pmol) and methyl (35)- l-[(25)-3-(4-bromothiazol-2-yl)-2-(tert-butoxycarbonylamino)propanoyl]hexahydropyridazine- 3-carboxylate (Intermediate B, 342 mg, 716.91 umol) in 1,4-dioxane (7 mL)/water (2 mL) was added KPO4 (400 mg, 1.89 mmol) and Pd(dtbpf)C12 (49 mg, 75.46 umol) in one portion. The mixture was degassed, purged with nitrogen for three times and then stirred at 70 TS for 15 hrs. After being cooled to room temperature, the reaction mixture was filtered and the filtrate was concentrated under vacuum to give crude product methyl (35)-l-[(25)-3-[4-[10-benzyloxy-3-(3- hydroxy-2,2-dimethyl-propyl)-2-[2-[(15)-l-metho xyethyl]-5-morpholino-3-pyridyl]-l- azatricyclo[6.3.1.0 4’12]dodeca-2,4(12),5,7-tetraen-6-yl]thiazol-2-yl]-2-(terL butoxycarbonylamino)propanoyl]hexahydropyridazine-3-carboxylate (compound T9, 700 mg) as black oil, which was used in the next step without purification. MS calc ’d 966.5 (MH), measured 966.5 (MH ).
Step 10: Preparation of (35)-l-[(2lS)-3-[4-[10-benzyloxy-3-(3-hydroxy-2,2-dimethyl- propyl)-2-[2-[(llS)-l-methoxyethyl]-5-morpholino-3-pyridyl]-l- azatricyclo[6.3.1.0412]dodeca-2,4(12),5,7-tetraen-6-yl]thiazol-2-yl]-2-(tert- butoxycarbonylamino)propanoyl]hexahydropyridazine-3-carboxylic acid (compound T10) A solution of methyl (3S)-l-[(2S)-3-[4-[10-benzyloxy-3-(3-hydroxy-2,2-dimethyl-propyl)- 2-[2-[(1S)-1-metho xyethyl]-5-morpholino-3-pyridyl] -1-azatricyclo [6.3.1.04’12] dodeca- 2,4(12),5,7-tetraen-6-yl]thiazol-2-yl]-2-(tert- butoxycarbonylamino)propanoyl]hexahydropyridazine-3-carboxylate (compound T9, 700mg, 700 mg, 0.725 mmol) in MeOH (10 mL)/THF (10 mL) was added 2 M LiOH (2 mL, 4 mmol) and then stirred at rt for 2 hrs. The reaction mixture was acidified by 1 M solution of HCI until pH=5, and then extracted with EtOAc (40 mL, three times). The combined organic layer was concentrated and then purified by reversed-phase chromatography to afford (35)-l-[(2S)-3-[4- [10-benzyloxy-3-(3-hydroxy-2,2-dimethyl-propyl)-2-[2-[(lS)-l-methoxyethyl]-5-morpho lino-3- pyridyl]-l-azatricyclo[6.3.1.0 4’12]dodeca-2,4(12),5,7-tetraen-6-yl]thiazol-2-yl]-2-(tert- butoxycarbonylamino)propanoyl]hexahydropyridazine-3-carboxylic acid (compound T10, 4mg) as a light yellow powder. MS calc ’d 952.5 (MH+), measured 952.5 (MH+). Step 11: Preparation oftert-butylN-I(7S,13S)-23-benzyloxy-20-[2-I(1S)-1- methoxyethyl]-5-morpholino-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9,13.019,27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-7-yl]carbamate (compound Til) A solution of TCFH (229.8 mg, 819.18 umol) and NMI (269 mg, 261 LL, 3.28 mmol) in MeCN (103 mL) was stirred at rt for 15 min. Another solution of (3S)-l-[(2S)-3-[4-[10- benzyloxy-3-(3-hydroxy-2,2-dimethyl-propyl)-2-[2-[( 1S)-1 -methoxyethyl]-5-morpho lino-3- pyridyl]-l-azatricyclo[6.3.1.0 4’l2]dodeca-2,4(12),5,7-tetraen-6-yl]thiazol-2-yl]-2-(tert- butoxycarbonylamino)propanoyl]hexahydropyridazine-3-carboxylic acid (compound T10, 4mg, 454 umol) in acetonitrile (51 mL) was added dropwise to the reaction mixture and then stirred at it for l h. The solution was removed by reduce pressure under vacuum and then purified by silica gel chromatography to afford tert-butyl N־Y(TS, 13S)-23-benzyloxy-20-[2-[(lS)- -methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]carbamate (compound T11,514 mg) as light brown oil. MS calc ’d 934.4 (MH), measured 934.4 (MH+). - 5 [- l-methoxyethyl ،؟(- Step 12: Preparation of (7،S',13،S)-7-amino-23-benzyloxy-20-[2-[(l morpholino-3-pyridyl]-17,17-dimethyl-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate T) To a solution of tert-butylN-[(7S,13.S)-23-benzyloxy-20-[2-[(1S)-1-methoxyethyl]-5- morpholino-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]carbamate (compound Til, 300 mg, 321.15 umol) in DCM (2 mL) was added TFA (2 mL) and the mixture was stirred at 20 for 1 h. After the reaction was completed, the reaction mixture was concentrated under vacuum to afford (7.SJ 3S)-7-amino-23-bcnzyloxy-20-[2-[( l .S')- -methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate T, 300 mg) as light yellow oil. MS calc ’d 834.4 (MH+), measured 834.4 (MH+).
Intermediate U (7.S',13S)-7-amino-29-fluoro-(20A/)-20-[2-[(l 1S)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)- 3-pyridyl]-17,17-dimethyl-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione The title compound was prepared in analogy to the preparation of Intermediate E by using 6-bromo-5-fluoro-8-iodo-l,2,3,4-tetrahydroquinoline (intermediate D10) instead of 6-bromo-8- iodo-l,2,3,4-tetrahydroquinoline (Intermediate Dl).
Intermediate V Benzyl 4-[(5A/)-5-[(7S,135)-7-(^rt-butoxycarbonylamino)-17,17-dimethyl-8,14-dioxo-15,24- dioxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-20-yl] -6- [(1S)-1 -methoxyethyl] -3-pyridyl] piperazine-1- carboxylate Cbz BocHN The title compound was prepared in analogy to the preparation of Intermediate E10by using 7-bromo-5-iodo-3,4-dihydro-277-l,4-benzoxazine (Intermediate D2)instead of 6-bromo-8- iodo-1,2,3,4-tetrahydroquino line (Intermediate D1).
Example 1 (IS^^-iY-^TS^lSyE^OAf^O-^-KiyEl-methoxyetliyy-S-morpholino-S-pyridyl]-!?,!?- dimethyl-8,14-dioxo-l 5-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9l3.0l9’27.02l’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 15 7-yl]-2-methyl-cyclopropanecarboxamide To a solution of (75’.l 35)-7-amino-(20yW)-20-[2-[(L$ ,)-l -mctl1oxyctl1yl]-5-morpl1olino-3- pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F, 32.13 mg, 0.12 mmol) and (lS,2>S)-2-methylcyclopropanecarboxylic acid (33.0 mg, 0.33 mmol) in DMF (2 mL) were added DIEA (85.0 mg, 0.66 mmol), T3P (67.mg, 0.11 mmol) at 0 TL. After being stirred at 20 for l h, the reaction mixture was diluted with water (15 mL), extracted with EtOAc (15 mL, three times). The combined organic layer was washed with brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuo to get a residue. The residue was purified by prep-HPLC to afford Example 1 (26.6 mg) as a yellow solid. MS cak ’d 810.4 (MH+), measured 810.4 (MH+). 1H NMR (400 MHz, METHANOL-) 8 = 8.(s, 1H), 8.36 (d, J= 2.8 Hz, 1H), 7.86 (d, J= 2.4 Hz, 1H), 7.50 (s, 1H), 7.45 (s, 1H), 5.83 - 5.(m, 1H), 4.59 -4.38 (m, 1H), 4.21 - 4.17 (m, 1H), 4.16 - 4.08 (m, 1H), 3.86 (t, J= 4.8 Hz, 4H), 3.81 - 3.59 (m, 3H), 3.50 - 3.32 (m, 8H), 3.29 - 3.22 (m, 2H), 3.19 - 2.94 (m, 4H), 2.86 - 2.60 (m, 2H), 2.43 - 2.07 (m, 3H), 2.01 - 1.86 (m, 1H), 1.83 - 1.53 (m, 2H), 1.50 - 1.43 (m, 4H), 1.31 - 1.17 (m, 1H), 1.12 (d, J = 6.0 Hz, 3H), 1.09 - 1.02 (m, 2H), 0.99 (s, 3H), 0.66 - 0.63 (m, 1H), 0.62 (s, 3H).
Example 2 (lS,2S)-AM(7S,13S)-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-methyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate E) instead of (7S,13S)-7-amino-(207l7)-20-[2-[(15)-l-methoxyethyl]-5- morpholino-3-pyridyl]-17,1 7-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F).Example 2(16.2 mg) was obtained as a yellow solid. MS calc ’d 823.4 (MH+), measured 823.4 (MH+). 1H NMR (400 MHz, Methanol-d) 6 = 8.49 (d, J= 2.8 Hz, 1H), 8.39 (s, 1H), 7.67 (s, 1H), 7.49 (s, 1H), 7.43 (s, 1H), 5.83 - 5.73 (m, 1H), 4.85 - 4.77 (m, 1H), 4.54 - 4.40 (m, 2H), 4.25 - 4.16 (m, 2H), 3.85 - 3.67 (m, 3H), 3.66 - 3.57 (m, 2H), 3.46 - 3.33 (m, 6H), 3.30 - 3.22 (m, 2H), 3.18 - 2.92 (m, 7H), 2.82 - 2.71 (m, 1H), 2.67 - 2.58 (m, 1H), 2.39 - 2.25 (m, 1H), 2.23 - 2.13 (m, 2H), 1.98 - 1.89 (m, 1H), 1.84 - 1.69 (m, 1H), 1.66 - 1.53 (m, 1H), 1.51 - 1.43 (m, 4H), 1.37- 1.15 (m, 2H), 1.14- 1.10 (m,3H), 1.09- 1.04 (m, 1H), 0.98 (s, 3H), 0.67 - 0.61 (m, 1H), 0.56 (s, 3H).
Example 3 (15,25)-^-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin- l-yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-methyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,13S)-7-amino-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin-l-yl]- 3-pyridyl] -17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate G) instead of (7S,13S)-7-amino-(207l7)-20-[2-[(15)-l-methoxyethyl]-5- morpholino-3-pyridyl]-17,1 7-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F).Example 3(27.6 mg) was obtained as a yellow solid. MS cak ’d 891.4 (MH+), measured 891.4 (MH+). 1H NMR (400 MHz, Methanol-d4) 6 = 8.42 (s, 1H), 8.(d, J= 2.8 Hz, 1H), 7.83 (d, J= 2.8 Hz, 1H), 7.50 (s, 1H), 7.45 (s, 1H), 5.85 - 5.75 (m, 1H), 4.- 4.48 (m, 1H), 4.47 - 4.39 (m, 1H), 4.22 (dd, J= 3.2, 11.8 Hz, 1H), 4.17 - 4.09 (m, 1H), 3.81 - 3.72 (m, 2H), 3.70 - 3.62 (m, 1H), 3.51 - 3.46 (m, 4H), 3.42 (s, 3H), 3.30 - 2.95 (m, 7H), 2.90 - 2.85 (m, 4H), 2.81 - 2.65 (m, 2H), 2.39 - 2.27 (m, 1H), 2.24 - 2.13 (m, 2H), 1.98 - 1.89 (m, 1H), 1.82 - 1.67 (m, 1H), 1.66- 1.52 (m, 1H), 1.49 - 1.43 (m, 4H), 1.27- 1.18 (m, 1H), 1.14- 1.10 (m, 3H), 1.09 - 1.04 (m, 1H), 1.00 (s, 3H), 0.67 - 0.58 (m, 4H).
Example 5 (lS,2S)-AM(7S43S)-(20A0-20-[2-[(lS)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin- l-yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-methyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,13S)-7-amino-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin-l-yl]- 3-pyridyl]- 17,17-dimethyl- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate 1) instead of (7S,13S)-7-amino-(207W)-20-[2-[(lS)-l-methoxyethyl]-5- morpholino-3-pyridyl] -17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F).Example 5(22.11 mg) was obtained as a light yellow solid. MS cak ’d 893.4 (MH+), measured 893.4 (MH+). 1H NMR (400 MHz, DMSO-،/6) d = 8.52 (d, J= 8.Hz, 1H), 8.44 (d, J = 2.7 Hz, 1H), 8.12 (s, 1H), 7.74 (s, 1H), 7.18 (d, J= 2.8 Hz, 1H), 7.15 (s, 1H), 5.55 (t, J = 9.0 Hz, 1H), 5.04 (d, J= 12.1 Hz, 1H), 4.68 -4.54 (m, 2H), 4.35 - 4.15 (m, 4H), 3.74 - 3.67 (m, 1H), 3.62 - 3.56 (m, 2H), 3.28 - 3.25 (m, 4H), 3.23 (s, 3H), 3.19 - 3.07 (m, 1H),.03 - 2.84 (m, 1H), 2.83 - 2.69 (m, 5H), 2.43 (s, 1H), 2.14 - 2.08 (m, 1H), 1.87 - 1.71 (m, 2H),.56 - 1.43 (m, 2H), 1.33 (d,J=6.1 Hz, 3H), 1.23 (s, 1H), 1.08- 1.01 (m, 6H), 0.94 (s, 3H), 0.87- 0.82 (m, 1H), 0.58 - 0.48 (m, 1H), 0.38 (s, 3H).
Example 6 (lS',21S)-2-(difluoromethyl)-A^-[(7A',13S)-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-morpholino-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl] cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (15,2S)-2-(difluoromethyl)cyclopropanecarboxylic acid instead of (lS,25)-2- methylcyclopropanecarboxylic acid. Example 6 (34.9 mg) was obtained as a yellow solid. MScak ’d 846.4 (MH+), measured 846.4 (MH+). 1H NMR (400 MHz, METHANOL-d4) 8 = 8.42 (s, 1H), 8.36 (d, J= 2.80 Hz, 1H), 7.82 (d, J= 2.80 Hz, 1H), 7.51 (s, 1H), 7.45 (s, 1H), 5.96 - 5.(m, 2H), 4.53 (4, J= 6.40 Hz, 1H), 4.47 - 4.38 (m, 1H), 4.24 - 4.09 (m, 2H), 3.87 (t, J= 4.80 Hz, 4H), 3.81 - 3.64 (m, 3H), 3.44 - 3.38 (m, 8H), 3.17 - 2.94 (m, 3H), 2.83 - 2.67 (m, 2H), 2.38 - 2.26 (m, 1H), 2.25 - 2.11 (m, 2H), 2.09 - 2.00 (m, 2H), 1.98 - 1.88 (m, 1H), 1.84 - 1.69 (m, 2H),1.67 - 1.54 (m, 1H), 1.48 (d, J= 6.40 Hz, 3H), 1.21 - 1.07 (m, 2H), 0.99 (s, 3 H), 0.62 (s, 3H).
Example 7 (lS,5/?,6r)-A^-[(7S,135)-(20A0-20-[2-[(15)-l-methoxyethyl]-5-morphoUno-3-pyridyl]-17,17- dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9l3.0l9’27.02l’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 15 7-yl] -3-oxabicyclo [3.1.0] hexane-6-carboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (l1S*,5R,6r)-3-oxabicyclo[3.1.0]hexane-6-carboxylic acid instead of (lS,25)-2- methylcyclopropanecarboxylic acid. Example 7 (29.3 mg) was obtained as a yellow solid. MS cak ’d 838.4 (MH+), measured 838.4 (MH+). 1H NMR (400 MHz, DMSO-d) 8 = 8.56 (d, J= 8.8Hz, 1H), 8.44 (d, J= 2.8 Hz, 1H), 8.34 (s, 1H), 7.71 (s, 1H), 7.45 (s, 1H), 7.34 (s, 1H), 5.58 (t, J= 8.80 Hz, 1H), 5.07 (d, J= 12.4 Hz, 1H), 4.39 - 4.31 (m, 1H), 4.27 - 4.13 (m, 3H), 3.85 - 3.(m, 8H), 3.29 - 3.24 (m, 7H), 3.17-2.84 (m, 6H), 2.81 - 2.70 (m, 1H), 2.29 - 2.04 (m, 4H), 1.- 1.71 (m, 5H), 1.67 - 1.41 (m, 3H), 1.35 (d, J= 6.40 Hz, 3H), 0.92 (s, 3H), 0.43 (s, 3H).
Example 8 (l1S',21S)-AL[(71S',13A)-(20A/)-20-[2-[(llS)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17- dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-methyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (7،S',135)-7-amino-(20Af)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17-dimethyl- 15,24-dioxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’l3.019’27.021’26]hentriaconta- (28),2,5(31 ),19,25(29),26-hexaene-8,14-dione (intermediate J) instead of (7S',135)-7-amino- (20A/)-20-[2-[( 1S)-1 -methoxy ethyl]-5-morpho lino -3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia- 9,21,30,31 -tetrazahexacyclo [23.3.1.12’5.19’13.0l9’27.02l’26]hentriaconta- 1 (28),2,5(31), 19,25(29),26- hexaene-8,14-dione (Intermediate F).Example 8(20 mg) was obtained as a light yellow solid. MS cak ’d 812.4 (MH+), measured 812.4 (MH+). ,H NMR (400 MHz, ACETONITRILE-^) 8 = 8.38 (d, J = 2.9 Hz, 1H), 8.20 (s, 1H), 7.44 (s, 1H), 7.29 (d, J = 2.8 Hz, 1H), 7.15-7.06 (m, 2H), 5.67 (t, J= 8.9 Hz, 1H),4.67 - 4.56 (m, 2H), 4.48 (d, J= 6.2 Hz, 1H), 4.45 -4.18 (m, 4H), 3.89 - 3.79 (m, 4H), 3.78 - 3.63 (m, 3H), 3.40 - 3.25 (m, 8H), 3.20 - 3.09 (m, 1H), 3.04 (br d, J= 14.Hz, 1H), 2.77 - 2.65 (m, 1H), 2.58 (br d, J= 14.3 Hz, 1H), 1.91 (br d, J= 12.6 Hz, 1H), 1.85 - 1.74 (m, 1H), 1.62 - 1.51 (m, 1H), 1.44 - 1.36 (m, 4H), 1.29 (br d, J= 6.0 Hz, 1H), 1.21 - 1.(m, 1H), 1.13 - 1.08 (m, 3H), 1.04 - 0.95 (m, 4H), 0.66 - 0.58 (m, 1H), 0.51 (s, 3H).
Example 9 (l1$',21S)-2-(difluoromethyl)-2V-[(7.S',13.S')-(20A/)-20-[2-[(llS')-l-methoxyethyl]-5-morpholino-3- pyridyl] -17,17-dimethyl-8,14-dioxo-l 5,24-dioxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl] cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,13S)-7-amino-(2037)-20-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17-dimethyl- 15,24-dioxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’l3.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (intermediate J) and (lS,25)-2- (difluoromethyl)cyclopropanecarboxylic acid instead of (7>S',13>S)-7-amino-(207l/)-20-[2-[(l lS)-l- methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’l3.0l9’27.02l’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F)and (l>S',2lS)-2-methylcyclopropanecarboxylic acid. Example 9(6 mg) was obtained as a light yellow solid. MS calc ’d 848.4 (MH+), measured 848.4 (MH+). 1H NMR (400 MHz, ACETONITRILE-d) <5 = 8.29 (d, J= 3.0 Hz, 1H), 8.22 (d, J= 0.8 Hz, 1H), 7.54 (d, J=3.0Hz, 1H), 7.45 (s, 1H), 7.33 - 7.26 (m, 1H), 7.13 (d, J= 1.0 Hz, 1H), 5.80 -5.48 (m, 2H), 4.65 - 4.55 (m, 3H), 4.53-4.35(m, 1H), 4.37 - 4.32 (m, 1H), 4.29 - 4.21 (m, 2H), 3.85 - 3.79 (m, 5H), 3.72 (d, J= 6.8 Hz, 2H), 3.41 - 3.31 (m, 8H), 3.20 - 3.11 (m, 1H), 3.03 (br d, J= 14.3 Hz, 1H), 2.73 (br d, J= 3.0 Hz, 1H), 2.65 (br d, J= 14.3 Hz, 1H), 1.83 - 1.74 (m, 2H), 1.63 - 1.52 (m, 1H), 1.41 (d, J= 6.3 Hz, 3H), 1.32 - 1.25 (m, 3H), 1.12 (br s, 2H), 1.01 (s, 3H), 0.58 (s, 3H).
Example 10 (15,51?,6r)-A^-[(7A',13 1S)-(20A/)-20-[2-[(llS)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17- dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl] -3-oxabicyclo [3.1.0] hexane-6-carboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17-dimethyl- 15,24-dioxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (intermediate J) and (lS,5R,673-(״- oxabicyclo [3.1.0]hexane-6-carboxylic acid instead of (7>S',13>S)-7-amino-(207l/)-20-[2-[(l lS)-l- methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F)and (l>S',2lS)-2-methylcyclopropanecarboxylic acid. Example 10(5.mg) was obtained as a light yellow solid. MS cak ’d 840.4 (MH+), measured 840.4 (MH+). *H NMR (400 MHz, ACETONITRILE-^) 6 = 8.34 (d, J= 3.0 Hz, 1H), 8.21 (s, 1H), 7.45 (s, 1H), 7.41 (d, J= 2.8 Hz, 1H), 7.12 (d, J= 1.0 Hz, 2H), 5.92-5.63 (m, 2H), 4.67 - 4.58 (m, 2H), 4.53 (d, J= 6.3 Hz, 1H), 4.45 - 4.37 (m, 1H), 4.35 - 4.28 (m, 2H), 4.22 (br d, J= 3.0 Hz, 1H), 3.88 (s, 2H), 3.85 - 3.79 (m, 4H), 3.76 (s, 1H), 3.74 - 3.66 (m, 4H), 3.39 - 3.29 (m, 8H), 3.17-3.10 (m, 1H), 3.04 (d, J= 14.5 Hz, 1H), 2.75 - 2.68 (m, 1H), 2.64 - 2.60 (m, 1H), 2.03 (s, 1H), 2.01 - 1.(m, 1H), 1.94- 1.87 (m, 1H), 1.84- 1.73 (m, 1H), 1.56 (br t, J= 3.3 Hz, 2H), 1.41 (d, J = 6.3 Hz, 3H), 1.00 (s, 3H), 0.55 (s, 3H).
Example 11 (15,25)-2-(difluoromethyl)-A-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,2,2- trifluoroethyl)piperazin-l-yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-7-yl]cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,13S)-7-amino-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin-l-yl]- 3-pyridyl]- 17,17-dimethyl- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate 1) and (lS,25)-2-(difluoromethyl)cyclopropanecarboxylic acid instead of (75,135)-7-amino-(20A/)-20-[2-[(l>S)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17- dimethyl-15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (lS,25)-2- methylcyclopropanecarboxylic acid. Example 11(22.1 mg) was obtained as a light yellow solid. MS cak ’d 929.4 (MH+), measured 929.4 (MH+). 1H NMR (400 MHz, ACETONITRILE-^) 8 = 8.40 (d, J = 2.8 Hz, 1H), 8.17 (s, 1H), 7.41 (s, 1H), 7.22- 7.16 (m, 1H), 7.15 - 7.11 (m, 1H), 7.- 7.03 (m, 1H), 5.77 - 5.66 (m, 1H), 4.66 - 4.52 (m, 2H), 4.44 - 4.34 (m, 3H), 4.33 - 4.18 (m, 2H), 3.76 - 3.63 (m, 3H), 3.37 (d, J= 15.5 Hz, 1H), 3.30 - 3.24 (m, 7H), 3.19 - 3.06 (m, 4H), 3.00 (d, J= 15.0 Hz, 1H), 2.83 - 2.79 (m, 4H), 2.74 - 2.63 (m, 2H), 2.58 - 2.49 (m, 2H), 1.79 - 1.76 (m, 2H), 1.60 - 1.52 (m, 2H), 1.37 (d, J= 6.1 Hz, 3H), 1.13 - 1.06 (m, 2H), 0.96 (s, 3H), 0.47 (s, 3H).
Example 12 (LS'.5/?,6/)--|(7.S'J3.V)-(2()l/)-2()-|2-|(LV)-l-mclhoxyclhyl]-5-|4-(2,2,2- trifluoroethyl)piperazin-l-yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-7-yl] -3-oxabicyclo [3.1.0] hexane-6-carboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75J3S)-7-amino-(2037)-20-[2-[(lS)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin-l-yl]- 3-pyridyl]- 17,17-dimethyl- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate 1) and (lS,57?,6r)-3-oxabicyclo[3.1.0]hexane-6-carboxylic acid instead of (75,135)-7-amino-(20A/)-20-[2-[(l>S)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17- dimethyl-15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’l3.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (lS,25)-2- methylcyclopropanecarboxylic acid. Example 12(13.4 mg) was obtained as a white solid. MS cak ’d 921.4 (MH+), measured 921.4 (MH+). *H NMR (400 MHz, ACETONITRILE-d) ،5 = 8.- 8.37 (m, 1H), 8.20 - 8.14 (m, 1H), 7.44 - 7.38 (m, 1H), 7.16 - 7.12 (m, 1H), 7.06 (d, J= 1.0 Hz, 1H), 7.02 - 6.97 (m, 1H), 5.71 - 5.60 (m, 1H), 4.61 - 4.52 (m, 2H), 4.40 - 4.36 (m, 2H), 4.30 - 4.19 (m, 2H), 3.89 - 3.82 (m, 2H), 3.75 - 3.66 (m, 4H), 3.41 - 3.32 (m, 2H), 3.30 - 3.24 (m, 7H), 3.17 - 3.05 (m, 4H), 3.00 (d, J= 13.9 Hz, 1H), 2.83 - 2.79 (m, 4H), 2.74 - 2.65 (m, 2H), 2.56 - 2.52 (m, 1H), 2.00 (s, 1H), 1.78 - 1.75 (m, 1H), 1.55 - 1.50 (m, 2H), 1.37 (d, J= 6.1 Hz, 3H), 1.30 - 1.26 (m, 1H), 1.00 - 0.93 (m, 3H), 0.92 - 0.87 (m, 1H), 0.51 - 0.41 (m, 3H).
Example 13 (LS'.5/?,6/)--|(7.S'J3.V)-(2()l/)-2()-|2-|(LV)-1-mclhoxyclhyl]-5-|4-(2,2,2- trifluoroethyl)piperazin-l-yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-7-yl] -3-oxabicyclo [3.1.0] hexane-6-carboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,13S)-7-amino-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin-l-yl]- 3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate G) and (lS,57?,6r)-3-oxabicyclo[3.1.0]hexane-6-carboxylic acid instead of (75,135)-7-amino-(20A/)-20-[2-[(l>S)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17- dimethyl-15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’l3.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (lS,25)-2- methylcyclopropanecarboxylic acid. Example 13(11.9 mg) was obtained as a yellow solid. MS cak ’d 919.4 (MH+), measured 919.4 (MH+). *H NMR (400 MHz, METHANOL-d) 8 = 8.45 - 8.33 (m, 2H), 7.84 - 7.83 (m, 1H), 7.54 - 7.43 (m, 2H), 5.81 (d, J= 8.4 Hz, 1H), 4.52 (d, J= 6.Hz, 1H), 4.43 (d, J= 1.6 Hz, 1H), 4.25 - 4.17 (m, 1H), 4.17 - 4.08 (m, 1H), 3.92 (t, J= 8.8 Hz, 2H), 3.81 - 3.67 (m, 5H), 3.52 - 3.38 (m, 8H), 3.25 - 2.99 (m, 6H), 2.91 - 2.85 (m, 4H), 2.82 - 2.66 (m, 2H), 2.37-2.15 (m,3H), 2.13 - 2.04 (m, 2H), 1.98 - 1.88 (m, 1H), 1.81 - 1.57(m, 3H), 1.48 (d, J= 6.0 Hz, 3H), 1.05 - 0.95 (m, 3H), 0.66 - 0.57 (m, 3H).
Example 14 (lS,2S)-2-(difluoromethyl)-AM(7S,13S)-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-(4- methylpiperazin-l-yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl] cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazm-l-yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate E) and (lS,2>S)-2-(difluoromethyl)cyclopropanecarboxylic acid instead of (75,135)-7-amino-(20A/)-20-[2-[(l>S)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17- dimethyl-15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’l3.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (lS,25)-2- methylcyclopropanecarboxylic acid. Example 14(28.7 mg) was obtained as a yellow solid. MS cak ’d 859.4 (MH+), measured 859.5 (MH+). *H NMR (400 MHz, METHANOL- 8 = 8.47 (d, J= 2.8 Hz, 1H), 8.38 (s, 1H), 7.51 - 7.47 (m, 2H), 7.41 (s, 1H), 5.82 - 5.79 (m, 2H), 4.44 (m, 2H), 4.26 - 4.19 (m, 2H), 4.12 - 4.02 (m, 1H), 3.80 - 3.68 (m, 3H), 3.65 - 3.49 (m, 2H), 3.45 - 3.40 (m, 2H), 3.38 - 3.33 (m, 5H), 3.29 - 3.26 (m, 1H), 3.15 - 3.01 (m, 3H), 3.01 - 2.97 (m, 4H), 2.73 - 2.81 (m, 1H), 2.64-2.57 (m, 1H), 2.35 - 2.26 (m, 1H), 2.21 -2.14(m, 2H), 2.12- 1.94(m,2H), 1.83 - 1.73 (m, 2H), 1.66- 1.58 (m, 1H), 1.45 (d,J=6.0Hz, 3H), 1.34- 1.28 (m, 1H), 1.18- 1.09 (m, 2H), 0.96 (s, 3H), 0.55 (s, 3H).
Example 15 (lS,5.R,6r)-AM(7S,13S)-(20A/)-20-[2-[(LS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-3-oxabicyclo[3.1.0]hexane-6-carboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazm-l-yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate E) and (lS,57?,6r)-3-oxabicyclo[3.1.0]hexane-6-carboxylic acid instead of (75,135)-7-amino-(20A/)-20-[2-[(l>S)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17- dimethyl-15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’l3.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (lS,25)-2- methylcyclopropanecarboxylic acid. Example 15(26.8 mg) was obtained as a yellow solid. MS cak ’d 851.4 (MH+), measured 851.4 (MH+). *H NMR (400 MHz, Methanol-J 4) 8 = 8.48 (d, J= 2.8 Hz, 1H), 8.39 (s, 1H), 7.59 (d, J= 2.8 Hz, 1H), 7.50 (s, 1H), 7.43 (s, 1H), 5.77 (d, J= 8.0 Hz, 1H), 4.90 - 4.88 (m, 1H), 4.50 - 4.41 (m, 2H), 4.25 - 4.18 (m, 2H), 4.14 - 4.01 (m, 1H), 3.99 - 3.86 (m, 3H), 3.81 - 3.70 (m, 5H), 3.66 - 3.52 (m, 3H), 3.45 - 3.39 (m, 2H), 3.38 (s, 3H), 3.28 - 3.24 (m, 1H), 3.14- 3.07 (m, 2H), 2.99 (s, 4H), 2.81 - 2.74 (m, 1H), 2.62 (d, J= 14.4 Hz, 1H), 2.36 - 2.27 (m, 1H), 2.21-2.14 (m, 2H), 2.12 - 2.09 (m, 1H), 2.08 - 2.04 (m, 1H), 1.97 - 1.90 (m, 1H), 1.82- 1.73 (m, 1H), 1.69 (t, J= 2.8 Hz, 1H), 1.65 - 1.57 (m, 1H), 1.46 (d, J= 6.4 Hz, 3H), 1.39 - 1.25 (m, 1H), 0.97 (s, 3H), 0.56 (s, 3H).
Example 16 (l/?,25)-2-cyclopropyl-^-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4- methylpiperazin-l-yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl] cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate E) and (17?,2S)-2-cyclopropylcyclopropanecarboxylic acid instead of (75,135)-7-amino-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-morphohno-3-pyridyl]-l 7,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (lS,25)-2- methylcyclopropanecarboxylic acid. Example 16(8 mg) was obtained as a yellow solid. MS cak ’d 849.4 (MH+), measured 849.4 (MH+). 1H NMR (400 MHz, METHANOL-d) 8 = 8.48 (d, J= 3.2 Hz, 1H), 8.39 (d, J= 2.4 Hz, 1H), 7.63 (d, J =2.8 Hz, 1H), 7.50 (d, J=8.0 Hz, 1H), 7.(d, J= 2.8 Hz, 1H), 5.77 (d, J= 8.4 Hz, 1H), 4.53 - 4.39 (m, 2H), 4.28 - 4.05 (m, 3H), 3.83 - 3.(m, 3H), 3.65 - 3.50 (m, 3H), 3.47 - 3.34 (m, 6H), 3.29 - 3.24 (m, 1H), 3.15 - 2.93 (m, 7H), 2.- 2.72 (m, 1H), 2.61 (d,J= 14.4 Hz, 1H), 2.38 - 2.27 (m, 1H), 2.23-2.13 (m, 2H), 1.98- 1.(m, 1H), 1.83 - 1.70 (m, 1H), 1.66- 1.54 (m, 2H), 1.46 (d, J = 6.4 Hz, 3H), 1.33 - 1.28 (m, 1H), 1.09 - 0.71 (m, 6H), 0.71 - 0.63 (m, 1H), 0.61 - 0.50 (m, 3H), 049 - 0.39 (m, 2H), 0.20 - 0.13 (m, 2H).
Example 17 (15,2S)-A,-[(7S',135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-methyl-cyclopropanecarboxamide -ill- The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazm-l-yl)-3-pyridyl]- 17,17-dimethyl- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate H) instead of (7S,13S)-7-amino-(207W)-20-[2-[(lS)-l-methoxyethyl]-5- morpholino-3-pyridyl] -17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F).Example 17(4.8 mg) was obtained as a white solid. MS calc ’d 825.4 (MH+), measured 825.4 (MH+). 1H NMR (400 MHz, ACETONITRILE-d) d = 8.42 (d, J= 3.0 Hz, 1H), 8.24 - 8.10 (m, 1H), 7.46 - 7.37 (m, 1H), 7.14 (d, J= 3.1 Hz, 1H), 7.08 - 6.94 (m, 2H), 5.64 (s, 1H), 4.67 - 4.53 (m, 2H), 4.52 - 4.34 (m, 3H), 4.31 - 4.15 (m, 2H), 3.77 - 3.61 (m, 3H), 3.60 - 3.44 (m, 1H), 3.40 (s, 5H), 3.26 (s, 3H), 3.17 - 3.07 (m, 1H), 3.05 - 2.97 (m, 1H), 2.95 - 2.85 (m, 4H), 2.73 - 2.63 (m, 2H), 2.55 (s, 4H), 1.77 (td, J= 2.6, 4.9 Hz, 1H), 1.59 - 1.(m, 2H), 1.37 (d,J= 6.1 Hz, 3H), 1.30- 1.25 (m, 1H), 1.19- 1.13 (m, 1H), 1.10- 1.06 (m,3H), 0.97 (s, 3H), 0.63 - 0.56 (m, 1H), 0.46 (s, 3H).
Example 18 (15,25)-^-[(75,135)-23,23-difluoro-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4- methylpiperazin-l-yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-methyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-23,23-difluoro-(20A/)-20-[2-[(l>S)-l-methoxyethyl]-5-(4-methylpiperazin-l- yl)-3-pyridyl] -17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate K) instead of (7S,13S)-7-amino-(207l7)-20-[2-[(15)-l-methoxyethyl]-5- morpholino-3-pyridyl]-17,1 7-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F).Example 18(11.2 mg) was obtained as a yellow solid. MS cak ’d 859.4 (MH+), measured 859.4 (MH+). 1H NMR (400 MHz, Methanol-d4) 6 = 8.55 - 8.46 (m, 2H), 7.56 (s, 2H), 7.53 (d, J= 2.8 Hz, 1H), 5.82 - 5. 73 (m, 1H), 4.63 - 4.38 (m, 3H), 4.24 (dd, J= 11.6, 2.8 Hz, 1H), 4.18 - 3.85 (m, 3H), 3.82 - 3.68 (m, 3H), 3.68 - 3.45 (m, 5H), 3.45 - 3.39 (m, 2H), 3.37 (s, 3H), 3.30 - 3.24 (m, 2H), 3.14 - 3.08 (m, 1H), 2.98 (s, 3H), 2.82 - 2.72 (m, 1H), 2.65 - 2.57 (m, 1H), 2.23 - 2.12 (m, 1H), 2.01 - 1.87 (m, 1H), 1.85 - 1.71 (m, 1H), 1.68 - 1.54 (m, 1H), 1.52- 1.45 (m, 4H), 1.28- 1.18 (m, 1H), 1.16- 1.11 (m, 3H), 1.09- 1.04 (m, 1H), 0.98 (s, 3H), 0.67 - 0.61 (m, 1H), 0.56 (s, 3H).
Example 19 2,2-difluoro-A^-[(75,135)-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-l-methyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazm-l-yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate E) and 2,2-difluoro-l-methyl-cyclopropanecarboxylic acid instead of (75,135)-7-amino-(2037)-20-[2-[(15)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.0l9’27.02l’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 19(11 mg) was obtained as a yellow solid. MS cak ’d 859.4 (MH+), measured 859.6 (MH+). *H NMR (400 MHz, METHANOL-d) 8 = 8.49 (d, J= 2.8 Hz, 1H), 8.39 (d, J= 6.4 Hz, 1H), 7.66 - 7.57 (m, 1H), 7.53 - 7.47 (m, 1H), 7.43 (s, 1H), 5.85 - 5.70 (m, 1H), 4.53 - 4.46 (m 1H), 4.42 (d, J= 12.4 Hz, 1H), 4.29 - 4.18 (m, 2H), 4.15 - 4.04 (m, 1H), 3.77 - 3.73 (m, 2H), 3.66 - 3.52 (m, 3H), 3.47 - 3.39 (m, 6H), 3.38 - 3.33 (m, 3H), 3.15 - 3.08 (m, 2H), 3.01 - 2.95 (m, 4H), 2.82 - 2.73 (m, 1H), 2.59 (d, J= 14.4 Hz, 1H), 2.34 - 2.26 (m, 1H), 2.23 -2.14 (m, 2H), 2.13-2.02 (m, 1H), 1.98 - 1.90 (m, 1H), 1.85 - 1.73 (m, 1H), 1.57 (s, 4H), 1.46 (d, J= 6.4 Hz, 3H), 1.41-1.28 (m, 2H), 0.99 (s, 3H), 0.54 (s, 3H).
Example 21 (15,25)-2-(difluoromethyl)-2V-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,2,2- trifluoroethyl)piperazin-l-yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-7-yl]cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,13S)-7-amino-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin-l-yl]- 3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate G) and (lS,2>S)-2-(difluoromethyl)cyclopropanecarboxylic acid instead of (75,135)-7-amino-(20A/)-20-[2-[(l>S)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17- dimethyl-15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (lS,25)-2- methylcyclopropanecarboxylic acid. Example 21(7.3 mg) was obtained as a yellow solid. MS cak ’d 927.4 (MH+), measured 927.4 (MH+). 1H NMR (400 MHz, METHANOL-d) d = 8.42 (s, 1H), 8.37 (d, J= 2.8 Hz, 1H), 7.80 (d, J= 2.8 Hz, 1H), 7.50 (s, 1H), 7.45 (s, 1H), 5.94 - 5.66 (m, 2H), 4.54 - 4.48 (m, 1H),4.42 (d, J= 11.6 Hz, 1H), 4.21 (dd, J= 2.8, 12.4 Hz, 1H), 4.16 - 4.(m, 1H), 3.80 - 3.72 (m, 2H), 3.49 - 3.45 (m, 4H), 3.42 - 3.40 (m, 3H), 3.29 - 3.23 (m, 1H), 3.- 3.11 (m, 3H), 3.11 - 3.00 (m, 3H), 2.89 - 2.85 (m, 4H), 2.81 - 2.74 (m, 1H), 2.73 - 2.67 (m, 1H), 2.36 - 2.29 (m, 1H), 2.21 -2.13(m, 2H), 2.07 - 2.02 (m, 1H), 1.95 - 1.89 (m, 1H), 1.81 - 1.72 (m, 2H), 1.65 - 1.57 (m, 1H), 1.47 (d, J= 6.4 Hz, 3H), 1.30 - 1.27 (m, 1H), 1.16 - 1.08 (m, 2H), 0.(s, 3H), 0.62 (s, 3H).
Example 22 (lS',21S)-7V-[(7.S',13A)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-phenyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazm-l-yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate E) and (15,25)-2-phenylcyclopropanecarboxylic acid instead of (75,135)-7-amino-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.0l9’27.02l’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 22(21.7 mg) was obtained as a yellow solid. MS cak ’d 885.4 (MH+), measured 885.4 (MH+). *H NMR (400 MHz, Methanol-J 4) 8 = 8.48 (d, J= 2.8 Hz, 1H), 8.40 (s, 1H), 7.58 (d, J= 2.8 Hz, 1H), 7.51 (s, 1H), 7.43 (s, 1H), 7.29 - 7.24 (m, 2H), 7.20 - 7.13 (m, 3H), 5.82 (d, J= 7.2 Hz, 1H), 4.92 - 4.87 (m, 1H), 4.50 - 4.40 (m, 2H), 4.26 - 4.19 (m, 2H), 4.15 - 3.81 (m, 2H), 3.76 (d, J= 1.6 Hz, 2H), 3.65 - 3.51 (m, 3H), 3.45 - 3.40 (m, 2H), 3.38 (s, 3H), 3.29 - 3.22 (m, 2H), 3.18 - 3.05 (m, 3H), 2.99 (s, 4H), 2.82 - 2.75 (m, 1H), 2.62 (d,J= 14.0 Hz, 1H), 2.38 - 2.30 (m, 2H), 2.23 - 2.15 (m, 2H), 2.08 - 2.04 (m, 1H), 1.97- 1.91 (m, 1H), 1.81 - 1.72 (m, 1H), 1.66- 1.58 (m, 1H), 1.54- 1.49 (m, 1H), 1.46 (d, J= 6.4 Hz, 3H), 1.32 - 1.28 (m, 1H), 0.97 (s, 3H), 0.56 (s, 3H).
Example 24 (lr,27?,35)-7V-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2,3-dimethyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,13S)-7-amino-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate E) and (l/2,־S,3R)-2,3-dimethylcyclopropanecarboxylic acid (CAS 34669-51-7) instead of (75,13S)-7-amino-(207IT)-20-[2-[(l lS)-l-methoxyethyl]-5-morpholino-3- pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F)and (lS,2>S)-2-methylcyclopropanecarboxylic acid. Example 24(7.mg) was obtained as a white solid. MS cak ’d 837.4 (MH+), measured 837.4 (MH+). 1H NMR (400 MHz, Methanol-d.) <5 = 8.33 - 8.25 (m, 2H), 7.37 (s, 1H), 7.29 (s, 1H), 7.17 (d, J= 2.8 Hz, 1H), 5.72 - 5.64 (m, 1H), 4.47 (br s, 2H), 4.36 - 4.24 (m, 2H), 4.17 - 4.08 (m, 2H), 3.66 - 3.62 (m, 2H), 3.54 - 3.45 (m, 1H), 3.34 - 3.26 (m, 5H), 3.18 - 3.13 (m, 1H), 3.02 - 2.85 (m, 3H), 2.73 - 2.61 (m, 5H), 2.50 (br d, J= 14.3 Hz, 1H), 2.38 (s, 3H), 2.25 - 2.15 (m, 1H), 2.12-2.02 (m, 2H), 1.82(brd, 13.3 Hz, 1H), 1.71 - 1.58 (m, 1H), 1.49 (dq, J= 3.6, 12.5 Hz, 1H), 1.36- 1.31 (m,3H), 1.30-1.21 (m, 2H), 1.08 - 0.94 (m, 8H), 0.86 - 0.81 (m, 3H), 0.46 - 0.40 (m, 3H).
Example 25 (lS,2S)-AM(7S,13S)-(20A/)-20-[5-[(9«S)-3,4,6,7,9,9«-hexahydro-EH-pyrazino[2,l- c][l,4]oxazin-8-yl]-2-[(l،؟)-l-methoxyethyl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4- thia-9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l913.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-7-yl]-2-methyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-(20A/)-20-[5-[(9rz5)-3,4,6,7,9,9rz-hexahydro-177-pyrazino[2,l-c][l,4]oxazin-8-yl]-2- [(15)- l-methoxyethyl]-3-pyridyl]-7-amino- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate L) instead of (75,135)-7-amino-(20X)-20-[2-[(15)-l-methoxyethyl]-5- morpholino-3-pyridyl]-17,1 7-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F).Example 25(35.4 mg) was obtained as a yellow solid. MS calc ’d 865.4 (MH+), measured 865.5 (MH+). 1H NMR (400 MHz, METHANOL-d4) 5 = 8.48 (s, 1H), 8.39 (s, 1H), 7.71 - 7.59 (m, 1H), 7.50 (s, 1H), 7.43 (s, 1H), 5.77 (d, J= 8.4 Hz, 1H), 4.51 - 4.(m, 2H), 4.31 - 4.15 (m, 3H), 4.11- 3.92 (m, 4H), 3.89 - 3.84 (m, 1H), 3.84 - 3.68 (m, 3H), 3.67 - 3.58 (m, 4H), 3.51 - 3.45 (m, 1H), 3.43 - 3.40 (m, 1H), 3.39 - 3.29 (m, 3H), 3.27 - 3.19 (m, 1H), 3.17 - 3.05 (m, 3H), 3.05 - 2.94 (m, 2H), 2.81 - 2.72 (m, 1H), 2.61 - 2.43 (m, 1H), 2.37 - 2.28 (m, 1H), 2.17- 1.98 (m, 2H), 1.94- 1.88 (m, 1H), 1.82- 1.73 (m, 1H), 1.66 - 1.56 (m, 1H), 1.50- 1.45 (m, 4H), 1.27- 1.19 (m, 1H), 1.12 (d, J= 6.0 Hz, 3H), 1.10- 1.01 (m, 1H), 0.98 (s, 3H), 0.66-0.61 (m, lH),0.56(s, 3H).
Example 28 and Example 29 (ll?,21?)-2-(2-fluorophenyl)-^-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4- methylpiperazin-l-yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl] cyclopropanecarboxamide and (15,25)-2-(2-fluorophenyl)-7V-[(75,135)-(20A/)-20-[2- [(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15- oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-7-yl]cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20L/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazm-l-yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate E) and t/־،z«5-2-(2-fluorophenyl)cyclopropanecarboxylic acid instead of (75,13S)-7-amino-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]-l 7,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.0l9’27.02l’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid and then purified by prep-HPLC and SEC.SEC conditions: Instrument: SEC 150 Mgm; Column: TCI Chiral MB-S 250x30 mml.D., pm. Mobile phase: A for CO2 and B for IP A (0.1%NH3H2O); Gradient: B 35%; Flow rate: 80mL /min; Back pressure: 100 bar Column temperature: 35°C.Example 28(4.8 mg, SEC, slower eluted) was obtained as a yellow solid. MS calc ’d 903.(MH+), measured 903.4 (MH+). ,H NMR (400 MHz, Methanol-،/ 4) 8 = 8.47 (d, J= 3.2 Hz, 1H), 8.40 (s, 1H), 7.52 - 7.48 (m, 2H), 7.42 (s, 1H), 7.26 - 7.20 (m, 1H), 7.14 - 7.04 (m, 3H), 5.87 - 5.81 (m, 1H), 4.48 - 4.42 (m, 2H), 4.28 - 3.97 (m, 4H), 3.76 (s, 3H), 3.62 - 3.55 (m, 2H), 3.46 -3.41 (m, 2H), 3.39 - 3.37 (m, 3H), 3.28 - 3.25 (m, 1H), 3.13 - 3.08 (m, 2H), 2.99 (s, 5H), 2.82 -2.75 (m, 1H), 2.61 - 2.52 (m, 2H), 2.35 - 2.28 (m, 1H), 2.27 - 2.00 (m, 4H), 1.97 - 1.91 (m, 1H),1.82 - 1.73 (m, 1H), 1.65 - 1.58 (m, 1H), 1.50 - 1.43 (m, 4H), 1.42 - 1.23 (m, 2H), 1.00 - 0.95 (m,3H), 0.57 - 0.51 (m, 3H).Example 29(5.3 mg, SEC, faster eluted) was obtained as a white solid. MS calc ’d 903.(MH+), measured 903.4 (MH+). 1H NMR (400 MHz, Methanol-،/ 4) 8 = 8.47 - 8.39 (m, 2H), 7.- 7.49 (m, 1H), 7.46 - 7.39 (m, 1H), 7.30 - 7.20 (m, 2H), 7.19 - 7.02 (m, 3H), 5.93 - 5.83 (m, 1H), 4.73 - 4.50 (m, 6H), 4.47 - 4.36 (m, 1H), 4.31 - 4.21 (m, 1H), 3.80 - 3.57 (m, 3H), 3.51 - 3.41 (m, 1H), 3.32 - 3.27 (m, 3H), 3.17 - 2.97 (m, 2H), 2.86 - 2.75 (m, 1H), 2.70 - 2.60 (m, 4H), 2.58 -2.51 (m, 1H), 2.41 - 2.29 (m, 3H), 2.25 - 2.12 (m, 3H), 1.98 - 1.90 (m, 1H), 1.84 - 1.69 (m, 1H),1.66 - 1.58 (m, 1H), 1.56 - 1.50 (m, 1H), 1.48 - 1.41 (m, 3H), 1.38 - 1.34 (m, 1H), 1.33 - 1.27 (m,3H), 1.00 - 0.94 (m, 3H), 0.93 - 0.84 (m, 1H), 0.61 - 0.50 (m, 3H).
Example 30 (15,25)-7V-[(75,135)-(20Af)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-(2-pyridyl)cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20A/)-20-[2-[( 15)-1 -metho xyethyl]-5-(4-methylpiperazin- 1 -yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo [23.3.1.12’5. l9J3.0l9’27.0212]hentriaconta- 1(28),2,5(31), 19,25(29),26-hexaene-8,14-dione (Intermediate E) and h־،z?J5-2-(2-pyridyl)cyclopropanecarboxylic acid instead of (75,131S)-7-amino-(20vW)-20-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid and then purified by prep-HPLC and SEC.SEC conditions: Instrument: SEC 150 Mgm; Column: TCI Chiral MB-S 250><30 mm I.D., 5pm. Mobile phase: A for CO2 and B for IP A (0.1%NH3H2O); Gradient: B 35%; Flow rate: 80mL /min; Back pressure: 100 bar Column temperature: 35°C.
Example 30(3.2 mg, SEC, faster eluted) was obtained as a yellow solid. MS calc ’d 886.(MH+), measured 886.4 (MH+). 1H NMR (400 MHz, Methanol-d4) d 8.26 - 8.33 = ־ (m, 3H), 7.- 7.56 (m, 1H), 7.41 - 7.37 (m, 1H), 7.31 - 7.28 (m, 1H), 7.25 - 7.21 (m, 1H), 7.16 - 7.13 (m, 1H), 7.13 - 7.07 (m, 1H), 5.76 - 5.68 (m, 1H), 4.53 - 4.42 (m, 6H), 4.34 - 4.25 (m, 2H), 4.16 - 4.09 (m, 2H), 3.69 - 3.63 (m, 2H), 3.54 - 3.47 (m, 1H), 3.35 - 3.29 (m, 1H), 3.04 - 2.89 (m, 3H), 2.73 - 2.62 (m, 1H), 2.57 - 2.48 (m, 5H), 2.44 - 2.37 (m, 1H), 2.28 - 2.17 (m, 5H), 2.14 - 2.03 (m, 2H), 1.86 - 1.79 (m, 1H), 1.71 - 1.42 (m, 5H), 1.37 - 1.32 (m, 3H), 0.89 - 0.75 (m, 4H), 0.49 - 0.41 (m, 3H).
Example 31 (lS,2S)-^-[(7S,135)-23,23-difluoro-(20A0-20-[2-[(15)-l-methoxyethyl]-5-(4- methylpiperazin-l-yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7- yl]-2-(difluoromethyl)cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (IS, 13S)-7-amino-23,23-difluoro-(20Tf)-20-[2-[(lS)- 1 -methoxyethyl]-5-(4-methylpiperazin- 1 - yl)-3-pyridyl] -17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate K) and (lS',2S)-2-(difluoromethyl)cyclopropanecarboxylic acid instead of (71S,,131S)-7-amino-(20vW)-20-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17- dimethyl-15-oxa-4-thia-9, 21,30,31-tetrazahexacyc 10[23.3.1.12’5.19,13.019’27.021,26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (lS,25)-2- methylcyclopropanecarboxylic acid. Example 31(5.1 mg) was obtained as a yellow solid. MS calc ’d 895.4 (MH+), measured 895.4 (MH+). 1H NMR (400 MHz, METHANOL-d) 8 = 8.51 - 8.48 (m, 2H), 7.58 - 7.55 (m, 2H), 7.39 (d, J= 2.8 Hz, 1H), 5.84 - 5.65 (m, 2H), 4.61 - 4.55 (m, 1H), 4.49 - 4.41 (m, 2H), 4.25 (dd, J= 2.8, 12.0 Hz, 1H), 4.10 - 3.99 (m, 2H), 3.94 - 3.86 (m, 1H), 3.81 - 3.68 (m, 3H), 3.66 - 3.56 (m, 3H), 3.53 - 3.40 (m, 3H), 3.35 (s, 4H), 3.28 (s, 1H), 3.14-3.11 (m, 1H), 2.99 (s, 3H), 2.82 - 2.76 (m, 1H), 2.62-2.56 (m, 1H), 2.21 -2.15 (m, 1H), 2.08 - 2.03 (m, 1H), 1.97 - 1.92 (m, 1H), 1.83 - 1.74 (m, 2H), 1.65 - 1.59 (m, 1H), 1.46 (d, J= 6.0 Hz, 3H), 1.32 - 1.28 (m, 1H), 1.19 - 1.10 (m, 2H), 0.97 (s, 3H), 0.55 (s, 3H).
Example 33 (15,27?)-7V-[(75,135)-(20Af)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-methyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75. l35)-7-amino-(20A/)-20-[2-[(l5)-l-mcthoxycthyl]-5-(4-mcthylpipcrazin-l -yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31-tetrazahexacyclo [23.3.1.12’5. l9J3.0l9’27.0212]hentriaconta- 1(28),2,5(31), 19,25(29),26-hexaene- 8,14-dione (Intermediate E) and (15,27?)-2-methylcyclopropanecarboxylic acid instead of (75,135)-7-amino-(20A/)-20-[2-[( 15)-1 -methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 -tetrazahexacyclo[23.3. 1.12’19,13.0 .נl9,27.021,26]hentriaconta-(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 33 (12.5 mg) was obtained as a white solid. MS calc ’d 824.4 (MH+), measured 824.4 (MH+). 1H NMR (400 MHz, METHANOL- 8 = 8.40 -8.36 (m, 1H), 8.32 - 8.28 (m, 1H), 7.46 - 7.43 (m, 1H), 7.42 - 7.38 (m, 1H), 7.35 - 7.30 (m, 1H),5.71 - 5.66 (m, 1H), 4.40 - 4.35 (m, 1H), 4.34 - 4.28 (m, 1H), 4.18 - 4.07 (m, 2H), 4.03 - 3.85 (m,1H), 3.72 - 3.55 (m, 3H), 3.54 - 3.45 (m, 2H), 3.40 - 3.35 (m, 1H), 3.34 - 3.31 (m, 1H), 3.31 -3.24 (m, 6H), 3.17 (br d, J= 8.8 Hz, 2H), 3.04 - 2.97 (m, 2H), 2.93 - 2.87 (m, 4H), 2.72 - 2.(m, 1H), 2.52 - 2.47 (m, 1H), 2.27 - 2.16 (m, 1H), 2.13 - 2.04 (m, 2H), 1.89 - 1.81 (m, 1H), 1.75 - 1.61 (m, 2H), 1.56 - 1.45 (m, 1H), 1.39 - 1.33 (m, 3H), 1.21 - 1.13 (m, 1H), 1.02 - 0.98 (m, 3H), 0.89 - 0.86 (m, 3H), 0.86 - 0.80 (m, 1H), 0.76 - 0.70 (m, 1H), 0.47 - 0.42 (m, 3H).
Example 34 (lS,2S)-2-(difluoromethyl)-A4(7S,13S)-(20A0-20-[2-[(lS)-l-methoxyethyl]-5-(4- methylpiperazin-l-yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl] cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20Af)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazm-l-yl)-3-pyridyl]- 17,17-dimethyl- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate H) and (15,2S)-2-(difluoromethyl)cyclopropanecarboxylic acid instead of (75,135)-7-amino-(20A/)-20-[2-[( 15)-1 -methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9, 21,30,31-tetrazahexacyclo [23.3.1.12,19,13.0 .נl9,27.02l,26]hentriaconta-(28),2,5(31), 19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 34(38.2 mg) was obtained as a light yellow solid. MS calc ’d 861.4 (MH+), measured 861.4 (MH+). 1H NMR (400 MHz, METHANOL-d4) 8 = 8.(d, J= 2.9 Hz, 1H), 8.24 - 8.15 (m, 1H), 7.61 - 7.52 (m, 1H), 7.49 (s, 1H), 7.10 (s, 1H), 5.99 -5.62 (m, 2H), 4.66 - 4.57 (m, 2H), 4.51 (q, J= 63 Hz, 1H), 4.43 (d, J= 12.5 Hz, 1H), 4.33 - 4.(m, 2H), 4.18 - 3.89 (m, 2H), 3.80 - 3.64 (m, 4H), 3.63 - 3.49 (m, 2H), 3.47 - 3.35 (m, 6H), 3.- 3.23 (m, 2H), 3.16 - 3.10 (m, 1H), 2.99 (s, 3H), 2.83 - 2.72 (m, 1H), 2.59 (d, J= 14.5 Hz, 1H), 2.25 - 2.16 (m, 1H), 2.09 - 2.02 (m, 1H), 1.95 (d, J = 12.6 Hz, 1H), 1.87 - 1.71 (m, 2H), 1.68 - 1.55 (m, 1H), 1.46 (d, J = 6.3 Hz, 3H), 1.21 - 1.08 (m, 2H), 1.00 (s, 3H), 0.53 (s, 3H).
Example 35 (lS,57?,6r)-A,-[(7S,135)-(20Af)-20-[2-[(l lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl] -3-oxabicyclo [3.1.0] hexane-6-carboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (7S,135)-7-amino-(20Af)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]- 17,17-dimethyl- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate H) and (IS.5/?,6/3-(׳-oxabicyclo[3. 1.0]hcxanc-6-carboxylic acid instead of (75,135)-7-amino-(20Af)-20-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17- dimethyl-15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- (28),2,5(31 ),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (lS,25)-2- methylcyclopropanecarboxylic acid. Example 35(42.0 mg) was obtained as a light yellow solid. MS cak ’d 853.4 (MH+), measured 853.4 (MH+). ׳H NMR (400 MHz, METHANOL-،/4) <5 = 8.(d,J=2.8Hz, 1H), 8.19 (s, 1H), 7.51 - 7.48 (m, 2H), 7.09 (d,J=0.9Hz, 1H), 5.73 (d,J=7.Hz, 1H), 4.64 - 4.57 (m, 2H), 4.52 - 4.40 (m, 2H), 4.35 - 4.23 (m, 2H), 3.99 - 3.98 (m, 1H), 4.- 3.97 (m, 1H), 3.93 (d, J= 8.6, 11.6 Hz, 2H), 3.80 - 3.67 (m, 6H), 3.58 (d, J= 6.0 Hz, 2H), 3.- 3.34 (m, 6H), 3.30 - 3.19 (m, 4H), 3.12 (d, J= 14.3 Hz, 1H), 2.78 (t, J= 2.8, 13.0 Hz, 1H), 2.(d, J= 14.5 Hz, 1H), 2.26 - 2.16 (m, 1H), 2.14 - 2.09 (m, 1H), 2.09 - 1.99 (m, 2H), 1.99 - 1.(m, 1H), 1.87 - 1.73 (m, 1H), 1.69 (t,J= 3.1 Hz, 1H), 1.67 - 1.55 (m, 1H), 1.46 (d,J=6.1 Hz, 3H), 1.00 (s, 3H), 0.52 (s, 3H).
Example 37 (ll?,21S)-2-cyclopropyl-A,-[(75,131S)-(20A/)-20-[2-[(l1S)-l-methoxyethyl]-5-morpholino-3- pyridyl] -17,17-dimethyl-8,14-dioxo-l 5-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7- yl] cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (17?,25)-2-cyclopropylcyclopropanecarboxylic acid instead of (lS,25)-2- methylcyclopropanecarboxylic acid. Example 37(23.1 mg) was obtained as a yellow solid. MS cak ’d 836.4 (MH+), measured 836.6 (MH+). ,H NMR (400 MHz, METHANOL-d) 8 = 8.41 (d, J= 2.4 Hz, 1H), 8.37 (d, J= 2.8 Hz, 1H), 7.73 (d, J= 2.4 Hz, 1H), 7.50 (d, J= 8.4 Hz, 1H), 7.(d, J= 4.0 Hz, 1H), 5.80 (d, J= 7.2 Hz, 1H), 4.55 - 4.48 (m, 1H), 4.42 (d, J= 13.2 Hz, 1H), 4.- 4.18 (m, 1H), 4.18-4.11 (m, 1H), 3.86 (t, J= 4.8 Hz, 4H), 3.75 (d, J= 6.4 Hz, 2H), 3.70 - 3.(m, 1H), 3.61 (d, J= 6.8 Hz, 1H), 3.42 - 3.37 (m, 8H), 3.28 - 3.23 (m, 1H), 3.11 - 3.03 (m, 2H), 2.81 - 2.72 (m, 1H), 2.71 - 2.64 (m, 1H), 2.22 - 2.14 (m, 2H), 1.97 - 1.89 (m, 1H), 1.80 - 1.70 (m, 1H), 1.64- 1.54 (m, 2H), 1.47 (d, J= 6.0 Hz, 3H), 1.34- 1.29 (m, 1H), 1.20- 1.16 (m, 1H), 1.- 0.94 (m, 4H), 0.91 - 0.86 (m, 1H), 0.70 - 0.64 (m, 1H), 0.60 (s, 3H), 0.49 - 0.39 (m, 2H), 0.20 - 0.14 (m, 2H).
Example 38 (15,25)-^-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-morphoUno-3-pyridylJ- 17,17,23,23-tetramethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l913.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-methyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-morphohno-3-pyridyl]-l 7,17,23,23- tetramethyl- 15,24-dioxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate M) instead of (75,135)-7-amino-(207l7)-20-[2-[(15)-l-methoxyethyl]-5- morpholino-3-pyridyl]-17,1 7-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F).Example 38(8.3 mg) was obtained as a white solid. MS calc ’d 840.4 (MH+), measured 840.4 (MH+). 1H NMR (400 MHz, METHANOL-d4) 5 = 8.37 (d, J= 2.Hz, 1H), 8.21 (s, 1H), 7.75 (s, 1H), 7.48 (s, 1H), 7.08 (s, 1H), 5.82 - 5.80 (m, 1H), 4.74 - 4.60 (m, 1H), 4.50 - 4.38 (m, 1H), 4.28 - 4.16 (m, 1H), 4.03 - 3.92 (d, J=12.4 Hz 1H), 3.90 - 3.82 (t, J=4.8, 5H), 3.81 - 3.74 (s, 2H), 3.64 (d, J= 12.4 Hz, 1H), 3.42 - 3.38 (m, 7H), 3.14 - 3.01 (m, 1H), 2.-2.73 (m, lH),2.69(d, J= 14.3 Hz, 1H), 2.20 (m, 1H), 2.01 - 1.88 (m, 1H), 1.81 - 1.69 (m, 1H), 1.68 - 1.56 (m, 1H), 1.53 - 1.48 (m, 6H), 1.48 - 1.44 (m, 1H), 1.35 (s, 3H), 1.31 - 1.18 (m, 2H), 1.12 (d, 6.0 Hz, 3H), 1.09 - 1.03 (m, 1H), 1.02- 0.97(8, 3H), 0.69 - 0.60 (m, 4H).
Example 40 (15,51?,6r)-7V-[(75,135)-(20A/)-20-[5-[(9«5)-3,4,6,7,9,9a-hexahydro-lJ7-pyrazino[2,l- c][l,4]oxazin-8-yl]-2-[(15)-l-methoxyethyl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4- thia-9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l913.019’27.021’26]hentriaconta- l(28),2,5(31),19,25(29),26-hexaen-7-yl]-3-oxabicyclo[3.1.0]hexane-6-carboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-(207M)-20-[5-[(9،z5)-3,4,6,7,9,9،z-hexahydro-l/7-pyrazino[2,l-c][l,4]oxazin-8-yl]-2- [(15)- l-methoxyethyl]-3-pyridyl]-7-amino- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate L) and (15,57?,6r)-3-oxabicyclo[3.1.0]hexane-6-carboxylic acid instead of (75,135)-7-amino-(20Af)-20-[2-[(15)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17- dimethyl-15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’l3.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 40(17.1 mg) was obtained as a yellow solid. MS cak ’d 893.4 (MH+), measured 893.4 (MH+). *H NMR (400 MHz, Methanol-J 4) 8 = 8.49 (d, J= 2.8 Hz, 1H), 8.40 (s, 1H), 7.54 - 7.50 (m, 2H), 7.44 (s, 1H), 5.78 (d, J= 8.0 Hz, 1H), 4.87 - 4.(m, 1H), 4.49 - 4.42 (m, 2H), 4.28 - 4.20 (m, 2H), 4.16 - 4.05 (m, 4H), 3.98 - 3.92 (m, 2H), 3.- 3.83 (m, 1H), 3.80 - 3.74 (m, 4H), 3.65 - 3.57 (m, 4H), 3.53 - 3.48 (m, 1H), 3.46 - 3.40 (m, 2H), 3.39 (s, 3H), 3.29 - 3.25 (m, 1H), 3.15 - 3.08 (m, 2H), 3.05 - 2.90 (m, 2H), 2.84 - 2.76 (m, 1H), 2.61 (d, J= 14.0 Hz, 1H), 2.37 - 2.29 (m, 1H), 2.24 - 2.17 (m, 2H), 2.15 - 2.07 (m, 2H), 1.99 - 1.91 (m, 1H), 1.85 - 1.75 (m, 1H), 1.71 (t, J=3.2Hz, 1H), 1.66- 1.57 (m, 1H), 1.47 (d, J= 6.Hz, 3H), 1.38 - 1.28 (m, 1H), 0.98 (s, 3H), 0.57 (s, 3H).
Example 41 (15,25)-7V-[(75,135)-(20Af)-20-[5-[(9a5)-3,4,6,7,9,9«-hexahydro-l/7-pyrazino[2,l- c][l,4]oxazin-8-yl]-2-[(15)-l-methoxyethyl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4- thia-9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l913.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-7-yl]-2-(difluoromethyl)cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-(20A/)-20-[5-[(9،z5)-3,4,6,7,9,9،z-hexahydro-177-pyrazino[2,l-c][l,4]oxazin-8-yl]-2- [(15)- l-methoxyethyl]-3-pyridyl]-7-amino- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate L) and (15,25)-2-(difluoromethyl)cyclopropanecarboxylic acid instead of (75,135)-7-amino-(20Af)-20-[2-[(15)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17- dimethyl-15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’l3.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 41(16.4 mg) was obtained as a yellow solid. MS cak ’d 901.4 (MH+), measured 901.4 (MH+). *H NMR (400 MHz, Methanol-J 4) 8 = 8.47 (d, J= 2.8 Hz, 1H), 8.39 (s, 1H), 7.52 - 7.49 (m, 2H), 7.42 (s, 1H), 5.96 - 5.66 (m, 2H), 4.85 - 4.81 (m, 1H), 4.47 - 4.40 (m, 2H), 4.26 - 4.19 (m, 2H), 4.14 - 4.04 (m, 4H), 3.89 - 3.83 (m, 1H), 3.78 - 3.73 (m, 2H), 3.64 - 3.56 (m, 4H), 3.53 - 3.43 (m, 2H), 3.43 - 3.38 (m, 2H), 3.37 (s, 3H), 3.27 - 3.25 (m, 1H), 3.12 - 3.05 (m, 2H), 3.02 - 2.90 (m, 2H), 2.82 - 2.74 (m, 1H), 2.60 (d, J= 14.4 Hz, 1H), 2.35 - 2.28 (m, 1H), 2.21 -2.14(m, 2H), 2.08 - 2.04 (m, 1H), 1.97-1.91 (m, 1H), 1.82- 1.74 (m,2H), 1.65 - 1.56 (m, 1H), 1.45 (d, J=6.0Hz, 3H), 1.19- 1.10 (m,2H), 0.96 (s, 3H), 0.55 (s, 3H).
Example 42 (17?,55,6s)-A^-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-3-oxabicyclo[3.1.0]hexane-6-carboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazm-l-yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate E) and (17?,5S,6s)-3-oxabicyclo[3.1.0]hexane-6-carboxylic acid instead of (75,135)-7-amino-(20A/)-20-[2-[(l>S)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17- dimethyl-15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’l3.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (lS,25)-2- methylcyclopropanecarboxylic acid. Example 42(9 mg) was obtained as a white solid. MS cak ’d 851.4 (MH+), measured 851.6 (MH+). *H NMR (400 MHz, METHANOL-4 ) d = 8.48 (br s, 1H), 8.39 (s, 1H), 7.56 (br s, 1H), 7.49 (s, 1H), 7.41 (s, 1H), 5.78 (br d, J = 7.0 Hz, 1H), 4.51 - 4.38 (m, 2H), 4.29 -4.14 (m, 2H), 3.90 (br d, J= 12.3 Hz, 3H), 3.82 - 3.67 (m, 5H), 3.66 - 3.(m, 3H), 3.36 (s, 7H), 3.28 - 3.22 (m, 1H), 3.17 - 3.02 (m, 3H), 2.97 (s, 4H), 2.83 - 2.71 (m, 1H), 2.69 - 2.56 (m, 1H), 2.17(brd,J= 12.0 Hz, 3H), 2.12 - 2.01 (m, 2H), 1.98 - 1.85 (m, 1H), 1.83- 1.54 (m, 3H), 1.45 (d, J = 6.1 Hz, 3H), 0.96 (s, 3H), 0.55 (s, 3H).
Example 43 (15,25)-^-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-morphoUno-3-pyridyl]-17,17- dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7- yl]-2-phenyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,13S)-7-amino-(2037)-20-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17-dimethyl- 15,24-dioxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’n.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (intermediate J) and (lS,25)-2- phenylcyclopropanecarboxylic acid instead of (7S,135)-7-amino-(20Af)-20-[2-[(15')-l- methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F) and (l>S,,25)-2-methylcyclopropanecarboxylic acid. Example 43 (14.54 mg) was obtained as a light yellow solid. MS cak ’d 874.4 (MH+), measured 874.4 (MH+). 1H NMR (400 MHz, METHANOL-t/4) 8 = 8.37 (d, J = 3.0 Hz, 1H), 8.23 (s, 1H), 7.81 (br d, J = 0.9 Hz, 1H), 7.51 (s, 1H), 7.29 - 7.25 (m, 2H), 7.19 (d, J = 7.5 Hz, 1H), 7.16 - 7.13 (m, 3H), 5.(br d, J = 7.8 Hz, 1H), 4.68 - 4.55 (m, 4H), 4.45 - 4.40 (m, 1H), 4.26 (br d, J = 8.4 Hz, 2H), 3.- 3.84 (m, 5H), 3.77 (d, J = 3.8 Hz, 2H), 3.43 (s, 5H), 3.40 (br s, 3H), 3.17 - 3.13 (m, 1H), 2.(brd, J= 14.1 Hz, 1H), 2.39 - 2.32 (m, 1H), 2.20 (br d, J = 12.6 Hz, 1H), 2.06 - 2.02 (m, 1H), 1.99- 1.91 (m, 1H), 1.85 - 1.73 (m, 1H), 1.69 - 1.59 (m, 1H), 1.49 (d,J= 6.1 Hz, 4H), 1.33- 1.28 (m, 2H), 1.03 (s, 3H), 0.59 (s, 3H).
Example 44 (lS',21S)-A-[(7lS',135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin- l-yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7- yl]-2-phenyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(2037)-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin-l-yl]- 3-pyridyl]- 17,17-dimethyl- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate 1) and (15,25)-2-phenylcyclopropanecarboxylic acid instead of (75,135)-7-amino-(2037)-20-[2-[(15)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.0l9’27.02l’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 44(21.3 mg) was obtained as a light yellow solid. MS cak ’d 955.4 (MH+), measured 955.4 (MH+). *H NMR (400 MHz, METHANOL-d) ،5 = 8.37 (d, J= 2.8 Hz, 1H), 8.22 (s, 1H), 7.66 (d, J = 2.9 Hz, 1H), 7.50 (s, 1H), 7.29 - 7.25 (m, 2H), 7.19 (d, J =7.3 Hz, 1H), 7.14 (d, J = 7.4 Hz, 2H), 7.12 (s, 1H), 5.84 - 5.78 (m, 1H),4.61 (br d, J = 3.9 Hz, 2H), 4.54 (br d, J = 6.3 Hz, 1H), 4.43(brd,J= 10.5 Hz, 1H), 4.26 (dd, J =2.6, 12.Hz, 2H), 3.76 (s, 3H), 3.44 (dt, 5H), 3.40 (s, 3H), 3.28 - 3.22 (m, 1H), 3.19 - 3.11 (m, 3H), 2.(br t, J = 4.8 Hz, 4H), 2.79 (dt, J = 2.9, 13.0 Hz, 1H), 2.65 (d, J = 14.6 Hz, 1H), 2.39 - 2.32 (m, 1H), 2.24-2.17 (m, 1H), 2.09 - 2.04 (m, 1H), 1.99- 1.91 (m, 1H), 1.78 (br d, J = 11.9 Hz, 1H), 1.62 (brdd, J= 3.9, 12.2 Hz, 1H), 1.54- 1.50 (m, 1H), 1.47 (d, J =6.3 Hz, 3H), 1.33 - 1.28 (m, 1H), 1.02 (s, 3H), 0.57 (s, 3H).
Example 45 (lr,25,3/i)-A,-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2,3-dimethyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(2037)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazm-l-yl)-3-pyridyl]- 17,17-dimethyl- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate H) and (l/2,3-(?25,37,־-dimethylcyclopropanecarboxylic acid instead of (75,135)-7-amino-(2037)-20-[2-[(15)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.0l9’27.02l’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 45(32.0 mg) was obtained as a light yellow solid. MS cak ’d 839.4 (MH+), measured 839.4 (MH+). *H NMR (400 MHz, METHANOL-d) ،5 = 8.(d, J =2.8 Hz, 1H), 8.19 (s, 1H), 7.56 - 7.44 (m, 2H), 7.09 (d, J = 1.0 Hz, 1H), 5.73 (d, J = 7.Hz, 1H), 4.86 - 4.83 (m, 1H), 4.66 - 4.57 (m, 2H), 4.51 - 4.39 (m, 2H), 4.37 - 4.23 (m, 2H), 4.(d, J= 2.9 Hz, 2H), 3.79 - 3.69 (m, 3H), 3.61 (d, J = 7.0 Hz, 2H), 3.37 (s, 4H), 3.28 - 3.08 (m, 4H), 2.99 (s, 3H), 2.82 - 2.72 (m, 1H), 2.62 - 2.53 (m, 1H), 2.20 (d, J = 2.8, 12.8 Hz, 1H), 2.00 - 1.91 (m, 1H), 1.86- 1.72 (m, 1H), 1.68 - 1.55 (m, 1H), 1.45 (d, J=6.3Hz, 3H), 1.42 - 1.27 (m, 3H), 1.19 - 1.09 (m, 7H), 1.04 - 0.96 (m, 3H), 0.52 (s, 3H).
Example 46 (15,25)-^-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-morphoUno-3-pyridyl]-17,17- dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7- yl]-2-phenyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (15,25)-2-phenylcyclopropanecarboxylic acid instead of (lS,25)-2- methylcyclopropanecarboxylic acid. Example 46(8 mg) was obtained as a yellow solid. MScak ’d 872.4 (MH+), measured 872.6 (MH+). 1H NMR (400 MHz, METHANOL-d4) 8 = 8.38 (s, 2H), 7.49 (s, 1H), 7.40 (s, 1H), 7.30 - 7.23 (m, 3H), 7.21 - 7.12 (m, 3H), 5.92 - 5.74 (m, 1H), 4.45 - 4.37 (m, 2H), 4.28 - 4.21 (m, 2H), 3.86 (t, J= 4.4 Hz, 4H), 3.76 (s, 2H), 3.62 - 3.56 (m, 1H), 3.46 - 3.42 (m, 1H), 3.14 - 2.97 (m, 4H), 2.82 - 2.74 (m, 1H), 2.65 - 2.59 (m, 1H), 2.39 - 2.29 (m, 2H), 2.23 - 2.16 (m, 2H), 2.08 - 2.03 (m, 1H), 1.96 - 1.90 (m, 1H), 1.80 - 1.72 (m, 1H), 1.67 - 1.54 (m,2H), 1.54- 1.49 (m, 1H), 1.44 (d, J = 6.0 Hz, 3H), 1.34- 1.27 (m, 6H), 0.96 (s, 3H), 0.92 - 0.87 (m, 1H), 0.55 (s, 3H).
Example 47 (l1S',2S)-7V-[(71S',135)-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.Ll2’5.l9l3.0l9’27.02l’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-pyrimidin-5-yl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20vW)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31־ tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate E) and P^n5-2-pyrimidin-5-ylcyclopropanecarboxylic acid (Intermediate RI) instead of (7S,135)-7-amino-(2037)-20-[2-[(15)-l-methoxyethyl]-5- morpho lino-3-pyridyl] -17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F) and (lS',25)-2-methylcyclopropanecarboxylic acid and then purified by prep-HPLC and SEC.SEC conditions: Column DAICEL CHIRALPAKIC (250mm><30mm, 10um); Condition: CO2-EtOH (0.1%NH3H2O); Begin B 70 End B 70; Gradient Time (min) 6.8 100%B Hold; Flow Rate: (mL/min) 100.Example 47(13 mg, SEC, faster eluted) was obtained as a yellow solid. MS cak ’d 887.(MH+), measured 887.6 (MH+). 1H NMR (400 MHz, METHANOL-d4) 8 = 8.91 (s, 1H), 8.60 - 8.50 (s, 2H), 8.38 - 8.24 (d, J= 30 Hz, 2H), 7.45 - 7.37 (s, 1H), 7.33 - 7.25 (d, J = 11.2 Hz, 2H), 5.75 - 5.66 (m, 1H), 4.36 - 4.30 (m, 2H), 4.16-4.11 (m, 2H), 4.03 - 3.97 (m, 1H), 3.68 - 3.64 (s, 2H), 3.49 - 3.43 (m, 2H), 3.39 - 3.35 (m, 1H), 3.34 - 3.31 (s, 1H), 3.23 - 3.22 (m, 1H), 3.04 - 2.95 (m, 3H), 2.90 - 2.86 (s, 4H), 2.74 - 2.65 (m, 1H), 2.52 - 2.39 (m, 2H), 2.34 - 2.27 (m, 1H), 2.25 - 2.16 (m, 1H), 2.13 - 2.08 (m, 4H), 1.88 - 1.82 (m, 1H), 1.71 - 1.64 (m, 1H), 1.56 - 1.51 (m, 2H), 1.36- 1.31 (d, J= 6.4 Hz, 4H), 1.28 - 1.24 (d, J= 6.8 Hz, 2H), 1.20- 1.18 (s, 2H), 0.88 - 0.83 (s, 3H), 0.82 - 0.77 (m, 1H), 0.47 - 0.40 (s, 3H).
Example 48 - l-methoxyethyl]-5-(4-methylpiperazin ،؟(- 20A/)-20-[2-[(l ؟(-) ، 13 ؟, ، 7 -]) 57 -)? 3,3 - difluoro-7V ،؟, l ) l-yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl] bicyclo [3.1.0] hexane-6-carboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(2037)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazm-l-yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate E) and (lS,57?)-3,3-difluorobicyclo[3.1.0]hexane-6-carboxylic acid instead of (75,135)-7-ammo-(2037)-20-[2-[(l lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F) and (lS,25)-2-methylcyclopropanecarboxylic acid. Example 48 (18.1 mg) was obtained as a yellow solid. MS cak ’d 885.4 (MH+), measured 885.6 (MH+). *H NMR (400 MHz, Methanol-،/ 4) <5 = 8.47 (d, J = 2.8 Hz, 1H), 8.38 (s, 1H), 7.52 - 7.48 (m, 2H), 7.42 (s, 1H), 5.77 - 5.71 (m, 1H), 4.89 (s, 1H), 4.48 - 4.40 (m, 2H), 4.26 - 4.19 (m, 2H), 4.17 - 3.85 (m, 2H), 3.75 (s, 2H), 3.67 - 3.52 (m, 3H), 3.37 (s, 3H), 3.28 - 3.24 (m, 1H), 3.12 - 3.06 (m, 2H), 2.99 (s, 4H), 2.81 - 2.73 (m, 1H), 2.60 (d, J = 14.4 Hz, 1H), 2.57 - 2.40 (m, 3H), 2.33 - 2.(m, 6H), 1.97 - 1.83 (m, 4H), 1.82- 1.73 (m, 2H), 1.64 - 1.57 (m, 1H), 1.45 (d, J =6.0 Hz, 3H), 1.34 - 1.29 (m, 1H), 0.96 (s, 3H), 0.55 (s, 3H). Example 49 - 2-135 (-) 20 -^ 20 [- 5 ([- 9 « 7 -)? 1,3,4,6,7,8,9,9a-octahydropyrido[l,2-a]pyrazin ،؟, 7 ؟-]) 7 ،؟(- 2 ،؟, 1 ) yl]-2-[(15)-l-methoxyethyl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-methyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,13S)-(20A/)-20-[5-[(9،zR)-l,3,4,6,7,8,9,9،z-octahydropyrido[l,2-a]pyrazin-2-yl]-2-[(lS)-l- methoxyethyl]-3-pyridyl]-7-amino- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - 5 9 13 19 27 21 tetrazahexacyclo[23.3.1.1 ’ .1 ’ .0 ’ .0 ]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate L2)instead of (7S,13S)-7-amino-(207W)-20-[2-[(lS)-l-methoxyethyl]- 5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F). Example 49(29.8 mg) was obtained as a yellow solid. MS calc ’d 863.5 (MH+), measured 863.6 (MH+). 1H NMR (400 MHz, Methanol-d4) 8 = 8.50 (d, J = 2.8 Hz, 1H), 8.39 (s, 1H), 7.66 (s, 1H), 7.50 (s, 1H), 7.43 (s, 1H), 5.79 - 5.74 (m, 1H), 4.52 - 4.47 (m, 1H), 4.43 ^J= 10.8 Hz, 1H), 4.23 (dd, J =3.0, 12.0 Hz, 1H), 4.21 - 4.07 (m, 3H), 3.78 - 3.(m, 2H), 3.64 - 3.52 (m, 3H), 3.39 (s, 5H), 3.36 - 3.33 (m, 1H), 3.30 - 3.22 (m, 2H), 3.14 - 3.(m, 3H), 3.04 - 2.95 (m, 2H), 2.81 - 2.73 (m, 1H), 2.61 (d, J= 14.4 Hz, 1H), 2.37-2.28 (m, 1H), 2.22-2.14(m, 2H), 2.07- 1.92 (m, 4H), 1.87 - 1.74 (m, 2H), 1.68 - 1.56 (m, 3H), 1.51-1.45 (m, 4H), 1.27 - 1.20 (m, 1H), 1.12 (d, J = 6.0 Hz, 3H), 1.09 - 1.05 (m, 1H), 0.98 (s, 3H), 0.66 - 0.(m, 1H), 0.56 (s, 3H).
Example 50 (lS,2S)-AM(7S,13S)-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l913.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-pyrimidin-4-yl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(2037)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazm-l-yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate E)and 2-pyrimidin-4-ylcyclopropanecarboxylic acid (Intermediate R3) instead of (75,135)-7-ammo-(2037)-20-[2-[(l lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F) and (lS,25)-2-methylcyclopropanecarboxylic acid and then purified by prep-HPLC and SEC.SEC conditions: Column: Chiralpak IG-3 50>4.6mm I.D.,3um; Mobile phase: Phase A for CO2,and Phase B for EtOH+ACN(0.05%DEA); Gradient elution: 60% EtOH+ACN(0.05%DEA) in CO2 , Flow rate:3mL/min; Detector: PDA; Column Temp:35C;Back Pressure: lOOBarExample 50(16.9 mg, SEC, faster eluted) was obtained as a white solid. MS calc ’d 887.(MH+), measured 887.5 (MH+). ,H NMR (400 MHz, METHANOL-،/4) 5 = 8.89 (s, 1H), 8.54 - 8.43 (d, .7=5.2 Hz 1H), 8.35 - 8.23 (m, 2H), 7.44 - 7.38 (d, J=^A Hz, 1H), 7.35 (s, 1H), 7.28 (s, 1H), 7.19 - 7.14 (d,J=2.4 Hz, 1H), 5.81 - 5.69 (d,>8.8 Hz,l H), 4.37 - 4.23 (m, 2H), 4.18 - 4.(m, 2H), 4.03 - 3.96 (m, 3H), 3.60 (s, 2H), 3.52 - 3.45 (m, 1H), 3.27 (s, 3H), 2.98 - 2.90 (m, 2H), 2.63 (s, 3H), 2.55 - 2.48 (m, 1H), 2.42 - 2.39 (m, 1H), 2.36 - 2.28 (m, 3H), 2.13 - 2.07 (m, 3H), 1.87 - 1.80 (m, 1H), 1.71 - 1.59 (m, 1H), 1.56 - 1.46 (m, 3H), 1.30 - 1.35 (d, J= 6.0 Hz, 3H), 1.27 (s, 2H), 1.25 (s, 2H), 1.19 (s, 3H), 0.85 (s, 3H), 0.49 - 0.39 (m, 3H).
Example 51 (15,25)-A,-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl] -17,17-dimethyl-8,14-dioxo-l 5,24-dioxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7- yl]-2-phenyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20Af)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazm-l-yl)-3-pyridyl]- 17,17-dimethyl- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate H) and (15,25)-2-phenylcyclopropanecarboxylic acid instead of (75,135)-7-amino-(2037)-20-[2-[(l lS)-l-methoxyethyl]-5-morphohno-3-pyridyl]-l 7,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 51(19.1 mg) was obtained as a light yellow solid. MS cak ’d 887.4 (MH+), measured 887.4 (MH+). ׳H NMR (400 MHz, METHANOL-،/4) 5 = 8.(d, J = 2.4 Hz, 1H), 8.21 (s, 1H), 7.64 (d, J = 2.6 Hz, 1H), 7.50 (s, 1H), 7.31-7.22 (m, 1H), 7.- 7.00 (m, 5H), 5.78 (d, J = 8.5 Hz, 1H), 4.64 - 4.52 (m, 3H), 4.42 (d, J = 11.8 Hz, 1H), 4.34 - 4.24 (m, 2H), 4.21 - 3.92 (m, 2H), 3.76 (s, 4H), 3.68 - 3.52 (m, 2H), 3.44 - 3.37 (m, 6H), 3.28 - 3.21 (m, 2H), 3.14 (d, J = 14.6 Hz, 1H), 2.98 (s, 3H), 2.78 (d, J = 2.6 Hz, 1H), 2.60 (d, J = 14.Hz, 1H), 2.35 (d, J = 2.8, 6.1 Hz, 1H), 2.21 (d, J= 10.0 Hz, 1H), 2.09 - 2.03 (m, 1H), 1.99 - 1.(m, 1H), 1.85 - 1.73 (m, 1H), 1.66 - 1.56 (m, 1H), 1.54 - 1.45 (m, 4H), 1.32 - 1.26 (m, 1H), 1.(s, 3H), 0.54 (s, 3H).
Example 52 (17?,55,6s)-A,-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl] -17,17-dimethyl-8,14-dioxo-l 5,24-dioxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl] -3-oxabicyclo [3.1.0] hexane-6-carboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,13S)-7-amino-(2037)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]- 17,17-dimethyl- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate H) and (1/?.556.s)-3-oxabicyclo[3. 1.0]hcxanc-6-carboxylic acid instead of (75,135)-7-amino-(20A/)-20-[2-[(l>S)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17- dimethyl-15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (lS,25)-2- methylcyclopropanecarboxylic acid. Example 52(28.2 mg) was obtained as a light yellow solid. MS cak ’d 853.4 (MH+), measured 853.4 (MH+). 1H NMR (400 MHz, METHANOL-،/4) d = 8.(d, J =2.8 Hz, 1H), 8.22 (s, 1H), 7.68 - 7.57 (m, 1H), 7.51 (s, 1H), 7.12(s, 1H), 5.75 (d, J=8.Hz, 1H), 4.71 - 4.59 (m, 2H), 4.54 (q, J = 5.9 Hz, 1H), 4.49 - 4.41 (m, 1H), 4.38 - 4.25 (m, 2H), 4.24 - 4.01 (m, 2H), 4.00 - 3.86 (m, 3H), 3.84 - 3.71 (m, 6H), 3.70 - 3.54 (m, 2H), 3.52 - 3.38 (m, 6H), 3.28 (d, J= 5.8 Hz, 1H), 3.17 - 3.12 (m, 1H), 3.01 (s, 3H), 2.84 - 2.75 (m, 1H), 2.68 - 2.(m, 1H), 2.29 - 2.18 (m, 1H), 2.16 - 2.05 (m, 2H), 2.02 - 1.92 (m, 1H), 1.89 - 1.75 (m, 1H), 1.(t, J=3.1 Hz, 1H), 1.64 (d, J =3.2, 12.7 Hz, 1H), 1.55 - 1.44 (m, 3H), 1.03 (s, 3H), 0.55 (s, 3H).
Example 53 (lS,2^-7V-[(7S,13S,22S)-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17,22-trimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-methyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135,225)-7-amho-(20A/)-20-[2-[(l>S)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17,22- trimethyl- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate N) instead of (7S,13S)-7-amino-(207W)-20-[2-[(lS)-l-methoxyethyl]-5- morpholino-3-pyridyl] -17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F).Example 53(11 mg) was obtained as a white solid. MS calc ’d 826.(MH+), measured 826.4 (MH+). 1H NMR (400 MHz, METHANOL-d) 5 = 8.44 - 8.41 (d, J = 2.8 Hz, 1H), 8.26 (s, 1H), 7.44 - 7.40 (m, 2H), 7.09 - 7.05 (m, 1H), 6.38 (t, J= 6.8 Hz, 1H), 4.- 4.36 (m, 5H), 3.92 - 3.85 (m, 5H), 3.83 - 3.76 (m, 2H), 3.38 - 3.35 (m, 1H), 3.31 - 3.24 (m, 4H), 3.20 - 3.15 (d, J =8.4 Hz, 1H), 3.10 - 3.05 (m, 3H), 2.80-2.71 (m, 1H), 2.43 - 2.36 (d, J = 14.Hz, 1H), 1.79 - 1.67 (m, 2H), 1.63 - 1.58 (m,3H), 1.53 - 1.44(m, 1H), 1.42 - 1.29 (m, 3H), 1.- 1.20 (m, 1H), 1.19- 1.15 (d, 6.8 Hz, 3H), 1.13- 1.08 (m, 3H), 1.05 -0.98 (m, 1H), 0.97-0.(m, 3H), 0.60 - 0.54 (m, 2H), 0.53 (s, 2H).
Example 54 2,2-difluoro-A^-[(75,135)-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7- yl]-l-methyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazm-l-yl)-3-pyridyl]- 17,17-dimethyl- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate H) and 2,2-difluoro-l-methyl-cyclopropanecarboxylic acid instead of (75,135)-7-amino-(2037)-20-[2-[(15)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.0l9’27.02l’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 54(34 mg) was obtained as a light yellow solid. MS cak ’d 861.4 (MH+), measured 861.4 (MH+). *H NMR (400 MHz, METHANOL-d) ،5 = 8.55 - 8.46 (m, 1H), 8.20 (br d, J = 6.1 Hz, 1H), 7.62 (br s, 1H), 7.49 (s, 1H), 7.10 (s, 1H), 5.88 - 5.63 (m, 1H), 4.67 - 4.50 (m, 4H), 4.43 (br d, J = 11.1 Hz, 1H), 4.36 - 4.23 (m, 2H), 4.20 - 3.(m, 2H), 3.78 - 3.69 (m, 3H), 3.67 - 3.52 (m, 2H), 3.40 (s, 7H), 3.16 (br d, J = 14.4 Hz, 2H), 2.(s, 3H), 2.85 - 2.73 (m, 1H), 2.58 (br d, J= 14.0 Hz, 1H), 2.23 (br d, J = 11.4 Hz, 1H), 2.15- 1.90 (m, 2H), 1.89 - 1.73 (m, 1H), 1.69 - 1.54 (m,4H), 1.52- 1.36 (m,4H), 1.02 (s, 3H), 0.52 (s, 3H).
Example 55 7V-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]- 17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7- yl]-l,2-dimethyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazm-l-yl)-3-pyridyl]- 17,17-dimethyl- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate H) and 1,2-dimethylcyclopropanecarboxylic acid instead of (75,135)-7- amino-(2037)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl-15-oxa-4- thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (lS,25)-2- methylcyclopropanecarboxylic acid. Example 55(19.8 mg) was obtained as a light yellow solid. MS cak ’d 839.4 (MH+), measured 839.4 (MH+). 1H NMR (400 MHz, METHANOL-d) ،5 = 8.(s, 1H), 8.26 (s, 1H), 7.66 (s, 1H), 7.52 (s, 1H), 7.16 (s, 1H), 5.80 - 5.65 (m, 1H), 4.74 - 4.46 (m, 4H), 4.46 - 4.38 (m, 1H), 4.37 - 4.22 (m, 2H), 4.20 - 3.91 (m, 2H), 3.75 (s, 4H), 3.68 - 3.53 (m, 2H), 3.52 - 3.34 (m, 8H), 3.21 - 3.08 (m, 2H), 2.84 - 2.71 (m, 1H), 2.64 - 2.50 (m, 1H), 2.31 - 2.15 (m, 1H), 2.03- 1.91 (m, 1H), 1.89 - 1.75 (m, 1H), 1.65 - 1.54 (m, 1H), 1.49- 1.24 (m, 9H), 1.16 (t, 5.3 Hz, 3H), 1.02 (s, 3H), 0.52 (s, 3H), 0.32 (s, 1H).
Example 56 (lS,2S)-AM(7S,13S)-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-(3-pyridyl)cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(2037)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazm-l-yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate E) and (15,25)-2-(3-pyridyl)cyclopropanecarboxylic acid instead of (75,135)-7-amino-(2037)-20-[2-[(15)-l-methoxyethyl]-5-morphohno-3-pyridyl]-l 7,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.0l9’27.02l’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 56(11.6 mg) was obtained as a yellow solid. MS cak ’d 886.4 (MH+), measured 886.6 (MH+). *H NMR (400 MHz, Methanol-J 4) 8 = 8.78 (s, 1H), 8.68 (d, J = 5.2 Hz, 1H), 8.48 (d, J = 3.2 Hz, 1H), 8.40 (s, 1H), 8.33 (d, J = 7.6 Hz, 1H), 7.(dd, J= 8.0, 6.0 Hz, 1H), 7.55 - 7.49 (m, 2H), 7.43 (s, 1H), 5.86 - 5.76 (m, 1H), 4.89 (s, 1H), 4.48 - 4.41 (m, 2H), 4.27 - 4.19 (m, 2H), 4.17 - 3.88 (m, 2H), 3.76 (s, 3H), 3.70 - 3.55 (m, 3H), 3.51 - 3.42 (m, 3H), 3.37 (s, 3H), 3.28 - 3.24 (m, 1H), 3.14 - 3.07 (m, 2H), 2.99 (s, 4H), 2.84 - 2.76 (m, 1H), 2.66 - 2.57 (m, 2H), 2.34 -2.16 (m, 4H), 1.99 - 1.92 (m, 1H), 1.86 - 1.75 (m, 1H), 1.74- 1.69 (m, 1H), 1.67 - 1.59 (m, 1H), 1.58 - 1.54 (m, 1H), 1.46 (d, J = 6.4 Hz, 3H), 0.97 (s, 3H), 0.56 (s, 3H). Example 57 and Example 58 (15,25)-7V-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-(4-pyridyl)cyclopropanecarboxamide and (lR,2.R)-7V-[(75,135)-(20A/)-20-[2-[(15)-l- methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4- thia-9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l913.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-7-yl]-2-(4-pyridyl)cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,13S)-7-amino-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate E) and P־،zw5-2-(4-pyridyl)cyclopropanecarboxylic acid (Intermediate R4)instead of (75,135)-7-amino-(207l7)-20-[2-[(l lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F) and (lS,25)-2-methylcyclopropanecarboxylic acid and then purified by prep-HPLC and SEC.SEC conditions: Column DAICEL CHIRALCEL OJ(250mm><30mm,10pm); Condition CO2-EtOH(0.1%NH3H2O); Begin B 30 End 30; Gradient Time(min) 4 100%B Hold; Flow Rate(mL/min) 120Example 57(6.5 mg, SEC, faster eluted) was obtained as a white solid. MS calc ’d 886.(MH+), measured 886.4 (MH+). 1H NMR (400 MHz, Methanol-،/ 4) 8 = 8.43 - 8.35 (m, 4H), 7.(s, J= 2.0 Hz, 1H), 7.40 (s, 1H), 7.28 - 7.19 (m, 3H), 5.81 (d, J= 8.8 Hz, 1H), 4.45 - 4.35 (m, 2H), 4.27 - 4.18 (m, 2H), 3.75 (s, 2H), 3.64 - 3.54 (m, 1H), 3.43 (d, J= 15.2 Hz, 1H), 3.38 - 3.(m, 2H), 3.29 - 3.20 (m, 2H), 3.14 - 2.91 (m, 4H), 2.78 (t, J= 12.8 Hz, 1H), 2.67 - 2.60 (m, 5H), 2.40 - 2.35 (m, 4H), 2.32 - 2.25 (m, 1H), 2.23 - 2.13 (m, 3H), 1.98 - 1.89 (m, 1H), 1.80 - 1.69 (m, 1H), 1.66 - 1.57 (m, 2H), 1.43 (d, J= 6.0 Hz, 4H), 1.38 - 1.22 (m, 2H), 1.03 - 0.82 (m, 4H), 0.(s, 3H).Example 58(7.6 mg, SEC, slower eluted) was obtained as a white solid. MS calc ’d 886.(MH+), measured 886.4 (MH+). 1H NMR (400 MHz, Methanol-،/ 4) 8 = 8.45 - 8.35 (m, 4H), 7.48 (s, 1H), 7.39 (s, 1H), 7.33 - 7.27 (m, 1H), 7.25 (d, J= 5.2 Hz, 2H), 5.84 (d, J= 9.2 Hz, 1H), 4.- 4.34 (m, 2H), 4.28 - 4.19 (m, 2H), 3.76 (s, 2H), 3.64 - 3.54 (m, 1H), 3.49 - 3.41 (m, 4H), 3.27 - 3.22 (m, 1H), 3.13 - 2.97 (m, 4H), 2.95 - 2.90 (m, 2H), 2.82 - 2.75 (m, 1H), 2.64 - 2.51 (m, 4H), 2.46 - 2.38 (m, 1H), 2.34 - 2.26 (m, 1H), 2.23 - 2.16 (m, 3H), 1.99 - 1.89 (m, 1H), 1.83 - 1.72 (m, 1H), 1.69 - 1.49 (m, 4H), 1.44 (d, J= 6.0 Hz, 4H), 1.36 - 1.21 (m, 2H), 1.03 - 0.93 (m, 4H), 0.(s, 3H).
Example 59 2-(4-fluorophenyl)-7V-[(75,135)-(203/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l- yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7- yl] cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using(75,135)-7-amino-(20A/)-20-[2-[( 1 Sy 1 -metho xyethyl]-5-(4-methylpiperazin- 1 -yl)-3-pyridyl]-17,17- dimethyl- 15,24-dioxa-4-thia-9,2 1,30,31 -tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate H) and 2-(4-fluorophenyl)cyclopropanecarboxylic acid instead of(75,135)-7-amino-(20j ׳W)-20-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2-methylcyclopropanecarboxylic acid. Example 59(37.8 mg) was obtained as a light yellow solid.MS cak ’d 905.4 (MH+), measured 905.5 (MH+). 1H NMR (400 MHz, METHANOL-d) 5 = 8.(d, J = 2.8 Hz, 1H), 8.28 (s, 1H), 7.72 (s, 1H), 7.49 (d, J = 3.4 Hz, 1H), 7.24 - 6.97 (m, 5H), 5.86 - 5.72 (m, 1H), 4.71 - 4.51 (m, 3H), 4.43 (br d, J= 12.4 Hz, 1H), 4.34 - 4.22 (m, 2H), 4.21 - 3.(m, 2H), 3.76 (s, 3H), 3.63 - 3.55 (m, 1H), 3.46 - 3.36 (m, 6H), 3.29 - 3.21 (m, 2H), 3.14 (br d, J = 14.8 Hz, 1H), 2.98 (s, 3H), 2.78 (br t, J = 12.4 Hz, 1H), 2.60 (br d, J = 14.3 Hz, 1H), 2.44 - 2.31 (m, 1H), 2.21 (br d, J = 10.9 Hz, 1H), 2.01 - 1.90 (m, 2H), 1.81 - 1.16 (m, 9H), 1.01 (s, 3H), 0.54 (s, 3H).
Example 60 (LS;5/<6/)-V-|(75,L35)-23,23-difh1oro-(203/)-20-|2-|(15)-l-mcThoxycThyl|-5-(4- methylpiperazin-l-yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl] -3-oxabicyclo [3.1.0] hexane-6-carboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-23,23-difluoro-(20A7)-20-[2-[(15)- 1 -methoxyethyl]-5-(4-methylpiperazin- 1 - yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 -tetrazahexacyclo [23.3.1.12’5. l9J3.0l9’27.0212]hentriaconta- 1(28),2,5(31), 19,25(29),26-hexaene- 8,14-dione (intermediate K) and (15,57?,6r)-3-oxabicyclo[3.1.0]hexane-6-carboxylic acid instead of (75,135)-7-amino-(20vW)-20-[2-[( 15)-1 -methoxyethyl]-5-morpholino-3-pyridyl] -17,17- dimethyl-15-oxa-4-thia-9, 21,30,31-tetrazahexacyclo[23. 3.1.l2’l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F)and (15,25)-2-methylcyclopropanecarboxylic acid. Example 60(19.3 mg) was obtained as a white solid. MS cak ’d 887.4 (MH+), measured 887.4 (MH+), 1H NMR (400 MHz, Methanol-d4) 8 = 8.48 (s, 1H), 8.43 (d, J = 2.8 Hz, 1H), 7.57 - 7.51 (m, 2H), 7.28 - 7.24 (m, 1H), 5.80 - 5.72 (m, 1H), 4.67 - 4.55 (m, 1H), 4.45 - 4.39 (m, 2H), 4.24 (dd, J = 3.2, 12.0 Hz, 1H), 3.98 - 3.87 (m, 3H), 3.78 - 3.70 (m, 4H), 3.67 - 3.45 (m, 3H), 3.40 - 3.33 (m, 6H), 3.29 - 3.22 (m, 1H), 3.11 - 3.04 (m, 1H), 2.81 - 2.72 (m, 1H), 2.70 - 2.65 (m, 4H), 2.64 - 2.58 (m, 1H), 2.39 (s, 3H), 2.21 - 2.15 (m, 1H), 2.12 - 2.03 (m, 2H), 1.97 - 1.89 (m, 1H), 1.82 - 1.72 (m, 1H), 1.70 - 1.68 (m, 1H), 1.65 - 1.56 (m, 1H), 1.44 (d, J = 6.0 Hz, 3H), 1.29 (s, 1H), 0.98 - 0.94 (m, 3H), 0.55 (s, 3H).
Example 61 (lr,2.R,35)-7V-[(75,135)-(20A0-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17,23,23-tetramethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2,3-dimethyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(2037)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]-l 7,17,23,23- tetramethyl- 15,24-dioxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate M) and (lr,27?,35)-2,3-dimethylcyclopropanecarboxylic acid instead of (75,135)-7-amino-(20A/)-20-[2-[( 15)-1 -methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9, 21,30,3 l-tetrazahexacyclo[23. 3.1.12,נ. I9’13.019’27.02l,26]hentriaconta-(28),2,5(31 ),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 61(18 mg) was obtained as a white solid. MS cak ’d 854.4 (MH+), measured 854.5 (MH+). 1H NMR (400 MHz, Methanol-d4) 8 = 8.45 - 8.(d, J=3.2 Hz, 1H), 8.25 - 8.20 (s, 1H), 7.85 - 7.77 (d, J = 2.8 Hz, 1H), 7.53 - 7.46 (s, 1H), 7.- 7.8 (s, 1H), 5.86 - 5.79 (d, J = 6.8 Hz, 1H), 4.74 - 4.64 (d, J = 6.4 Hz, 1H), 4.49 - 4.40 (d, J = 11.6 Hz, 1H), 4.37 -4.20 (dd, J = 3.2 Hz, 12 Hz, 1H), 4.03 - 3.93 (d, J = 12.4 Hz, 1H), 3.91 - 3.84 (t, J = 4.8 Hz, 5H), 3.84 - 3.79 (s, 2H), 3.73 - 3.62 (d, J = 12.4 Hz, 1H), 3.47 - 3.43 (s, 3H), 3.41 - 3.37 (m, 1H), 3.30 - 3.24 (m, 1H), 3.12 - 3.05 (d, J = 13.6 Hz, 1H), 2.85 - 2.67 (m, 2H), 2.21 -2.21 (dd, 5= 2 Hz, 13.2 Hz, 1H), 1.98 - 1.89 (d, J = 11.6 Hz, 1H), 1.81 - 1.60 (m, 2H), 1.57 - 1.49 (m, 7H), 1.45 - 1.29 (m, 6H), 1.20 - 1.11 (m, 8H), 1.05 - 0.95 (s, 3H), 0.72 - 0.68 (s, 3H).
Example 63 (l1S,,21S)-7V-[(71S',13*S)-(20A/)-20-[2-[(llS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-pyridazin-3-yl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using(7،S',135)-7-amino-(20Af)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazm-l-yl)-3-pyridyl]-17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31־ tetrazahexacyclo [23.3.1.12’5.19’13.0l9’27.021 ’26]hentriaconta- 1 (28),2,5(31), 19,25(29),26-hexaene- 8,14-dione (Intermediate E) and h־،z?J5-2-pyridazin-3-ylcyclopropanecarboxylic acid (Intermediate R2)instead of (7S(13S)-7-amino-(20Tf)-20-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,1 7-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F)and (lS',2S)-2-methylcyclopropanecarboxylic acid. Example 63(6.mg) was obtained as a yellow solid. MS calc ’d 887.4 (MH+), measured 887.5 (MH+). 1H NMR (400 MHz, Methanol-d2) J = 9.10 - 9.04 (m, 1H), 8.53 - 8.46 (m, 1H), 8.44 - 8.36 (m, 1H), 7.77 -7.66 (m, 2H), 7.60 (d, J = 2.8 Hz, 1H), 7.50 (s, 1H), 7.43 (s, 1H), 5.87 - 5.81 (m, 1H), 4.49 - 4.(m, 2H), 4.26 - 4.16 (m, 2H), 3.78 - 3.72 (m, 2H), 3.67 - 3.58 (m, 2H), 3.48-3.39 (m, 3H), 3.39 - 3.35 (m, 4H), 3.28-3.23 (m, 1H), 3.16 - 3.04 (m, 3H), 3.02 - 2.97 (m, 4H), 2.87 - 2.74 (m, 2H), 2.74 - 2.67 (m, 1H), 2.66 - 2.60 (m, 1H), 2.59 - 2.53 (m, 1H), 2.38 - 2.26 (m, 1H), 2.24 - 2.13 (m, 2H), 1.99- 1.90 (m, 1H), 1.81 - 1.58 (m, 4H), 1.50 (d, J = 6.4 Hz, 4H), 1.35 - 1.28 (m, 1H), 1.- 0.96 (m, 3H), 0.64 - 0.57 (m, 3H) Example 64 (17?,21S)-2-cyclopropyl-AL[(75,131S)-(203/)-20-[2-[(l 1S)-l-methoxyethyl]-5-(4- methylpiperazin-l-yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7- yl] cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20Af)-20-[2-[(l ،S)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]- 17,17-dimethyl- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate H) and (17?,2S)-2-cyclopropylcyclopropanecarboxylic acid instead of (75,135)-7-amino-(20A/)-20-[2-[( 15)-1 -methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9, 21,30,31-tetrazahexacyc 10[23.3.1.12,נ. I9’13.019,27.02l,26]hentriaconta-(28),2,5(31 ),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 64(45.0 mg) was obtained as a light yellow solid. MS cak ’d 851.4 (MH+), measured 851.4 (MH+). 1H NMR (400 MHz, METHANOL-d4) 8 = 8.(d, J = 2.6 Hz, 1H), 8.01 (d, J = 3.0 Hz, 1H), 7.35 (d, J = 2.8 Hz, 1H), 7.28 (d, J = 8.0 Hz, 1H), 6.90 (d, J = 3.3 Hz, 1H), 5.57 (d, J = 8.8 Hz, 1H), 4.56 (s, 3H), 4.46 - 4.37 (m, 2H), 4.32 (q, J = 6.5 Hz, 1H), 4.24 (d, J = 13.3 Hz, 1H), 4.14 - 4.04 (m, 2H), 3.62 - 3.46 (m, 4H), 3.39 - 3.22 (m, 4H), 3.18 (d, J = 1.5 Hz, 4H), 3.07 (d, J = 5.9 Hz, 1H), 2.93 (d, J = 12.6 Hz, 1H), 2.79 (s, 3H), 2.64-2.52 (m, 1H), 2.39 (d, J = 14.5 Hz, 1H), 2.06 - 1.95 (m, 1H), 1.80-1.71 (m, 1H), 1.68- 1.52 (m, 1H), 1.48 - 1.35 (m, 2H), 1.27 (d, J = 6.1 Hz, 3H), 1.16 - 1.07 (m, 1H), 0.85 - 0.74 (m, 4H), 0.73 - 0.65 (m, 1H), 0.48 (dd, J = 7.0 Hz, 11.0 Hz, 1H), 0.34 (s, 3H), 0.29 - 0.17 (m, 2H), 0.05 - 0.09 (m, 2H).
Example 65 3,3-difluoro-7V-[(7l$,,13.S)-(20Af)-20-[2-[(llS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl] cyclopentanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using(7،S',135)-7-amino-(20Af)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazm-l-yl)-3-pyridyl]-17,17- dimethyl- 15-oxa-4-thia-9,2 1,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate E) and 3,3-difluorocyclopentanecarboxylic acid instead of (7S,,135)-7- amino-(20A/)-20-[2-[( 15)-1 -metho xyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4- thia-9,21,30,31-tetrazahexacyc 10[23.3.1.12’19,13.019,27.02 .נl,26]hentriaconta-(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (lS,25)-2- methylcyclopropanecarboxylic acid. Example 65(13.9 mg) was obtained as a light yellow solid. MS cak ’d 873.4 (MH+), measured 873.5 (MH+). 1H NMR (400 MHz, METHANOL-d4) 8 = 8.- 8.42 (m, 1H), 8.36 (d, J= 2.5 Hz, 1H), 8.29 (s, 1H), 7.39 (s, 1H), 7.34 - 7.30 (m, 2H), 5.65 (br t, J= 8.1 Hz, 1H), 4.36 - 4.29 (m, 2H), 4.15 (br d, J= 10.4 Hz, 2H), 3.66 (s, 2H), 3.54 - 3.43 (m, 3H), 3.31 (br s, 2H), 3.27 (s, 4H), 3.18 - 3.13 (m, 2H), 3.05 - 2.94 (m, 4H), 2.89 (s, 4H), 2.74 - 2.64 (m, 1H), 2.48 (br d, J = 14.6 Hz, 1H), 2.31 - 2.17 (m, 3H), 2.14 - 2.05 (m, 3H), 2.03 - 1.(m, 4H), 1.74 - 1.63 (m, 1H), 1.58 - 1.49 (m, 1H), 1.34 (d, J= 6.1 Hz, 3H), 1.24 - 1.17 (m, 1H), 0.87 (s, 3H), 0.43 (s, 3H).
Example 66 7V-[(75,135)-(20Af)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]- 17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl] -2-oxabicyclo [2.1.1] hexane-l-carboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20Af)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate E) and 2-oxabicyclo [2.1.1 ]hexane-1-carboxylic acid instead of (75,135)-7-amino-(20Af)-20-[2-[(15)-l-methoxyethyl]-5-morphohno-3-pyridyl]-l 7,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 66(13.4 mg) was obtained as a white solid. MS cak ’d 851.4 (MH+), measured 851.5 (MH+). ׳H NMR (400 MHz, METHANOL-،/4) 8 = 8.36 (br s, 1H), 8.30 (br s, 1H), 7.46 (br s, 1H), 7.38 (d, J= 3.1 Hz, 1H), 7.32 (br s, 1H), 5.86 - 5.76 (m, 1H), 4.39 - 4.30 (m, 2H), 4.18 - 4.05 (m, 3H), 3.88 - 3.81 (m, 2H), 3.67 (br s, 2H), 3.55 - 3.47 (m, 3H), 3.34 - 3.30 (m, 2H), 3.29 - 3.25 (m, 5H), 3.04 - 2.94 (m, 3H), 2.89 (br d, J= 3.1 Hz, 5H), 2.69 (brt, J= 12.7 Hz, 1H), 2.52 (br d, J= 14.4 Hz, 1H), 2.26-2.18 (m, 1H), 2.15-2.02 (m, 4H), 1.90 - 1.81 (m, 1H), 1.73 - 1.64 (m, 1H), 1.63 - 1.48 (m, 4H), 1.40 - 1.33 (m, 3H), 1.19 (br s, 1H), 0.86 (br s, 3H), 0.47 (br s, 3H).
Example 67 (15,25)-7V-[(75,135)-23,23-difluoro-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-[4-(2,2,2- trifluoroethyl)piperazin-l-yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia- 9,21,30,31-tetrazahexacyclo [23.3.1. l2’5.l9’13.019’27.021’26] hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-7-yl]-2-methyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-23,23-difluoro-(20A/)-20-[2-[(l>S)-l-methoxyethyl]-5-[4-(2,2,2- trifluoroethyl)piperazin- 1 -yl]-3-pyridyl] -17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate O) instead of (7S,13S)-7-amino-(207W)-20-[2-[(lS)-l-methoxyethyl]-5- morpholino-3-pyridyl]-17,1 7-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F).Example 67(22.8 mg) was obtained as a yellow solid. MS calc ’d 927.4 (MH+), measured 927.6 (MH+), 1H NMR (400 MHz, METHANOL-d) J = 8.51 (s, 1H), 8.40 (d, J= 2.8 Hz, 1H), 7.65 (d, J= 2.8 Hz, 1H), 7.60 - 7.54 (m, 2H), 5.79 (dd, J= 1.2, 8.8 Hz, 1H), 4.57 - 4.38 (m, 3H), 4.23 (dd, J= 3.2, 12.0 Hz, 1H), 4.06 - 3.94 (m, 1H), 3.82 - 3.48 (m, 5H), 3.47 - 3.43 (m, 4H), 3.39 (s, 3H), 3.29 - 3.24 (m, 1H), 3.21 - 3.08 (m, 3H), 2.91 - 2.85 (m, 4H), 2.82- 2.73 (m, 1H), 2.71 - 2.64 (m, 1H), 2.21 -2.13(m, 1H), 1.98 - 1.89 (m, 1H), 1.82- 1.70 (m, 1H), 1.65 - 1.55 (m, 1H), 1.50- 1.45 (m,4H), 1.27- 1.18 (m, 1H), 1.15- 1.10 (m,3H), 1.09 - 1.04 (m, 1H), 1.00 (s, 3H), 0.67 - 0.56 (m, 4H).
Example 68 (lr,21?,35)-A^-[(7A',13A)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17- dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,13S)-7-amino-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17-dimethyl- 15,24-dioxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (intermediate J) and (b',2S,37?)-2,3- dimethylcyclopropanecarboxylic acid instead of (7>S,,13>S)-7-amino-(20Af)-20-[2-[(15)-l- methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F)and (l>S,,2lS)-2-methylcyclopropanecarboxylic acid. Example 68(mg) was obtained as a yellow solid. MS calc ’d 826.4 (MH+), measured 826.6 (MH+). 1H NMR (400 MHz, METHANOL-،/4) <5 = 8.41 (d, J = 2.6 Hz, 1H), 8.24 (s, 1H), 7.90 (d, J= 2.Hz, 1H), 7.48 (s, 1H), 7.14 (s, 1H), 5.77 (br d, J= 8.4 Hz, 1H), 4.71 - 4.52 (m, 3H), 4.45- 4.(m, 1H), 4.25 (br d, J= 9.0 Hz, 2H), 3.91 - 3.80 (m, 5H), 3.76 (br d, J= 5.9 Hz, 2H), 3.42 (s, 7H), 3.37 (s, 1H), 3.30 - 3.21 (m, 1H), 3.16 (br d, J= 14.4 Hz, 1H), 2.80 - 2.62 (m, 2H), 2.26 - 2.12 (m, 1H), 1.99 - 1.86 (m, 1H), 1.85 - 1.68 (m, 1H), 1.65 - 1.55 (m, 1H), 1.50 (d, J= 6.3 Hz, 3H), 1.43 - 1.29 (m, 2H), 1.20 - 1.10 (m, 7H), 1.04 (s, 3H), 0.60 (s, 3H).
Example 69 (lr,2S,3.R)-AM(7S,13S)-(20A/)-20-[2-[(LS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17,23,23-tetramethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2,3-dimethyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,13S)-7-amino-(2037)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]- 17,17,23,23-tetramethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate P) and (l/2,־S,37?)-2,3-dimethylcyclopropanecarboxylic acid instead of (75,135)-7-amino-(2037)-20-[2-[(15)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (lS,25)-2- methylcyclopropanecarboxylic acid. Example 69(6 mg) was obtained as a white solid. MS cak ’d 865.5 (MH+), measured 865.5 (MH+). 1H NMR (400 MHz, METHANOL-4 ) d = 8.49 (br d, J = 2.4 Hz, 1H), 8.41 (s, 1H), 7.52 (d, J = 2.6 Hz, 1H), 7.49 (s, 1H), 7.41 (s, 1H), 5.83 (dd, J = 1.9, 8.4 Hz, 1H), 4.57 - 4.47 (m, 2H), 4.45 - 4.35 (m, 1H), 4.24 -4.15 (m, 1H), 3.84 - 3.74 (m, 3H), 3.67 - 3.34 (m, 8H), 3.29 - 3.21 (m, 2H), 3.08 - 3.00 (m, 1H), 2.99 - 2.95 (m, 3H), 2.94 - 2.87 (m, 1H), 2.81 -2.71 (m, 2H), 2.70 - 2.62 (m, 1H), 2.17-2.06 (m, 1H), 1.95 - 1.84 (m, 1H), 1.76 - 1.68 (m, 1H), 1.66 (d, J = 7.0 Hz, 3H), 1.60 (brs, 1H), 1.47 (d, J =6.1 Hz, 3H), 1.42- 1.27 (m, 3H), 1.17 - 1.10 (m, 9H), 0.92 (s, 3H), 0.88 - 0.84 (m, 3H), 0.61 (s, 3H).
Example 70 ،ra«s-7V-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazi11-l-yl)-3-pyridyl]- 17,17-dimethyl-8,14-dioxo-l 5-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7- yl]-4-(l-methyltetrazol-5-yl)cyclohexanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazh-l-yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate E) and trans-^-{ 1 -methyltetrazol-5-yl)cyc 10hexanecarboxylic acid instead of (75,135)-7-ammo-(2047)-20-[2-[(l lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F)and (lS,25)-2-methylcyclopropanecarboxylic acid. Example 70(mg) was obtained as a white solid. MS cak ’d 933.5 (MH+), measured 933.5 (MH+). 1H NMR (400 MHz, METHANOL-d4) 8 = 8.44 - 8.35 (m, 2H), 7.46 (s, 1H), 7.38 (s, 1H), 7.26 (d, J= 2.Hz, 1H), 5.85 - 5.66 (m, 1H), 4.48 - 4.34 (m, 2H), 4.30 - 4.21 (m, 2H), 4.04 (s, 3H), 3.80 - 3.(m, 2H), 3.62 - 3.51 (m, 1H), 3.47 - 3.40 (m, 1H), 3.40 - 3.35 (m, 4H), 3.35 - 3.32 (m, 3H), 3.- 3.22 (m, 1H), 3.15 - 2.90 (m, 4H), 2.86 - 2.70 (m, 4H), 2.65 (s, 1H), 2.59 (d, J= 14.4 Hz, 1H), 2.52 - 2.47 (m, 1H), 2.44 (s, 3H), 2.35 - 2.23 (m, 1H), 2.23 - 2.13 (m, 2H), 2.12 - 1.98 (m, 4H), 1.98 - 1.86 (m, 1H), 1.84 - 1.55 (m, 6H), 1.43 (d, J= 6.1 Hz, 3H), 0.96 (s, 3H), 0.52 (s, 3H).
Example 71 trtirMS-4-hydroxy-A^-[(75,13A)-(20A/)-20-[2-[(lA)-l-methoxyethyl]-5-(4-methylpiperazin-l- yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-4-methyl-cyclohexanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate E) and P־yMs-4-hydroxy-4-methyl-cyclohexanecarboxylic acid instead of (75,135)-7-amino-(20A/)-20-[2-[(l>S)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17- dimethyl-15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’l3.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (lS,25)-2- methylcyclopropanecarboxylic acid. Example 71(12.3 mg) was obtained as a white solid. MS cak ’d 881.5 (MH+), measured 881.5 (MH+). *H NMR (400 MHz, METHANOL-d4) 8 = 8.34 - 8.26 (m, 2H), 7.37 (s, 1H), 7.29 (s, 1H), 7.15 (d, J= 2.8 Hz, 1H), 5.64 (br d, J= 8.3 Hz, 1H), 4.47 (br s, 1H), 4.35 - 4.25 (m, 2H), 4.15 (br dd, J= 2.6, 11.9 Hz, 2H), 3.65 (s, 2H), 3.57 - 3.(m, 2H), 3.30 - 3.26 (m, 4H), 3.24 (s, 2H), 3.18-3.12 (m, 1H), 3.03 - 2.94 (m, 2H), 2.93 - 2.(m, 1H), 2.71 -2.61 (m, 5H), 2.49 (br d, J= 14.4 Hz, 1H), 2.33 (s, 3H), 2.30-2.14 (m, 3H), 2.- 2.05 (m, 2H), 1.87 - 1.79 (m, 2H), 1.76 - 1.68 (m, 2H), 1.67-1.61 (m, 2H), 1.58 - 1.49 (m, 3H), 1.47 - 1.39 (m, 2H), 1.33 (d, J=6A Hz, 3H), 1.14 (s, 3H), 0.86 (s, 3H), 0.43 (s, 3H).
Example 72 7V-[(75,135)-(20A/)-20-[2-[(lA)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]- 17,17-dimethyl-8,14-dioxo-l 5-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.125.l9 13.01927.02126]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl] tricyclo [3.1.1.03) heptane-6-carboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20vW)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate E) and tricyclo[3.1.1.0 3,6]heptane-6-carboxylic acid instead of (75,135)-7-amino-(20vW)-20-[2-[(15)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 72(6.7 mg) was obtained as a white solid. MS cak ’d 861.4 (MH+), measured 861.4 (MH+). 1H NMR (400 MHz, METHANOL-^) § = 8.29 (s, 2H), 7.37 (s, 1H), 7.29 (s, 1H), 7.15 (s, 1H), 5.71 (dd, J=2.8, 6.8 Hz, 1H), 4.47 (s, 1H), 4.37 - 4.25 (m, 2H), 4.18 - 4.10 (m, 2H), 3.66 (s, 2H), 3.52 - 3.43 (m, 1H), 3.34 - 3.30 (m, 2H), 3.24 (s, 5H), 3.09 - 3.02 (m, 3H), 3.01 - 2.86 (m, 6H), 2.73 - 2.65 (m, 1H), 2.61 (br s, 3H), 2.50 (br d, J= 14.5 Hz, 1H), 2.31 (s, 3H), 2.17 (br d, J= 11.3 Hz, 4H), 2.13 - 2.05 (m, 2H), 1.88- 1.81 (m, 1H), 1.72 - 1.63 (m, 1H), 1.57 - 1.46 (m, 1H), 1.35- 1.31 (m, 3H), 1.24- 1.13 (m, 1H), 0.86 (s, 3H), 0.82 - 0.68 (m, 1H), 0.43 (s, 3H). Example 73 (lr.25.3/?)--[(75.l35)-(20lf)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl|-17.17- dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2,3-dimethyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (lr,25,37?)-2,3-dimethylcyclopropanecarboxylic acid instead of (lS,25)-2-methylcyclopropanecarboxylic acid. Example 73(28 mg) was obtained as a yellow solid. MScak ’d 824.4 (MH+), measured 824.6 (MH+). 1H NMR (400 MHz, Methanol-rZ 4) 8 = 8.42 (s, 1H), 8.36 (d, J= 2.8 Hz, 1H), 7.89 - 7.83 (m, 1H), 7.51 (s, 1H), 7.45 (s, 1H), 5.84 - 5.78 (m, 1H), 4.-4.50 (m, 1H), 4.43 = H.6Hz, 1H), 4.25-4.17 (m, 1H), 4.16-4.09 (m, 1H), 3.86 (t, J =4.4 Hz, 4H), 3.79 - 3.72 (m, 2H), 3.71 - 3.65 (m, 1H), 3.43 (s, 7H), 3.38 (s, 1H), 3.29 - 3.22 (m, 1H), 3.14 - 3.01 (m, 3H), 2.80 - 2.67 (m, 2H), 2.37 - 2.29 (m, 1H), 2.23 - 2.12 (m, 2H), 1.97 -1.88 (m, 1H), 1.80- 1.69 (m, 1H), 1.65 - 1.55 (m, 1H), 1.48 (d, J = 6.4 Hz, 3H), 1.40 - 1.32 (m, 2H), 1.17 - 1.11 (m, 7H), 0.99 (s, 3H), 0.62 (s, 3H).
Example 75 (15,25)-^-[(75,135)-23,23-difluoro-(20T0-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3- pyridyl]-! 7,17-dimethyl-8,l 4-dioxo-l 5-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9l3.0l9’27.02l’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-methyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-23,23-difluoro-(2047)-20-[2-[(15)-l-metho xyethyl]-5-morpho lino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate Q) instead of (75,135)-7-amino-(2047)-20-[2-[(15)-l-methoxyethyl]-5- morpholino-3-pyridyl]-17,1 7-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F). Example 75(19.5 mg) was obtained as a yellow solid. MS calc ’d 846.4 (MH+), measured 846.4 (MH+). 1H NMR (400 MHz, METHANOL-d4) 5 = 8.52 (s, 1H), 8.40 (d, J = 2.8 Hz, 1H), 7.77 (s, 1H), 7.58 (d, J = 7.2 Hz, 2H), 5.80 (d, J = 8.4 Hz, 1H), 4.57 - 4.41 (m, 3H), 4.22 (d, J = 8.8 Hz, 1H), 4.04 (d, J = 14.4 Hz, 1H), 3.86 (d, J = 4.4 Hz, 4H), 3.- 3.71 (m, 2H), 3.69 - 3.47 (m, 3H), 3.45 - 3.39 (m, 8H), 3.26 (d, J = 8.8 Hz, 1H), 3.11 (d, J = 15.2 Hz, 1H), 2.82 -2.67 (m, 2H), 2.17 (d, J = 11.6 Hz, 1H), 1.94 (d, J= 12.8 Hz, 1H), 1.75 (s, 1H), 1.61 (d, J= 15.2 Hz, 1H), 1.49 (d, J= 6.4 Hz, 3H), 1.23 - 1.03 (m, 6H), 1.01 (s, 3H), 0.(s, 3H). Example 76 (lr,25,37?)-A^-[(75,135)-23,23-difluoro-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26[he11triaco11ta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2,3־dimethyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using(75,135)-7-amino-23,23-difluoro-(207ff)-20-[2-[(15)-l-methoxyethyl]-5-morpho lino-3-pyridyl]-17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate Q) and (lr,25,37?)-2,3-dimethylcyclopropanecarboxylic acid instead of (75,135)-7-amino-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,3 1-tctrazahcxacyclo[23.3. 1.125.191,.0l927.02l26]henlriaconla-1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 76(16.7 mg) was obtained as a yellow solid. MS cak ’d 860.4 (MH+), measured 860.4 (MH+). 1H NMR (400 MHz, METHANOL-d4) 5 = 8.52 (s, 1H), 8.40 (d, J = 3.2 Hz, 1H), 7.66 (s, 1H), 7.59 - 7.56 (m, 2H), 5.79 (d, J = 7.6 Hz, 1H), 4.56 - 4.49 (m, 2H), 4.46 - 4.40 (m, 1H), 4.25 - 4.20 (m, 1H), 4.05 - 3.95 (m, 1H), 3.86 (t, J= 4.4 Hz, 4H), 3.81 - 3.77 (m, 1H), 3.74 - 3.70 (m, 1H), 3.69 - 3.58 (m, 2H), 3.57 - 3.48 (m, 1H), 3.41 - 3.37 (m, 7H), 3.28 - 3.23 (m, 1H), 3.10 (d, J = 14.4 Hz, 1H), 2.81-2.73 (m, 1H), 2.68 (d, J = 14.4 Hz, 1H), 2.21 - 2.14 (m, 1H), 1.97 - 1.89 (m, 1H), 1.81 - 1.70 (m, 1H), 1.64 - 1.56 (m, 1H), 1.48 (d, J = 6.4 Hz, 3H), 1.40 - 1.33 (m, 2H), 1.16 - 1.11 (m, 7H), 1.00 (s, 3H), 0.61 (s, 3H).
Example 77 [- l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl ،؟(- 20Af)-20-[2-[(l ،؟(-) 13 ،؟, 7 -]) 7V 17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]tetrahydropyran-4-carboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,131S)-7-amino-(20j'W)-20-[2-[(l 1S)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate E) and tetrahydropyran-4-carboxylic acid instead of (75,135)-7-amino- (20vW)-20-[2-[(15)-1 -metho xyethyl]-5-morpho lino -3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26- hexaene-8,14-dione (Intermediate F) and (15,2S)-2-methykyclopropanecarboxylic acid.Example 77 (11.4 mg) was obtained as a light yellow solid. MS cak ’d 853.4 (MH ), measured 853.5 (MH+). 1H NMR (400 MHz, METHANOL-d) 3 = 8.37 (d, J= 2.9 Hz, 1H), 8.30 (s, 1H), 7.44 (d, J= 2.9 Hz, 1H), 7.39 (s, 1H), 7.32 (s, 1H), 5.65 (br d, J= 7.5 Hz, 1H), 4.46 - 4.29 (m, 2H), 4.18 - 4.08 (m, 2H), 3.89 (tdd, J= 3.3, 7.0, 10.8 Hz, 3H), 3.66 (s, 2H), 3.59 - 3.33 (m, 7H),3.32 - 3.26 (m, 5H), 3.19 - 3.13 (m, 2H), 3.05 - 2.96 (m, 2H), 2.89 (s, 4H), 2.72 - 2.64 (m, 1H),2.57 - 2.46 (m, 2H), 2.26 - 2.17 (m, 1H), 2.13 - 2.04 (m, 2H), 1.88 - 1.80 (m, 1H), 1.75 - 1.68 (m,3H), 1.67 - 1.60 (m, 2H), 1.57 - 1.47 (m, 2H), 1.36 (d, J= 6.1 Hz, 3H), 0.88 (s, 3H), 0.45 (s, 3H).
Example 78 (15,25)-7V-[(75,135)-23,23-difluoro-(20Af)-20-[2-[(15)-l-n1ethoxyethyl]-5-(4- methylpiperazin-l-yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-phenyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using(75,135)-7-amino-23,23-difluoro-(20A7)-20-[2-[(15)- 1 -methoxyethyl]-5-(4-methylpiperazin- 1 - yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 -tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate K) and (15,25)-2-phenylcyclo propanecarboxy lie acid instead of(75,135)-7-amino-(20j ׳W)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2-methylcyclopropanecarboxylic acid. Example 78 (25.9 mg) was obtained as a yellow solid. MS cak ’d 921.4 (MH+), measured 921.6 (MH+). 1H NMR (400 MHz, Methanol-d) 3 = 8.53 - 8.(m, 2H), 7.61 - 7.55 (m, 2H), 7.42 (d, J= 2.8 Hz, 1H), 7.30 - 7.24 (m, 2H), 7.21 - 7.12 (m, 3H), 5.85 - 5.78 (m, 1H), 4.87 - 4.85 (m, 1H), 4.63 - 4.53 (m, 1H), 4.51 - 4.39 (m, 2H), 4.25 (dd, J= 12.0, 2.8 Hz, 1H), 4.18 - 3.83 (m, 3H), 3.81 - 3.72 (m, 2H), 3.68 - 3.44 (m, 5H), 3.41 (s, 1H), 3.35 (s, 5H), 3.26 (d, J= 8.8 Hz, 1H), 3.13 - 3.08 (m, 1H), 2.99 (s, 3H), 2.83 - 2.75 (m, 1H), 2.(d, J= 15.2 Hz, 1H), 2.39 - 2.33 (m, 1H), 2.22 -2.15 (m, 1H), 2.08 - 2.03 (m, 1H), 1.97 - 1.(m, 1H), 1.82 - 1.71 (m, 1H), 1.68 - 1.59 (m, 1H), 1.54 - 1.49 (m, 1H), 1.47 (d, J= 6.4 Hz, 3H), 1.32 - 1.28 (m, 1H), 0.97 (s, 3H), 0.56 (s, 3H).
Example 79 - 3 - l-methoxyethyl]-5-morpholino ،؟(- 23,23 - difluoro-(20Af)-20-[2-[(l ،؟(־ 13 ،؟, 7 -]) 2 ، S)-7V ،؟, l ) pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-phenyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-23,23-difluoro-(20T/)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo [23.3.1.12’5. l9J3.0l9’27.0212]hentriaconta- 1(28),2,5(31), 19,25(29),26-hexaene- 8,14-dione (Intermediate Q) and (1525)-2-pl1enylcyclopropanecarboxylic acid instead of (75,135)-7-amino-(20M)-20-[2-[(l 5)- l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- (28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 79(20 mg) was obtained as a yellow solid. MS cak ’d 908.4 (MH+), measured 908.6 (MH+). 1H NMR (400 MHz, Methanol-d4) 5 = 8.54 (s, 1H), 8.40 (d, J= 2.8 Hz, 1H), 7.78 (d, J= 2.8 Hz, 1H), 7.60 - 7.58 (m, 2H), 7.28 - 7.24 (m, 2H), 7.18 - 7.13 (m, 3H), 5.87 - 5.83 (m, 1H), 4.88 - 4.85 (m, 1H), 4.55 (d, J= 6.4 Hz, 1H), 4.51 - 4.40 (m, 2H), 4.23 (dd, J = 12.0, 2.8 Hz, 1H), 4.07 - 3.99 (m, 1H), 3.87 (t, J=4.8 Hz, 4H), 3.77 (d, J = 17.6 Hz, 2H), 3.65 - 3.52 (m, 2H), 3.43 - 3.40 (m, 7H), 3.30 - 3.24 (m, 1H), 3.13 - 3.07 (m, 1H), 2.83 - 2.76 (m, 1H), 2.71 (d, J= 14.0 Hz, 1H), 2.38 - 2.34 (m, 1H), 2.20 - 2.14 (m, 1H), 2.08 -2.03 (m, 1H), 1.96 - 1.91 (m, 1H), 1.81 - 1.72 (m, 1H), 1.68 - 1.52 (m, 2H), 1.51 - 1.49 (m, 3H),1.32 - 1.27 (m, 1H), 1.01 (s, 3H), 0.63 (s, 3H).
Example 80 and Example 81 (LS’,25)-.V-|(75’,135)-(201/)-20-|2-|(LS’)-l-methoxyethyl|-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-pyrimidin-2-yl-cyclopropanecarboxamide and (11?,21?)-7¥-[(75,135)-20-[2-[(15)-1- methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4- thia-9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-7-yl]-2-pyrimidin-2-yl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using(75,135)-7-amino-(20A/)-20-[2-[( 1 Sy 1 -metho xyethyl]-5-(4-methylpiperazin- 1 -yl)-3-pyridyl]-17,17- dimethyl- 15-oxa-4-thia-9,2 1,30,31 -tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate E)and 2-pyrimidin-2-ylcyclopropanecarboxylic acid (Intermediate R5) instead of (75,135)-7-amino-(20M)-20-[2-[(l5)- l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2-methylcyc lo propanecarboxy lie acid and then purified by prep-HPLC and SEC.
SFC conditions: Column DAICEL CHIRALCEL IG(250mmx30mm,10pm); Condition CO2-EtOH(0.1%NH3H2O); Begin B 75 End 75 Gradient Time(min) 3.3 100%B Hold; Flow Rate(mL/min) 100.Example 80(13.4 mg, SFC, faster eluted) was obtained as a white solid. MS calc ’d 887.(MH+), measured 887.4 (MH+). 1H NMR (400 MHz, Methanol-d.) d 8.67 = ־ (d, J= 4.8 Hz, 2H), 8.44 (s, 1H), 8.38 (s, 1H), 7.46 (s, 1H), 7.39 (s, 1H), 7.33 (s, 1H), 7.30 (t, J= 5.0 Hz, 1H), 5.(d, J= 8.4 Hz, 1H), 4.45 - 4.39 (m, 2H), 4.26 - 4.21 (m, 2H), 3.76 (s, 2H), 3.58 - 3.49 (m, 5H), 3.43 (m, 1H), 3.39 (s, 1H), 3.26 - 3.21 (m, 2H), 3.13 - 3.04 (m, 2H), 3.01 - 2.93 (m, 1H), 2.81 (s, 5H), 2.71 - 2.65 (m, 1H), 2.59 (m, 1H), 2.50 - 2.44 (m, 1H), 2.34 - 2.26 (m, 1H), 2.21 - 2.15 (m, 2H), 1.96 - 1.91 (m, 1H), 1.77 (m, 1H), 1.64 - 1.54 (m, 4H), 1.44 (d, J= 6.8 Hz, 3H), 1.29 (s, 3H), 0.95 (s, 3H), 0.55 (s, 3H).Example 81(7.6 mg, SFC, slower eluted) was obtained as a white solid. MS calc ’d 887.(MH+), measured 887.4 (MH+). 1H NMR (400 MHz, Methanol-d4) 8 = 8.65 (d, J= 4.8 Hz, 2H), 8.41 - 8.37 (m, 2H), 8.37 (s, 2H), 7.30 - 7.24 (m, 2H), 5.84 (d, J= 8.8Hz, 1H), 4.44 - 4.35 (m, 2H), 4.28 - 4.20 (m, 2H), 3.76 (s, 2H), 3.64 - 3.56 (m, 1H), 3.49 - 3.35 (m, 4H), 3.25 (m, 1H), 3.15 - 2.94 (m, 4H), 2.81 - 2.74 (m, 1H), 2.69 - 2.61 (m, 6H), 2.49 (m, 2H), 2.37 (s, 3H), 2.34 - 2.13 (m, 4H), 1.95 - 1.89 (m, 1H), 1.73 (s, 1H), 1.63 - 1.57 (m, 3H), 1.44 (d, J= 6.0 Hz, 3H), 1.32 - 1.28 (m, 1H), 0.95 (s, 3H), 0.55 (s, 3H).
Example 83 (lr,2S,3/?)-A^[(7S,135)-23,23-difluoro-(20A0-20-[2-[(15)-l-methoxyethyl]-5-(4- methylpiperazin-1 -yl)-3-pyridyl] -17,17-dimethyl-8,l 4-dioxo-l 5-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9l3.0l9’27.02l’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-23,23-difluoro-(2047)-20-[2-[(15)-l-metho xyethyl]-5-(4-methylpiperazin-l- yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate K) and (lr,25,37?)-2,3-dimethylcyclopropanecarboxylic acid instead of (75,135)-7-amino-(207M)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 83(16 mg) was obtained as a yellow solid. MS cak ’d 873.4 (MH+), measured 873.6 (MH+). 1H NMR (400 MHz, Methanol-rZ 4) 8 = 8.52 - 8.(m, 2H), 7.58 - 7.55 (m, 2H), 7.48 (d, J= 2.8 Hz, 1H), 5.80 - 5.74 (m, 1H), 4.91 - 4.87 (m, 1H), 4.58 - 4.41 (m, 3H), 4.24 (dd, J= 12.0, 3.2 Hz, 1H), 4.13 - 3.86 (m, 3H), 3.82 - 3.68 (m, 3H), 3.68 - 3.53 (m, 4H), 3.45 - 3.38 (m, 2H), 3.36 (s, 3H), 3.27 - 3.24 (m, 1H), 3.11 (d, J= 14.4 Hz, 1H), 2.99 (s, 3H), 2.81 - 2.74 (m, 1H), 2.60 (d, J= 14.4 Hz, 1H), 2.20 - 2.14 (m, 1H), 1.97 - 1.(m, 1H), 1.82 - 1.73 (m, 1H), 1.66 - 1.58 (m, 1H), 1.47 (d, J= 6.4 Hz, 3H), 1.40 - 1.33 (m, 2H), 1.19 - 1.09 (m, 8H), 0.98 (s, 3H), 0.56 (s, 3H).
Example 85 (lr.25.3/?)-V-|(75J35)-(2()lD-2()-|2-|(LSh-l-methoxyethyl]-5-|4-(2.2.2- trifluoroethyl)piperazin-l-yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-7-yl]-2,3-dimethyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20vW)-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin-l-yl]- 3-pyridyl]- 17,17-dimethyl- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate I) and (h2,3-(?25,37,״-dimethylcyclopropanecarboxylic acid instead of (75,135)-7-amino-(20vW)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 85(22.2 mg) was obtained as a yellow solid. MS cak ’d 907.4 (MH+), measured 907.5 (MH+). 1H NMR (400 MHz, METHANOL-d4) 8 = 8.(d, J= 3.0 Hz, 1H), 8.24 (s, 1H), 7.91 (d, J= 2.9 Hz, 1H), 7.52 (s, 1H), 7.15 (d, J= 1.0 Hz, 1H), 5.78 (d, J= 7.4 Hz, 1H), 4.72 - 4.57 (m, 3H), 4.45 (d, J= 12.0 Hz, 1H), 4.32 - 4.20 (m, 2H), 3.- 3.73 (m, 3H), 3.56 - 3.49 (m, 4H), 3.47 - 3.39 (m, 4H), 3.31 - 3.14 (m, 5H), 2.96 - 2.86 (m, 4H), 2.79 (t, J= 2.8, 12.9 Hz, 1H), 2.69 (d, J= 14.4 Hz, 1H), 2.27 - 2.16 (m, 1H), 2.00 - 1.92 (m, 1H), 1.86 - 1.73 (m, 1H), 1.69 - 1.57 (m, 1H), 1.51 (d, J= 6.3 Hz, 3H), 1.42 - 1.34 (m, 2H), 1.18 - 1.13 (m, 6H), 1.05 (s, 3H), 0.62 (s, 3H).
Example 86 (lr,2/?,3S)-AL[(75,135)-(20A0-20-[2-[(lS)-l-methoxyethyl]-5-[4-(2,2,2- trifluoroethyl)piperazin-l-yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-7-yl]-2,3-dimethyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20vW)-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin-l-yl]- 3-pyridyl] -17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate G) and (h2,3-(?25,37,״-dimethylcyclopropanecarboxylic acid instead of (75,135)-7-amino-(20vW)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 86(30.1 mg) was obtained as a light yellow solid. MS cak ’d 905.4 (MH+), measured 905.6 (MH+). 1H NMR (400 MHz, METHANOL-d) 8 = 8.- 8.40 (m, 1H), 8.39 - 8.32 (m, 1H), 7.94 - 7.87 (m, 1H), 7.54 - 7.49 (m, 1H), 7.46 (s, 1H), 5.(br d, J= 7.5 Hz, 1H), 4.54 (q, J= 63 Hz, 1H), 4.47 - 4.38 (m, 1H), 4.23 -4.16 (m, 1H), 4.15 - 4.06 (m, 1H),3.79 - 3.66 (m, 3H), 3.50 - 3.36 (m, 9H), 3.28 - 2.96 (m, 8H), 2.89 (br s, 3H),2.81 - 2.64 (m, 4H), 2.32 (br d, J= 4.4 Hz, 1H), 2.23 - 2.12 (m, 2H), 1.96 - 1.89 (m, 1H), 1.82 - 1.(m, 1H), 1.66 - 1.55 (m, 1H), 1.42-1.31 (m, 2H), 1.15 - 1.09 (m, 6H), 1.00 (s, 3H), 0.63 (s, 3H).
Example 87 (lr.25.3/?)-V-|(75J35)-23.23-dilluoro-(2()3D-2()-|2-|(LSh-l-metl1oxyetl1yl]-5-|4-(2.2.2- trifluoroethyl)piperazin-l-yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-7-yl]-2,3-dimethyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-23,23-difluoro-(20A015)]-2]-20 ־)-l-methoxyethyl]-5-[4-(2,2,2- trifluoroethyl)piperazin- 1 -yl]-3-pyridyl] -17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate O) and (lr,25,37?)-2,3-dimethylcyclopropanecarboxylic acid instead of (75,135)-7-amino-(20vW)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 87(32.4 mg) was obtained as a light yellow solid. MS cak ’d 941.4 (MH+), measured 941.4 (MH+). 1H NMR (400 MHz, METHANOL-d) 8 = 8.(s, 1H), 8.44 - 8.38 (m, 1H), 7.83 - 7.78 (m, 1H), 7.62 - 7.57 (m, 2H), 5.80 (br d, J= 7.0 Hz, 1H), 4.55 - 4.40 (m, 3H), 4.22 (dd, J= 2.9, 12.0 Hz, 1H), 4.09 - 3.98 (m, 1H), 3.83 - 3.76 (m, 1H), 3.75 - 3.69 (m, 1H), 3.68 - 3.56 (m, 2H), 3.51 - 3.46 (m, 4H), 3.44 - 3.38 (m, 4H), 3.28 - 3.08 (m, 4H), 2.92 - 2.86 (m, 4H), 2.80 - 2.67 (m, 2H), 2.23 - 2.11 (m, 1H), 1.96 - 1.91 (m, 1H), 1.83 - 1.70 (m, 1H), 1.67 - 1.57 (m, 1H), 1.49 (d,J=6.3Hz, 3H), 1.39-1.31 (m, 2H), 1.16- 1.11 (m, 7H), 1.01 (s, 3H), 0.63 (s, 3H).
Example 88 (15,25)-^-[(75,135)-(20A0-20-[2-[(15)-l-methoxyethyl]-5-morphoUno-3-pyridyl]-17,17- dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-pyrimidin-5-yl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20A/)-20-[2-[(15)- 1-metho xyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15,24-dioxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9 13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (intermediate J) and tra/752- ־-pyrimidin-5- ylcyclopropanecarboxylic acid (Intermediate RI) instead of (7>S',135)-7-amino-(20A/)-20-[2- [(IS)- l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F) and (l>S,,2،S)-2-methylcyclopropanecarboxylic acid and then purified byprep-HPLC. Example 88(30 mg, prep-HPLC, faster eluted) was obtained as a light yellow solid. MS cak ’d 876.4 (MH+), measured 876.4 (MH+). 1H NMR (400 MHz, METHANOL-d4) = 9.0 (s, 1H), 8.67 (s, 2H), 8.42 - 8.33 (d, J= 3.2 Hz, 1H), 8.28 - 8.20 (s, 1H), 7.90 - 7.80 (d, J=2.8 Hz, 1H), 7.52 (s, 1H), 7.18 (s, 1H), 5.87 - 5.68 (d, >1.6 Hz, 1H), 4.70 - 4.57 (m, 3H), 4.- 4.39 (m, 1H), 4.32 - 4.19 (m, 2H), 3.90 - 3.85 (m, 4H), 3.79 - 3.74 (m, 2H), 3.50 - 3.45 (m, 1H), 3.45 - 3.40 (m, 8H), 3.28 - 3.22 (m, 1H), 3.19 - 3.10 (m, 1H), 2.86 - 2.73 (m, 1H), 2.72 - 2.62 (d, J=14.4 Hz 1H), 2.44 - 2.36 (m, 1H), 2.27 - 2.16 (m, 2H), 1.99 - 1.90 (m, 1H), 1.87 - 1.73 (m, 1H), 1.69 - 1.59 (m, 2H), 1.52 - 1.45 (m, 4H), 1.04 (s, 3H), 0.60 (s, 3H).
Example 89 (l1S',2S)-/V-[(71S',135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17- dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26[hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-(3-pyridyl)cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (l،S,,2،S)-2-(3-pyridyl)cyclopropanecarboxylic acid instead of (18',25)-2- methylcyclopropanecarboxylic acid. Example 89(17.8 mg) was obtained as a yellow solid. MS cak ’d 873.4 (MH+), measured 873.4 (MH+). 1H NMR (400 MHz, METHANOL-d) 8 = 8.79 (s, 1H), 8.69 (d, J = 5.2 Hz, 1H), 8.43 (s, 1H), 8.39 - 8.34 (m, 2H), 7.97 (dd, J= 6.0, 8.0 Hz, 1H), 7.86 (d, J= 2.4 Hz, 1H), 7.52 (s, 1H), 7.46 (s, 1H), 5.84 (d, J= 7.6 Hz, 1H), 4.54 (q, J= 6.0 Hz, 1H), 4.47-4.41 (m, 1H), 4.23 (dd, J= 2.8, 11.6 Hz, 1H), 4.17-4.10 (m, 1H), 3.86 (t, J= 4.8 Hz, 4H), 3.77 (s, 2H), 3.69 (m, 1H), 3.43 (s, 6H), 3.28 - 3.23 (m, 1H), 3.18 - 2.96 (m, 4H), 2.83 - 2.75 (m, 1H), 2.74 - 2.68 (m, 1H), 2.63 - 2.57 (m, 1H), 2.37 - 2.31 (m, 1H), 2.29 - 2.24 (m, 1H), 2.22 - 2.15 (m, 2H), 1.97 - 1.91 (m, 1H), 1.82 - 1.74 (m, 1H), 1.73 - 1.68 (m, 1H), 1.65 - 1.59 (m, 1H), 1.57 - 1.52 (m, 1H), 1.49 (d, J= 6.4 Hz, 3H), 1.37 - 1.27 (m, 1H), 1.00 (s, 3H), 0.64 (s, 3H).
Example 90 (15,25)-AL[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin- l-yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-(3-pyridyl)cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20Af)-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin-l-yl]- 3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 -tetrazahexacyclo [23.3.1.12’5. l9J3.0l9’27.0212]hentriaconta- 1(28),2,5(31), 19,25(29),26-hexaene-8,14-dione (intermediate G) and (15,25)-2-(3-pyridyl)cyclopropanecarboxylic acid instead of (75,135)-7-amino-(20A/)-20-[2-[( 15)-1 -methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F)and (15,25)-2-methylcyclopropanecarboxylic acid. Example 90(26.0 mg) was obtained as a yellow solid. MS cak ’d 954.4 (MH+), measured 954.4 (MH+). 1H NMR (400 MHz, METHANOL-d4) 8 = 8.79 (s, 1H), 8.69 (d, J = 5.2 Hz, 1H), 8.44 (s, 1H), 8.39 - 8.34 (m, 2H), 7.97 (dd, J= 6.0, 8.0 Hz, 1H), 7.88 (s, 1H), 7.53 (s, 1H), 7.46 (s, 1H), 5.84 (d, J = 7.6 Hz, 1H), 4.54 (q, J= 6.0 Hz, 1H), 4.46 - 4.40 (m, 1H), 4.23 (dd, 5=2.8, 11.6 Hz, 1H), 4.16-4.10 (m, 1H), 3.77 - 3.76 (m, 1H), 3.72 -3.67 (m, 1H), 3.63 - 3.58 (m, 2H), 3.51 - 3.49 (m, 3H), 3.43 (s, 3H), 3.18 (q, J= 9.6 Hz, 3H), 3.13 - 3.06 (m, 2H), 2.90 - 2.88 (m, 3H), 2.83 - 2.76 (m, 1H), 2.73 - 2.68 (m, 1H), 2.63 - 2.58 (m, 1H), 2.36 - 2.30 (m, 1H), 2.28 - 2.24 (m, 1H), 2.21 - 2.17 (m, 1H), 1.98 - 1.92 (m, 1H), 1.83 - 1.74 (m, 1H), 1.73 - 1.68 (m, 1H), 1.62 (dd, J= 3.2, 12.4 Hz, 1H), 1.58 - 1.54 (m, 1H), 1.48 (d, J = 6.4 Hz, 3H), 1.33 - 1.29 (m, 1H), 1.18 (t, J= 7.2 Hz, 3H), 1.01 (s, 3H), 0.64 (s, 3H).
Example 91 (15,2.S)-^-[(75,135)-23,23-dinuoro-(20Af)-20-[2-[(l lS)-l-methoxyethyl]-5-morpholino-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-(3-pyridyl)cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-23,23-difluoro-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-morphohno-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate Q) and (15,25)-2-(3-pyridyl)cyclopropanecarboxylic acid instead of (75,135)-7-amino-(20A/)-20-[2-[( 1 Sy 1 -methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9, 21,30,3 l-tetrazahexacyclo[23. 3.1.12,נ. I9’13.019’27.02l,26]hentriaconta-(28),2,5(31 ),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 91(24.6 mg) was obtained as a yellow solid. MS cak ’d 909.4 (MH+), measured 909.4 (MH+). 1H NMR (400 MHz, METHANOL-d4) 8 = 8.78 (s, 1H), 8.68 (d, J= 4.8 Hz, 1H), 8.53 (s, 1H), 8.42 (d, J= 2.8 Hz, 1H), 8.33 (d, J= 8.0 Hz, 1H), 7.95 (dd, J= 6.0, 8.0 Hz, 1H), 7.70 (d, J= 2.8 Hz, 1H), 7.60 (s, 2H), 5.82 (d, J= 8.0 Hz, 1H), 4.57 - 4.49 (m, 2H), 4.46 - 4.41 (m, 1H), 4.25 (dd, J= 2.8, 11.6 Hz, 1H), 4.06 - 3.97 (m, 1H), 3.86 (t, J= 4.8 Hz, 4H), 3.81 - 3.72 (m, 2H), 3.64 - 3.58 (m, 2H), 3.51 - 3.42 (m, 2H), 3.40 (s, 3H), 3.29 - 3.24 (m, 1H), 3.12 - 3.04 (m, 1H), 2.83 - 2.76 (m, 1H), 2.73 - 2.67 (m, 1H), 2.62 - 2.57 (m, 1H), 2.28 - 2.23 (m, 1H), 2.22 - 2.17 (m, 1H), 1.98 - 1.92 (m, 1H), 1.85 - 1.75 (m, 1H), 1.73 - 1.68 (m, 1H), 1.65 - 1.60 (m, 1H), 1.57 - 1.52 (m, 1H), 1.49 (d, J= 6.4 Hz, 3H), 1.33 - 1.29 (m, 1H), 1.18 (t, J= 7.2 Hz, 2H), 1.01 (s, 3H), 0.62 (s, 3H).
Example 92 (15,25)-7V-[(75435)-23,23-dinuoro-(20Af)-20-[2-[(15)-l-methoxyethyl]-5-(4- methylpiperazin-l-yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-(3-pyridyl)cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-23,23-difluoro-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l- yl)-3-pyridyl] -17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate K) and (15,25)-2-(3-pyridyl)cyclopropanecarboxylic acid instead of (75,135)-7-amino-(2037)-20-[2-[(l lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]-l 7,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 92(23.3 mg) was obtained as a yellow solid. MS cak ’d 922.4 (MH+), measured 922.4 (MH+). ׳H NMR (400 MHz, METHANOL-،/4) 8 = 8.78 (s, 1H), 8.68 (d, J= 5.2 Hz, 1H), 8.52 - 8.49 (m, 2H), 8.32 (d, J= 8.4 Hz, 1H), 7.95 (dd, J= 5.6, 8.Hz, 1H), 7.59 (s, 1H), 7.57 (s, 1H), 7.47 (d, J= 2.8 Hz, 1H), 5.80 (d, J= 8.4 Hz, 1H), 4.62 - 4.(m, 1H), 4.51 - 4.42 (m, 2H), 4.26 (dd, J= 3.2, 12.4 Hz, 1H), 4.00 - 3.87 (m, 2H), 3.82 - 3.71 (m, 3H), 3.61 (q, J= 7.2 Hz, 3H), 3.46 (d, J= 14.8 Hz, 2H), 3.36 (s, 3H), 3.13 - 3.08 (m, 1H), 2.99 (s, 3H), 2.83 - 2.76 (m, 1H), 2.63 - 2.57 (m, 2H), 2.29 - 2.24 (m, 1H), 2.21 - 2.17 (m, 1H), 1.96 (d, J = 13.2 Hz, 1H), 1.85 - 1.76 (m, 1H), 1.73 - 1.69 (m, 1H), 1.63 (dd, J= 3.2, 12.4 Hz, 1H), 1.57 - 1.52 (m, 1H), 1.47 (d, J = 6.0 Hz, 3H), 1.34 - 1.29 (m, 3H), 1.18 (t, J= 7.2 Hz, 2H), 0.99 (s, 3H), 0.57 (s, 3H).
Example 93 (l1$',21S)-7V-[(7*S',13*S)-(20A/)-20-[2-[(llS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl] -17,17-dimethyl-8,14-dioxo-l 5,24-dioxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-pyrimidin-5-yl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(2037)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazm-l-yl)-3-pyridyl]- 17,17-dimethyl- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate H) and P־،z«5-2-pyrimidin-5-ylcyclopropanecarboxylic acid (Intermediate RI) instead of (7S,135)-7-amino-(207l7)-20-[2-[(lS)-l-methoxyethyl]-5- morpholino-3-pyridyl] -17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F) and (lS,25)-2-methylcyclopropanecarboxylic acid and then purified by prep-HPLC. Example 93(36.6 mg, prep-HPLC, faster eluted) was obtained as a light yellow solid. MS calc ’d 889.4 (MH+), measured 889.6 (MH+). 1H NMR (400 MHz, METHANOL-،/4) = 9.00 (s, 1H), 8.65 (s, 2H), 8.50 (d, J= 3.2 Hz, 1H), 8.24 (s, 1H), 7. (d, J= 4.4 Hz, 1H), 7.52 (s, 1H), 7.10 (s, 1H), 5.76 (d, J= 8.0 Hz, 1H), 4.65 (m, 2H), 4.53 (m, 1H), 4.47 - 4.40 (m, 1H), 4.- 4.25 (m, 2H), 4.20 - 3.93 (m, 2H), 3.79 - 3.72 (m, 3H), 3.67 - 3.52 (m, 2H), 3.48 - 3.41 (m, 2H), 3.39 - 3.37 (m, 3H), 3.29 - 3.23 (m, 2H), 3.16 - 3.10 (m, 1H), 3.07 - 2.86 (m, 4H), 2.82 - 2.73 (m, 1H), 2.64 - 2.57 (m, 1H), 2.42 - 2.35 (m, 1H), 2.26 - 2.16 (m, 2H), 1.98 - 1.89 (m, 1H), 1.(q, J= 12.8 Hz, 1H), 1.60 (td, J= 4.9, 9.4 Hz, 2H), 1.54 - 1.14 (m, 5H), 1.05 - 0.97 (m, 3H), 0.- 0.48 (m, 3H).
Example 94 (LS'.25)-V-|(75.13.V)-(20W)-20-|2-|(LV)-l-mcthoxycthyl|-5-morpholino-3-pyridyl|-17.17- dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-pyrimidin-5-yl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using tra«5-2-pyrimidin-5-ylcyclopropanecarboxylic acid (Intermediate RI) instead of (15,2S)-2- methylcyclopropanecarboxylic acid and then purified by prep-HPLC. Example 94(15 mg, prep- HPLC, slower eluted) was obtained as a light yellow solid. MS calc ’d 874.4 (MH+), measured 874.4 (MH+). 1H NMR (400 MHz, METHANOL-d4) 8 = 9.01 (s, 1H), 8.66 (s, 2H), 8.44 (s, 1H), 8.37 (d, J= 2.8 Hz, 1H), 7.86 (d, J= 2.8 Hz, 1H), 7.52 (s, 1H), 7.46 (s, 1H), 5.84 (dd, J= 0.8, 8.4 Hz, 1H), 4.54 (q,J=6.4 Hz, 1H), 4.44 (d, J= 11.6 Hz, 1H), 4.22 (dd, J= 2.8, 11.6 Hz, 1H), 4.16 - 4.09 (m, 1H), 3.87 (t, J= 4.8 Hz, 4H), 3.77 (d, J= 4.4 Hz, 2H), 3.72 - 3.66 (m, 1H), 3.(s, 7H), 3.29 - 3.23 (m, 1H), 3.22 - 2.87 (m, 4H), 2.84 - 2.75 (m, 1H), 2.71 (d, J= 14.4 Hz, 1H), 2.43 - 2.38 (m, 1H), 2.37 - 2.29 (m, 1H), 2.23 - 2.15 (m, 3H), 1.98 - 1.90 (m, 1H), 1.82 - 1.71 (m, 1H), 1.65 - 1.57 (m, 2H), 1.49 (d, J=6.4Hz, 3H), 1.47- 1.42 (m, 1H), 1.00 (s, 3H), 0.64 (s, 3H).
Example 95 (15,25)-^-[(75,135)-23,23-difluoro-(20T0-20-[2-[(15)-l-methoxyethyl]-5-(4- methylpiperazin-l-yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l913.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-pyrimidin-5-yl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-23,23-difluoro-(207IT)-20-[2-[(l lS)-l-methoxyethyl]-5-(4-methylpiperazin-l- yl)-3-pyridyl] -17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate K) and tz־،z«5-2-pyrimidin-5-ylcyclopropanecarboxylic acid (Intermediate RI) instead of (7S,13>S)-7-amino-(207l7)-20-[2-[(15)-l-methoxyethyl]-5- morpholino-3-pyridyl]-17,1 7-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F) and (lS,2>S)-2-methylcyclopropanecarboxylic acid and then purified by prep-HPLC. Example 95(15 mg, prep-HPLC, slower eluted) was obtained as a light yellow solid. MS calc ’d 923.4 (MH+), measured 923.4 (MH+). *H NMR (400 MHz, METHANOL-^) = 9.01 (s, 1H), 8.67 (s, 2H), 8.53 - 8.50 (m, 2H), 7.59 - 7.56 (m, 2H), 7.54 (d, J= 2.8 Hz, 1H), 5.80 (d, J= 8.0 Hz, 1H), 4.59 - 4.52 (m, 1H), 4.50 (d, J= 6.0 Hz, 1H), 4.44 (d, J = 12.0 Hz, 1H), 4.26 (dd, J=3.2, 12.0 Hz, 1H),4.O1 - 3.87 (m, 2H), 3.82 - 3.70 (m, 3H), 3.65 - 3.51 (m, 4H), 3.46 (d, J= 14.8 Hz, 2H), 3.37 (s, 4H), 3.29 - 3.25 (m, 2H), 3.15 - 3.03 (m, 2H), 2.99 (s, 3H), 2.83 - 2.76 (m, 1H), 2.62 (d, J = 14.0 Hz, 1H), 2.43 - 2.38 (m, 1H), 2.24-2.17 (m, 2H), 1.95 (d, J= 12.8 Hz, 1H), 1.83 - 1.75 (m, 1H), 1.65 - 1.59 (m, 2H), 1.48 (d, J= 6.0 Hz, 3H), 1.46 - 1.(m, 1H), 0.99 (s, 3H), 0.57 (s, 3H).
Example 96 (lS,2S)-AM(7S43S)-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- 2,5 9,13 19,27 21,26 tetrazahexacyclo[23.3.1.1 .1 .0 .0 ]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-(3-pyridyl)cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]- 17,17-dimethyl- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate H) and (15,25)-2-(3-pyridyl)cyclopropanecarboxylic acid instead of (75,135)-7-amino-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.0l9’27.02l’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 96(14.9 mg) was obtained as a white solid. MS cak ’d 888.4 (MH+), measured 888.4 (MH+). *H NMR (400 MHz, METHANOL-d) d = 8.44 - 8.36 (m, 3H), 8.19 (d, J= 0.8 Hz, 1H), 7.65 - 7.57 (m, 1H), 7.47 (s, 1H), 7.41 - 7.34 (m, 1H), 7.29 (d, J= 2.8 Hz, 1H), 7.07 (d, J= 0.8 Hz, 1H), 5.78 (d, J= 7.6 Hz, 1H), 4.60 (dd, J= 2.8 Hz, 5.8 Hz, 2H), 4.46 - 4.39 (m, 2H), 4.38 - 4.25 (m, 2H), 3.78 - 3.71 (m, 3H), 3.39 (s, 3H), 3.34 (s, 3H), 3.27 - 3.22 (m, 1H), 2.75 (s, 4H), 2.63 - 2.53 (m, 1H), 2.47 - 2.43 (m, 3H), 2.23 -2.19 (m, 1H), 2.17-2.11 (m, 1H), 1.97 - 1.90 (m, 1H), 1.64- 1.56 (m, 2H), 1.44 (d, J= 6.4 Hz, 3H), 1.- 1.34 (m, 7H), 0.994 (s, 3H), 0.516 (s, 3H).
Example 97 (15,25)-^-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-morphoUno-3-pyridyl]-17,17- dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- 2,5 9,13 19,27 21,26 tetrazahexacyclo[23.3.1.1 .1 .0 .0 ]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-(3-pyridyl)cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(2037)-20-[2-[(15)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17-dimethyl- 15,24-dioxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’n.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (intermediate J) and (lS,25)-2-(3- pyridyl)cyclopropanecarboxylic acid instead of (7S,13S)-7-amino-(20Af)-20-[2-[(15 ׳)-l- methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F)and (l>S,,2lS)-2-methylcyclopropanecarboxylic acid. Example 97(mg) was obtained as a white solid. MS cak ’d 875.4 (MH+), measured 875.4 (MH+). 1H NMR (400 MHz, METHANOL-d) <5 = 8.77 (d, >1.6 Hz, 1H), 8.67 (d, J= 5.6 Hz, 1H), 8.39 (d, J= 3.2 Hz, 1H), 8.3 (d, J= 8.4 Hz, 1H) 8.22 (s, 1H), 7.94 - 7.92 (m, 1H), 7.71 - 7.7 (m, 1H), 7.50 (s, 1H), 7.12 (s, 1H), 5.81-5.77 (m, 1H), 4.62 - 4.56 (m, 3H), 4.29 (d, J= 3.6 Hz, 1H), 4.28 - 4.(m, 2H), 3.86 - 3.76 (m, 7H), 3.43-3.42 (m, 8H), 3.39-3.37 (m, 1H), 3.26 - 3.12 (m, 1H), 2.82- 2.72 (m, 1H), 2.67 - 2.64 (m, 1H), 2.61 - 2.52 (m, 1H), 2.26 - 2.24 (m, 2H), 2.05 - 1.90 (m, 1H), 1.89- 1.81 (m, 1H), 1.80- 1.75 (m, 1H), 1.69- 1.68 (m, 1H), 1.67- 1.66 (m, 1H), 1.54 (d, J = 6.4 Hz, 3H), 1.03 (s, 3H), 0.57 (s, 3H).
Example 98 (lS',21S)-A^-[(7S',135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin- l-yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- 2,5 9,13 19,27 21,26 tetrazahexacyclo[23.3.1.1 .1 .0 .0 ]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-(3-pyridyl)cyclopropanecarboxamide F The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin-l-yl]- 3-pyridyl]- 17,17-dimethyl- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate 1) and (15,25)-2-(3-pyridyl)cyclopropanecarboxylic acid instead of (75,135)-7-amino-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 98(24.8 mg) was obtained as a light yellow solid. MS cak ’d 956.4 (MH+), measured 956.4 (MH+). 1H NMR (400 MHz, METHANOL-44) 8 = 8.(s, 1H), 8.69 (d, J= SA Hz, 1H), 8.41 - 8.31 (m, 2H), 8.23 (s, 1H), 8.01 - 7.93 (m, 1H), 7.88 - 7.74 (m, 1H), 7.51 (s, 1H), 7.13 (s, 1H), 5.79 (d, J= 8.0 Hz, 1H), 4.66 - 4.56 (m, 3H), 4.48 - 4.(m, 1H), 4.31 - 4.20 (m, 2H), 3.86 - 3.73 (m, 3H), 3.60-3.32 (m, 5H), 3.42 (s, 3H), 3.28 - 3.14 (m, 4H), 2.92 - 2.86 (m, 4H), 2.84 - 2.75 (m, 1H), 2.70 - 2.57 (m, 2H), 2.30 - 2.18 (m, 2H), 2.00 - 1.92 (m, 1H), 1.88 - 1.76 (m, 1H), 1.74 - 1.66 (m, 1H), 1.65 - 1.53 (m, 2H), 1.49 (d, J= 6.4 Hz, 3H), 1.04 (s, 3H), 0.59 (s, 3H).
Example 99 (15,25)-7V-[(75,135)-(20Af)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-pyrazin-2-yl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate E) and trans ־( IS,2>S)-2-pyrazin-2-ylcyclopropanecarboxylic acid (intermediate R6)instead of (7S,13S)-7-amino-(207l7)-20-[2-[(lS)-l-methoxyethyl]-5- morpholino-3-pyridyl]-17,1 7-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F) and (lS,2>S)-2-methylcyclopropanecarboxylic acid and then purified by reversed phase chromatography and Prep-HPLC. Example 99(1 mg, slower eluted) was obtained as a white solid. MS cak ’d 887.4 (MH+), measured 887.4 (MH+). ׳H NMR (400 MHz, METHANOL-،/4) d = 8.62 (d, J= 1.6 Hz, 1H), 8.53 - 8.51 (m, 1H), 8.44 - 8.40 (m, 3H), 7.52 (s, 1H), 7.44 - 7.38 (m, 1H), 7.28 (d, > 2.8 Hz, 1H), 5.86 - 5.79 (m, 1H), 4.48 - 4.38 (m, 2H), 4.30 - 4.23 (m, 2H), 3.76 (s, 2H), 3.67 - 3.59 (m, 1H), 3.52 - 3.41 (m, 2H), 3.36 (s, 4H), 3.28 - 3.25 (m, 1H),3.15 - 3.00 (m, 3H), 2.84 - 2.75 (m, 1H), 2.68-2.64 (m, 5H), 2.62 - 2.58 (m, 2H), 2.48-2.(m, 1H), 2.38 (s, 3H), 2.26 - 2.18 (m, 2H), 1.95 (s, 1H), 1.81 - 1.73 (m, 1H), 1.66 - 1.58 (m, 3H), 1.44 (d, > 6.4 Hz, 3H), 1.39 - 1.30 (m, 2H), 0.97 (s, 3H), 0.56 (s, 3H).
Example 100 (lr.2/?.3،S')-V-|(7S. 13S)-(2017)-20-|2-|(LS')-l-mctl1oxyctl1yl|-5-(4-metl1ylpip€1־azin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15,25-dioxa-4-thia-9,21,31,32- tetrazahexacyclo[24.3.1.12’5.l9 13.019’28.021’27]dotriaconta-l(29),2,5(32),19,26(30),27-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazm-l-yl)-3-pyridyl]- 17,17-dimethyl- 15,25-dioxa-4-thia-9,2 1,31,32- tetrazahexacyclo[24.3.1.1 2’5.l9’13.019’28.021’27]dotriaconta-l(29),2,5(32),19,26(30),27-hexaene- 8,14-dione (intermediate S) and (l/2,3-(?25,37,־-dimethylcyclopropanecarboxylic acid instead of (75,135)-7-amino-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.0l9’27.02l’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 100(17.2 mg) was obtained as a yellow solid. MS cak ’d 853.4 (MH+), measured 853.4 (MH+). *H NMR (400 MHz, METHANOL-d) d = 8.47 (d, J= 2.8 Hz, 1H), 8.22 (s, 1H), 7.56 - 7.49 (m, 2H), 7.28 (s, 1H), 5.75 (d, J= 7.6 Hz, 1H), 4.59 - 4.52 (m, 1H), 4.51 - 4.41 (m, 2H), 4.25 - 4.08 (m, 3H), 4.05 - 3.90 (m, 2H), 3.71 (q, J= 11.2 Hz, 6H), 3.45 - 3.35 (m, 6H), 3.29 - 3.22 (m, 2H), 3.07 (d, J = 14.8 Hz, 1H), 3.00 (s, 3H), 2.77 (s, 1H), 2.61 ^J= 14.0 Hz, 1H), 2.46 - 2.32 (m, 1H), 2.27 (s, 1H), 2.15 (d, J = 14.0 Hz, 1H), 1.(s, 1H), 1.82- 1.68 (m, 1H), 1.61 (s, 1H), 1.49- 1.29(m, 6H), 1.14 (dd, J= 6.0, 11.2 Hz, 6H), 0.93 (s, 3H), 0.50 (s, 3H).
Example 101 (lr,25,31?)-A^-[(75,135)-(20A/)-20-[5-[(9«l?)-l,3,4,6,7,8,9,9«-octahydropyrido[l,2-a]pyrazin- 2-yl]-2-[(15)-l-methoxyethyl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-7-yl]-2,3-dimethyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-(20A/)-20-[5-[(9،z7?)-l,3,4,6,7,8,9,9،z-octahydropyrido[l,2-a]pyrazin-2-yl]-2-[(15)-l- methoxyethyl]-3-pyridyl]-7-amino- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate L2)and (l/2,3-(?25,37,־-dimethylcyclopropanecarboxylic acid instead of (75,135)-7-amino-(20Af)-20-[2-[(15)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 101(15.1 mg) was obtained as a yellow solid. MS cak ’d 877.4 (MH+), measured 877.4 (MH+). 1H NMR (400 MHz, METHANOL-d) d = 8.48 (d, J= 2.8 Hz, 1H), 8.39 (s, 1H), 7.57 (s, 1H), 7.50 (s, 1H), 7.43 (s, 1H), 5.77 (d, J= 7.2 Hz, 1H), 4.51 -4.41 (m, 2H),4.23 (dd,J=2.8, 11.6 Hz, 2H), 4.11 (d,J= 13.6 Hz, 2H), 3.80 - 3.72 (m, 2H), 3.62 - 3.53 (m, 3H), 3.43 - 3.36 (m, 6H), 3.29 - 3.24 (m, 2H), 3.14 - 3.07 (m, 3H), 2.99 (d, J = 11.2 Hz, 2H), 2.82 - 2.73 (m, 1H), 2.60 (d,J= 14.4 Hz, 1H), 2.31 (d, J = 4.0 Hz, lH),2.17(d, J= 12.8 Hz, 2H), 2.07 - 1.93 (m, 4H), 1.86 - 1.52 (m, 6H), 1.46 (d, J= 6.0 Hz, 3H), 1.42 - 1.(m, 2H), 1.16 - 1.12 (m, 6H), 0.97 (s, 3H), 0.55 (s, 3H).
Example 102 (15,25)-^-[(75,135)-(20^-20-[5-[(9«7?)-1,3,4,6,7,8,9,9«-octahydropyrido[l,2-a]pyrazin-2- yl]-2-[(15)-l-methoxyethyl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-(3-pyridyl)cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-(20A/)-20-[5-[(9rz7?)-l,3,4,6,7,8,9,9rz-octahydropyrido[l,2-a]pyrazin-2-yl]-2-[(15)-l- methoxyethyl]-3-pyridyl]-7-amino- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate L2)and (15,25)-2-(3-pyridyl)cyclopropanecarboxylic acid instead of (75,135)-7-amino-(20A/)-20-[2-[(l>S)-l-methoxyethyl]-5-morphohno-3-pyridyl]-l 7,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.0l9’27.02l’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 102(24.3 mg) was obtained as a light yellow solid. MS cak ’d 926.5 (MH+), measured 926.5 (MH+). *H NMR (400 MHz, METHANOL-d4) ،5 = 8.(s, 1H), 8.70 - 8.65 (m, 1H), 8.49 (d, J= 3.2 Hz, 1H), 8.40 (s, 1H), 8.34 - 8.30 (m, 1H), 7.97 - 7.92 (m, 1H), 7.56 (d, J= 3.2 Hz, 1H), 7.51 (s, 1H), 7.43 (s, 1H), 5.83 - 5.79 (m, 1H), 4.48 - 4.(m, 2H), 4.27 - 4.18 (m, 2H), 4.13 - 4.07 (m, 2H), 3.76 (s, 2H), 3.61 - 3.52 (m, 3H), 3.47 - 3.(m, 1H), 3.37 (s, 3H), 3.35 - 3.32 (m, 1H), 3.29 - 3.24 (m, 2H), 3.12 - 3.00 (m, 5H), 2.83 - 2.(m, 1H), 2.64 - 2.57 (m, 2H), 2.31 - 2.17 (m, 4H), 2.06 - 1.94 (m, 4H), 1.86 - 1.76 (m, 2H), 1.- 1.67 (m, 2H), 1.66 - 1.58 (m, 3H), 1.57 - 1.52 (m, 1H), 1.46 (d, J= 6.0 Hz, 3H), 0.98 (s, 3H), 0.57 (s, 3H).
Example 103 (15,25)-7V-[(75,135)-(20A/)-20-[5-[(9a7?)-l,354,6,7,8,9,9a-octahydropyrido[l,2-a]pyrazin-2- yl]-2-[(15)-l-methoxyethyl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-pyrimidin-5-yl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,13S)-(20A/)-20-[5-[(9،zR)-l,3,4,6,7,8,9,9،z-octahydropyrido[l,2-a]pyrazin-2-yl]-2-[(lS)-l- methoxyethyl]-3-pyridyl]-7-amino- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate L2)and P־،zw،s’-2-pyrimidin-5-ylcyclopropanecarboxylic acid (Intermediate RI) instead of (7S,135)-7-amino-(207l7)-20-[2-[(15)-l-methoxyethyl]-5- morpholino-3-pyridyl]-17,1 7-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F) and (lS,25)-2-methylcyclopropanecarboxylic acid and then purified by prep-HPLC. Example 103(26.2 mg, prep-HPLC, slower eluted) was obtained as a yellow solid. MS calc ’d 927.5 (MH+), measured 927.5 (MH+). *H NMR (400 MHz, METHANOL-^) = 9.00 (s, 1H), 8.66 (s, 2H), 8.50 (d, J= 2.8 Hz, 1H), 8.41 (s, 1H), 7.65 (d, J= 2.8 Hz, 1H), 7.(s, 1H), 7.44 (s, 1H), 5.84 - 5.79 (m, 1H), 4.52 - 4.42 (m, 2H), 4.27 - 4.09 (m, 5H), 3.76 (s, 2H), 3.63 - 3.53 (m, 3H), 3.47 - 3.42 (m, 1H), 3.39 (s, 4H), 3.29 - 3.24 (m, 2H), 3.14 - 2.99 (m, 6H), 2.82 - 2.75 (m, 1H), 2.63 (d, J= 14.4 Hz, 1H), 2.43 - 2.38 (m, 1H), 2.35 - 2.29 (m, 1H), 2.22 - 2.16 (m, 3H), 2.06 - 1.93 (m, 4H), 1.83 - 1.78 (m, 1H), 1.68 - 1.60 (m, 4H), 1.49 - 1.45 (m, 4H), 0.98 (s, 3H), 0.58 (s, 3H).
Example 104 (lS,2S)-AM(7S,13S)-(20A/)-20-[5-[(9«S)-3,4,6,7,9,9«-hexahydro-LH-pyrazino[2,l- c][l,4]oxazin-8-yl]-2-[(15)-l-methoxyethyl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4- thia-9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l913.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-7-yl]-2-(3-pyridyl)cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-(20A/)-20-[5-[(9rz5)-3,4,6,7,9,9rz-hexahydro-177-pyrazino[2,l-c][l,4]oxazin-8-yl]-2- [(15)- l-methoxyethyl]-3-pyridyl]-7-amino- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate Li) and (15,25)-2-(3-pyridyl)cyclopropanecarboxylic acid instead of (75,135)-7-amino-(2037)-20- [2-[(15)-1-methoxyethyl]-5-morpholino-3-pyridyl] -17,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.0l9’27.02l’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 104(16.4 mg) was obtained as a light yellow solid. MS cak ’d 928.4 (MH+), measured 928.4 (MH+). *H NMR (400 MHz, METHANOL-d) 8 = 8.- 8.72 (m, 1H), 8.71 - 8.58 (m, 1H), 8.49 - 8.45 (m, 1H), 8.39 (s, 1H), 8.20 - 8.13 (m, 1H), 7.89 - 7.79 (m, 1H), 7.51 (s, 1H), 7.45 (d, J= 2.8 Hz, 1H), 7.42 (s, 1H), 5.83 - 5.78 (m, 1H), 4.45 - 4.(m, 2H), 4.27 - 4.21 (m, 2H), 4.12 - 3.99 (m, 5H), 3.89 - 3.84 (m, 1H), 3.76 (s, 2H), 3.62 - 3.(m, 4H), 3.49 - 3.42 (m, 3H), 3.36 (s, 3H), 3.27 - 3.23 (m, 2H), 3.14 - 2.99 (m, 4H), 2.82 - 2.(m, 1H), 2.63 - 2.55 (m, 2H), 2.34 - 2.28 (m, 1H), 2.25 - 2.17 (m, 3H), 1.97-1.91 (m, 1H), 1.- 1.59 (m, 2H), 1.52 - 1.49 (m, 1H), 1.45 (d, J= 6.0 Hz, 3H), 1.33 - 1.28 (m, 1H), 0.97 (s, 3H), 0.55 (s, 3H).
Example 105 (15,25)-^-[(75,135)-(20A/)-20-[5-[(9«5)-3,4,6,7,9,9«-hexahydro-l^-pyrazino[2,l- c][l,4]oxazin-8-yl]-2-[(15)-l-methoxyethyl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4- thia-9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l913.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-7-yl]-2-pyrimidin-5-yl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-(20A/)-20-[5-[(9rz5)-3,4,6,7,9,9rz-hexahydro-177-pyrazino[2,l-c][l,4]oxazin-8-yl]-2- [(15)- l-methoxyethyl]-3-pyridyl]-7-amino- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate Li) and p-tzns^-pyrimidin-S-ylcyclopropanecarboxylic acid (intermediate RI) instead of (75,135)-7-amino-(20X)-20-[2-[(15)-l-methoxyethyl]-5- morpholino-3-pyridyl]-17,1 7-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F) and (15,25)-2-methylcyclopropanecarboxylic acid and then purified by prep-HPLC. Example 105(22.4 mg, prep-HPLC, slower eluted) was obtained as a yellow solid. MS calc ’d 929.4 (MH+), measured 929.4 (MH+). *H NMR (400 MHz, METHANOL-،/4) = 9.00 (s, 1H), 8.67 - 8.65 (m, 2H), 8.48 (d, J= 2.8 Hz, 1H), 8.40 (s, 1H), 7.59 (d, J= 2.8 Hz, 1H), 7.52 (s, 1H), 7.44 - 7.42 (m, 1H), 5.82 - 5.78 (m, 1H), 4.49 - 4.42 (m, 2H), 4.28 - 4.20 (m,2H), 4.15 - 4.03 (m, 5H), 3.91 - 3.85 (m, 1H), 3.76 (s, 2H), 3.65 - 3.58 (m, 4H), 3.47 - 3.42 (m,2H), 3.38 (s, 3H), 3.29 - 3.24 (m, 2H), 3.13 - 3.07 (m, 2H), 3.03 - 2.96 (m, 2H), 2.82 - 2.76 (m,1H), 2.64 - 2.59 (m, 1H), 2.43 - 2.38 (m, 1H), 2.35 - 2.29 (m, 1H), 2.27 -2.14 (m, 4H), 1.97 - 1.92 (m, 1H), 1.83 - 1.75 (m, 1H), 1.65 - 1.59 (m, 2H), 1.46 (d, J= 6.4 Hz, 4H), 0.98 (s, 3H), 0.56 (s, 3H).
Example 106 (lr,27?,35)-7V-[(75,135)-(20A/)-20-[5-(4-cyclopropylpiperazin-l-yl)-2-[(15)-l-methoxyethyl]- 3-pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2,3-dimethyl-cyclopropanecarboxamide The compound was prepared according to the following scheme: Cbz TFADCM Intermediate V106-1 106-2 106-3 106-4 106 Step 1: Preparation of benzyl 4-[(5A/)-5-[(75',13S)-7-an1ino-17,17-din1ethyl-8,14-dioxo- 5 15,24-dioxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.Ll 2’5.l9 13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-20-yl]-6-[(15)-l-methoxyethyl]-3-pyridyl]piperazine-l- carboxylate (compound 106-1) To a solution of benzyl 4-[(5A/)-5-[(75,135)-7-(terLbutoxycarbonylamino)-17,17-dimethyl- 8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-20- yl]-6-[(15)-l-methoxyethyl]-3-pyridyl]piperazine-l-carboxylate (Intermediate V, 2.5 g, 1.mmol) in DCM (25 mL) was added TFA (15.0 mL) in one portion. After being stirred at for l h, the reaction mixture was concentrated under vacuum to afford benzyl 4-[(5A/)-5- [(75,135)-7-amino- 17,17-dimethyl-8,14-dioxo- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-20- yl]-6-[(15)-l-methoxyethyl]-3-pyridyl]piperazine-l-carboxylate (compound 106-1,2.71 g) as light brown oil, which was used directly in the next step. MS calc ’d 863.4 (MH+), measured 863.4 (MH+). Step 2: Preparation of benzyl 4-[(5A0-5-[(75,135)-7-[[(lr,25,37?)-2,3- dimethylcyclopropanecarbonyl]amino]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-20-yl]-6-[(15)-l-methoxyethyl]-3-pyridyl]piperazine-l- carboxylate (compound 106-2) To a solution of (b2,3 -(?25,37,־-dimethylcyclopropanecarboxylic acid (205. 8 mg, 1.mmol) in MeCN (11.8 mL) was added 1-methylimidazole (455.4 mg, 442 uL, 5.mmol) and TCFH (583.7 mg, 2.08 mmol) at rt. After being stirred at rt for l h, the reaction mixture was added with benzyl 4-[(5A/)-5-[(75,135)-7-amino-l 7,17-dimethyl-8,14-dioxo- 15,24- dioxa-4-thia-9,2 1,30,31-tetrazahexacyclo [23.3.1.12’19,13.0 .נl9,27.02l,26]hentriaconta- (28),2,5(31), 19,25(29),26-hexaen-20-yl]-6-[( 15)-1 -methoxyethyl]-3-pyridyl]piperazine- 1 - carboxylate;2,2,2-trifluoroacetic acid (compound 106-1,2.71 g, 1.39 mmol) and then stirred for another 2 hrs. The solvent was concentrated under vacuum and purified by silica gel chromatography to afford benzyl 4-[(5Af)-5-[(75,135)-7-[[(lr,25,37?)-2,3- dimethylcyclopropanecarbonyl]amino]- 17,17-dimethyl-8,14-dioxo- 15,24-dioxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26- hexaen-20-yl]-6-[(15)-l-methoxyethyl]-3-pyridyl]piperazine-l-carboxylate (compound 106-2, 730 mg) as a light yellow powder. MS calc ’d 959.4 (MH ), measured 959.4 (MH ). Step 3: Preparation of tert-butyl 4-[(5A/)-5-[(75,135)-7-[[(lr,27?,35)-2,3- dimethylcyclopropanecarbonyl]amino]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia- 9,21,30,31-tetrazahexacyclo [23.3.1. l2’5.l9’13.019’27.021’26] hentriaconta- 1(28),2,5(31), 19,25(29),26-hexaen-20-yl] -6- [(1S)-1 -methoxyethyl] -3-pyridy 1] piperazine-1- carboxylate (compound 106-3) To a solution of benzyl 4-[(5/f/)-5-[(7S 13S)-7-[[( lr,2S37?)-2,3- dimethylcyclopropanecarbonyl]amino]- 17,17-dimethyl-8,14-dioxo- 15,24-dioxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9 13.019’27.021'26]hentriaconta-l(28), 2,5(31),19,25(29)26י- hexaen-20-yl]-6-[(l،S)-l-methoxyethyl]-3-pyridyl]piperazine-l-carboxylate (compound 106-2, 730 mg, 0.76 mmol) and BoczO (332 mg, 1.52 mmol) in methanol (20 mL) was added Pd(OH)on activated carbon (73 mg, 10% w/w) under nitrogen atmosphere. The reaction mixture was degassed and purged with H2 for three times and then it was stirred at rt for 2 hrs under hydrogen atmosphere. After the reaction completed, the reaction mixture was filtered and the filtrate was concentrated under vacuum to give crude tert-butyl 4-[(5A/)-5-[(7S,135)-7-[[(lr,2R,35)-2,3- dimethylcyclopropanecarbonyl] amino] -17,17-dimethyl-8,14-dioxo- 15,24-dioxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26- hexaen-20-yl]-6-[(llS)-l-methoxyethyl]-3-pyridyl]piperazine-l-carboxylate (compound 106-3, 1g) as a yellow solid, which was used in the next step without purification. MS calc ’d 925.(MH+), measured 925.5 (MH+). Step 4: Preparation of (lr,27?,3S)-A-[(7S,135)-(20710-20-[2-[(15)-l-methoxyethyl]-5- piperazin-l-yl-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2,3-dimethyl-cyclopropanecarboxamide (compound 106-4) To a solution of tert-butyl 4-[(5A075,13)]-5־S)-7-[[(lr,27?,35)-2,3- dimethylcyclopropanecarbonyl] amino] -17,17-dimethyl-8, 14-dioxo- 15,24-dioxa-4-thia- 9,21,30,31 -tetrazahexacyclo [23.3.1.12’5.19’13.019’27.021’26]hentriaconta- 1 (28),2,5(31), 19,25(29),26- hexaen-20-yl]-6-[( 15’)-1 -methoxyethyl]-3-pyridyl]piperazine- 1 -carboxylate (compound 106-3, 1g, 1.08 mmol) in DCM (10 mL) was added TFA (5.0 mL) in one portion. After being stirred at for 1 h, the reaction mixture was concentrated under vacuum to afford a crude, which was purified by reversed-phase chromatography to afford (1^27?,35)-^-[(75,135)-(2071/)-20-[2-[(1،5)- -methoxyethyl]-5-piperazin- 1 -yl-3 -pyridyl] -17,17-dimethyl-8,14-dioxo- 15,24-dioxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26- hexaen-7-yl]-2,3-dimethyl-cyclopropanecarboxamide (compound 106-4,340 mg) as a light yellow powder. MS cak ’d 825.4 (MH), measured 825.4 (MH ).
Step 5: Preparation of (lr,27?,35)-A,-[(75,135)-(20A/)-20-[5-(4-cyclopropylpiperazin-l- yl)-2-[(llS)-l-methoxyethyl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-7-yl]-2,3-dimethyl-cyclopropanecarboxamide (Example 106) A solution of (l-ethoxycyclopropoxy)trimethylsilane (22.3 mg, 26 pL, 127.umol), (lr,2R,35)-7V-[(75,13.S)-(20Af)-20-[2-[(l lS)-l-methoxyethyl]-5-piperazin-l-yl-3-pyridyl]- 17,17-dimethyl-8,14-dioxo- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide (compound 106-4,40 mg, 42.6 pmol) and acetic acid (24 pL, 425.96 umol) in methano !(extra dry, 400 pL)/tetrahydrofuran (extra dry, 400 pL) was stirred at 50 for 1 h under nitrogen atmosphere. The reaction mixture was added withNaBH3CN (8.0 mg, 127.79 umol) and then stirred at 50° for 3 hrs. The solvent was removed under vacuum and purified by prep-HPLC to afford (lr,2R,35)-7V-[(75',135)-(207f/)-20- [5-(4-cyclopropylpiperazin- 1 -yl)-2-[(l>$)-1 -methoxyethyl] -3-pyridyl] -17,17-dimethyl-8, 14- dioxo-15,24-dioxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’l3.019’27.021’26]hentriaconta- 1(28),2,5(31 ),19,25(29),26-hexaen-7-yl]-2,3-dimethyl-cyclopropanecarboxamide (Example 106, mg) as a white powder. MS calc ’d 865.4 (MH+), measured 865.4 (MH+). 1H NMR (400 MHz, METHANOL-d) <5 = 8.41 (hr s, 1H), 8.20 (s, 1H), 7.48 (s, 1H), 7.28 (br s, 1H), 7.09 (d, J= 1.Hz, 1H), 5.77 (br d, J= 8.4 Hz, 1H), 4.59 (br s, 7H), 4.48 - 4.41 (m, 2H), 4.39 - 4.33 (m, 1H), 4.31 - 4.26 (m, 1H), 3.78 - 3.75 (m, 2H), 3.45 - 3.42 (m, 1H), 3.35 (br s, 3H), 3.28 - 3.23 (m, 1H), 3.15-3.07 (m, 1H), 2.88 - 2.82 (m, 4H), 2.80- 2.70 (m, 1H), 2.61 (br d, J= 13.8 Hz, 1H), 2.26- 2.19 (m, 1H), 1.96(brd,J= 12.8 Hz, 1H), 1.86- 1.74 (m, 2H), 1.68 - 1.58 (m, 1H), 1.45 (br d, J = 5.9 Hz, 3H), 1.42- 1.34 (m, 2H), 1.33 - 1.30 (m, 1H), 1.16 (br dd, J= 5.6, 12.0 Hz, 7H), 1.(s, 3H), 0.58 - 0.49 (m, 6H).
Example 107 (lr,27?,35)-A-[(7A',13A',23lS)-23-hydroxy-(20A/)-20-[2-[(llS)-l-methoxyethyl]-5-morpholino-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2,3-dimethyl-cyclopropanecarboxamide The compound was prepared according to the following scheme: Intermediate T 107-1 107 Step 1: Preparation of (lr,27?,35)-/V-[(75,135)-23-benzyloxy-20-[2-[(LS)-l- methoxyethyl]-5-morpholino-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26[hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-7-yl[-2,3-dimethyl-cyclopropanecarboxamide (compound 107-1) To a solution of (h2,3-(?25,37,־-dimethylcyclopropanecarboxylic acid (43 mg, 379.umol) in DMF (1 mL) was added HATU (156 mg, 411.37 umol) and DIEA (332 uL, 1.9 mmol) at rt. After being stirred at rt for l h, the reaction mixture was added with (75,135)-7-amino-23- benzyloxy-20-[2-[(15)- 1 -methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’l3.0l9’27.02l’26]hentriaconta-l(28),2,5(31),19,25(29),26- hexaene-8,14-dione (Intermediate T, 300 mg, 0.316 mmol). After being stirred for another 2 hrs, the reaction mixture was concentrated under vacuum and then purified by re versed-phase chromatography to afford (h7-(35,?27,־V-[(75,135)-23-benzyloxy-20-[2-[(15)-l-methoxyethyl]-5- morpholino-3-pyridyl]-17,1 7-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide (compound 107-1,142 mg) as a light yellow powder MS calc ’d 930.5 (MH+), measured 930.5 (MH+).
Step 2: Preparation of (lr,2^,35)-^-[(75,135,235)-23-hydroxy-(20A015)]-2]-20־)-l- methoxyethyl]-5-morpholino-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-7-yl]-2,3-dimethyl-cyclopropanecarboxamide (Example 107) To a solution of (b27?,3S)-7V-[(7S',13S)-23-benzyloxy-20-[2-[(15)-l-methoxyethyl]-5- morpholino-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide (compound 107-1,120 mg, 129 pmol) inDCM (extra dry, 3 mL) at -78 T2 was added dropwise 1 M boron trichloride (645 pL) under nitrogen atmosphere. The mixture was stirred for 1 hour at -78 T7 and then was quenched by the addition of MeOH (8 mL) and then allowed to warm to room temperature. The solvent was removed under vacuum to get a residue. The resulting residue was purified by prep-HPLC to afford (lr,27?,35)-7V-[(75,13S',23S)-23-hydroxy-(207lf)-20-[2-[(15)-l-methoxyethyl]-5- morpholino-3-pyridyl]-17,1 7-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide (Example 107,8.6 mg, slower eluted) as white powder. MS calc ’d 840.4 (MH+), measured 840.4 (MH+). 1HNMR (400 MHz, METHANOL-^) d = 8.45 - 8.42 (m, 1H), 8.42 (s, 1H), 7.53 - 7.48 (m, 2H), 7.47 - 7.45 (m, 1H), 7.31 - 7.26 (m, 1H), 5.86 - 5.79 (m, 1H), 5.73 - 5.66 (m, 1H), 4.58 - 4.49 (m, 1H), 4.49 - 4.37 (m, 2H), 4.34 - 4.19 (m, 1H), 3.90 - 3.86 (m, 6H), 3.82 - 3.78 (m, 1H), 3.78 - 3.75 (m, 2H), 3.51 - 3.39 (m, 2H), 3.16 - 3.06 (m, 2H), 2.91 - 2.87 (m, 1H), 2.83 - 2.74 (m, 1H), 2.32 - 2.25 (m, 1H), 2.20 -2.12 (m, 1H), 1.98 - 1.90 (m, 1H), 1.63 - 1.57 (m, 1H), 1.52 - 1.48 (m, 2H), 1.47 - 1.43 (m, 2H), 1.39 (td, J =4.9, 9.4 Hz, 3H), 1.20- 1.17 (m, 4H), 1.15 (dd, J = 4.0, 6.1 Hz, 5H), 1.04-1.01 (m, 2H), 0.97 - 0.94 (m, 2H), 0.60 - 0.57 (m, 3H).
Example 108 (lr,21?,35)-A^-[(7A',13A)-(20A/)-20-[2-[(llS)-l-methoxyethyl]-5-piperazin-l-yl-3-pyridyl]- 17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’s.l913.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2,3-dimethyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of compound 106-4by using benzyl 4-[(5vW)-5-[(75,13،S)-7-(te/7-butoxycarbonylamino)- 17,17-dimethyl-8, 14-dioxo- 15-oxa-4- thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.02126־]hentriaconta- l(28),2,5(31),19,25(29),26-hexaen-20-yl]-6-[(l>S)-l-methoxyethyl]-3-pyridyl]piperazme-l- carboxylate (compound E10) instead of benzyl 4-[(537)-5-[(7>77^)-7-(135,؟- butoxycarbonylamino)- 17,17-dimethyl-8,14-dioxo- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-20- yl]-6-[(LS)-l-mcthoxycthyl]-3-pyridyl]pipcrazmc- l-carboxylatc (Intermediate V).Example 108 (637 mg) was obtained as a light yellow solid. MS cak ’d 823.4 (MH+), measured 823.4 (MH+). 1H NMR (400 MHz, METHANOL-،/4) d = 8.49 (br d, J= 1.4 Hz, 1H), 8.40 (s, 1H), 7.58 (br s, 1H), 7.52 (s, 1H), 7.44 (s, 1H), 5.80 (br d, J= 8.4 Hz, 1H), 4.53 - 4.41 (m, 2H), 4.27 -4.17 (m, 2H), 3.77 (br s, 2H), 3.69 - 3.59 (m, 5H), 3.44 (br s, 5H), 3.40 (s, 3H), 3.31 - 3.25 (m, 1H), 3.(br d, J= 14.3 Hz, 2H), 3.05 - 2.96 (m, 1H), 2.79 (br t, J= 12.3 Hz, 1H), 2.63 (br d, J= 14.3 Hz, 1H), 2.39-2.28 (m, 1H), 2.18 (br d, J= 11.5 Hz, 2H), 1.95 (br d, J= 13.0 Hz, 1H), 1.83 - 1.(m, 1H), 1.68 - 1.58 (m, 1H), 1.48 (br d, J=6.1 Hz, 3H), 1.44- 1.32(m, 2H), 1.19- 1.12 (m, 7H), 0.98 (s, 3H), 0.58 (s, 3H).
Example 109 (lr,27?,35)-V-[(7A',13A)-20-[5-[4-(2,2-difluoroethyl)piperazi11-l-yl]-2-[(lS)-l-methoxyethyl]- 3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaco11ta-l(28),2,5(31),19,25(29),26-hexae11- 7-yl]-2,3-dimethyl-cyclopropanecarboxamide The compound was prepared according to the following scheme: 108A suspension of (b3,?27, ־S)-7V-[(75,13S)-(207l7)-20-[5-(4-cyclopropylpiperazin-l-yl)-2-[(1S)-1-methoxyethyl] -3-pyridyl]-! 7,17-dimethyl-8,14-dioxo-l 5,24-dioxa-4-thia-9,21 ,30,31 -tetrazahexacyclo[23.3.1.1 2’5.l9,13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide (example 108,30 mg, 32.01umol), trifluoromethanesulfonic acid 2,2-difluoroethyl ester (10 mg, 7 uL, 48.02 umol) and DIEA (13 mg, 17 pL, 96.04 umol) in tetrahydro furan (extra dry, 300 pL) was stirred at rt for 12hrs. The solvent was concentrated and then purified by Prep-HPLC to afford (l r,2R,3S)-N- [(75,13،S)-20-[5-[4-(2,2-difluoroethyl)piperazin- 1-yl]-2-[( 1S)-1-methoxyethyl] -3-pyridyl] -17,17- dimethyl-8, 14-dioxo- 15-oxa-4-thia-9,2 1,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide (example 109,10 mg) as a white powder. MS calc ’d887.4 (MH+), measured 887.4 (MH+). 1H NMR (400 MHz, METHANOL-d4) 8 = 8.30 - 8.25 (m, 2H), 7.36 (s, 1H), 7.28 (s, 1H), 7.13 (d, J = 2.9 Hz, 1H), 6.07 - 5.88 (m, 1H), 5.79 - 5.74 (m, 1H), 5.71 - 5.65 (m, 1H), 4.70 (br d, J = 12.4 Hz, 2H), 4.54 - 4.41 (m, 2H), 4.35 - 4.23 (m, 2H), 4.17 - 4.08 (m, 2H), 3.64 (s, 2H), 3.47 (ddd, J= 3.4, 8.6, 12.2 Hz, 1H), 3.33 - 3.28 (m, 1H), 3.19 - 3.(m, 2H), 3.02 - 2.85 (m, 3H), 2.77 - 2.64 (m, 7H), 2.50 (br d, J= 14.3 Hz, 1H), 2.19 (tdd, J= 4.2, 8.7, 13.1 Hz, 1H), 2.12 - 2.02 (m, 2H), 1.87 - 1.77 (m, 1H), 1.71 - 1.57 (m, 1H), 1.55 - 1.43 (m, 1H), 1.35 - 1.30 (m, 3H), 1.30-1.15 (m, 3H), 1.08 - 1.00 (m, 7H), 0.84 (s, 3H), 0.48 - 0.40 (m, 3H).
Example 110 (lr,2.R,3S)-7V-[(7S,13£)-(20A0-20-[5-[4-(2-nuoroethyl)piperazin-l-yl]-2-[(15)-l- methoxyethyl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2,3-dimethyl-cyclopropa11ecarboxamide The title compound was prepared in analogy to the preparation of Example 109by using 1- fluoro-2-iodo-ethane instead of trifluoromethane sulfonic acid 2,2-difluoroethyl ester. Example 110(17 mg) was obtained as a white solid. MS cak ’d 869.4 (MH+), measured 869.4 (MH+). *H NMR (400 MHz, METHANOL-،/4) <5 = 8.31 - 8.26 (m, 2H), 7.37 (s, 1H), 7.29 (s, 1H), 7.14 (d, J = 2.9 Hz, 1H), 5.68 (dd, J= 1.6, 8.5 Hz, 1H), 4.61 - 4.55 (m, 2H), 4.49 - 4.42 (m, 2H), 4.37 - 4.24 (m, 2H), 4.16 - 4.08 (m, 2H), 3.65 (s, 2H), 3.49 (ddd, J= 3.5, 8.6, 12.2 Hz, 1H), 3.33 - 3.(m, 2H), 3.18 - 3.13 (m, 1H), 3.02 - 2.83 (m, 4H), 2.73 - 2.60 (m, 8H), 2.51 (br d, J= 14.4 Hz, 1H), 2.26-2.15 (m, 1H), 2.13-2.02 (m, 2H), 1.82 (brd, J= 12.6 Hz, 1H), 1.70 - 1.58 (m, 1H), 1.48 (dq, V=3.7, 12.5 Hz, 1H), 1.36- 1.31 (m, 3H), 1.30- 1.21 (m, 2H), 1.14 - 1.09 (m, 2H), 1.07 - 1.01 (m, 7H), 0.85 (s, 3H), 0.44 (s, 3H).
Example ill (lr,21?,31S)-A-[(7A',13lS)-(20Af)-20-[5-[4-(3-hydroxypropyl)piperazin-l-yl]-2-[(l lS)-l- methoxyethyl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]he11triaco11ta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2,3-dimethyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 109by using 3- bromo-1-propanol and sodium iodide instead of trifluoromethanesulfonic acid 2,2-difluoroethyl ester. Example ill(15 mg) was obtained as a white solid. MS calc ’d 881.5 (MH+), measured 881.5 (MH+). 1H NMR (400 MHz, METHANOL-d4) = 8.32 - 8.25 (m, 2H), 7.37 (s, 1H), 7.(d, J= 0.9 Hz, 1H), 7.14 (d, J= 2.9 Hz, 1H), 5.68 (dd, J= 1.6, 8.5 Hz, 1H), 4.72 - 4.68 (m, 4H), 4.57 - 4.40 (m, 2H), 4.36 - 4.24 (m, 2H), 4.17 - 4.09 (m, 2H), 3.65 (s, 2H), 3.58 - 3.52 (m, 2H), 3.51 - 3.45 (m, 1H), 3.34 - 3.27 (m, 1H), 3.18 - 3.13 (m, 1H), 3.04 - 2.83 (m, 3H), 2.71 - 2.62 (m, 1H), 2.58 (br t, J= 4.9 Hz, 4H), 2.51 (d, J= 14.4 Hz, 1H), 2.47 - 2.42 (m, 2H), 2.25 - 2.14 (m, 1H), 2.13 - 2.03 (m, 2H), 1.86 - 1.78 (m, 1H), 1.72 - 1.65 (m, 2H), 1.64 - 1.58 (m, 1H), 1.55 - 1.43 (m, 1H), 1.33 (d, J= 6.1 Hz, 3H), 1.30 - 1.20 (m, 2H), 1.19-1.10 (m, 1H), 1.07 - 1.00 (m, 7H), 0.84 (s, 3H), 0.44 (s, 3H).
Example 112 (l/?,2/?)-^-[(7S,135)-(20A0-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’l3.0l9’27.02l’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-(4-methylpyrimidin-5-yl)cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20Af)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate E) and t/7ms-(15,2S)-2-(4-methylpyrimidin-5- yl)cyclopropanecarboxylic acid (intermediate R7)instead of (75,135)-7-amino-(20A/)-20-[2- [(15)- l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F) and (15,25)-2-methylcyclopropanecarboxylic acid and then purified by Prep-HPLC. Example 112(4.5 mg, slower eluted) was obtained as a white solid. MS cak ’d 901.5 (MH+), measured 901.5 (MH+). 1H NMR (400 MHz, METHANOL-d4) 5 = 8.90 (s, 1H), 8.49 (s, 1H), 8.45 - 8.38 (m, 2H), 7.51 (s, 1H), 7.42 (s, 1H), 7.29 (d, J= 2.6 Hz, 1H), 5.85 (hr d, J= 8.3 Hz, 1H), 4.59 (s, 9H), 4.50 - 4.42 (m, 1H), 4.42 - 4.38 (m, 1H), 4.30 - 4.24 (m, 1H), 3.(s, 2H), 3.67 - 3.57 (m, 1H), 3.48 (br d, J= 14.6 Hz, 1H), 3.40 (br d, J= 4.0 Hz, 3H), 3.16 - 3.(m, 3H), 2.79 (br s, 4H), 2.66 (s, 3H), 2.48 (s, 3H), 2.43 - 2.38 (m, 1H), 2.35 - 2.28 (m, 1H), 2.(br d, J= 12.3 Hz, 2H), 2.10 - 2.04 (m, 1H), 2.01 - 1.93 (m, 1H), 1.84 - 1.76 (m, 1H), 1.70 - 1.(m, 2H), 1.45 (d, J= 6.1 Hz, 3H), 0.98 (s, 3H), 0.56 (s, 3H).
Example 113 (lr,27?,35)-7V-[(75,135)-(20A/)-20-[5-(4-ethylpiperazin-l-yl)-2-[(15)-l-methoxyethyl]-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2,3-dimethyl-cyclopropanecarboxamide A solution of (lr,27?,35)-A-[(75,135)-(20Af)-20-[5-(4-cyclopropylpiperazin-l-yl)-2-[(15)-l- methoxyethyl] -3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15,24-dioxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide (example 108,30 mg, 32.01 pmol), 5 M acetaldehyde (13 pL, 64.03 umol) and acetic acid (18 pL, 320.14 umol) in methanol (extra dry, 0.3 mL) was stirred at rt for 1 hour. The reaction mixture was added with NaBH3CN (6.04 mg, 96.04 umol) and then stirred at it for 2 hrs. The solvent was removed under vacuum and then purified by prep-HPLC to afford (lr.2/?,3.S)-A-[(7.SJ3.S)-(20M)-20-[5-(4-cthylpipcrazin-l-yl)-2- [(15)-1-methoxy ethyl]-3-pyridyl]- 17,17-dimethyl- 8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide (Example 113,10.1 mg) as white powder. MS cak ’d 851.5 (MH+), measured 851.5 (MH+). 1H NMR (400 MHz, METHANOL-d4) 5 = 8.44 (d, J= 2.Hz, 1H), 8.39 (s, 1H), 7.50 (s, 1H), 7.41 (s, 1H), 7.32 (d, J= 2.9 Hz, 1H), 5.80 (br d, J= 7.1 Hz, 1H), 4.64 - 4.56 (m, 1H), 4.48 - 4.38 (m, 2H), 4.30 - 4.20 (m, 2H), 3.77 (s, 2H), 3.67 - 3.56 (m, 2H), 3.50 - 3.43 (m, 4H), 3.35 (s, 3H), 3.17 - 2.95 (m, 7H), 2.91 - 2.73 (m, 3H), 2.66 - 2.58 (m, 1H), 2.36 - 2.27 (m, 1H), 2.26 - 2.15 (m, 2H), 1.98 - 1.91 (m, 1H), 1.83 - 1.71 (m, 1H), 1.67 - 1.56 (m, 1H), 1.45 (d, J= 6.1 Hz, 3H), 1.42 - 1.34 (m, 2H), 1.28 (t, J= 13 Hz, 3H), 1.20-1.(m, 7H), 0.96 (s, 3H), 0.55 (s, 3H).
Example 114 (17?,27?)-A^-[(75,,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-thiazol-4-yl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20j ׳W)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate E) and traM5-(15,2S)-2-thiazol-4-ylcyclopropanecarboxylic acid (intermediate R8)instead of (75,13S)-7-amino-(20Af)-20-[2-[(15)-l-methoxyethyl]-5- morpholino-3-pyridyl]-17,1 7-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F) and (lS',2S)-2-methylcyclopropanecarboxylic acid and then purified by Prep-HPLC. Example 114(1.5 mg, slower eluted) was obtained as a white solid. MS calc ’d 892.4 (MH+), measured 892.4 (MH+). 1H NMR (400 MHz, METHANOL-d4) 8 = 8.79 (d, J= 1.Hz, 1H), 8.38 - 8.35 (m, 1H), 8.30 (s, 1H), 7.41 (s, 1H), 7.33 (s, 1H), 7.21 (d, J= 2.0 Hz, 1H), 5.76 - 5.71 (m, 1H), 4.16 - 3.94 (m, 1H), 3.68 - 3.65 (m, 1H), 3.57 - 3.47 (m, 3H), 3.39 - 3.32 (m, 1H), 3.31 - 3.27 (m, 4H), 3.15 - 3.10 (m, 1H), 3.05 - 2.95 (m, 2H), 2.93 - 2.87 (m, 4H), 2.73 - 2.53 (m, 1H), 2.53 - 2.42 (m, 1H), 2.29 - 2.16 (m, 2H), 2.12 - 2.02 (m, 2H), 1.95 - 1.92 (m, 2H), 1.88 - 1.79 (m, 1H), 1.69 - 1.59 (m, 1H), 1.57 - 1.43 (m, 2H), 1.39 - 1.34 (m, 4H), 1.30 - 1.25 (m, 1H), 1.23 - 1.16 (m, 5H), 1.11 - 1.00 (m, 2H), 0.89 - 0.85 (m, 3H), 0.81 - 0.76 (m, 1H), 0.50 - 0.44 (m, 3H).
Example 115 - l-methoxyethyl]-5-[4-(2-methoxyethyl)piperazin ،؟(- 20A/)-20-[2-[(l ،؟(-) 13 ،؟, 7 -]) N ؛(- 37 ،؟, 2 , lr ) l-yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2,3-dimethyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 109by using 2- bromoethyl methyl ether and sodium iodide instead of trifluoromethanesulfonic acid 2,2- difluoroethyl ester. Example 115(18 mg) was obtained as a white solid. MS calc ’d 881.5 (MH+), measured 881.5 (MH+). 1H NMR (500 MHz, METHANOL-d4) 8 = 8.41 - 8.34 (m, 2H), 7.47 (s, 1H), 7.41 - 7.35 (m, 1H), 7.27 - 7.19 (m, 1H), 5.83 - 5.73 (m, 1H), 4.65 - 4.54 (m, 1H), 4.46 - 4.34 (m, 2H), 4.26 - 4.19 (m, 2H), 3.74 (s, 2H), 3.57 (s, 3H), 3.42 - 3.37 (m, 1H), 3.35 (s, 3H), 3.34 - 3.32 (m, 6H), 3.28 - 3.22 (m, 1H), 3.14 - 2.93 (m, 3H), 2.80 - 2.73 (m, 1H), 2.73 - 2.67 (m, 4H), 2.66 - 2.57 (m, 3H), 2.37 - 2.25 (m, 1H), 2.21 - 2.10 (m, 2H), 1.96 - 1.87 (m, 1H), 1.79 - 1.67 (m, 1H), 1.65 - 1.53 (m, 1H), 1.46 - 1.41 (m, 3H), 1.40 - 1.31 (m, 2H), 1.18 - 1.11 (m, 7H), 0.94 (s, 3H), 0.53 (s, 3H).
Example 116 - 3 (- l-methoxyethyl]-5-(4-methylpiperazin-l-yl ،؟(- 20Af)-20-[2-[(l ،؟(-) 13 ،؟, 7 -]) ll?,21?)-7V ) pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-(2-methyl-3-pyridyl)cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20Af)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazm-l-yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate E) and //•«H,s’-(IS2S’)-2-(2-mcthyl-3-pyridyl)cyclopropanccarboxylic acid (intermediate R9)instead of (7S,13S)-7-amino-(207IT)-20-[2-[(lS)-l-methoxyethyl]-5- morpholino-3-pyridyl]-17,1 7-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F) and (1 S,,2S)-2-methylcyclopropanecarboxylic acid and then purified by Prep-HPLC. Example 116 (5mg, slower eluted) was obtained as a white solid. MS calc ’d 900.5 (MH+), measured 900.5 (MH+). ׳H NMR (500 MHz, METHANOL-،/4) d = 8.48 - 8.41 (m, 1H), 8.39 (s, 1H), 8.28 - 8.24 (m, 1H), 7.57 - 7.53 (m, 1H), 7.49 (s, 1H), 7.4l(s, 1H), 7.32 (d, J= 2.9 Hz, 1H), 7.23 (dd, J= 5.0, 7.7 Hz, 1H), 5.95 - 5.68 (m, 1H), 4.67 - 4.52 (m, 2H), 4.40 (br d, J = 6.3 Hz, 2H), 4.30 - 4.20 (m, 2H), 3.76 (s, 2H), 3.62 - 3.53 (m, 1H), 3.49 (br s, 5H), 3.35 (s, 3H), 3.12 (br s, 6H), 3.02 - 2.92 (m, 1H), 2.84 - 2.74 (m, 1H), 2.72 (s, 3H), 2.62 (s, 3H), 2.45 - 2.(m, 1H), 2.35 - 2.25 (m, 1H), 2.23 - 2.14 (m, 2H), 1.99 - 1.89 (m, 2H), 1.84 - 1.70 (m, 1H), 1.- 1.58 (m, 1H), 1.58 - 1.51 (m, 1H), 1.44 (d, J = 63 Hz, 3H), 1.39 - 1.33 (m, 1H), 0.96 (s, 3H), 0.54 (s, 3H).
Example 117 (lr,27?,31$)-7V-[(7.S',13.S)-(20A/)-20-[2-[(LS)-l-methoxyethyl]-5-(4-tetrahydropyran-4- ylpiperazin-l-yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2,3-dimethyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 113by using tetrahydro-4h-pyran-4-one instead of acetaldehyde. Example 117(16 mg) was obtained as a white solid. MS cak ’d 907.5 (MH+), measured 907.9 (MH+). *H NMR (500 MHz, METHANOL-^) 5 = 8.52 - 8.46 (m, 1H), 8.42 - 8.39 (m, 1H), 8.38 - 8.35 (m, 1H), 7.48 (s, 1H), 7.42 - 7.36 (m, 1H), 7.30 - 7.24 (m, 1H), 5.86 - 5.71 (m, 1H), 5.49 (s, 1H), 4.47 - 4.35 (m, 2H), 4.28 - 4.17 (m, 2H), 4.08 - 3.99 (m, 2H), 3.75 (s, 2H), 3.63 - 3.54 (m, 1H), 3.47 - 3.37 (m, 6H), 3.33 (s, 3H), 3.27 - 3.22 (m, 1H), 3.13 - 3.03 (m, 2H), 3.01 - 2.90 (m, 4H), 2.70 (br s, 2H), 2.64 - 2.56 (m, 1H), 2.35 - 2.25 (m, 1H), 2.24 - 2.12 (m, 2H), 1.98 - 1.87 (m, 3H), 1.80 - 1.67 (m, 1H), 1.66 - 1.54 (m, 3H), 1.43 (d, J= 6.3 Hz, 3H), 1.39 - 1.30 (m, 2H), 1.18 - 1.09 (m, 7H), 0.95 (s, 3H), 0.53 (s, 3H).
Example 118 (1 r,2R,3S)- N- [(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl] -5- [4-(oxetan-3-yl)piperazin-l - yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l913.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2,3-dimethyl-cyclopropanecarboxamide בס!- ­ The title compound was prepared in analogy to the preparation of Example 113by using 3- oxetanone instead of acetaldehyde. Example 118 (13 mg) was obtained as a white solid. MScak ’d 879.5 (MH+), measured 879.5 (MH+). 1H NMR (500 MHz, METHANOL-d) 8 = 8.43 -8.36 (m, 2H), 7.48 (s, 1H), 7.39 (d, J= 0.8 Hz, 1H), 7.29 (d, J= 2.7 Hz, 1H), 5.85 - 5.70 (m, 1H), 4.76 (s, 2H), 4.69 - 4.64 (m, 2H), 4.45 - 4.34 (m, 2H), 4.26 - 4.19 (m, 2H), 3.75 (s, 3H), 3.63 - 3.55 (m, 1H), 3.47 - 3.36 (m, 5H), 3.33 (s, 3H), 3.30 - 3.22 (m, 1H), 3.13 - 2.93 (m, 3H), 2.83 - 2.56 (m, 6H), 2.35 - 2.23 (m, 1H), 2.22 - 2.12 (m, 2H), 1.95 - 1.88 (m, 1H), 1.80 - 1.69 (m, 1H), 1.64 - 1.53 (m, 1H), 1.43 (d, J= 63 Hz, 3H), 1.41 - 1.26 (m, 2H), 1.15 (d, J= 6.1 Hz, 4H), 1.12(d, J= 6.1 Hz, 3H), 0.95 (s, 3H), 0.54 (s, 3H).
Example 119 (lr,2S,3/?)-^-[(7S,135)-(20A0-20-[2-[(15)-l-methoxyethyl]-5-[4-[[(2lS)-morphoUn-2- yl]methyl]piperazin-l-yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 15 7-yl]-2,3-dimethyl-cyclopropanecarboxamide The compound was prepared according to the following scheme: 119-a 119-b Step 1: Preparation of tert-butyl (25)-2- (trifluoro methylsulfonyloxymethyl)morpholine-4-carboxylate (compound 119-b) To a solution of tert-butyl (2>S)-2-(hydroxymethyl)morpholine-4-carboxylate (100 mg, 460.28 umol) and 2,6-lutidine (107 pL, 920.56 umol) in dichloromethane (2 mL) was added Tf2O (93 pL, 552.33 umol) at 0 ،C. The reaction mixture was stirred at 0 ،C for l h. The reaction mixture was diluted with DCM (10 mL) and then washed with sat. NaHCO3 aq. (10 mL), brine (5 mL). The organic layer was dried and then purified by silica gel chromatography to afford crude product tert-butyl (2>S)-2-(trifluoromethylsulfonyloxymethyl)morpholine-4- carboxylate (compound 119-b,100 mg) as light brown oil, which was used in the next step. MS calc ’d 350.1 (MH+), measured 293.9 (M-CML+ll). Step 2: Preparation of tert-butyl (2/0-2-[[4-[(5tl^-5-[(75,135)-7-[[(lr,2^ dimethylcyclop ropanecarbonyl] amino] -17,17-dimethyl-8,l 4-dioxo-l 5-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9l3.0l9’27.02l’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 20-yl]-6-[(15)-l-methoxyethyl]-3-pyridyl]piperazin-l-yl]methyl]morpholine-4-carboxylate (compound 119-c) A suspension of (lr,27?,3S)-A-[(7S',13S)-(20Af)-20-[5-(4-cyclopropylpiperazin-l-yl)-2- [(l،S)-l-methoxyethyl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide (example 108,30 mg, 32.01 umol), tert-butyl (25)- 2-(trifluoromethylsulfonyloxymethyl)morpholine-4-carboxylate (compound 119-b, 100mg) and DIEA (17 pL, 96.04 umol) in tetrahydro furan (extra dry, 300 pL) was stirred at rt for 2 hrs. The solvent was removed under vacuum to get a residue. The residue was purified by silica gel chromatography to afford tert-butyl (27?)-2-[[4-[(57IT)-5-[(7S',13lS)-7-[[(lr,25,37?)-2,3- dimethylcyclopropanecarbonyl] amino] -17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-20- yl]-6-[(15)-l-methoxyethyl]-3-pyridyl]piperazin-l-yl]methyl]morpholine-4-carboxylate (compound 119-c,68 mg) as light brown oil. MS calc ’d 1022.5 (MH+), measured 1022.5 (MH+). - 4 -] 5 [- l-methoxyethyl ،؟(- 20Af)-20-[2-[(l ،؟(-) 13 ،؟, 7 -]) 31 -)? A ،؟, 2 , Step 3: Preparation of (lr [[(2lS)-morpholin-2-yl]methyl]piperazin-l-yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa- 4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaen-7-yl]-2,3-dimethyl-cyclopropanecarboxamide (Example 119) A solution of tert-butyl (27?)-2-[[4-[(57l7)-5-[(7S,13S)-7-[[(lr,2S^^ dimethylcyclopropanecarbonyl] amino] -17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-20- yl]-6-[(15)-l-methoxyethyl]-3-pyridyl]piperazin-l-yl]methyl]morpholine-4-carboxylate (compound 119-c,68 mg, 66.52 umol) and TFA (1 mL) in dichloromethane (2 mL) was stirred at rt for 2 hrs. The solvent was removed under vacuum and then purified by prep-HPLC to afford (lr,25,3R)-A-[(75,13S)-(2047)-20-[2-[(lS)-l-methoxyethyl]-5-[4-[[(2.S)-morpholin-2- yl]methyl]piperazin- 1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo- 15-oxa-4-thia-9,21 ,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide (Example 119,18.4 mg) as light a yellow powder. MS calc ’d 922.5 (MH+), measured 922.5 (MH+). 1H NMR (400 MHz, METHANOL-d) ،5 = 8.(d, J= 2.5 Hz, 1H), 8.40 (s, 1H), 7.53 - 7.49 (m, 2H), 7.43 (s, 1H), 5.79 (br d, J= 8.6 Hz, 1H), 4.47 (brd, J =6.0 Hz, 1H), 4.44 (br s, 1H), 4.38 - 4.31 (m, 1H), 4.27 - 4.17 (m, 3H), 3.99 - 3.(m, 1H), 3.77 (br s, 2H), 3.71 - 3.61 (m, 5H), 3.54 (br s, 4H), 3.39 (s, 7H), 3.31 - 3.25 (m, 2H), 3.24 - 3.19 (m, 1H), 3.13 - 3.06 (m, 2H), 3.05 - 2.96 (m, 2H), 2.79 (brt, J= 12.4 Hz, 1H), 2.(br d, J= 14.3 Hz, 1H), 2.38 - 2.28 (m, 1H), 2.18 (br d, J= 10.0 Hz, 2H), 1.96 (br d, J= 13.5 Hz, 1H), 1.84 - 1.71 (m, 1H), 1.68 - 1.57 (m, 1H), 1.47 (br d, J= 6.3 Hz, 3H), 1.43 - 1.34 (m, 2H), 1.19 - 1.13 (m, 7H), 0.98 (s, 3H), 0.57 (s, 3H).
Example 120 (1/?.2/?)-V-|(7،S. 13،S')-(201/)-20-|2-|( LS')-l-methoxyethyl|-5-(4-n1ethylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2-(5-methyl-3-pyridyl)cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-(20vW)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate E) and //•«/rs ’-(l525)-2-(5-mctl1yl-3-pyridyl)cyclopropanccarboxylic acid (intermediate R10)instead of (7S,13S)-7-amino-(207W)-20-[2-[(15)-l-methoxyethyl]-5- morpholino-3-pyridyl] -17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31- tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (Intermediate F) and (l>S,,2lS)-2-methylcyclopropanecarboxylic acid and then purified by Prep-HPLC. Example 120(11.6 mg, slower eluted) was obtained as a yellow solid. MS calc ’d 900.5 (MH+), measured 900.5 (MH+). 1H NMR (500 MHz, METHANOL-d) d = 8.61 - 8.57 (m, 1H), 8.55 - 8.51 (m, 1H), 8.48 - 8.46 (m, 1H), 8.39 (s, 1H), 8.18 (br d, J = 7.0 Hz, 1H), 7.53 - 7.49 (m, 1H), 7.44 (br d, J = 2.9 Hz, 1H), 7.41 (br s, 1H), 5.88 - 5.74 (m, 1H), 4.50 - 4.40 (m, 2H), 4.30 -4.18 (m, 2H), 4.12 - 3.94 (m, 1H), 3.76 (s, 2H), 3.66 - 3.54 (m, 3H), 3.49 - 3.41 (m, 2H), 3.36 (s, 4H), 3.29 - 3.24 (m, 2H), 3.14 - 3.03 (m, 3H), 3.02 - 2.96 (m, 4H), 2.83 - 2.75 (m, 1H), 2.63 - 2.55 (m, 2H), 2.55 - 2.51 (m, 3H), 2.36 - 2.26 (m, 1H), 2.25 -2.12 (m, 3H), 1.99 - 1.89 (m, 1H), 1.82 - 1.73 (m, 1H), 1.72 - 1.59 (m, 2H), 1.57-1.51 (m, 1H), 1.45 (d, J = 6.3 Hz, 3H), 1.37 - 1.28 (m, 1H), 0.97 (s, 3H), 0.55 (s, 3H) Example 121 (lr,27?,35)-AL[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-[4-[2-(2-oxopyrrondin-l- yl)ethyl]piperazin-l-yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2,3-dimethyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 109by using 1- (2-bromoethyl)pyrrolidin-2-one and sodium iodide instead of trifluoromethanesulfonic acid 2,2- difluoroethyl ester. Example 121(12 mg) was obtained as a white solid. MS cak ’d 934.5 (MH+), measured 934.5 (MH+). 1H NMR (400 MHz, METHANOL-d) 8 = 8.43 - 8.35 (m, 2H), ר Al (s, 1H), 7.39 (s, 1H), 7.25 (d, J= 2.9 Hz, 1H), 5.84 - 5.73 (m, 1H), 4.63 - 4.52 (m, 1H), 4.48 - 4.(m, 2H), 4.29 - 4.18 (m, 2H), 3.75 (s, 2H), 3.64 - 3.56 (m, 1H), 3.55 - 3.46 (m, 4H), 3.33 (br s, 6H), 3.28 - 3.22 (m, 1H), 3.15 - 2.93 (m, 4H), 2.85 - 2.71 (m, 5H), 2.69 - 2.56 (m, 3H), 2.41 - 2.35 (m, 2H), 2.33 - 2.25 (m, 1H), 2.25 - 2.12 (m, 2H), 2.11 - 2.00 (m, 2H), 1.97 - 1.88 (m, 1H), 1.81 - 1.66 (m, 1H), 1.66 - 1.51 (m, 1H), 1.43 (d, J= 6.1 Hz, 3H), 1.40 - 1.28 (m, 2H), 1.14 (dd, J= 6.0, 11.3 Hz, 7H), 0.94 (s, 3H), 0.54 (s, 3H).
Example 122 (lr,2/?,3S)-A4(7S,13S)-(20A0-20-[2-[(lS)-l-methoxyethyl]-5-[4-(2-tetrahydrofuran-3- yloxyethyl)piperazin-l-yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’l3.0l9’27.02l’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2,3-dimethyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 109by using 4- methylbenzenesulfonic acid 2-tetrahydro furan-3-yloxyethyl ester and sodium iodide instead of trifluoromethanesulfonic acid 2,2-difluoroethyl ester. Example 122(4 mg) was obtained as a white solid. MS cak ’d 959.5 (MNa+), measured 959.5 (MNa+). 1H NMR (500 MHz, METHANOL-^) 5 = 8.42 - 8.32 (m, 2H), 7.47 (s, 1H), 7.39 (s, 1H), 7.23 (d, J= 2.9 Hz, 1H), 5.78 (br d, J= 7.5 Hz, 1H), 4.80 (br d, J= 12.2 Hz, 1H), 4.46 - 4.34 (m, 2H), 4.27 - 4.12 (m, 3H), 3.90 - 3.72 (m, 6H), 3.68 - 3.54 (m, 4H), 3.38 (s, 5H), 3.29 - 3.23 (m, 1H), 3.05 (br d, J= 14.Hz, 3H), 2.79 - 2.69 (m, 5H), 2.65 (br t, J= 5.5 Hz, 3H), 2.34 - 2.24 (m, 1H), 2.23 - 2.12 (m, 2H), 2.04 - 1.97 (m, 2H), 1.95 - 1.87 (m, 1H), 1.78 - 1.78 (m, 1H), 1.80 - 1.67 (m, 1H), 1.58 (dq, J= 3.3, 12.5 Hz, 1H), 1.43 (d, J= 6.1 Hz, 3H), 1.40 - 1.32 (m, 2H), 1.28 - 1.20 (m, 1H), 1.18 - 1.(m, 7H), 0.94 (s, 2H), 0.53 (s, 3H).
Example 123 (lr.2/?.3.S)-V-|(7S. 13.S)-(20.Vr)-20-|2-|(l.S)-l-methoxyethyl|-5-|4-(3-methoxy-3-methyl- butyl)piperazin-l-yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2,3-dimethyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 109by using 4- methylbenzenesulfonic acid (3-methoxy-3-methyl-butyl) ester and sodium iodide instead oftrifluoromethanesulfonic acid 2,2-difluoroethyl ester. Example 123 (7.8 mg) was obtained as a white solid. MS cak ’d 923.5 (MH+), measured 923.5 (MH+). 1H NMR (500 MHz, METHANOL-d) § = 8.44 - 8.33 (m, 2H), 7.52 - 7.45 (m, 1H), 7.43 - 7.35 (m, 1H), 7.29 - 7.(m, 1H), 5.82 - 5.74 (m, 1H), 4.46 - 4.34 (m, 2H), 4.27 - 4.17 (m, 2H), 3.79 - 3.70 (m, 2H), 3.- 3.54 (m, 1H), 3.43 - 3.38 (m, 1H), 3.37 - 3.32 (m, 7H), 3.29 - 3.24 (m, 1H), 3.20 (s, 3H), 3.12 - 2.93 (m, 3H), 2.81 - 2.67 (m, 5H), 2.65 - 2.56 (m, 1H), 2.56 - 2.48 (m, 2H), 2.36 - 2.25 (m, 1H), 2.23 - 2.12 (m, 2H), 1.97 - 1.87 (m, 1H), 1.82 - 1.70 (m, 3H), 1.64 - 1.53 (m, 1H), 1.43 (d, J= 6.1 Hz, 3H), 1.41 -1.31 (m, 2H), 1.20 (s, 6H), 1.14 (dd, J= 6.0, 14.2 Hz, 7H), 0.95 (s, 3H), 0.(s, 3H).
Example 124 (lr,25,31?)-A,-[(75,135)-29-fluoro-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin- l-yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen- 7-yl]-2,3-dimethyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 1 by using (75,135)-7-amino-29-fluoro-(20d7)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]- 17,17-dimethyl- 15-oxa-4-thia-9,2 1,30,31 - tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaene- 8,14-dione (intermediate U) and (l/2,3-(?25,37,־-dimethylcyclopropanecarboxylic acid instead of (75,135)-7-amino-(2037)-20-[2-[(l lS)-l-methoxyethyl]-5-morphohno-3-pyridyl]-l 7,17-dimethyl- 15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.1 2’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31),19,25(29),26-hexaene-8,14-dione (Intermediate F) and (15,25)-2- methylcyclopropanecarboxylic acid. Example 124(12.3 mg) was obtained as a yellow solid. MS cak ’d 855.4 (MH+), measured 855.4 (MH+). 1H NMR (400 MHz, METHANOL-،/4) 8 = 8.47 (s, 2H), 7.63 - 7.58 (m, 1H), 7.51 - 7.44 (m, 1H), 5.78 (d, J= 9.2 Hz, 1H), 4.93 - 4.89 (m, 1H), 4.- 4.42 (m, 2H), 4.22 - 4.14 (m, 3H), 3.80 - 3.69 (m, 3H), 3.56 (s, 3H), 3.49 - 3.37 (m, 4H), 3.(s, 1H), 3.19 - 3.10(m, 2H), 3.06 - 2.91 (m, 7H), 2.82 - 2.76 (m, 1H), 2.62 (d, J= 14.0 Hz, 1H), 2.31 - 2.22(m, 2H), 2.17 (d, J= 13.6 Hz, 1H), 1.95 (d, J= 12.4 Hz, 1H), 1.83 - 1.75(m, 1H), 1.- 1.60(m, 1H), 1.45 (d, J= 6.0 Hz, 3H), 1.40 - 1.33 (m, 2H), 1.17 - 1.12 (m, 7H), 0.94 (s, 3H), 0.56 (s, 3H).
Example 125 (15,25)-A-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17,22,22-tetramethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- 2,5 9,13 19,27 21,26 tetrazahexacyclo [23.3.1.1 .1 .0 .0 ]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7- yl]-2-methyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 38by using 6-bromo-8-iodo-2,2-dimethyl-3,4-dihydro-lH-quinoline instead of 7-bromo-5-iodo-2,2- dimethyl-3,4-dihydro-l,4-benzoxazine (Intermediate D4). Example 125(6.3 mg) was obtainedas a white solid. MS calc ’d 838.4 (MH+), measured 838.4 (MH+). 1H NMR (500 MHz, CHLOROFORM-d) 8 = 8.37 (s, 1H), 8.06 (s, 1H), 7.35 - 7.30 (m, 1H), 7.24 - 7.23 (m, 1H), 7.(d, J= 2.1 Hz, 1H), 6.86 (br d, J= 6.9 Hz, 1H), 6.34 - 6.25 (m, 1H), 5.28 - 5.20 (m, 1H), 4.51 (br d, J= 11.6 Hz, 1H), 4.21 (br d, J= 10.5 Hz, 1H), 4.09 - 4.01 (m, 2H), 3.90 (br d, J= 1.8 Hz, 4H), 3.69 - 3.61 (m, 2H), 3.57 - 3.49 (m, 2H), 3.41 (dd, J= 3.2, 14.3 Hz, 1H), 3.32 (br dd, J= 6.3,16.3 Hz, 1H), 3.23 (br d, J= 4.0 Hz, 4H), 3.16 (s, 2H), 3.11 (s, 3H), 3.08 - 2.97 (m, 4H), 2.61 (dt, J= 2.7, 12.9 Hz, 1H), 2.25 - 2.15 (m, 2H), 1.97 - 1.86 (m, 2H), 1.82 (br dd, J= 2.4, 13.0 Hz, 1H), 1.75 - 1.69 (m, 1H), 1.31 (s, 2H), 1.22 (s, 2H), 0.97 (s, 3H), 0.80 (s, 3H), 0.65 (s, 3H), 0.63 (s, 3H), 0.58 - 0.53 (m, 1H) Example 126 (lr,27?,3S)-A4(7S,13S)-(203^-20-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridylH7,17- dimethyl-8,1 4-dioxo-l 5-oxa-4-thia-9,21,31,32- 2,5 9,13 19,28 21,27 tetrazahexacyclo[24.3.1.1 .1 .0 .0 ]dotriaconta-l(29),2,5(32),19,26(30),27-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 73by using 7-bromo-9-iodo-2,3,4,5-tetrahydro-lH-l-benzazepine instead of 6-bromo-8-iodo-l ,2,3,4- tetrahydroquinoline (Intermediate Dl).Example 126(4 mg) was obtained as a yellow solid. MS cak ’d 838.4 (MH+), measured 838.4 (MH+). 1H NMR (400 MHz, Methanol-،/4) 8 = 8.43 - 8.(m, 1H), 7.70 - 7.63 (m, 1H), 7.56 (s, 1H), 7.53 - 7.45 (m, 1H), 5.79 - 5.74 (m, 1H), 4.57 - 4.(m, 4H), 4.47 - 4.38 (m, 1H), 4.21 - 4.14 (m, 1H), 4.13 - 4.03 (m, 1H), 3.93 - 3.81 (m, 4H), 3.- 3.61 (m, 3H), 3.43 (br s, 3H), 3.40 - 3.35 (m, 5H), 3.12 - 3.05 (m, 1H), 2.83 - 2.72 (m, 1H), 2.70 - 2.63 (m, 1H), 2.28 - 2.02 (m, 4H), 1.97 - 1.73 (m, 3H), 1.62 - 1.56 (m, 1H), 1.51 - 1.41 (m, 3H), 1.40 - 1.33 (m, 2H), 1.29 - 1.26 (m, 1H), 1.17 - 1.10 (m, 7H), 0.98 - 0.91 (m, 3H), 0.52 (s, 3H) Example 127 (lr,27?,3^-iV-[(7S,13S)-(20M)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-! 7,17-dimethyl-8,l 4-dioxo-l 5-oxa-4-thia-9,21,32,33- 2,5 9,13 19,29 21,28 tetrazahexacyclo[25.3.1.1 .1 .0 .0 ]tritriaconta-1 (30),2,5(33),19,27(31 ),28-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide The title compound was prepared in analogy to the preparation of Example 24by using 8-bromo-10-iodo-l,2,3,4,5,6-hexahydro-l-benzazocme instead of 6-bromo-8-iodo-l,2,3,4- tetrahydroquinoline (Intermediate Dl).Example 127(4 mg) was obtained as a white solid. MScak ’d 865.5 (MH+), measured 865.5 (MH+). ,H NMR (400 MHz, Methanol-r/4) 8 = 8.40 (d, J= 2.9 Hz, 1H), 8.37 (d, J= 1.0 Hz, 1H), 7.51 (s, 1H), 7.35 - 7.24 (m, 2H), 5.91 - 5.79 (m, 1H), 4.(brt, 11.3 Hz, 1H), 4.42 (br d, J= 11.8 Hz, 1H), 4.27-4.16 (m, 2H), 4.14-4.07 (m, 1H), 3.82 - 3.68 (m, 3H), 3.44 - 3.34 (m, 6H), 3.29 - 3.23 (m, 4H), 3.06 (br dd, J= 6.4, 13.1 Hz, 1H), 2.92 (br d, J= 15.8 Hz, 1H), 2.80 - 2.59 (m, 6H), 2.41 (s, 3H), 2.08 (br d, J= 12.1 Hz, 1H), 2.03- 1.96 (m, 1H), 1.93 - 1.80 (m, 2H), 1.74 - 1.64 (m, 2H), 1.62 - 1.53 (m, 2H), 1.44 (d, J= 6.1 Hz, 3H), 1.39 - 1.33 (m, 2H), 1.13 (dd, J= 5.8, 9.3 Hz, 8H), 0.92 - 0.82 (m, 3H), 0.56 (s, 3H).
BIOLOGICAL EXAMPLE Compound A122(page 70,Table. 1 a) and Compound A252(page 95, Table. 1 a) fromWO2022060836 were cited as reference compound for this invention.
(A252) Example 128 Single dose pharmacokinetics (PK) study in female BALB/c mice The purpose of this study was to determine the pharmacokinetics of selected compounds following single intravenous bolus or oral gavage administration in female BALB/c mice. Briefly, two groups of female BALB/c mice (available from Shanghai LingchangBiotechnology Co., Ltd) (N=3/group) were treated with a single dose of compound intravenously at 3 mg/kg (IV) or orally at 30 mg/kg (PO). Blood samples were collected at 5 min (only for IV), min, 30 min, 1 h, 2 h, 4 h, 7 h and 24 h post-dose. Blood samples were placed on ice until centrifugation to obtain plasma samples. The concentration of compound in plasma samples was determined using LC-MS/MS method. The pharmacokinetic parameters were calculated by non- compartmental analysis.
Table 1. Results of SDPK compound 3 mg/kg, iv 30 mg/kg, po CL (mL/min/kg) Cmax (ng/mL) AUCo-last (h>ng/mL) A122 33.9 2530 9760 A252 37.8 2435 14642 Example 24 5.3 10498 57240 Example 73 5.8 15058 69514 From Table 1, it can be seen that Example 24 has excellent pharmacokinetic properties in mouse model. Especially Example 24 has 4.3-fold increase in Cmax, 4-fold increase in AUC0-1ast and significant lower clearance compared with compound A252, and almost 4-fold increase in Cmax, 6-fold-increase in AUCo-iast and significant lower clearance compared with compound A122.Similarly, Example 73 also has excellent pharmacokinetic properties in mouse model. Especially Example 73 exhibits 6.2-fold increase in Cmax, 4.7-fold increase in AUC0-1ast and significant lower clearance compared with compound A252, and 5.9-fold increase in Cmax> 7.1- fold increase in AUC0-1ast and significant lower clearance compared with compound A122.Above improvement over reference compounds (A252 and A122) demonstrated that the compounds of this invention are more suitable for treating cancers with RAS mutation as an orally therapeutic active ingredient in clinic.
Example 129 Human hepatocyte stability Assay The hepatocyte stability assay measures the rate of disappearance of a compound from incubations with cryopreserved suspension hepatocytes from human. Positive controls, including Midazolam, Raloxifene and Dextromethorphan, are included in every experiment. Incubations consist of 1 pM tested compound and suspension of human hepatocytes (1x10 cells/mL) in supplemented Williams’ E Medium with 10% FBS and 0.5% Penicillin- streptomycin. The hepatocyte suspension was incubated with intermittent shaking 900 rpm at 37،C, in a 5% CO2 incubator. The reaction was stopped by adding methanol containing internal standard (2 pM Tolbutamide) at 2, 10, 20, 40, 60 and 120 minutes after compound addition, depletion of the parent compound was monitored by LC-MS/MS analysis. Table 2. Human hepatocytes stability of Examples and Compounds of present invention Example Hepatic clearance (Human) (mL/min/kg) A122 9 A252 9.2 Example 24 3.4 Above result clearly shows that reference compounds (A122 and A252) had much higher clearance while Example 24 maintained the low clearance in human hepatocytes stability assay. Achieving low clearance is advantageous to improve in vivo performance of the compound, such as dose reduction, exposure enhancement, and half-life prolongation.
Example 130 In vivo xenograft studies The purpose of the study was to assess the anti-tumor activity in difficult KRAS mutated xenograft tumor model using SHP-77 (small cell lung cancer, SCLC; ATCC CRL-2195 ) by examining the time-dependent effects on MAPK pathway modulation and tumor suppression post-administration of Example 24 and reference compound A122.Studies were conducted at Wuxi AppTec (Nantong, China). All CDX mouse studies and procedures related to animal handling, care and treatment were conducted in compliance with all applicable regulations and guidelines of the relevant Institutional Animal Care and Use Committee (IACUC). Mice were maintained under pathogen-free conditions, and food and water was provided ad libitum.Female CB17-SCID mice at 6-8 weeks old from Vital River Co., LTD. were used for these studies. In order to generate subcutaneous xenograft tumors, each mouse was inoculated at the right flank with tumor cells in 100 pL of PBS and Matrigel matrix in the right hind flank with xlO7 cells. Mouse health was monitored daily, and caliper measurements began when tumorsךwere palpable. Tumor volume measurements were determined utilizing the formula 0.5 XLXW in which L refers to length and W refers to width of each tumor. When tumors reached an average tumor volume of approximately 100-200 mm3 for efficacy study and 300-500 mm3 for single-dose PK/PD study, mice were randomized into treatment groups.Mice were treated by oral gavage at 10 mg/kg with either vehicle consisting of DMSO: Solutol HS15 :water=10:10:80 (%v/v/v) or compounds (Example 24, A122) in vehicle at indicated doses. For efficacy studies, animals were orally administered daily, tumor volumes and body weights were measured 3 times per week. Study day on efficacy plots indicates the day after which compound treatment was initiated. For single-dose PK/PD study, at the indicated time points after a single dose of Example 24 at the indicated dose levels, tumor samples were collected for PD analysis. RNA extraction and analysis of DUSP6 levels by in tumor tissue were performed as described in Example 134.A single oral dose of 30 mg/kg Example 24 or A122 was sufficient to maximally suppress tumor DUSP6 levels at 24 h for both Example 24 (3.9% remaining) and A122 (4.3% remaining). Notably, the inhibitory effect of A122 to DUSP6 began to diminish after 48 hours (67% remaining) and vanish at 72 hours (126% remaining). In contrast, the inhibitory effect of Example 24 on DUSP6 expression was sustained at 48 hours (31% remaining) and remained effective at 72 hours (73.7% remaining) post-dose. (Figure 5)Daily administration of Example 24 at 30 mg/kg was well-tolerated based on body weights (Figure 6) and resulted in 70% mean tumor growth inhibition (TGI) following 14 days treatment in comparison to A122 that lead to only 43% TGI at same dose regiments. (Figure 6)Based on above comparison data, Example 24 exhibited longer and sustained pathway inhibition over treatment period (Figure 5), and demonstrated significantly enhanced anti-tumor activities (Figure 6) compared with reference compound that potentially could result in more durable anti-tumor responses in clinic.
Example 131 Cell proliferation analysis The objective of this study was to evaluate the extent and degree to which Example 24 or A122 inhibits cell proliferation in a panel of 119 human cancer cell lines with RAS mutations or amplifications across various histological subtypes.On Day -1, cells were plated in 384-well round-bottom ultra-low adhesion plates (cat. Coming 3830, with cell density adjusted according to Table 3. The assay plate was then centrifuged at 1000 rpm for 1 minute to ensure even distribution of cells. The plate was incubated at 37،C in a 5% CO2 atmosphere (it is worth noting that for SW1271 cell plate, it needs to be incubated in an incubator without additional CO2).
On Day 0, Example 24 or Al22 was added to each well using a Tecan HP D300E dispenser, with a 3-fold dilution across 9 doses. The final concentration of DMSO was normalized to 0.2%. The assay plate was then centrifuged at 1000 rpm for 1 minute and incubated for 7 days.On Day 7, CellTiter-Glo (CTG) 3D reagent (Promega G9683) was dispensed into each well of a 384-well plate using a multi-drop dispenser (Thermo Scientific 66413). A liquid handling automation workstation (Bravo with a 384-well head) was used to mix the CTG reagents. Plates were left on a shaker for 30 minutes at 450 rpm, shielded from light. Following this, plates were incubated for an additional 10 minutes, also protected from light, before being read on an EnVision Luminometer.For data analysis, the XL-fit software (Supplier: ID Busmess Solutions Ltd., Software version: XL fit 5.0) was utilized. The percentage of inhibition was calculated using the formula: Inhibition% = (Max - Sample value) / (Max - Min) x !00. Curve fitting was performed as follows: For complete dose-response curves, the relative IC50 was reported from the fit. For incomplete curves, if minimal inhibition was greater than 50%, an IC50 less than the lowest compound concentration was reported. If minimal inhibition was between 20% and 50%, the bottom was locked at 0% and the IC50 was reported. If maximal inhibition was less than 50%, an IC50 greater than the highest compound concentration was reported. For maximal inhibition between 50% and 85%, the top was locked at 100% and the IC50 was reported.Results from in vitro cell proliferation assays statistically showed that Example exhibited a more potent inhibitory effect on cell growth compared to A122, with a statistically significant difference (P < 0.0001) (Figure 7). The median IC50 for Example 24 was 0.95nM, which is twice effective compared to A122, that had a median IC50 of 1.90nM. This enhanced potency suggests that Example 24 could potentially have more effective anti-tumor effects in clinical settings. Table 3. Anti-proliferationIC5q Values of each cell line_________________________________ Cell lineExample IC50 (nM) A1IC(nM)Mutation Medium typeCells per well 1 LS1034 12 7.3KRAS (A146T)RPMI-1640+10%FBS 1000 2 PL-21 1 2.1KRAS (Al 46 V)RPMI-1640+10%FBS 1000 3 KMS-28BM 0.63 0.88KRAS (G12A)RPMI1640+10%FBS 1000 4 NCI-H1573 0.82 1.2KRAS (G12A)RPMI1640+10%FBS 1000 MM. IS 0.3 0.55KRAS (G12A)RPMI1640+10%FBS 1300 6 RPMI8226 0.38 0.52KRAS (G12A)RPMI 1640+10%FBS 1300 7 RERF-LC-Adl 0.3 0.22KRAS (G12A)RPMI1640+10%FBS 1300 8 EU99 0.59 0.91KRAS (G12C)RPMI 1640+10%FBS 1000 9 Mia-pa-ca-2 0.064 0.082KRAS (G12C)RPMI 1640+10%FBS 1000 NCI-H1792 0.21 0.43KRAS (G12C)RPMI 1640+10%FBS 1000 11 NCI-H2030 0.34 0.56KRAS (G12C)RPMI 1640+10%FBS 1000 12 NCI-H2122 0.39 0.62KRAS (G12C)RPMI 1640+10%FBS 1000 13 NCI-H23 0.17 0.33KRAS (G12C)RPMI 1640+10%FBS 1000 14 NCI-H358 0.12 0.27KRAS (G12C)RPMI 1640+10%FBS 1000 SW 837 0.22 0.67KRAS (G12C)RPMI 1640+10%FBS 1000 16 AsPc-1 0.65 0.55KRAS (G12D)RPMI 1640+10%FBS 1000 17 PANC-1 0.95 0.68KRAS (G12D)RPMI 1640+10%FBS 1000 18 PK-59 0.44 0.62KRAS (G12D)RPMI 1640+10%FBS 1000 19 SK-LU-1 0.5 0.56KRAS (G12D)EMEM+10%FBS 1300 SW 1990 1.6 1.5KRAS (G12D)RPMI 1640+10%FBS 1300 21 GP2d 0.63 0.55KRAS (G12D)DMEM+10% FBS 1000 22 HEC-1-A 1.6 1.9KRAS (G12D)McCoy's 5a+10%FBS 1000 23 LS513 0.68 0.47KRAS (G12D)RPMI 1640+10%FBS 1000 24 GP5d 0.48 0.41KRAS (G12D)DMEM + 10% FBS 1300 HPAC 0.31 0.3KRAS (G12D)RPMI 1640+10%FBS 2000 26 Pane 02.03 3.2 5.2KRAS (G12D) RPMI- 1640+15%FBS+Units/ml human recombinant insulin1000 27 NCI-H2291 0.55 1KRAS (G12F)RPMI 1640+10%FBS 1000 28 CAE-62 1.1 8.8KRAS (G12R)DMEM + 10% FBS 1000 29 PSN-1 0.85 1.2KRAS (G12R)RPMI 1640+10%FBS 1000 30MDA-MB-134-VI1.5 2.6KRAS (G12R)RPMI 1640+20%FBS 2000 31 KP-2 0.35 0.43KRAS (G12R)RPMI 1640+10%FBS 1000 32 A549 0.72 1.1KRAS (G12S)RPMI-1640+10%FBS 1000 33 Capan-2 0.23 0.59KRAS (G12V)McCoy's 5a+10%FBS 1000 34 COR-L23 0.53 0.78KRAS (G12V)RPMI 1640+10%FBS 1000 LCLC-97TM1 0.092 0.17KRAS (G12V)RPMI 1640+20%FBS 1000 36 SK-CO-I 0.18 0.33KRAS (G12V)EMEM+10%FBS 1000 37 SW480 1.2 2KRAS (G12V)RPMI 1640+10%FBS 1000 38 NCI-H2444 0.17 0.29KRAS (G12V)RPMI 1640+10%FBS 1300 39 SW 900 0.28 0.23KRAS (G12V)RPMI 1640+10%FBS 1000 40 NCI-H441 0.25 0.49KRAS (G12V)RPMI 1640+10%FBS 1300 41 CFPAC-1 0.54 1.1KRAS (G12V)IMDM+10%FBS 1000 42 RKN 0.045 0.066KRAS (G12V)Ham's F12 + 10% FBS 1000 43 NCI-H727 0.14 0.16KRAS (G12V)RPMI 1640+10%FBS 1000 44 RCM-1 2.2 6.5KRAS (G12V)RPMI 1640+10%FBS 1300 45 SW620 0.1 0.23KRAS (G12V)RPMI 1640+10%FBS 1000 46 NCI-H1355 22 33KRAS (G13C)RPMI 1640+10%FBS 1000 47 TOV-21G 4.9 33KRAS (G13C)DMEM+10% FBS 1000 48 NCI-H1734 0.74 1.3KRAS (G13C)RPMI 1640+10%FBS 2000 49 HCT-15 100 100KRAS (G13D)RPMI 1640+10%FBS 1000 50 HCT-116 1.9 1.9KRAS (G13D)RPMI 1640+10%FBS 1000 51 MDA-MB-231 27 20KRAS (G13D)RPMI 1640+10%FBS 1000 52 DV-90 3.9 4.7 KRAS RPMI 1640+10%FBS 1000 (G13D) 53 HCT-8 80 69KRAS (G13D)RPMI 1640+10%FBS 1000 54 NCI-H1944 1.6 1.7KRAS (G13D)RPMI 1640+10%FBS 1000 55 LoVo 0.55 0.36KRAS (G13D)RPMI 1640+10%FBS 1000 56 Toledo 100 100KRAS (G13D)RPMI 1640+10%FBS 1000 57 T84 100 100KRAS (G13D)RPMI 1640+10%FBS 1000 58 NCI-H747 0.72 0.91KRAS (G13D)RPMI-1640+10%FBS 1300 59 NOMO-1 0.47 0.86KRAS (G13D)RPMI-1640+10%FBS 1000 60 DLD-1 18 20KRAS (G13D)RPMI 1640+10%FBS 1000 61 SKM-1 0.93 1.3KRAS (K117N)RPMI 1640+10%FBS 1000 62 NCI-H2347 2 4.2KRAS (L19F)RPMI 1640+10%FBS 1000 63 Hs-766T 100 100KRAS (Q61H)DMEM+10%FBS 1000 64 SJSA-1 2.6 3.1KRAS (Q61H)RPMI 1640+10%FBS 1000 65 Calu-6 0.65 1.3KRAS (Q61K)RPMI 1640+10%FBS 1000 66 SNU-668 2 4.3KRAS (Q61K)RPMI 1640+10%FBS 1000 67 SW 948 2.9 8.5KRAS (Q61L)RPMI 1640+10%FBS 1300 68 NCI-H650 2.3 9.6KRAS (Q61L)RPMI 1640+10%FBS 1000 69 Pane 02.13 4 15KRAS (Q61R) RPMI-16Medium+ 15%FBS+Units/ml human recombinant insulin1000 70 KMS26 50 48KRAS (WT ampl)RPMI 1640+10%FBS 1000 71 CHEI 8.1 9.3KRAS (WT ampl)DMEM+10%FBS 1000 72 MKN-1 28 40KRAS (WT ampl)RPMI 1640+10%FBS 1000 73 TT 2.9 5.9KRAS (WT ampl)F-12KMedium+ 10%FBS1500 74 UMC-11 100 100KRAS (WT ampl)RPMI 1640+10%FBS 1000 75 KLE 100 100KRAS (WT ampl)DMEM:F12 + 10%FBS 2000 76 BEN 40 43KRAS (WT ampl)DMEM +10% FBS 1000 77 KURAMOCHI 100 100KRAS (WT ampl)RPMI1640+10%FBS 3000 78 NCI-H838 100 100KRAS (WT ampl)RPMI 1640+10%FBS 1000 79 MOLT-4 1000 1000NRAS (p.G12C)RPMI 1640+10%FBS 1000 80 THP-1 0.26 0.18NRAS (p.G12D)RPMI1640+10%FBS+0.05mM2-mercaptoethanol1000 81 PA-1 0.46 0.42NRAS (p.G12D)EMEM+10% h.i. FBS 1000 82 TYK-nu 0.34 0.68NRAS (p.G12D and p.Q61K)EMEM+10%FBS 1000 83 HAL-01 13 14NRAS (p.G12S)RPMI 1640+ 10%h.i. FBS1000 84 GA-10 1000 1000NRAS (p.G12V)RPMI 1640+10%FBS 1000 85 Mino 3.8 1000NRAS (p.G13D)RPMI 1640+15% FBS 1300 86 NCI-H929 7.3 8.7NRAS (p.G13D) RPMI1640+10%FBS+2- mercapto ethanol (final cone.: 0.05 mM)2000 87 AML-193 1.1 2.1NRAS (p.G13V) IMDM + 0.005 mg/ml insulin + 0.005 mg/ml transferrin + 5 ng/ml GM-CSF + 5%FBS1300 88 RD 0.36 0.7NRAS (P.Q61H)DMEM+10%FBS 1000 89 OCI-Lyl9 1.9 2.4NRAS (P.Q61K)MEM a + 20% FBS 1000 90 NCI-H2087 0.21 0.44NRAS (P.Q61K)RPMI 1640+5%FBS 1300 91 HuT78 0.3 0.55NRAS (P.Q61K)IMDM+20%FBS 1500 92 SNU-387 0.43 1.1NRAS (P.Q61K)RPMI 1640+10%FBS 2000 93 HCC-15 0.68 1.7NRAS (P.Q61K)RPMI 1640+10%FBS 1000 94 H9 0.72 1.6NRAS (P.Q61K)RPMI 1640+10%FBS 1000 95 CHP-212 0.35 1.1NRAS (P.Q61K)EMEM:F12Medium=l:l +10%FBS1000 96 HT1080 0.36 0.49NRAS (P.Q61K)EMEM+10%FBS 1000 97 NCI-H1299 0.93 1.5NRAS (P.Q61K)RPMI 1640+10%FBS 1000 98 SK-N-AS 0.47 1.9NRAS (P.Q61K)DMEM+10%FBS+0.mM NEAA1000 99 SK-N-SH 1000 580NRAS (P.Q61K)EMEM+10%FBS 1000 100 NCI-H2135 0.71 1.2NRAS (P.Q61K)HITES medium supplemented with 5% fetal bovine serum1000 101 HepG2 2.1 5.5NRAS (P.Q61L)EMEM+10%FBS 1300 102 GAK 10 19NRAS (P.Q61L)Ham's F12 + 10% FBS 1300 103 MOLP8 11 22NRAS (P.Q61L)RPMI 1640 + 20% h.i. FBS1500 104 OCI-AML-3 3.3 8.9NRAS (P.Q61L)RPMI-1640+20%FBS 1000 105 TF-1 130 100NRAS (P.Q61P)RPMI 1640+10%FBS+ng/ml GM-CSF1500 106 SK-MEL-2 2 3NRAS (P.Q61R)EMEM+10%FBS 1000 107 KU1919 2.2 2.8NRAS (P.Q61R)RPMI 1640+10%FBS 1000 108 ONS-76 0.9 2.1NRAS (P.Q61R)RPMI 1640+10%FBS 1000 109 SW1271 1.7 3NRAS (P.Q61R)Leibovitz's L- 15+10%FBS1000 110 HT-1197 1.4 2.5NRAS (P.Q61R)EMEM+10%FBS 1300 ill SUM 159PT 4.5 3HRAS (p.G12D) Ham’s F-12+10mM HEPES+5pg/ml Insulin+lpg/mlHydrocortisone+5% FBS1000 112 HS 578T 1.7 3.1HRAS (p.G12D) DMEM + 2mM Glutamine + 10ug/ml Bovine Insulin + 10% FBS2000 113 T24 0.3 0.57HRAS (p.G12V)McCoy's 5a + 10%FBS 1000 114 RL95-2 1.3 2.6HRAS (P.Q61H)DMEM:F- 12+10%FBS+0.0mg/ml insulin1000 115 KNS-62 2.6 6.4HRAS (P.Q61L)EMEM+20%FBS 1000 116 NCI-H1915 3.6 10HRAS (P.Q61L)RPMI 1640+10%FBS 1000 117 KYSE-30 0.46 1HRAS (P.Q61L)RPMI-1640+10%FBS 3000 118 NCI-H1876 3.1 3.6NRAS (P.Q61K) DMEM:F12+0.0mg/ml Insulin+0.mg/mlTransferrin+30nMSodium selenite +10 nM Hydro cortisone+ 10 nM beta-estradiol+2mM L- glutamine+5% EBS 2000 119 SW 1088 0.75 2.6NRAS (P.Q61K)RPMI 1640+10%FBS 2000 Example 132 Wild type (WT) KRAS/HRAS/NRAS-BRAF with CYPA (500 nM) interaction assay for selectivity test The purpose of this test is to determine the selectivity of compounds of this invention.In this example, TR-FRET was used to measure the compound or compound-CYPA dependent disruption of the KRAS G12V-BRAF complex to assess inhibition efficacy. The ICratio between WT KRAS/HRAS/NRAS and KRAS G12V mutant was calculated as selective index, which indicated tolerability and safety profile. Disruption of WT KRAS/HRAS/NRAS- BRAF complex by compounds was detected respectively. In assay buffer containing 25mM HEPES (PH=7.4, 4-(2-hydroxyethyl)- 1-piperazineethanesulfonic acid, Thermo, 15630080), 0.002% Tween20, 0.1% BSA, lOOmM NaCI, 5mM MgCl2, 10 pM GMPPNP (Guanosine 5׳-[P,y- imido]triphosphate trisodium salt hydrate, Sigma, G0635), tagless CYPA and GMPPNP loaded 6His-RAS proteins, and GST-BRAFrbd were mixed in a well of a 384-well assay plate at final concentrations of 50 nM, 6.25 nM and InM, respectively. Compound was present in plate wells as a 16-point 3-fold dilution series starting at a final concentration of 10 pM and incubated for hours. A mixture of MAb Anti-6His-XL665 (Cisbio, 61HISXLB) and Mab anti-GST-TB cryptate (Cisbio, 61GSTTLB) was then added at a final concentration of 6.67 nM and 0.21 nM, respectively, and the plate was incubated for an additional 1.5 hours. TR-FRET signal was read on a PHERstar FSX microplate reader (Ex320 nm, Em 665/615 nm). Compounds that facilitate disruption of the RAS-BRAF complex were identified as those eliciting a decrease in the TR- FRET ratio relative to DMSO control wells.The G12V biochemical assay is very stable and robust, making it as a feasible representative mutant for most other RAS mutants. Table 4. Activity and selective ratio of Examples and Compounds of present invention in WT KRAS/HRAS/NRAS-BRAF with CYPA (500 nM) interaction assay A122 A252 Example 24 IC50 (nM) KRAS G12V 8 9 7 WT KRAS 16 18 32 WT HRAS 10 23 38 WT NRAS 10 19 35 Selectivity Index (IC50 ratio) WT KRAS/KRAS G12V 2.0 2.0 4.6 WT HRAS/KRAS G12V 1.3 2.6 5.4 WT NRAS/ KRAS G12V 1.3 2.1 5.0 Wild type (WT) KRAS/HRAS/NRAS inhibition could increase the risk of toxicity, Example 24 demonstrated much higher selectivity compared to Al22 and A252, potentially indicating an improved tolerability and safety profile.
Example 133 Stable KRAS mutant cell lines and cell viability assay. The aim of the study was to determine the potency and efficacy of compounds for cell proliferation using CellTiter-Glo® (CTG) Luminescent Cell Viability Assay (Promega Corp., Madison, WI) . We cloned 14 KRASG12C variant sequences with secondary mutations (V8A, V9Y, S17E, T58I, A59T, S65W, R68S, D69P, M72I, D92R, H95N, Y96D, Q99W and F156L) into the Miapaca-2. Totally 14 stable Miapaca-2 mutant cell lines were established through lentivirus infection. For the cell viability assay, cells were dosed with compounds in a 9-point dose-response using a 4 fold dilution series at a top dose of lOpM. KRAS mutant cells were maintained in DMEM+10%FBS+2.5%HI Horse serum+l%PS+ lug/mL Puromycin and seeded into 96-well plates at 800-1,500 cells per well 24 h before compound addition and then incubated with compound for 3 d before assaying viability (CellTiter-Glo, Promega). Assays were performed in biological duplicates. Nonlinear regression curves were fitted using Xfit. IC(absolute IC50) is the dose at which the estimated viability is 50% relative to untreated wells. Inhibition rate of the compound is calculated according to the formula below: %inhibition=100- 100 ^Luminescence value-HPE) / (ZPE-HPE).HPE: Luminescence value from the wells with only mediumZPE: Luminescence value from the wells with DMSO Table 5. cell viability in mutant cells with KRAS G12C and other mutations 2 1o n OO > no s 1o n so no s w n tono s w D > Uh so to os ro o<3! OO os ro D o Os SO to nS w D 00 Os Uh nS w o Os OO I— os ro o 1o 1— os ro o 6 so oVis w o so Uh oVis 1o o so Os ס 1-H oVis 1o oo so so oVis 1o o to Uh Os to o LZi s Exampl e 241 3 6 2 2 1 2 1 2 1 2 5 1Exampl e 731 1 4 2 1 1 2 / 2 1 2 3 2 Example 134 Brain metastasis intracranial model The purpose of this assay is to determine whether brain exposure of the compounds of current invention was sufficient to mediate regression of tumors in experimental Brain Metastases (BM) models. Cell culture NCI-H1373 cell line was purchased from the ATCC(CRL-5866). NCI-H1373-Luc cells were generated by WuXi AppTec. For generating NCI-H1373-Luc cell line, NCI-H1373 cells were transduced with GFP-Luc-puro lentivirus vector (HBLV-1014, HANBIO, canying cDNA coding for firefly luciferase) and then selected with 1 ug/mL puromycin. All cells were authenticated by short tandem repeat fingerprinting, and periodically tested to be Mycoplasma free. H1373-luc cells were cultured in medium containing RPMI1640 (Thermo Fisher Scientific)plus 10% Fetal Bovine Serum (FBS, Thermo Fisher Scientific, 2.5 ug/mL puromycin and 1% Antibiotic-Antimycotic (Thermo Fisher Scientific ), at 37 °C in an atmosphere of 5% CO2 in air. The medium was renewed every 2 to 3 days and tumor cells were routinely sub- cultured at a confluence of 80-90%. Cells growing in an exponential growth phase were harvested and counted for inoculation. In vivo efficacy and PD studies Example 24, formulated in 10% DMSO, 10% Solutol HS15, 80% water, was dosed orally to 7-9 weeks female BALB/c nude mice (Vital River Co., LTD.) in v at 30mg/kg (dosing volume of lOml/kg) once daily for 14 days. Terminal tissue and blood harvest was performed at 6 hours after post last dose of test articles, using 4 mice per group. In brief, whole blood was collected into K2-EDTA tubes and subjected to centrifugation to separate plasma. Brains were collected, rinsed, and homogenized. Mice Brain were analyzed using qPCR using DUSP6 and ACTB TaqMan probes (ABI-4369016 , ABI-4351370 ).Murine studies were conducted at the WuXi AppTec and were performed in compliance with all applicable regulations and guidelines of the Institutional Animal Care and Use Committee (IACUC). Mice were maintained in a special pathogen-free environment and in individual ventilation cages, and food and water will be sterilized before use. 8 to 9 weeks female NU/NU nude mice (Charles River Lab.) were implanted intracarotid injection with 0.5 x 105 NCI-H1373-Luc cells in 100 pL serum-free media. When bioluminescence reached a mean of 1.28E+08 photons/second (range of 5.79E+07 - 2.685E+08 photons /second) at day 15 post inoculation, tumor-bearing mice were randomized into different groups with 4 mice in each group. The randomization date was denoted as treatment day 0. Afterwards, oral daily dosing of vehicle or Example 24 began and continued for 14 days. Baseline bio luminescent imaging (BLI) began 24 hours prior to initial dosing with vehicle or test articles, and additional imaging time points for all animals were measured twice a week by Xenogen machine (PerkinElmer I VIS Lumina II) between 0-14 days post grouping. Animals were injected intraperitoneally with luciferin (150 mg/kg, 0.01 mL/g) based on body weight and pre-anesthetized using l%-2% isoflurane in oxygen at 1-2 L/minute, the animals were moved into the imaging chamber for bio luminescence measurements with IVIS in a complete anesthetic state. Images were acquired beginning at 15 minutes after luciferin injection. Data analysis of efficacy studies For imaging analysis, region of interest (ROI) analysis was completed on BLI (bioluminescence imaging) images using Living image software. BLI images were generated by overlaying BLI signals for each animal onto theft respective white-light images for anatomic reference. Brain ROIs were generated using a fixed-area circle, and were placed on the basis of the BLI signal in the relevant area, using the photographic anatomical reference images. BLI signals in images were scaled in units of radiance (photons per second per square millimeter per steradian). The BLI density was then used for calculations of T/C value. The T/C value (in percent) is an indication of antitumor effectiveness; T and C are the mean volumes of the treated and control groups, respectively, on a given day.TGI (tumor growth inhibition) was calculated for each group using the formula: TGI (%) = [l-(Ti-TO)/ (Vi-VO)] xlOO; Ti is the average tumor bio luminescence of a treatment group on a given day, TO is the average tumor bio luminescence of the treatment group on the day of treatment start, Vi is the average tumor bio luminescence of the vehicle control group on the same day with Ti, and VO is the average tumor bio luminescence of the vehicle group on the day of treatment start.Summary statistics, including mean and the standard error of the mean (SEM), were provided for the tumor volume of each group at each time point. Statistical analysis of difference in tumor volume among the groups was conducted using the data obtained on dayl4 (Intracranial inoculation). To compare individual groups of interest, data were analyzed using Student ’s One- tailed t test by Prism GraphPad 9.5.1 software. Statistical comparisons between two groups were considered significant when the adjusted P value was below 0.05. Data analysis for DUSP6 All the targets mRNA expression levels were normalized to the housekeeping gene, and the data were represented as fold-changes according to the 2-AACt method, where ACt=Ct target gene - Ct housekeeping gene and AACt=ACt treatment - ACt reference, ACt reference was chosen as the vehicle group. The data were interpreted by GraphPad Prism, and statistical analysis of difference in the each targets mRNA expression among the groups were conducted. For comparison between two groups, an independent sample t-test will be used. For comparison among three or more groups, a one-way ANOVA (Dunnett's multiple comparisons test) will be performed, p < 0.05 was considered to be statistically significant.
Results The result below showed significant inhibition of brain tumor growth (Table 6), meanwhile mice were well tolerated with no sign of overt toxicity or animal weight loss (Figure 2 and Figure 3). In line with these potent anti-BM effects, Example 24 significantly decreased MAPK activation (DUSP6) in the brain of the NCI-H1373-Luc model, providing critical on-target pharmacodynamic evidence (Figure 4). Together, these data demonstrated target pathway inhibition and tumor regression in NSCLC BM mouse models treated with an efficacious dose of Example 24.
Table 6. Tumor growth inhibition analysis (T/C and TGI on day 14) Treatment ROI (x10 photon/s) T/C (%) TGI (%) p value (vs. Vehicle, t- test, One- tailed) Vehicle 259.21 ±116.10— — --Example 24mg/kg, PO, QD1.34 ±0.75 0.52 104.68 p < 0.05 Example 135 Cell viability assay The purpose of this cellular assay was to determine the effects of test compounds on the proliferation of human cancer cell lines NCI-H358 (ATCC-CRL5807) cells, AGS (ATCC-CRL- 1739) cells, SW620 (ATCC-CCL-227) over a 3-day treatment period by quantifying the amountof NADPH present at endpoint using Cell Counting Kit-8.Cells were seeded at 5,000 cells/well (NCI-H358), 2,000 cells/well (AGS) 2,0cells/well (SW620) in 96-well assay plates (Corning-3699) and incubated overnight. On the day of the assay, diluted compounds were then added in a final concentration of 0.5% DMSO. After72 hrs incubation, a tenth of the volume of cell counting kit 8(Dnjindo-CK04) was added into each well. Read the signal (OD450 minus OD650) using EnVision after 2 hrs incubation. ICwas determined by fitting a 4-parameter sigmoidal concentration response model. Table 7. Activity of Examples and Compounds of present invention in KRAS Cell viability assay Example G12C TC50 (nM) G12D IC50 (nM) G12V IC50 (nM) Example 1 2.742.2 2.7 Example 2 10.129.9 1.2 Example 5 17.370.0 4.6 Example 6 3.019.4 1.6 Example 7 2.413.1 0.8 Example 8 5.918.7 1.1 Example 9 2.87.6 <0.6 Example 10 2.24.6 <0.6 Example 11 18.838.4 2.4 Example 12 12.525.0 2.0 Example 13 6.423.0 0.7 Example 14 3.617.5 1.0 Example 15 6.615.9 1.2 Example 16 7.325.9 1.6 Example 17 10.321.7 1.1 Example 18 18.054.5 2.9 Example 19 17.198.7 3.8 Example 21 15.356.2 1.9 Example 22 3.114.2 0.8 Example 24 1.34.7 0.3 Example 25 6.732.6 1.8 Example 28 7.022.3 1.5 Example 29 2.511.4 0.8 Example 30 4.923.4 1.3 Example 31 3.121.8 <0.6 Example 33 32.3100.5 7.4 Example 34 4.712.4 1.1 Example 35 4.313.0 1.0 Example 37 7.828.3 2.1 Example 38 89.4119.6 18.0 Example 40 3.011.8 0.8 Example 41 3.614.0 0.9 Example 42 5.422.4 1.3 Example 43 3.611.9 0.9 Example 44 16.833.9 3.1 Example 45 1.83.6 0.2 Example 46 8.132.2 2.4 Example 47 2.510.2 0.9 Example 48 9.526.5 1.7 Example 49 9.729.1 1.7 Example 50 24.172.6 3.8 Example 51 5.913.3 1.4 Example 52 7.012.0 1.1 Example 54 12.136.8 3.0 Example 55 48.369.1 5.6 Example 56 1.25.2 0.3 Example 57 5.427.6 1.5 Example 58 7.638.5 2.0 Example 59 33.787.2 7.4 Example 60 8.232.0 1.7 Example 61 22.633.4 3.0 Example 63 10.678.0 4.2 Example 64 8.021.9 1.3 Example 68 3.27.8 0.5 Example 69 19.275.4 4.4 Example 70 24.798.7 17.9 Example 73 2.27.4 0.3 Example 75 20.258.7 3.6 Example 76 2.14.9 0.3 Example 78 9.830.6 2.3 Example 79 13.257.0 3.2 Example 81 5.323.4 0.8 Example 83 3.19.2 0.5 Example 85 9.0 13.0 1.0 Example 86 14.145.2 2.5 Example 87 30.0 58.0 4.0 Example 88 2.0 4.0 0.4 Example 89 1.56.0 0.3 Example 90 3.316.8 0.8 Example 91 2.89.7 0.6 Example 92 2.58.8 0.7 Example 93 3.0 5.0 1.0 Example 94 2.36.9 0.5 Example 95 4.08.7 1.3 Example 96 1.01.7 0.2 Example 97 1.92.6 0.3 Example 98 4.08.1 0.6 Example 99 2.17.8 0.4 Example 100 2.78.2 0.7 Example 101 1.86.9 0.3 Example 102 1.24.9 0.4 Example 103 1.35.2 0.4 Example 104 0.83.8 0.2 Example 105 1.56.8 0.6 Example 136 Example 106 4.48.7 0.4 Example 107 8.45.4 1.2 Example 108 2.21.8 0.5 Example 109 2.85.1 0.6 Example 110 1.82.6 0.4 Example 111 1.00.8 0.2 Example 112 2.23.4 0.8 Example 113 2.11.5 0.3 Example 114 4.55.1 1.3 Example 115 1.73.4 0.4 Example 116 1.43.5 0.5 Example 117 1.52.5 0.2 Example 118 1.11.3 0.2 Example 119 3.54.4 0.8 Example 120 1.42.2 0.4 Example 121 1.62.4 0.3 Example 122 1.83.4 0.5 Example 123 3.05.1 0.6 Example 124 8.913.8 1.6 Example 125 1104 4716 208 Example 126 757 7.0 Example 127 1000 1000 27 KRAS-BRAF with CYPA (500 nM) interaction assay In this example, TR-FRET was also used to measure the compound or compound-CYPA dependent disruption of the KRAS G12C-BRAF complex. This protocol was also used to measure disruption of KRAS G12D or KRAS G12V binding to BRAF by a compound of the invention, respectively. In assay buffer containing 25mM HEPES PH=7.4 (4-(2-hydroxyethyl)- 1-piperazineethanesulfonic acid, Thermo, 15630080), 0.002% Tween20, 0.1% BSA, lOOmM NaCI, 5mM MgC12, 10 pM GMPPNP (Guanosine 5'-[P,y-imido]triphosphate trisodium salthydrate, Sigma, G0635), tagless CYPA, GMPPNP loaded 6His-KRAS proteins, and GST- BRAFrbd were mixed in a well of a 384-well assay plate at final concentrations of 50 nM, 6.nM and InM, respectively. Compound was present in plate wells as a 16-point 3-fold dilution series starting at a final concentration of 10 pM and incubated for 3 hours. A mixture of MAh Anti-6His-XL665 (Cisbio, 61HISXLB) and Mab anti-GST-TB cryptate (Cisbio,61GSTTLB)was then added at a final concentration of 6.67 nM and 0.21 nM, respectively, and the plate was incubated for an additional 1.5 hours. TR-FRET signal was read on a PHERstar FSX microplate reader (Ex320 nm, Em 665/615 nm). Compounds that facilitate disruption of the KRAS-BRAF complex were identified as those eliciting a decrease in the TR-FRET ratio relative to DMSO control wells.15 Table 8. Activity of Examples and Compounds of present invention in KRAS-BRAF with CYPA (500 nM) interaction assay Example G12C IC50 (nM) G12D IC50 (pM) G12V ICso (pM) Example 1 14.9121.3 21.0 Example 2 28.8119.9 43.0 Example 3 31.4293.6 38.5 Example 5 34.8205.1 39.3 Example 6 11.161.2 15.5 Example 7 9.457.7 18.6 Example 8 23.766.9 37.9 Example 9 21.180.3 26.8 Example 10 5.924.4 8.1 Example 11 12.431.2 18.7 Example 12 12.031.0 15.6 Example 13 1.515.8 2.8 Example 14 22.2217.0 26.1 Example 15 11.968.2 13.6 Example 16 10.240.7 14.9 Example 17 25.489.2 46.2 Example 18 14.7277.8 20.6 Example 21 15.0372.3 26.8 Example 22 6.4295.3 16.6 Example 24 9.749.5 7.1 Example 25 32.6144.8 36.7 Example 28 53.8351.8 62.3 Example 29 12.766.2 8.9 Example 30 17.278.3 16.8 Example 33 19.5110.7 25.7 Example 34 31.8117.3 49.8 Example 35 14.554.5 20.9 Example 37 20.5175.0 15.8 Example 40 13.047.1 14.3 Example 41 23.8298.7 30.0 Example 42 20.571.3 22.8 Example 45 14.157.6 16.5 Example 47 21.2173.0 44.5 Example 48 4.430.0 7.8 Example 49 17.569.0 41.1 Example 50 22.0214.5 30.5 Example 51 21.177.1 39.2 Example 52 16.138.3 20.8 Example 53 65.7170.6 99.1 Example 54 23.3173.3 57.7 Example 55 23.688.5 28.3 Example 56 10.374.4 26.7 Example 57 8.077.1 24.8 Example 58 14.0111.2 17.7 Example 59 16.7394.5 32.6 Example 60 15.265.8 22.2 Example 61 50.9465.6 58.2 Example 63 34.0166.9 38.8 Example 64 17.273.2 25.4 Example 65 51.3 424 87.8 Example 66 50.5 157.9 53.2 Example 68 16.8 45.1 15.1 Example 69 35.7432.2 47.8 Example 71 28.9162.1 48.8 Example 72 31.5135.1 48.0 Example 73 8.944.4 7.2 Example 75 29.7355.9 19.1 Example 76 9.1107.5 9.8 Example 77 41.8259.7 80.6 Example 81 30.5 179.2 45.8 Example 83 10.381.9 13.9 Example 85 18.8116.8 12.0 Example 86 17.993.2 20.4 Example 87 32.6653.1 34.0 Example 88 9.751.1 16.3 Example 89 6.0 36.8 14.2 Example 90 6.4 466.2 13.9 Example 91 8.1 52.8 10.4 Example 92 16.0 93.4 25.9 Example 93 14.8 43.2 19.8 Example 94 6.950.4 14.6 Example 95 13.776.6 24.1 Example 96 9.442.2 16.0 Example 97 14.449.5 19.5 Example 98 11.147.3 20.8 Example 99 12.651.8 17.2 Example 100 33.1205.4 39.8 Example 101 5.441.3 4.5 Example 102 6.572.3 10.9 Example 103 6.071.1 11.2 Example 104 9.8103.0 22.1 Example 105 13.398.5 23.6 Example 106 10.841.8 8.7 Example 107 47.6260.0 74.5 Example 108 4.647.6 5.6 Example 109 6.042.8 7.5 Example 110 4.937.5 6.1 Example ill 4.751.4 7.4 Example 112 10.4138.4 22.2 Example 113 4.338.0 5.6 Example 114 8.964.3 14.0 Example 115 18.5176.8 25.6 Example 116 20.6244.7 31.8 Example 117 15.994.0 14.4 Example 118 13.579.8 13.4 Example 119 9.370.4 9.5 Example 120 20.4125.8 25.3 Example 121 13.078.4 12.0 Example 122 15.177.2 13.5 Example 123 13.778.8 12.6 Example 124 16.2112.5 19.3 Example 125 463 10000 1525 Example 126 151 3346 465 Example 127 1619 10000 3554 Example 137 pERK inhibition assay This assay is to measure the ability of test compounds in inhibiting the phosphorylationof ERK, the downstream signaling of KRAS G12C in NCI-H358 cells, KRAS G12D in AGS cells, and KRAS G12V in SW620. NCT-H358 (ATCC-CRL58O7) cells, AGS (ATCC-CRL-1739) cells, SW620 (ATCC-CCL-227) cells were all grown and maintained using RPMT-1640 medium (Thermo Fisher Scientific) with 10% fetal bovine serum and 1% penicillin/streptomycin. On the day prior to compound addition, cells were plated in tissue culture-treated 96 well plates(Corning-3699) at a density of 30,000 cell/well, 20,000 cell/well, 30,000 cell/well for NCI-H358, AGS and SW620 respectively, and allowed for attachment overnight. Diluted compounds were then added in a final concentration of 0.5% DMSO. After 4 hours of incubation, the medium was removed, 100 pL of 4% formaldehyde was added, and the assay plates were incubated at room temperature for 20 minutes. The plates were then washed once with phosphate buffered saline(PBS), and permeabilized with 100 pL of chilled methanol for 10 minutes. Non-specific antibody binding to the plates was blocked using 50 pL 1X BSA blocking buffer (Thermo-37520, -fold dilution by Phosphate-Buffered Saline Tween (PBST) for at least 1 hour at room temperature.The amount of phosphor-ERK was determined using an antibody specific for phosphorylated form of ERK. Primary antibody (pERK, CST-4370, Cell Signaling Technology)was diluted 1:300 in blocking buffer, with 50 pL aliquoted to each well, and incubated overnight at 4 °C. Cells was washed five times for 5 minutes with PBST. Secondary antibody (HRP-linked anti-rabbit IgG, CST-7074, Cell Signaling Technology) was diluted 1:1000 in blocking buffer, and 50 pL was added to each well and incubated 1-2 hrs at room temperature. Cells was washed times for 5 minutes with PBST, lOOpL TMB ELISA substrate (abcam-abl71523) were addedand gently shake for 20 minutes. 50pL stop solution (abcam-abl71529) were added, and then read the signal (OD450) by EnVision.IC50 was determined by fitting a 4-parameter sigmoidal concentration response model. Table 9. Activity of Examples and Compounds of present invention in KRAS pERK inhibition assay Example G12C IC50 (nM) G12D IC50 (nM) G12V IC50 (nM) Example 1 3.210.2 1.5 Example 2 3.43.0 1.4 Example 3 5.124.3 3.6 Example 5 6.221.2 2.8 Example 6 1.45.6 0.8 Example 7 1.67.9 1.2 Example 8 2.67.1 1.2 Example 9 2.31.8 0.8 Example 10 3.31.4 1.2 Example 11 5.12.9 0.8 Example 12 3.82.2 1.2 Example 13 3.010.8 1.5 Example 14 0.85.6 0.7 Example 15 0.75.2 0.8 Example 16 4.62.6 2.8 Example 17 2.92.7 1.8 Example 18 16.87.7 7.4 Example 19 1.920.7 2.7 Example 21 2.18.8 1.4 Example 22 0.63.8 0.7 Example 24 <0.60.9 <0.6 Example 25 1.011.3 0.8 Example 28 1.29.4 1.3 Example 29 <0.61.6 <0.6 Example 30 1.37.3 <0.6 Example 31 2.319.8 1.6 Example 33 8.523.1 2.7 Example 34 <0.64.6 <0.6 Example 35 1.04.7 <0.6 Example 37 0.99.1 0.6 Example 38 8.059.4 5.5 Example 40 0.65.6 0.4 Example 41 0.44.8 0.4 Example 42 0.98.1 1.4 Example 43 0.73.8 0.3 Example 44 2.19.1 1.4 Example 45 0.62.1 0.2 Example 46 0.99.1 1.0 Example 47 1.24.8 1.4 Example 48 1.210.1 1.0 Example 49 2.413.7 1.3 Example 50 3.520.1 2.4 Example 51 1.04.8 0.7 Example 52 1.45.1 0.7 Example 53 21.2176.0 24.5 Example 54 1.38.8 1.0 Example 55 4.918.1 3.1 Example 56 0.82.7 0.6 Example 57 1.16.1 1.3 Example 58 6.420.5 4.9 Example 59 8.821.3 3.0 Example 60 2.38.2 0.9 Example 61 8.510.3 1.1 Example 63 5.118.3 3.0 Example 64 1.23.7 0.6 Example 65 2.331.7 5.0 Example 66 2.640.2 3.3 Example 67 2.431.8 3.2 Example 68 0.23.9 0.3 Example 69 1.511.3 1.5 Example 70 1.827.9 5.5 Example 71 3.651.5 6.5 Example 72 2.341.5 4.8 Example 73 0.74.5 0.4 Example 75 4.923.6 2.6 Example 76 0.73.9 0.2 Example 77 4.426.1 4.0 Example 78 2.010.1 1.1 Example 79 1.616.2 1.4 Example 80 5.147.4 4.2 Example 81 1.66.5 1.2 Example 83 0.96.0 0.5 Example 85 1.75.6 0.6 Example 86 1.815.0 0.8 Example 87 4.840.6 1.5 Example 88 0.3 1.4 0.2 Example 89 0.64.8 0.4 Example 90 1.79.4 0.6 Example 91 0.53.2 0.6 Example 92 1.46.0 1.0 Example 93 1.2 3.5 1.2 Example 94 0.42.4 0.4 Example 95 0.53.4 0.4 Example 96 0.41.2 0.4 Example 97 0.41.4 0.3 Example 98 0.94.6 0.5 Example 99 0.51.9 0.4 Example 100 1.04.1 0.7 Example 101 0.92.6 0.2 Example 102 1.12.0 0.7 Example 103 0.72.4 0.7 Example 104 1.01.6 0.4 Example 105 1.52.2 0.4 Example 106 1.13.1 0.4 Example 107 2.77.4 1.5 Example 108 1.83.9 0.5 Example 109 0.94.1 0.3 Example 110 0.72.6 0.3 Example 111 0.62.0 0.4 Example 112 0.73.4 0.5 Example 113 0.62.2 0.4 Example 114 1.27.5 1.0 Example 115 0.82.6 0.2 Example 116 0.84.6 0.7 Example 117 0.74.1 0.3 Example 118 0.73.5 0.3 Example 119 1.76.9 1.2 Example 120 1.12.9 0.9 Example 121 0.93.4 0.3 Example 122 0.63.5 0.2 Example 123 0.87.1 0.6 Example 124 1.415.7 0.7 Example 125 303 481 84 Example 126 50 3 Example 127 697 30 Example 138 hERG potassium channel assays for non-clinical cardiac safety evaluation The purpose of the test was to screen compounds for the activity on hERG channels as a non-clinical cardiac safety evaluation.Advanced hERG experiments were performed at near-physiological temperature(34 ؟?) by HEKA EPC 10 manual patch system (heka elektronik, EPC 10 amplifier). The CHO cells (B’SYS GmbH) stably transfected hERG channel were initially held at 80־ mV, depolarized to voltages between -40mV(100 ms) to 20 mV(500 ms) to activate the hERG outward currents, and then repolarized to 40־ mV(500 ms) to record the hERG tail currents, with an interpulse interval of 15s. The recording environment included : Extracellular solution (in mM): 150 NaCI, 4 KC1, 1.2 CaC12,l MgC12 and 10 HEPES ; pH adjusted to 7.2-7.4 with 5 M NaOH; Intracellular solution (in mM): 125 KC1, 10 NaCI, 5 EGTA, 10 HEPES, 0.1 Na2GTP and 5 MgATP; pH adjusted to 7.2 with 1 M KOH. Current inhibitions in the presence of more than 4 concentrations in quadruplicate were used to fit hERG IC50 by Graphpad prism V8.0.Results from advanced hERG assay show that Example 24 exhibited a reduced inhibitory effect on hERG potassium channel compared to A122 and A252. The inhibitory concentration (IC20) for Example 24 was 13.8 pM, which is 3-fold higher compared to A122 ( IC20 4.6 pM) or 4- fold higher compared to A252 ( IC20 3.0 pM). This higher IC20 suggests that Example could have less concern regarding cardiovascular toxicity associated with hERG channel blockade. Table 10. hERG test results IC50 (pM) IC20 (pM) A252 11.0 3.0 A122 16.9 4.6 Example 24 63.7 13.8 Example 139 CYPA binding analysis by surface plasmon resonance (SPR) assay The compounds of this invention created a tri-complex involving the active RAS protein and CYPA, necessitating the initial formation of a binary complex through the compound's interaction with CYPA. The stability of the drag-target complex, as indicated by its equilibrium dissociation constant (Kq), is thought to influence the length of target engagement, which in turn could lead to a prolonged effect in the washout experiments. Therefore, the objective of this study is to evaluate the binding kinetics of the compounds with CYPA to determine the stability of the CYPA-compound binary complex and to evaluate whether this stability correlates with the sustained inhibition of the target.All SPR experiments were conducted on a Biacore 8K+ instrument (Cytiva). Recombinant biotinylated CYPA protein with a C-terminal AVI tag was purified and immobilized on flow cell 2 of SA chip (Cytiva, BR100531), with the flow cell 1 as the blank reference. The running buffer was HBS-P+ Buffer (Cytiva, BR100827, 0.01 M HEPES pH 7.4, 0.15 M NaQ, 0.05% v/v Surfactant P20), and the flow rate was 10 uL/min. The immobilization level was achieved to about 1800 response units (RU). Compounds were 3-fold serially diluted to 1.5-3333 nM using HBS-P+ Buffer with a final DMSO concentration of 1.5%, and then loaded to flow through the chip surface at a rate of 30 pE/min with HBS-P+ Buffer containing 1.5% DMSO as the running buffer. Experiments were performed at 25 *U. The contact time and dissociation time were set to 60 s and 200 s, respectively. After binding and dissociation of each sample, the chip was regenerated using 1 M NaCI with a short contact time of 19 s at a rate of uL/min. The sensorgrams were analyzed using Biacore Insight Evaluation software with 1:kinetics binding model to determine the association rate constant (^on ), dissociation rate constant (ko ff) and equilibrium dissociation constant (^d)■ Table 11. CYPA binding kinetics data in SPR assay Compound (nM) ־'( s ־' M ،) Aoff ($ ) A122 30 1.9x106 0.056 Example 24 13 1.4x106 0.019The CYPA binding kinetics data in SPR assay showed that, compared to Al 22, Example exhibited an obviously much higher binding affinity to CYPA (2.3-fold lower VD) and an obviously much lower dissociation rate (2.9-fold lower ،) that revealed a stronger stability of formed CYPA-compound binary complex. This result is consistent with the less potency shift of Example 24 observed in washout assay in Example 140. Example 140 Washout viability assay: The study aimed to investigate the relationship between the dynamics of target inhibition and its impact on cell proliferation by conducting in vitro washout experiments, with the understanding that thorough and persistent inhibition of the RAS-MAPK signaling pathway can be advantageous for achieving substantial efficacy.
Cancer cell lines NCI-H358, NCI-H2122, and SW480 (purchased from ATCC) were cultured in RPMI1640 (Thermo Fisher Scientific) medium plus 10% Fetal Bovine Serum (FBS, Thermo Fisher Scientific, 2.5 ug/mL puromycin and 1% Antibiotic-Antimycotic (Thermo Fisher Scientific ) and plated at a density of 2,000 cells per well in 96-well assay plates (Corning-3699) and incubated overnight. On the assay day, compounds diluted to a final DMSO concentration of 0.5% were added to the wells. Following a 4-hour incubation period, the culture medium was removed, and the cells were washed three times with RPMI1640 medium only before being cultured in the abovementioned culture medium (RPMI1640+10%FBS+l% antibiotic- antimycotic). After 72 hours, a tenth of the volume of Cell Counting Kit-8 (Dojindo-CK04) was added to each well. The absorbance was measured (OD450 minus OD650) using an EnVision plate reader after a further 2-hour incubation. The IC50 values were calculated by applying a four-parameter sigmoidal concentration-response curve fit to the data.Table 12 summarizes the IC50 values of Example 24 and A122 without or with washout. Without washout, Example 24 showed comparable or slightly higher potencies in individual cell lines in the anti-proliferation assay,. Applying washout conditions, more precisely 4-hour compound treatment followed by three washing steps and after 72-hour viability assessment, mean IC50 values increased for both compounds but differed in their extent. The IC50 values of Example 24 shifted 5.6-, 1.3-, 6.7-fold, inNCI-H358, NCI-H2122, SW480 respectively, while the IC50 values for A122 shifted by factors of 16.2-, 3.6-, 19.7-fold respectively.Based on above comparison, Example 24 exhibited less potency shift after washout, in comparison to that of reference compound Al 22, with a more persistent cell growth inhibition which would be advantageous for achieving durable efficacy in clinic. Table 12. IC50 shift in washout assay NCI-H3(KRAS G12C)NCI-H21(KRAS G12C)SW480(KRAS G12V)A122 Example A122 Example A122 Example No-washout IC50 (nM) 2.0 1.0 8.0 6.7 2.4 1.3Washout IC50 (nM) 32.1 5.9 29.0 9.0 47.3 8.4IC50 shift fold 16.2 5.6 3.6 1.3 19.7 6.7

Claims (33)

-244-
1. CLAIMS 1. A compound of formula (lb), whereinR1 is 2-oxabicyclo[2.1.1]hexanyl,3-oxabicyclo [3.1.0]hexanyl,6-bicyclo[3.1.0]hexanyl substituted twice by halogen,6-tricyclo [3.1.1.03,6]heptanyl,C3-7cycloalkyl substituted once, twice or three times by the substituentsindependently selected from C! -alkyl, C!-6alkylpyridinyl, C1-6alkylpyrimidinyl, C!-6alkyltetrazolyl, C3-7cycloalkyl, haloC-galkyl, halogen, halophenyl, hydroxy, phenyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl and thiazolyl, or tetrahydropyranyl;R2 is l,3,4,6,7,8,9,9a-octahydropyrido[l,2-a]pyrazinyl,3,4,6,7,9,9a-hexahydro-1 H-pyrazino[2,1-c][1,4]oxazinyl,morpholinyl, orpiperazinyl unsubstituted or substituted by substituents independently selected fromC1-6alkoxyC!-6alkyl, C!-6alkyl, C3-7cycloalkyl, haloC!-6alkyl, hydro xyC!.6alkyl, morpholinylC1-6alkyl, oxetanyl, oxopyn־olidinylC!.6alkyl and tetrahydro furanylo xyC! .galkyl;R3 is H or halogen;M is C1-zalkylene or O;L is C1-zalkylene, hydroxyCi-galkylene or haloC!.6alkylene;or a pharmaceutically acceptable salt thereof. -245-
2. A compound of formula (Ic), wherein R1 is 2-oxabicyclo[2.1.1]hexanyl,3-oxabicyclo[3.1.0]hexanyl,6-bicyclo[3.1.0]hexanyl substituted twice by halogen,6-tricyclo[3.1.1.03,6]heptanyl,C3-7cycloalkyl substituted once, twice or three times by the substituentsindependently selected from C! -alkyl, C!-6alkylpyridinyl, C1-6alkylpyrimidinyl, C!-6alkyltetrazolyl, C3-7cycloalkyl, haloC-galkyl, halogen, halophenyl, hydroxy, phenyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl and thiazolyl, or tetrahydropyranyl;R2 is l,3,4,6,7,8,9,9a-octahydropyrido[l,2-a]pyrazinyl,3,4,6,7,9,9a-hexahydro-1 H-pyrazino[2,1-c][1,4]oxazinyl, morpholinyl, orpiperazinyl unsubstituted or substituted by substituents independently selected fromC1-6alkoxyC!-6alkyl, C!-6alkyl, C3-7cycloalkyl, haloC!-6alkyl, hydroxyC!.6alkyl, mo1־pholinylC1-6alkyl, oxetanyl, oxopyrrolidinylC1-6alkyl and tetrahydro fur any lo xy C! -6 alkyl;לR is H or halogen;M is C!-6alkylene or O;L is C!-6alkylene, hydroxyC!-6alkylene or haloC!.6alkylene; or a pharmaceutically acceptable salt thereof. -246-
3. A compound according to claim 1 or 2, wherein R1 is C3-7cycloalkyl substituted once or twice by the substituents independently selected from C!.6alkyl and pyridinyl.
4. A compound according to any one of claims 1-3, wherein R1 is cyclopropyl once substituted by pyridinyl or twice substituted by methyl.
5. A compound according to any one of claims 1-4, wherein R1 is 2,3-dimethyl-cyclopropyl or 2- (3-pyridinyl)cyclopropyl.
6. A compound according to any one of claims 1-5, wherein R2 is morpholinyl or C1. 6alkylpiperazinyl.
7. I. A compound according to any one of claims 1-6, wherein R2 is morpholinyl or 4- methylpiperazin-1 -yl.
8. A compound according to any one of claims 1-7, wherein M is C!_6alkylene.
9. A compound according to any one of claims 1-8, wherein M is CH2.
10. A compound according to any one of claims 1-9, wherein L is ethylene or difluoro ethylene. kc-c^* H2 H2 ؟11. A compound according to any one of claims 1-10, wherein L is or
11. F , wherein bond “a” connects to M.
12. A compound according to claim 1 or 2, whereinR1 is C3-7cycloalkyl substituted once or twice by the substituents independently selected from C!-6alkyl and pyridinyl;R" is morpholinyl or C!-6alkylpiperazinyl;R3 is H;M is C!.6alkylene; -247- L is C1-6alkylene or haloC!-6alkylene;or a pharmaceutically acceptable salt thereof.
13. A compound according to claim 12, whereinR1 is 2,3-dimethyl-cyclopropyl or 2-(3-pyridinyl)cyclopropyl;R2 is morpholinyl or 4-methylpiperazin-1-yl;R3 is H;M is CH2; F LC_C ! -salF ؟ H2 H2 ؛L is or , wherein bond “a” connects to M;or a pharmaceutically acceptable salt thereof.
14. A compound selected from:(15,25)-A -[(75,135)-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17- dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] -2-methyl-cyclopropanecarboxamide ;(15,25)-A-[(7S,135)-(20Af)-20-[2-[(llS)-l-methoxyethyl]-5-(4-methylpiperazm-l-yl)-3- pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo [23.3.1.12’5.19’13.019’27.021’26]hentriaconta-1 (28),2,5(31), 19,25(29),26-hexaen-7- yl] -2-methyl-cyclopropanecarboxamide ;(1 S^SyN-V^S, 135)-(20M)-20-[2-[( 1S)-1 -methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin-1 -yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’l3.0l9’27.02l’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] -2-methyl-cyclopropanecarboxamide ;(lS,2S)-A-[(7S,13S)-(20A0-20-[2-[(lS)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin-1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26- hexaen-7-yl] -2-methyl-cyclopropanecarboxamide ;(lS,25)-2-(difluoromethyl)-A-[(7S,13S)-(20X)-20-[2-[(lS)-l-methoxyethyl]-5- morpholino-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - -248- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] cyclopropanecarboxamide;(15,57?, 6r)-7V-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 -tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-3-oxabicyclo[3.1.0]hexane-6-carboxamide;(15,25)-A^-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17- dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] -2-methyl-cyclopropanecarboxamide ;(15,25)-2-(difluoromethyl)-7V-[(75,135)-(20X)-20-[2-[(15)-l-methoxyethyl]-5- morpholino-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] cyclopropanecarboxamide;(15,57?, 6r)-7V-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31 -tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-3-oxabicyclo[3.1.0]hexane-6-carboxamide;(15,25)-2-(difluoromethyl)-7V-[(75,135)-(200-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,2,2- trifluoroethyl)piperazin- 1-yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26- hexaen-7-yl] cyclopropanecarboxamide;(15,57?, 6r)-^-[(75,135)-(20M)-20-[2-[( 15)-1 -methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin-1 -yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9’l3.0l9’27.02l’26]hentriaconta-l(28),2,5(31), 19,25(29),26- hexaen-7-yl]-3-oxabicyclo[3.1.0]hexane-6-carboxamide;(15,57?, 6r)-7V-[(75,135)-(207lO-20-[2-[(15)-1-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin-1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-3-oxabicyclo[3.1.0]hexane-6-carboxamide;(15,25)-2-(difluoromethyl)-7V-[(75,135)-(207k0-20-[2-[(15)-l-methoxyethyl]-5-(4- methylpiperazin-1 -yl)-3 -pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - -249- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] cyclopropanecarboxamide;(15,57?, 6r)-A^-[(75,13،S)-(20A/)-20-[2-[(l>S)-1-metho xyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021 26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-3-oxabicyclo[3.1.0]hexane-6-carboxamide;(17?,25)-2-cyclopropyl-7V-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4- methylpiperazin-1 -yl)-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] cyclopropanecarboxamide;(15,25)-A^-[(75,135)-(203/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] -2-methyl-cyclopropanecarboxamide ;(15,25)-JV-[(75,135)-23,23-difluoro-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4- methylpiperazin-1 -yl)-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] -2-methyl-cyclopropanecarboxamide ;2,2-difluoro-7V-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)- 3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9,13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] -1 -methyl-cyclopropanecarboxamide;(15,25)-2 -(difluoromethyl)-7V-[(75,135)-(20M)-20-[2-[( 15)-1 -methoxyethyl]-5-[4-(2,2,2- trifluoroethyl)piperazin-1 -yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5. l9J3.0l9’27.0212]hentriaconta-1(28),2,5(31), 19,25(29),26-hexaen-7- yl] cyclopropanecarboxamide;(15,25)-7V-[(75,13S)-(207l/)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] -2-phenyl-cyclopropanecarboxamide;(lr,27?,35)-7V-[(75,135)-(20A/)-20-[2-[(15)-1-metho xyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - -250- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(lS,2S)-A4(7S,13S)-(203y)-20-[5-[(9،zS)-31£62i9,9،z-hexahydro-l^pyrazino^^ c][l,4]oxazin-8-yl]-2-[(15)-l-methoxyethyl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4- thia-9,21,30,3 l-tetrazahexacyclo[23.3.1.I2’5.19 13.019’27.021-26]hentriaconta- 1(28),2,5(31), 19,25(29),26-hexaen-7-yl]-2-methyl-cyclopropanecarboxamide;(l/?,2^)-2-(2-fluorophenyl)-2V-[(75,13S)-(20A0-20-[2-[(lS)-l-methoxyethyl]-5-(4- methylpiperazin-1 -yl)-3 -pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] cyclopropanecarboxamide;(15,25)-2-(2-fluorophenyl)-7V-[(7S,13S)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4- methylpiperazin-1 -yl)-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] cyclopropanecarboxamide;(15,25)-A^-[(75,135)-(203/)-20-[2-[(llS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-(2-pyridyl)cyclopropanecarboxamide;(15,25)-^-[(75,135)-23,23-difluoro-(20A0-20-[2-[(lS)-l-methoxyethyl]-5-(4- methylpiperazin-1 -yl)-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9,13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7-yl]-2- (difluoromethyl)cyclopropanecarboxamide;(1 S,2K)-N-VC?S, 13S)-(20M)-20-[2-[( 1S)-1 -methoxyethyl]-5-(4-methylpiperazin- 1 -yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo [23.3.1.12’5. l9J3.0l9’27.021’2^hentriaconta-1(28),2,5(31), 19,25(29),26-hexa yl]-2-methyl-cyclopropanecarboxamide;(lS,2S)-2-(difluoromethyl)-7V-[(7S,13S)-(203^-20-[2-[(lS)-l-methoxyethyl]-5-(4- methylpiperazin-1 -yl)-3 -pyridyl] -17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] cyclopropanecarboxamide;(XS,5R, 6r)-N-[(2S, 13،S)-(20A/)-20-[2-[(l،S)-1 -metho xyethyl]-5-(4-methylpiperazin-1 -yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- -251- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-3-oxabicyclo[3.1.0]hexane-6-carboxamide;(17?,25)-2-cyclopropyl-7V-[(75,135)-(20Af)-20-[2-[(15)-l-methoxyethyl]-5-morpho lino-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7- yl] cyclopropanecarboxamide;(15,25)-A ^-[(75,135)-(20A/)-20-[2-[(1S)-1-metho xyethyl]-5-morpholino-3-pyridyl] - 17,17,23,23-tetramethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] -2-methyl-cyclopropanecarboxamide;(15,57?,6r)-A^-[(75,135)-(20Af)-20-[5-[(9a5)-3,4,6,7,9,9a-hexahydro-17/-pyrazino[2,l- c][l,4]oxazin-8-yl]-2-[(15)-l-methoxyethyl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4- thia-9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta- l(28),2,5(31),19,25(29),26-hexaen-7-yl]-3-oxabicyclo[3.1.0]hexane-6-carboxamide;(15,25)-A^-[(75,135)-(20Af)-20-[5-[(9a5)-3,4,6,7,9,9a-hexahydro-177-pyrazino[2,l- c][l,4]oxazin-8-yl]-2-[(15)-l-methoxyethyl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4- thia-9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta- 1(28),2,5(31), 19,25(29),26-hexaen-7-yl]-2-(difluoromethyl)cyclopropanecarboxamide;(17?,55 65)-A^-[(75,135)-(203Y)-20-[2-[(15)-1 -metho xyethyl]-5-(4-methylpiperazin-1 -yl)-3- pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9,13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-3-oxabicyclo[3.1.0]hexane-6-carboxamide;(15,25)-^-[(75,135)-(20M)-20-[2-[( 15)-1 -methoxyethyl]-5-morpholino-3-pyridyl]-17,17- dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31 -tetrazahexacyclo [23.3.1.12’5. l9>l3.0l9>27.0212]hentriaconta-1(29),2,5(31), 19,25,27-hexaen-7-yl]-2- pheny 1-cyc lopropanecar boxamide;(15,25)-A7-[(75,135)-(20A0-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin-1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27- hexaen-7-yl]-2-phenyl-cyclopropanecarboxamide;(Ir,25,37?)-7V-[(75,135)-(203Y)-20-[2-[(15)-l-metho xyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl] -17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- -252- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(15,25)-A^-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17- dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7-yl]-2- phenyl-cyclopropanecarboxamide;(15,25)-2V-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-pyrimidin-5-yl-cyclopropanecarboxamide;(15,57?)-3,3-difluoro-7V-[(75,135)-(20X)-20-[2-[(15)-l-methoxyethyl]-5-(4- methylpiperazin-1 -yl)-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]bicyclo [3.1.0]hexane-6-carboxamide;(15,25)-A^-[(75,135)-(20Af)-20-[5-[(9a7?)-l,3,4,6,7,8,9,9a-octahydropyrido[l,2-a]pyrazin- 2-yl]-2-[(15)-l-methoxyethyl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9, 21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-methyl-cyclopropanecarboxamide;(15,25)-A^-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-pyrimidin-4-yl-cyclopropanecarboxamide;(1 S,2S)-N-VC?S, 135)-(20M)-20-[2-[( 1S)-1 -methoxyethyl]-5-(4-methylpiperazin- 1 -yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31 -tetrazahexacyclo [23.3.1.12’5. l9>l3.0l9>27.0212]hentriaconta-1(29),2,5(31), 19,25,27-hexaen-7-yl]-2- phenyl-cyclopropanecarboxamide;(1^,55,6s>N-VC?S, 135)-(20M)-20-[2-[(15)-1 -methoxyethyl]-5-(4-methylpiperazin-1 -yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-3-oxabicyclo[3.1.0]hexane-6-carboxamide;(15,25)-A^-[(75,135,225)-(20M)-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3-pyridyl]- 17,17,22-trimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- -253- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] -2-methyl-cyclopropanecarboxamide;2,2-difluoro-7V-[(75J3S)-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)- 3-pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7-yl]-l- methyl- cyclopropanecarboxamide;A^-[(75,13S)-(20vW)2]-20־-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7-yl]- 1,2-dimethyl-cyclopropanecarboxamide;(15,2S)-A^-[(75,13S)-(203/)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-(3-pyridyl)cyclopropanecarboxamide;(15,25)-A^-[(75,135)-(203/)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-(4-pyridyl)cyclopropanecarboxamide;(17?,27?)-A^-[(75,135)-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-(4-pyridyl)cyclopropanecarboxamide;2-(4-fluorophenyl)-A^-[(75, 135)-(20M)-20-[2-[( 1S)-1 -methoxyethyl]-5-(4-methylpiperazin- -yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31 - tetrazahexacyclo [23.3.1.12’5. l9>l3.0l9>27.0212]hentriaconta-1(29),2,5(31), 19,25,27-hexaen-7- y 1] eye lopropanecarboxamide;(15,57?, 6^-^-[(75,13،S)-23,23-difluoro-(20A0-20-[2-[(lS)-1-methoxyethyl]-5-(4- methylpiperazin-1 -yl)-3 -pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-3-oxabicyclo[3.1.0]hexane-6-carboxamide;(Ir,27?,35)-Af-[(75,135)-(20A/)-20-[2-[(lS)-l-metho xyethyl]-5-morpho lino-3-pyridyl]- 17,17,23,23-tetramethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- -254- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(15,25)-jV-[(75,135)-(20.A/)-20-[2-[(llS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31־ tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-pyridazin-3-yl-cyclopropanecarboxamide;(l-R^^^-cyclopropyl-TV-^S^BSy^OAf^O-^-^lSyi-methoxyethylJ-S-^- methylpiperazin-1 -yl)-3 -pyridyl] -17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7- yl] cyclopropanecarboxamide;3,3-difluoro-7V-[(75,135)-(20Af)-20-[2-[(llS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)- 3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] cyclopentanecarboxamide;A^-[(75,135)-(20Af)-20-[2-[( 15)-1-methoxyethyl]-5-(4-methylpiperazin-1-yl)-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 -tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] -2-oxabicyclo [2.1.1 ]hexane-1 -carboxamide;(15,2S)-A4(7S,13S)-23,23-difluoro-(20^-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,2,2- trifluoroethyl)piperazin-1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9,13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-methyl-cyclopropanecarboxamide;(1 r,2R,3S)-N-VC?S, 13S)-(20M)-20-[2-[( 15)-1 -methoxyethyl]-5-morpholino-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31 -tetrazahexacyclo[23.3.1.12’5. l9J3.0l9’27.0212]hentriaconta-1(29),2,5(31), 19,25,27-hexaen-7-yl]- 2,3- dimethy 1-cyc lopropanecar boxamide;(lr,25,37?)-lV-[(75,13 1S)-(20A0-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl] -17,17,23,23-tetramethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;tran5-A^-[(75,13،S)-(20Af)2]-20־-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - -255- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7-yl]-4- (1 -methyltetrazo l-5-yl)cyclo hexanecarboxamide;iran5-4-hydroxy-A^-[(7S',13S)-(20A/)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l- yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-4-methyl-cyc 10 hexanecarboxamide;A^-[(75,13،S)-(20JW)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 -tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]tricyclo[3.1.1.03’6]heptane-6-carboxamide;(lr,25,37?)-7V-[(75,13.S)-(2037)-20-[2-[(llS)-l-methoxyethyl]-5-morphohno-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(15,2S)-AH(7S,13S)-23,23-difluoro-(20A0-20-[2-[(lS)-l-methoxyethyl]-5-morpholino-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] -2-methyl-cyclopropanecarboxamide;(lr,25,37?)-7V-[(75,13.S)-23,23-difluoro-(207l7)-20-[2-[(llS)-l-methoxyethyl]-5-morphohno- 3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;^-[(75,13،S)-(20A/)-20-[2-[( 1S)-1 -methoxyethyl]-5-(4-methylpiperazin- 1 -yl)-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 -tetrazahexacyclo [23.3.1.12’5. l9>l3.0l9>27.0212]hentriaconta-1(28),2,5(31), 19,25(29),26-hexaen-7- yl]tetrahydropyran-4-carboxamide;(l،S,,25)-^-[(7،S’,13،S)-23,23-difluoro-(20A0-20-[2-[(lS)-l-methoxyethyl]-5-(4- methylpiperazin-1 -yl)-3 -pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-phenyl-cyclopropanecarboxamide;(l،S,,2،S)-^-[(7،S,,13،S)-23,23-difluoro-(20A0-20-[2-[(15)-l-methoxyethyl]-5-morpholino-3- pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- -256- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-phenyl-cyclopropanecarboxamide;(15,25)-Af-[(75J35)-(203^-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31־ tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-pyrimidin-2-yl-cyclopropanecarboxamide;(17?,27?)-^-[(75,135)-20-[2-[( 1 ،S)-1-methoxyethyl]-5-(4-methylpiperazin-1-yl)-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 -tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-pyrimidin-2-yl-cyclopropanecarboxamide;(lr,25,3/?)-JV-[(75,13S)-23,23-difluoro-(20X)-20-[2-[(lS)-l-methoxye^methylpiperazin-1 -yl)-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7-yl]- 2,3-dimethyl-cyclopropanecarboxamide;(lr,2S,37?)-JV-[(7S,135)-(207l<)-20-[2-[(lS)-l-methoxyethyl]-5-^^trifluoroethyl)piperazin-1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26- hexaen-7-yl] -2,3 -dimethyl-cyclopropanecarboxamide;(lr,27?,3S)-7V-[(7S,13S)-(20X)-20-[2-[(lS)-l-methoxyethyl]-5-[4-(2,2^trifluoroethyl)piperazin-1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(1 r,2S3K)-N-VC?S, 135)-23,23-difluoro-(20M)-20-[2-[( 1S)-1 -methoxyethyl]-5-[4-(2,2,2- trifluoroethyl)piperazin-1 -yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5. l9’l3.0l9>27.0212]hentriaconta-1(28),2,5(31), 19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(1،S,,2،S,)-7V-[(7،S’, 13،S)-(20A0-20-[2-[( 1S)-1-methoxyethyl]-5-morpholino-3-pyridyl] -17,17- dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] -2-pyrim idin-5 -yl-cyclopropanecarboxamide;(15,2،S)-A^-[(75,135)-(20^/)-20-[2-[(15)-1-methoxyethyl]-5-morpholino-3-pyridyl] -17,17- dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- -257- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-(3-pyridyl)cyclopropanecarboxamide;(lS,2S)-A4(7S,13S)-(20A0-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin-1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-(3-pyridyl)cyclopropanecarboxamide;(15,25)-A4(75,135)-23,23-difluoro-(207l7)-20-[2-[(lS)-l-methoxyethyl]-5-morpholino-3- pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-(3-pyridyl)cyclopropanecarboxamide;(15,2S)-iV-[(75,13S)-23,23-difluoro-(20Af)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-1 -yl)-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-(3-pyridyl)cyclopropanecarboxamide;(15,25)-Af-[(75,13S)-(20d7)-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-pyrimidin-5-yl-cyclopropanecarboxamide;(15,2S)-Af-[(75,13S)-(20d7)-20-[2-[(lS)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17- dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-pyrimidin-5-yl-cyclopropanecarboxamide;(15,25)-A^-[(75, 135)-23,23-difluoro-(20M)-20-[2-[(15)-1 -methoxyethyl]-5-(4- methylpiperazin-1 -yl)-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5. l9J3.0l9’27.0212]hentriaconta-1(28),2,5(31), 19,25(29),26-hexaen-7- yl]-2-pyrimidin-5-yl-cyclopropanecarboxamide;(l،S,,2،S,)-^-[(7،S’,135)-(20A0-20-[2-[(lS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31-2,5 9,13 19,27 21,26tetrazahexacyclo [23.3.1.1 .1 .0 .0 ]hentnaconta-l(28),2,5(31),19,25(29),26-hexaen-7-yl]-2-(3-pyridyl)cyclopropanecarboxamide;(15,2،S)-A^-[(75,135)-(20^/)-20-[2-[(15)-1-methoxyethyl]-5-morpholino-3-pyridyl] -17,17- dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31- -258- 2,5 9,13 19,27 21,26tetrazahexacyclo [23.3.1.1 .1 .0 .0 ]hentnaconta-l(28),2,5(31),19,25(29),26-hexaen-7-yl]-2-(3-pyridyl)cyclopropanecarboxamide;(15,25)-iV-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-[4-(2,2,2-trifluoroethyl)piperazin-1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-2,5 9,13 19,27 21,269,21,30,31-tetrazahexacyclo[23.3.1.1 .1 .0 .0 ]hentnaconta-l(28),2,5(31),19,25(29),26-hexaen-7-yl]-2-(3-pyridyl)cyclopropanecarboxamide;(15,25)-A^-[(75,135)-(203/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-pyrazin-2-yl-cyclopropanecarboxamide;(lr,27?,35)-7V-[(75,135)-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15,25-dioxa-4-thia-9,21,31,32- tetrazahexacyclo[24.3.1.12’5.l9’13.019’28.021’27]dotriaconta-l(29),2,5(32),19,26(30),27-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(lr,25,37?)-7V-[(75,135)-(20A/)-20-[5-[(9،z7?)-l,3,4,6,7,8,9,9،z-octahydropyrido[l,2- a]pyrazin-2-yl]-2-[(15)-1 -methoxyethyl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia- 9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26- hexaen-7-yl] -2,3 -dimethyl-cyclopropanecarboxamide;(15,25)-A^-[(75,135)-(203/)-20-[5-[(9a7?)-l,3,4,6,7,8,9,9a-octahydropyrido[l,2-a]pyrazin- 2-yl]-2-[(15)-1-methoxyethyl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-(3-pyridyl)cyclopropanecarboxamide;(15,25)-A4(75,135)-(20ilf)-20-[5-[(9aR)-1,3,4,6,7,8,9,9a-octahydropyrido[ 1,2-a]pyrazin- 2-yl]-2-[( 15)-1 -methoxyethyl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’l3.0l9’27.02l’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl] -2-pyrimidin- 5 -yl-cyclopropanecarboxamide;(15,25)-7V-[(75,135)-(207^)-20-[5-[(9a5)-3,4,6,7,9,9a-hexahydro-l/7-pyrazino[2,l- c] [ 1,4]oxazin-8-yl]-2-[(15)-l-methoxyethyl]-3-pyridyl]-l 7,17-dimethyl-8,14-dioxo-15-oxa-4- thia-9,21,30,31-tetrazahexacyc lo[23.3.1.12,נ. I9’13.019,27.021,26]hentriaconta- 1(28),2,5(31), 19,25(29),26-hexaen-7-yl]-2-(3-pyridyl)cyclopropanecarboxamide;(15,25)-A^-[(75,135)-(207^)-20-[5-[(9ti5)-3,4,6,7,9,9ti-hexahydro-l//-pyrazino[2,l- c] [ 1,4]oxazin-8-yl]-2-[(15)-1-methoxyethyl]-3-pyridyl]-! 7,17-dimethyl-8,14-dioxo- 15-oxa-4- -259- thia-9,21,30,31-tetrazahexacyclo[23.3.1.12’5.l9 13.019’27.021’26]hentriaconta-1(28),2,5(31), 19,25(29),26-hexaen-7-yl]-2-pyrimidin-5-yl-cyclopropanecarboxamide;(1 r,2R3S)-N-V(2S, 135)-(20A/)-20-[5-(4-cyclopropylpiperazin-1 -yl)-2-[(1S)-1 - methoxyethyl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15,24-dioxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(lr,27?,35)-A4(7S,13S,23S)-23-hydroxy-(207l7)-20-[2-[(lS)-l-methoxyethyl]-5- morpholino-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(1 r,27?,35)-^-[(75,135)-(20A/)-20-[2-[( 15)-1-metho xyethyl]-5-p iperazin-1-yl-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 -tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(lr,27?,35)-7V-[(75,135)-20-[5-[4-(2,2-difluoroethyl)piperazin-l-yl]-2-[(15)-l- methoxyethyl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(1 ^27?,35)-^-[(75,13،20)-(؟JW)-20-[5-[4-(2-fluoroethyl)piperazin-1-yl]-2-[(15)-1 - methoxyethyl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9,13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(1 r,2R,3S)-N-VC?S, 135)-(20M)-20-[5-[4-(3-hydroxypropy^ 1 -yl]-2-[( 15)-1 - methoxyethyl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo [23.3.1.12’5. l9>l3.0l9>27.0212]hentriaconta-1(28),2,5(31), 19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(17?,27?)-^-[(75,13،S)-(20M)-20-[2-[(15)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-(4-methylpy1־imidin-5-yl)cyclopropanecarboxamide;- 3 - [ 1 - methoxyethyl ׳(- 13 ، S)-(20M)-20-[5-(4-ethylpiperazin-1-yl)-2-[(1S ،؟, 7 ^-]) 1 r,27?,3،S)-A )pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - -260- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(17?,27?)-A^-[(75,13lS)-(20A/)-20-[2-[(llS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-thiazol-4-yl-cyclopropanecarboxamide;(lr,25,3^)-iV-[(75,135)-(20A0-20-[2-[(15)-l-methoxyethyl]-5-[4-(2-metho xyethyl)piperazin-1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(17?,27?)-A^-[(75,13lS)-(20A/)-20-[2-[(llS)-l-methoxyethyl]-5-(4-methylpiperazin-l-yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-(2-methyl-3-pyridyl)cyclopropanecarboxamide;(lr,27?,3lS)-7V-[(75,13.S)-(20A/)-20-[2-[(llS)-l-methoxyethyl]-5-(4-tetrahydropyran-4- ylpiperazin-1 -yl)-3 -pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(lr,27?,35)-7V-[(7S,13lS)-(20A/)-20-[2-[(l>S)-l-methoxyethyl]-5-[4-(oxetan-3-yl)piperazin-l- yl]-3-pyridyl]-! 7,17-dimethyl-8,14-dioxo-l 5-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(1 r^3R)-N-VC?S, 13S)-(20M)-20-[2-[( 1S)-1 -methoxyethyl]-5-[4-[[(25)-morpholin-2- yl]methyl]piperazin-1 -yl]-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5. l9J3.0l9’27.0212]hentriaconta-1(28),2,5(31), 19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(17?,27?)-7V-[(7،S’, 1 3،S)-(2OM)-2O-[2-[( 15)-1-methoxyethyl]-5-(4-methylpiperazin-1-yl)-3 - pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2-(5-methyl-3-py1־idyl)cyclopropanecarboxamide;(lr,2/?,3،S)-JV-[(75,13،S)-(20A0-20-[2-[(l،S)-l-methoxyethyl]-5-[4-[2-(2-oxopyrrolidin-l- yl)ethyl]piperazin-1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - -261- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(Ir,27?,35)-Af-[(7SJ 35)-(20A/)-20-[2-[(lS)-1-metho xyethyl]-5-[4-(2-tetrahydrofuran-3- yloxyethyl)piperazin-1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(lr,27?,35)-A-[(75,135)-(20A/)-20-[2-[(llS)-l-methoxyethyl]-5-[4-(3-methoxy-3-methyl- butyl)piperazin-1 -yl]-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31 - tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(lr,25,37?)-A-[(7S,13S)-29-fluoro-(20A/)-20-[2-[(15)-l-methoxyethyl]-5-(4- methylpiperazin-1 -yl)-3-pyridyl] -17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31- tetrazahexacyclo[23.3.1.12’5.l9’13.019’27.021’26]hentriaconta-l(28),2,5(31),19,25(29),26-hexaen-7- yl]-2,3-dimethyl-cyclopropanecarboxamide;(15,25)-^-[(75,135)-(20A/)-20-[2-[( 1S)-1-methoxyethyl]-5-morpholino-3-pyridyl] - 17,17,22,22-tetramethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31-5 9 13 19 27 21 26tetrazahexacyclo[23.3.1.1 ’ .1 ’ .0 ’ .0 ]hentriaconta-l(29),2,5(31),19,25,27-hexaen-7-yl]-2-methyl- cyclopropanecarboxamide;(lr,27?,3S)-A-[(75,135)-(20A/)-20-[2-[(llS)-l-methoxyethyl]-5-morpholino-3-pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,31,32-2,5 9,13 19,28 21,27tetrazahexacyclo[24.3.1.1 .1 .0 .0 ]dotnaconta-l(29),2,5(32),19,26(30),27-hexaen-7-yl]-2,3-dimethyl-cyclopropanecarboxamide; and(1 r,27?,31S)-A-[(7.S', 135)-(20M)-20-[2-[( 15)-1 -metho xyethyl]-5-(4-methylpiperazin- 1 -yl)-3- pyridyl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,32,33-2,5 9,13 19,29 21,28tetrazahexacyclo [25.3.1.1 .1 .0 .0 ]tntnaconta-l(30),2,5(33),19,27(31),28-hexaen-7-yl]-2,3-dimethyl-cyclopropanecarboxamide;or a pharmaceutically acceptable salt thereof.
15. A compound selected from: -262- (Example 24); (Example 56); (Example 73); -263- (Example 89);or a pharmaceutically acceptable salt thereof. 5
16. A process for the preparation of a compound according to any one of claims 1 to 15comprising the following step:a) coupling reaction between compound of formula (lib), -264- in the presence of a coupling reagent and a base to form the compound of formula (lb); wherein R1, R2, M and L are defined as in any one of claims 1 to 13; the coupling reagent is T3P, HATU, PyBOP or EDCI/HOBt; the base is TEA, DIEP A or DMAP.
17. A compound or pharmaceutically acceptable salt according to any one of claims 1 to 15 for use as therapeutically active substance.
18. A pharmaceutical composition comprising a compound in accordance with any one of claims to 15 and a pharmaceutically acceptable excipient.
19. The use of a compound according to any one of claims 1 to 15 for treating a KRAS G12C protein-related disease.
20. The use of a compound according to any one of claims 1 to 15 for treating a KRAS G12C, G12D and G12 V protein-related disease.
21. The use of a compound according to any one of claims 1 to 15 for inhibiting RAS interaction with downstream effectors, wherein the downstream effectors are RAF and PI3K.
22. The use of a compound according to any one of claims 1 to 15 for inhibiting the propagating oncogenic MAPK and PI3K signaling.
23. The use of a compound according to any one of claims 1 to 15 for the treatment or prophylaxis of cancers in a subject in need thereof, wherein the cancer comprises a first RAS -265- mutation that is G12C and a second RAS mutation at a position selected from the group consisting 0fV8A, V9Y, S17E, A59T, T58I, D69P, M72I, S65W, R68S, D92R, H95N, Y96D, Q99W and F156L.
24. The use of a compound according to any one of claims 1 to 15 for the preparation of a medicament for the treatment or prophylaxis of cancers in a subject in need thereof, wherein the cancer comprises a first RAS mutation that is G12C and a second RAS mutation at a position selected from the group consisting of V8A, V9Y, S17E, A59T, T58I, D69P, M721, S65W, R68S, D92R, H95N, Y96D, Q99W and F156L.
25. The use of a compound according to any one of claims 1 to 15 for the treatment or prophylaxis of KRAS mutation driven cancers, wherein the cancer is selected from pancreatic cancer, colorectal cancer, lung cancer, esophageal cancer, gallbladder cancer, melanoma ovarian cancer and endometrial cancer.
26. The use of a compound according to any one of claims 1 to 15 for the treatment or prophylaxis of KRAS mutation driven cancers, wherein the cancer is selected from pancreatic adenocarcinoma, colorectal cancer and non-small cell lung cancer.
27. The use of a compound according to any one of claims 1 to 15 for the treatment or prophylaxis of primary central nervous system (CNS) tumors harboring RAS mutations or RAS driven cancers with brain metastases; wherein the CNS tumor is primary melanocytic tumors of the CNS harboring NR AS mutation; wherein the cancer is selected from pancreatic adenocarcinoma, colorectal cancer, non-small cell lung cancer.
28. The use of a compound according to any one of claims 1 to 15 for the treatment or prophylaxis of primary central nervous system (CNS) tumors harboring RAS mutations or RAS driven cancers with brain metastases; wherein the CNS tumor is primary melanocytic tumors of the CNS harboring NRAS mutation; wherein the cancer is non-small cell lung cancer.
29. A compound or pharmaceutically acceptable salt according to any one of claims 1 to 15 for the treatment or prophylaxis of KRAS mutation driven cancers, wherein the cancer is selected from pancreatic adenocarcinoma, colorectal cancer and non-small cell lung cancer. -266-
30. The use of a compound according to any one of claims 1 to 15 for the preparation of a medicament for the treatment or prophylaxis of KRAS mutation driven cancers, wherein the cancer is selected from pancreatic adenocarcinoma, colorectal cancer and non-small cell lung cancer.
31. A method for the treatment or prophylaxis of KRAS mutation driven cancers, wherein the cancer is selected from pancreatic adenocarcinoma, colorectal cancer and non-small cell lung cancer, which method comprises administering a therapeutically effective amount of acompound as defined in any one of claims 1 to 15.
32. A compound or pharmaceutically acceptable salt according to any one of claims 1 to 15, when manufactured according to a process of claim 16. 15
33. The invention as hereinbefore described.
IL322109A 2023-02-14 2024-02-08 Tricyclic compounds for the treatment of cancer IL322109A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2023075911 2023-02-14
CN2023115515 2023-08-29
CN2024074420 2024-01-29
PCT/CN2024/076886 WO2024169914A1 (en) 2023-02-14 2024-02-08 Tricyclic compounds for the treatment of cancer

Publications (1)

Publication Number Publication Date
IL322109A true IL322109A (en) 2025-09-01

Family

ID=90363897

Family Applications (1)

Application Number Title Priority Date Filing Date
IL322109A IL322109A (en) 2023-02-14 2024-02-08 Tricyclic compounds for the treatment of cancer

Country Status (13)

Country Link
US (2) US12247036B2 (en)
EP (1) EP4469164A1 (en)
JP (1) JP2026506637A (en)
KR (1) KR20250129811A (en)
CN (1) CN120813588A (en)
AU (1) AU2024220916A1 (en)
CL (1) CL2025002160A1 (en)
CO (1) CO2025010435A2 (en)
CR (1) CR20250329A (en)
IL (1) IL322109A (en)
MX (1) MX2025009239A (en)
PE (1) PE20252395A1 (en)
WO (1) WO2024169914A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4596552A1 (en) 2022-09-29 2025-08-06 Guangzhou Joyo Pharmatech Co., Ltd Macrocyclic derivative and use thereof
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025201453A1 (en) * 2024-03-28 2025-10-02 Beigene (Suzhou) Co., Ltd. Macrocyclic compounds as ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025252864A1 (en) * 2024-06-07 2025-12-11 F. Hoffmann-La Roche Ag Macrocyclic compounds for the treatment of cancer
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026022119A1 (en) * 2024-07-24 2026-01-29 F. Hoffmann-La Roche Ag Ras inhibitors in combination therapy for use in treating cancers
WO2026027450A1 (en) * 2024-07-29 2026-02-05 F. Hoffmann-La Roche Ag Solid forms of ras inhibitor
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026061441A1 (en) * 2024-09-19 2026-03-26 Beone Pharmaceutical (Suzhou) Co., Ltd. Macrocyclic compounds as ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026082180A1 (en) * 2024-10-18 2026-04-23 合肥盛浦医药科技有限公司 Macrocyclic compound, intermediate thereof, preparation method therefor and use thereof
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20260115199A1 (en) 2024-10-31 2026-04-30 Hoffmann-La Roche Inc. Tricyclic compounds for the treatment of cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019009903A2 (en) 2016-11-18 2019-08-13 Neurovive Pharmaceutical Ab sangliferin analog, combination, pharmaceutical composition, and method for treating a subject suffering from cancer or B-cell malignancy
IL317393A (en) 2018-12-21 2025-02-01 Revolution Medicines Inc Compounds that participate in cooperative binding and uses thereof
MX2022005359A (en) * 2019-11-04 2022-06-02 Revolution Medicines Inc Ras inhibitors.
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
CN121471132A (en) 2019-11-04 2026-02-06 锐新医药公司 RAS inhibitors
EP4208261A1 (en) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as ras inhibitors in the treatment of cancer
CR20230500A (en) 2021-04-02 2024-02-13 Massachusetts Gen Hospital Methods for inhibiting ras
CN117597354A (en) 2021-04-02 2024-02-23 综合医院公司 Ways to Inhibit RAS
CN117979966A (en) 2021-04-09 2024-05-03 锐新医药公司 Using SOS1 inhibitors and RAS inhibitors to treat cancer
PE20240088A1 (en) 2021-05-05 2024-01-16 Revolution Medicines Inc RAS INHIBITORS
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc Ras inhibitors for the treatment of cancer
WO2022251292A1 (en) 2021-05-25 2022-12-01 Revolution Medicines, Inc. Methods for inhibiting ras
WO2023015559A1 (en) 2021-08-13 2023-02-16 Nutshell Biotech (Shanghai) Co., Ltd. Macrocycle compounds as inhibitors of ras
AR126854A1 (en) 2021-08-27 2023-11-22 Hoffmann La Roche MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER
AR127308A1 (en) 2021-10-08 2024-01-10 Revolution Medicines Inc RAS INHIBITORS
US20250066386A1 (en) 2021-11-09 2025-02-27 Biomea Fusion, Inc. Inhibitors of kras
EP4463231A1 (en) 2022-01-10 2024-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
CN119156393A (en) 2022-04-25 2024-12-17 翰森生物有限责任公司 Cyclic compound, preparation method and medical application thereof
WO2023232776A1 (en) 2022-06-01 2023-12-07 F. Hoffmann-La Roche Ag Haloindole macrocyclic compounds for the treatment of cancer
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
AR129819A1 (en) 2022-07-04 2024-10-02 Hoffmann La Roche HALOALKYNYL COMPOUNDS FOR CANCER TREATMENT
EP4551295A1 (en) 2022-07-08 2025-05-14 F. Hoffmann-La Roche AG Macrocycle compounds useful as kras inhibitors
AR129934A1 (en) 2022-07-20 2024-10-16 Hoffmann La Roche MACROCYCLIC COMPOUNDS FOR CANCER TREATMENT
JP2025528836A (en) 2022-08-17 2025-09-02 ツリーライン バイオサイエンシズ インコーポレイテッド Pyridopyrimidine KRas inhibitors
CN117720555B (en) 2022-09-19 2026-05-05 杭州阿诺生物医药科技有限公司 An intermediate for preparing KRAS inhibitor compounds and its synthetic method
CN117903169A (en) 2022-09-19 2024-04-19 杭州阿诺生物医药科技有限公司 Pan-KRAS inhibitor compound
EP4596552A1 (en) 2022-09-29 2025-08-06 Guangzhou Joyo Pharmatech Co., Ltd Macrocyclic derivative and use thereof
CN120693161A (en) 2022-10-12 2025-09-23 锐新医药公司 Composition comprising a first RAS inhibitor, a second RAS inhibitor and a SHP2 inhibitor for treating cancer
JP2025539080A (en) 2022-11-14 2025-12-03 アムジエン・インコーポレーテツド Macrocyclic KRAS inhibitors and methods of use
LU505465B1 (en) 2022-11-16 2024-05-14 Adlai Nortye Biopharma Co Ltd A pan-KRAS inhibitor compound
CN118047799A (en) 2022-11-16 2024-05-17 杭州阿诺生物医药科技有限公司 Pan-KRAS inhibitor compound
LU505464B1 (en) 2022-11-18 2024-05-13 Adlai Nortye Biopharma Co Ltd A pan-KRAS inhibitor compound
CN117534684A (en) 2022-11-29 2024-02-09 杭州阿诺生物医药科技有限公司 A pan-KRAS inhibitor compound
EP4649081A1 (en) 2023-01-13 2025-11-19 F. Hoffmann-La Roche AG Sulfonylvinyl compounds for the treatment of cancer
CN120615093A (en) 2023-01-19 2025-09-09 劲方医药科技(上海)股份有限公司 Macrocyclic compound and its preparation method and use
CN121487738A (en) 2023-03-30 2026-02-06 锐新医药公司 Compositions for inducing RAS GTP hydrolysis and their uses
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
CN121487951A (en) 2023-04-07 2026-02-06 锐新医药公司 Macrocyclic RAS inhibitors

Also Published As

Publication number Publication date
PE20252395A1 (en) 2025-10-10
KR20250129811A (en) 2025-08-29
US20250376482A1 (en) 2025-12-11
CL2025002160A1 (en) 2025-08-22
AU2024220916A1 (en) 2025-05-29
CN120813588A (en) 2025-10-17
US12247036B2 (en) 2025-03-11
US20240417410A1 (en) 2024-12-19
CR20250329A (en) 2025-09-12
WO2024169914A1 (en) 2024-08-22
EP4469164A1 (en) 2024-12-04
MX2025009239A (en) 2025-09-02
CO2025010435A2 (en) 2025-08-19
JP2026506637A (en) 2026-02-25

Similar Documents

Publication Publication Date Title
US12247036B2 (en) Tricyclic compounds for the treatment of cancer
EP4558507B1 (en) Macrocycle compounds for the treatment of cancer
US20250206761A1 (en) Haloindole macrocyclic compounds for the treatment of cancer
US20250257075A1 (en) Macrocyclic inhibitors of kras for the treatment of cancer
EP4688791A1 (en) Tricyclic compounds for the treatment of cancer
WO2024008834A1 (en) Macrocycle compounds useful as kras inhibitors
WO2023141570A2 (en) Compounds and methods for the targeted degradation of kras
JP6242885B2 (en) 5-azaindazole compounds and methods of use
TW202448899A (en) Tricyclic compounds for the treatment of cancer
HK40128039A (en) Tricyclic compounds for the treatment of cancer
HK40119203A (en) Macrocycle compounds for the treatment of cancer
US20260115199A1 (en) Tricyclic compounds for the treatment of cancer
HK40128103A (en) Tricyclic compounds for the treatment of cancer
WO2026041636A1 (en) Macrocycle compounds for the treatment of cancer
KR20240174841A (en) Pyrimidine/pyridine derivatives or salts thereof and pharmaceutical compositions comprising the same
HK1196125B (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
HK1196125A (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use